1 00:00:10,985 --> 00:00:15,756 OUR NATIONAL ADVISORY DENTAL 2 00:00:15,756 --> 00:00:20,661 RESEARCH COUNCIL. I'M THE DES 3 00:00:20,661 --> 00:00:22,730 DESIGNATED OFFICIAL FOR THIS 4 00:00:22,730 --> 00:00:23,831 COUNCIL. FIRST SOME HOUSE 5 00:00:23,831 --> 00:00:29,070 KEEPING ITEMS. WE WILL NOT BE 6 00:00:29,070 --> 00:00:32,506 TAKING QUESTIONS FROM THE PUBLIC 7 00:00:32,506 --> 00:00:34,575 BUT WE WILL ACCEPT THEM AT THE 8 00:00:34,575 --> 00:00:35,643 E-MAIL ADDRESS THAT WILL BE 9 00:00:35,643 --> 00:00:38,946 DISPLAYED AT THE END OF THIS 10 00:00:38,946 --> 00:00:42,817 SESSION. A FEW TEAMS MEETING 11 00:00:42,817 --> 00:00:44,852 LOGISTICS, THOSE ATTENDING VIA 12 00:00:44,852 --> 00:00:46,887 TEAMS PLEASE ENSURE THAT YOUR 13 00:00:46,887 --> 00:00:48,155 MICROPHONES ARE SET ON MUTE 14 00:00:48,155 --> 00:00:51,158 UNLESS YOU ARE SPEAKING AND/OR 15 00:00:51,158 --> 00:00:52,259 PRESENTING. COUNCILMEMBERS, 16 00:00:52,259 --> 00:00:54,261 PLEASE KEEP YOUR VIDEO CAMERA 17 00:00:54,261 --> 00:00:57,498 ON, ALL OTHERS, PLEASE KEEP YOUR 18 00:00:57,498 --> 00:00:59,867 CAMERAS OFF UNLESS YOU ARE 19 00:00:59,867 --> 00:01:01,502 PRESENTING OR SPEAK THIS IS 20 00:01:01,502 --> 00:01:03,104 IMPORTANT IN THE WEBCASTING OF 21 00:01:03,104 --> 00:01:04,472 THE OPEN SESSION IF ANYONE 22 00:01:04,472 --> 00:01:07,975 PARTICIPATING VIA TEAMS NEEDS 23 00:01:07,975 --> 00:01:12,279 TECHNICAL ASSISTANCE, MASON 24 00:01:12,279 --> 00:01:14,215 FLETCHER AND DANIEL CARTER WILL 25 00:01:14,215 --> 00:01:17,218 BE ABLE TO ASSIST. FINALLY 26 00:01:17,218 --> 00:01:20,154 DURING THE VOTING PROCESS, IF 27 00:01:20,154 --> 00:01:22,056 ANY COUNCILMEMBER IS OPPOSED OR 28 00:01:22,056 --> 00:01:24,125 WOULD LIKE TO ABSTAIN WE ASK 29 00:01:24,125 --> 00:01:25,092 THAT YOU SPEAK UP AS WELL AS 30 00:01:25,092 --> 00:01:28,062 SEND A MESSAGE IN THE TEAMS 31 00:01:28,062 --> 00:01:29,830 CHAT. BEFORE WE BEGIN, I'D LIKE 32 00:01:29,830 --> 00:01:31,966 TO ASK THE COUNCILMEMBERS TO 33 00:01:31,966 --> 00:01:33,067 BRIEFLY INTRODUCE THEMSELVES, 34 00:01:33,067 --> 00:01:35,503 STATING THEIR NAMES, AFFILIATION 35 00:01:35,503 --> 00:01:38,439 AND EXPERTISE. WE WILL GO IN 36 00:01:38,439 --> 00:01:39,573 ALPHABETICAL ORDER WHEN I CALL 37 00:01:39,573 --> 00:01:40,908 YOUR NAMES. STARTING WITH 38 00:01:40,908 --> 00:01:44,979 DR. TERRY DICKINSON. PLEASE 39 00:01:44,979 --> 00:01:49,550 UNMUTE YOURSELVES AND INTRODUCE 40 00:01:49,550 --> 00:01:53,054 YOURSELF. 41 00:01:53,054 --> 00:01:55,022 >> GOOD MORNING, MY NAME IS 42 00:01:55,022 --> 00:01:59,060 TERRY DICKINSON AND I'M 43 00:01:59,060 --> 00:02:01,762 ASSOCIATED WITH VIRGINIA COMMON 44 00:02:01,762 --> 00:02:04,899 WEALTH UNIVERSITY SCHOOL OF 45 00:02:04,899 --> 00:02:05,166 DENTISTY. 46 00:02:05,166 --> 00:02:07,068 >> THANK YOU, DR. LISA. 47 00:02:07,068 --> 00:02:08,402 >> GOOD MORNING, EVERYONE, MY 48 00:02:08,402 --> 00:02:13,407 NAME IS LISA I'M FROM THE 49 00:02:13,407 --> 00:02:15,643 COLLEGE OF DENTISTY AND MY 50 00:02:15,643 --> 00:02:16,644 RESEARCH AREA IS TISSUE REGEN 51 00:02:16,644 --> 00:02:20,948 RATION AND WOUND HEALING. 52 00:02:20,948 --> 00:02:24,151 >> THANK YOU. DR. STEPHANIE. 53 00:02:24,151 --> 00:02:27,154 >> GOOD MORNING, I'M STEPHANIE 54 00:02:27,154 --> 00:02:30,858 FROM VANDERBILT UNIVERSITY 55 00:02:30,858 --> 00:02:34,495 MEDICAL CENTER, MY SPECIALTY IS 56 00:02:34,495 --> 00:02:35,062 BIOINFORMATICS. THANK YOU. 57 00:02:35,062 --> 00:02:37,465 >> GOOD MORNING, I'M PAUL FROM 58 00:02:37,465 --> 00:02:40,401 UCLA SCHOOL OF DENTISTY AND MY 59 00:02:40,401 --> 00:02:44,505 EXPERTISE ARE IN CELL AND 60 00:02:44,505 --> 00:02:45,973 MOLECULAR BIOLOGY OF TISSUES. 61 00:02:45,973 --> 00:02:47,975 >> THANK YOU, DR. JOSÉ. 62 00:02:47,975 --> 00:02:55,116 >> HI, I'M PROFESSOR OF THE 63 00:02:55,116 --> 00:02:58,219 ANESTHESIOLOGY. MY RESEARCH IS 64 00:02:58,219 --> 00:03:01,355 FOCUSED ON UNDERSTANDING THE 65 00:03:01,355 --> 00:03:05,926 INTERSECTION OF PAIN AND OPIATE 66 00:03:05,926 --> 00:03:07,161 ADDICTION. 67 00:03:07,161 --> 00:03:08,329 >> GOOD MORNING, I'M JACQUES 68 00:03:08,329 --> 00:03:15,202 NOR, FROM FES PROFESSOR IN 69 00:03:15,202 --> 00:03:15,703 DENT 70 00:03:15,703 --> 00:03:17,037 DENTISTY. OUR RESEARCH IS IN 71 00:03:17,037 --> 00:03:17,972 STEM CELL BIOLOGY. 72 00:03:17,972 --> 00:03:21,041 >> AND DR. AMY. 73 00:03:21,041 --> 00:03:25,346 >> I'M AMY SLAP, AT NEW YORK 74 00:03:25,346 --> 00:03:31,152 UNIVERSITY AND MY EXPERTISE IS 75 00:03:31,152 --> 00:03:36,590 IN INTERNAL -- INTERPERSONAL 76 00:03:36,590 --> 00:03:36,924 INTERACTIONS. 77 00:03:36,924 --> 00:03:38,592 >> THANK YOU AND DR. KOUG WILL 78 00:03:38,592 --> 00:03:40,161 NOT BE JOINING. THE NEXT ITEM 79 00:03:40,161 --> 00:03:43,097 IS THE APPROVAL OF THE MINUTES 80 00:03:43,097 --> 00:03:46,834 FROM THE PRIOR COUNCIL MEETING. 81 00:03:46,834 --> 00:03:48,769 THEY WERE MADE AVAILABLE TO THE 82 00:03:48,769 --> 00:03:49,403 COUNCILMEMBERS. ARE THERE 83 00:03:49,403 --> 00:03:51,038 COMMENTS OR CORRECTIONS FOR THE 84 00:03:51,038 --> 00:03:55,843 SEPTEMBER 2024 COUNCIL MEETING 85 00:03:55,843 --> 00:04:01,415 MINUTES? HEARING NONE, WOULD A 86 00:04:01,415 --> 00:04:03,117 MEMBER OF THE COUNCIL LIKE TO 87 00:04:03,117 --> 00:04:04,151 MAKE A MOTION. 88 00:04:04,151 --> 00:04:06,120 >> SO MOVED, JACQUES. 89 00:04:06,120 --> 00:04:09,456 >> SOMEONE LIKE TO SECOND THAT 90 00:04:09,456 --> 00:04:09,690 MOTION? 91 00:04:09,690 --> 00:04:11,058 >> I'LL SECOND. 92 00:04:11,058 --> 00:04:13,194 >> ALL IN FAVOR? 93 00:04:13,194 --> 00:04:13,694 >> YES. 94 00:04:13,694 --> 00:04:22,036 >> ANY OPPOSED? I'M HEARING 95 00:04:22,036 --> 00:04:24,038 NONE. THANK YOU SO MUCH. THE 96 00:04:24,038 --> 00:04:26,840 COUNCIL OPERATING PROCEDURES 97 00:04:26,840 --> 00:04:29,643 WERE REVISED DURING THE CLOSED 98 00:04:29,643 --> 00:04:33,247 SESSION OF THE JANUARY COUNCIL 99 00:04:33,247 --> 00:04:35,749 THAT TOOK PLACE IN 2025. A COPY 100 00:04:35,749 --> 00:04:37,885 IS AVAILABLE ON THE WEBSITE FOR 101 00:04:37,885 --> 00:04:38,919 EVERYONE'S INFORMATION. NOW, WE 102 00:04:38,919 --> 00:04:45,492 WILL GO TO THE NIDCR'S 103 00:04:45,492 --> 00:04:47,995 DIRECTOR'S REPORT BY THE ACTING 104 00:04:47,995 --> 00:04:54,001 DIRECTOR OF N IDCR, DR. WEBSTER. 105 00:04:54,001 --> 00:04:59,139 >> HOW WONDERFUL TO BE HERE. 106 00:04:59,139 --> 00:05:01,008 AND IT IS MY PLEASURE TO WELCOME 107 00:05:01,008 --> 00:05:02,009 YOU. WE HAVE A LOT TO SHARE 108 00:05:02,009 --> 00:05:06,747 WITH YOU, LOTS OF CHANGES. I'LL 109 00:05:06,747 --> 00:05:10,985 GO AHEAD AND PUT IT IN 110 00:05:10,985 --> 00:05:21,495 PRESENTATION MODE. SO AGAIN 111 00:05:25,199 --> 00:05:30,804 WELCOME, LOTS OF UPDATES AND 112 00:05:30,804 --> 00:05:32,306 NEWS TO SHARE WITH YOU IN 113 00:05:32,306 --> 00:05:33,907 REGARDS TO THE BUDGET, THE 114 00:05:33,907 --> 00:05:36,176 CONGRESSIONAL AND LEGISLATIVE 115 00:05:36,176 --> 00:05:37,945 UPDATES, ADMINISTRATION UPDATES 116 00:05:37,945 --> 00:05:39,680 RELATED TO OUR NEW 117 00:05:39,680 --> 00:05:42,416 ADMINISTRATION AND THE VISION. 118 00:05:42,416 --> 00:05:43,884 AS WELL AS ANNOUNCEMENTS FROM 119 00:05:43,884 --> 00:05:46,887 NIH AND NIDCR AND THEN 120 00:05:46,887 --> 00:05:48,422 AFTERWARDS, IN TERMS OF 121 00:05:48,422 --> 00:05:49,957 SCIENTIFIC ADVANCES WE'LL BE 122 00:05:49,957 --> 00:05:53,160 HIGHLIGHTING OUR INTRAMURAL 123 00:05:53,160 --> 00:05:58,499 PROGRAM. WE'LL START WITH 124 00:05:58,499 --> 00:06:02,102 APPROPRIATIONS AND BUDGET. SO 125 00:06:02,102 --> 00:06:07,141 THE 119TH CONGRESS CONVENED THIS 126 00:06:07,141 --> 00:06:09,176 JANUARY AND REELECTED MIKE 127 00:06:09,176 --> 00:06:15,149 JOHNSON AS SPEAKER OF THE HOUSE 128 00:06:15,149 --> 00:06:19,153 SINCE 2015 THIS IS THE FIRST 129 00:06:19,153 --> 00:06:20,554 TRIFECTA WHERE ALL ARE 130 00:06:20,554 --> 00:06:21,322 CONTROLLED BY A SINGLE PARTY. 131 00:06:21,322 --> 00:06:24,058 IN MARCH OF THIS YEAR PRESIDENT 132 00:06:24,058 --> 00:06:26,593 TRUMP SIGNED A CONTINUING 133 00:06:26,593 --> 00:06:29,830 RESOLUTION SO WE'LL CONTINUE TO 134 00:06:29,830 --> 00:06:33,300 OPERATE UNDER THIS CONTINUING 135 00:06:33,300 --> 00:06:34,468 RESOLUTION THROUGH SEPTEMBER 136 00:06:34,468 --> 00:06:37,204 30TH OF 2025 WHICH MEANS FOR US 137 00:06:37,204 --> 00:06:39,473 THAT AT NIH WE'LL HAVE THE SAME 138 00:06:39,473 --> 00:06:43,677 FUNDING LEVEL AS WE HAD IN 2024. 139 00:06:43,677 --> 00:06:47,147 WITH NO REDUCTION. THAT WAS 140 00:06:47,147 --> 00:06:53,153 48.9 BILLION FOR NIH AND FOR 141 00:06:53,153 --> 00:06:55,222 NIDCR 520 MILLION. SO IN TERMS 142 00:06:55,222 --> 00:06:58,926 OF 2026, EARLIER THIS MONTH ON 143 00:06:58,926 --> 00:07:01,528 MAY 2ND THE WHITE HOUSE RELEASED 144 00:07:01,528 --> 00:07:03,330 THE PRESIDENT'S BUDGET REQUEST 145 00:07:03,330 --> 00:07:07,167 FOR FY 26 AND IT ONLY OUTLINED 146 00:07:07,167 --> 00:07:08,902 MAJOR DISCRETIONARY FUNDING 147 00:07:08,902 --> 00:07:12,639 CHANGES. FOR NIH THAT MEANS THE 148 00:07:12,639 --> 00:07:18,612 PROPOSAL OF A 17.96 BILLION 149 00:07:18,612 --> 00:07:21,515 DOLLAR DECREASE FROM '25. WHICH 150 00:07:21,515 --> 00:07:24,017 BRINGS THE TOTAL FUNDING 151 00:07:24,017 --> 00:07:28,722 PROPOSED FUNDING FOR NIH TO 30 152 00:07:28,722 --> 00:07:31,058 BILLION AND FOR NIDCR WHAT HAS 153 00:07:31,058 --> 00:07:33,127 BEEN PROPOSED IS A 154 00:07:33,127 --> 00:07:36,663 REORGANIZATION OF THE ICS. 155 00:07:36,663 --> 00:07:38,365 CONSISTENT WITH OTHER RECENT 156 00:07:38,365 --> 00:07:42,202 REFORM PROPOSALS. WITH THE 157 00:07:42,202 --> 00:07:44,238 PROPOSAL, THAT NIDCR BE MERGED 158 00:07:44,238 --> 00:07:49,843 WITH NEA AND NINDS. UNDER THE 159 00:07:49,843 --> 00:07:52,780 NATIONAL, THE UMBRELLA NATIONAL 160 00:07:52,780 --> 00:07:54,681 INSTITUTE OF NEUROSCIENCE AND 161 00:07:54,681 --> 00:07:57,951 BRAIN RESEARCH. SO WHAT'S NEXT? 162 00:07:57,951 --> 00:07:59,186 CONGRESS HAS BEGUN TO HOLD 163 00:07:59,186 --> 00:08:04,057 BUDGET MEETINGS AND HEARINGS 164 00:08:04,057 --> 00:08:05,859 RELATED TO THIS REQUEST AND 165 00:08:05,859 --> 00:08:07,795 CONGRESS WILL BE RESPONSIBLE FOR 166 00:08:07,795 --> 00:08:08,695 DIRECTING THE GOVERNMENT 167 00:08:08,695 --> 00:08:11,498 SPENDING. SO WE'LL HAVE TO SEE. 168 00:08:11,498 --> 00:08:14,868 WITH REGARD TO LEGISLATIVE 169 00:08:14,868 --> 00:08:17,171 UPDATES, THERE ARE NOW FOUR 170 00:08:17,171 --> 00:08:21,008 DENTISTS IN THIS 119TH CONGRESS. 171 00:08:21,008 --> 00:08:22,643 THERE WAS A FIFTH WHO DECIDED 172 00:08:22,643 --> 00:08:26,180 NOT TO RUN FOR REELECTION AND 173 00:08:26,180 --> 00:08:29,983 THESE INCLUDES REPRESENTATIVES 174 00:08:29,983 --> 00:08:31,952 BABYLON BEGIN, GO SAR, AND DREW. 175 00:08:31,952 --> 00:08:33,120 WE'VE HAD THE OPPORTUNITY TO 176 00:08:33,120 --> 00:08:35,155 SHARE A BIT WITH CONGRESS ABOUT 177 00:08:35,155 --> 00:08:41,128 WHO WE ARE. AND IN 2024 THE 178 00:08:41,128 --> 00:08:43,597 OFFICE OF LEGISLATIVE POLICY 179 00:08:43,597 --> 00:08:45,399 CREATED A SERIES CALLED ALLERGY 180 00:08:45,399 --> 00:08:47,501 R LUNCH AND LEARN WHERE WE GET 181 00:08:47,501 --> 00:08:50,103 TO SPEAK WITH CONGRESSIONAL 182 00:08:50,103 --> 00:08:51,438 STAFF. 183 00:08:51,438 --> 00:08:53,273 WE PARTICIPATED IN THIS PAST 184 00:08:53,273 --> 00:08:56,009 JOON AND REVIEWED, WE OF COURSE 185 00:08:56,009 --> 00:08:57,444 COMPLETED OUR 75TH ANNIVERSARY. 186 00:08:57,444 --> 00:09:00,280 AND HAD THE OPPORTUNITY TO SHARE 187 00:09:00,280 --> 00:09:02,516 WITH THEM OUR YEARS OF 188 00:09:02,516 --> 00:09:05,118 ACHIEVEMENTS, WHAT OUR ROLE IS 189 00:09:05,118 --> 00:09:06,854 AND IMPACTING THE PATHWAY TO 190 00:09:06,854 --> 00:09:09,356 HEALTH AND HOW WE CANNOT HAVE 191 00:09:09,356 --> 00:09:11,058 HEALTH WITHOUT ORAL HEALTH. 192 00:09:11,058 --> 00:09:12,626 OKAY? WE'LL HAVE ANOTHER 193 00:09:12,626 --> 00:09:14,995 OPPORTUNITY NEXT WEEK, JUNE 6TH, 194 00:09:14,995 --> 00:09:18,732 WHERE WE'LL PRESENT AND RAISE 195 00:09:18,732 --> 00:09:20,534 AWARENESS OF NATIONAL ORAL 196 00:09:20,534 --> 00:09:22,269 HEALTH MONTH WHICH IS JUNE AND 197 00:09:22,269 --> 00:09:24,304 WE WILL ALSO BE PROMOTING OUR 198 00:09:24,304 --> 00:09:27,174 ROLE IN THE FIELD. SO AS YOU 199 00:09:27,174 --> 00:09:29,510 ARE ALL THE AWARE WE HAVE A NEW 200 00:09:29,510 --> 00:09:31,712 ADMINISTRATION THAT COMES WITH 201 00:09:31,712 --> 00:09:34,047 NEW VISION. SO WE HAVE A NEW 202 00:09:34,047 --> 00:09:41,989 HHS SECRETARY, ROBERT F. GENERAL 203 00:09:41,989 --> 00:09:44,458 KENNEDY JR. AND A NEW NIH 204 00:09:44,458 --> 00:09:45,158 DIRECTOR. 205 00:09:45,158 --> 00:09:47,194 I WILL SHARE PRIORITIES 206 00:09:47,194 --> 00:09:49,096 ARTICULATED BY OUR HHS SECRETARY 207 00:09:49,096 --> 00:09:52,466 AND THE VISION THAT'S BEEN 208 00:09:52,466 --> 00:09:57,170 SHARED BY JAY BARTY CHARIA. IN 209 00:09:57,170 --> 00:10:02,976 TERMS OF HHS THERE'S BEEN 210 00:10:02,976 --> 00:10:05,579 DISCUSSION ABOUT TACKLING MENTAL 211 00:10:05,579 --> 00:10:08,382 HEALTH AND ADDICTION. TO 212 00:10:08,382 --> 00:10:09,049 ADDRESS PHYSICAL ACTIVITIES AND 213 00:10:09,049 --> 00:10:11,852 HEALTHY LIFESTYLES. ALL 214 00:10:11,852 --> 00:10:15,188 IMPACTING ORAL HEALTH. TO FUND 215 00:10:15,188 --> 00:10:18,091 CUTTING EDGE RESEARCH AT NIH 216 00:10:18,091 --> 00:10:19,493 WHILE CUTTING NONESSENTIAL 217 00:10:19,493 --> 00:10:22,696 SERVICES. AND TO ELIMINATE DEI 218 00:10:22,696 --> 00:10:25,365 FUNDING TO FOCUS MORE ON 219 00:10:25,365 --> 00:10:26,867 POVERTY. AND THIS IS ALSO TO 220 00:10:26,867 --> 00:10:29,269 STRENGTHEN CYBERSECURITY AND 221 00:10:29,269 --> 00:10:36,643 HEALTH IT. TO FOCUS ON DATA AND 222 00:10:36,643 --> 00:10:39,746 SECURE USE OF AI AND TO SUPPORT 223 00:10:39,746 --> 00:10:43,183 PUBLIC TRUST WITH A NEW ERA OF 224 00:10:43,183 --> 00:10:47,187 TRANSPARENCY AND PUBLIC SERVICE. 225 00:10:47,187 --> 00:10:49,222 FOR DR. BHATTACHARYA HIS VISION 226 00:10:49,222 --> 00:10:51,191 INCLUDES IMPROVING POPULATION 227 00:10:51,191 --> 00:10:54,227 HEALTH. SPECIFICALLY IMPROVING 228 00:10:54,227 --> 00:10:54,795 PREVENTION, TREATMENT AND 229 00:10:54,795 --> 00:10:56,930 CURIOUS FOR CHRONIC DISEASE. 230 00:10:56,930 --> 00:10:59,299 WHICH RESONATES QUITE 231 00:10:59,299 --> 00:11:01,635 SIGNIFICANTLY WITH THE WORK WE 232 00:11:01,635 --> 00:11:03,370 DO AT NIDCR. TO ENSURE THE 233 00:11:03,370 --> 00:11:05,305 RESULTS THERE NIH FUNDED 234 00:11:05,305 --> 00:11:07,240 RESEARCH IS REPLICABLE AND 235 00:11:07,240 --> 00:11:09,509 GENERALIZABLE AND TO FOSTER 236 00:11:09,509 --> 00:11:11,478 INNOVATION, MAKE HUGE CHANGES. 237 00:11:11,478 --> 00:11:15,215 WHILE MAINTAINING HIGH ETHICAL 238 00:11:15,215 --> 00:11:16,950 STANDARDS, AND PRIORITIZING 239 00:11:16,950 --> 00:11:19,786 HUMAN BASED RESEARCH 240 00:11:19,786 --> 00:11:20,921 TECHNOLOGIES. TO WORK IN 241 00:11:20,921 --> 00:11:24,524 COMPANION WITH ANIMAL BASED 242 00:11:24,524 --> 00:11:27,027 STUDIES. TO REMAIN RESPECTFUL 243 00:11:27,027 --> 00:11:28,595 OF DIFFERENT PERSPECTIVES AND, 244 00:11:28,595 --> 00:11:32,099 AGAIN, TO RESTORE PUBLIC TRUST 245 00:11:32,099 --> 00:11:33,700 IN SCIENCE. OKAY? SO WHAT'S 246 00:11:33,700 --> 00:11:36,503 NEW HERE AT NIH? THERE HAVE 247 00:11:36,503 --> 00:11:39,106 BEEN A LOT OF CHANGES AND 248 00:11:39,106 --> 00:11:40,607 UPDATES SO LET'S START WITH 249 00:11:40,607 --> 00:11:44,011 POLICIES THAT HAVE CHANGED. 250 00:11:44,011 --> 00:11:48,048 OKAY? THE FIRST IS, WAS 251 00:11:48,048 --> 00:11:51,051 RELEASED JUST THIS PAST MAY. 252 00:11:51,051 --> 00:11:53,787 FOCUSED ON PAUSING POTENTIALLY 253 00:11:53,787 --> 00:11:54,421 DANGEROUS RESEARCH THAT COULD 254 00:11:54,421 --> 00:11:57,758 MAKE A NATURALLY OCCURRING 255 00:11:57,758 --> 00:11:59,726 PATHOGEN OR TOXIN MORE DANGEROUS 256 00:11:59,726 --> 00:12:03,063 TO OUR CITIZENS THIS WILL FOCUS 257 00:12:03,063 --> 00:12:04,031 ON ENSURING SAFE AND SECURE 258 00:12:04,031 --> 00:12:06,466 CONDUCT OF BIOLOGICAL RESEARCH 259 00:12:06,466 --> 00:12:07,934 AND THERE'LL BE MORE GUIDANCE 260 00:12:07,934 --> 00:12:11,204 COMING ON WHAT EXACTLY THAT'S 261 00:12:11,204 --> 00:12:13,740 GOING TO LOOK LIKE. OKAY? 262 00:12:13,740 --> 00:12:20,280 THERE'S ALSO THE SPRA INTRAMURAL 263 00:12:20,280 --> 00:12:21,348 ACCESS PLANNING POLICY. 264 00:12:21,348 --> 00:12:22,849 AND THIS IS TO MAKE SURE THAT 265 00:12:22,849 --> 00:12:24,284 THOSE DISCOVERIES THAT OCCUR IN 266 00:12:24,284 --> 00:12:27,220 THE CONTEXT OF THE INTRAMURAL 267 00:12:27,220 --> 00:12:28,622 RESEARCH PROGRAM AND THE 268 00:12:28,622 --> 00:12:30,791 INVENTIONS THAT RESULT IN DRUGS 269 00:12:30,791 --> 00:12:33,126 AND BIOLOGICS AND VACCINES AND 270 00:12:33,126 --> 00:12:34,661 DEVICES ARE ACCESSIBLE TO THE 271 00:12:34,661 --> 00:12:37,264 AMERICAN PEOPLE. OKAY? SO 272 00:12:37,264 --> 00:12:39,199 THOSE ORGANIZATIONS WHO WILL BE 273 00:12:39,199 --> 00:12:41,802 APPLYING TO NIH FOR LICENSES 274 00:12:41,802 --> 00:12:42,903 WILL BE REQUIRED TO SUBMIT 275 00:12:42,903 --> 00:12:48,742 ACCESS PLANS TO MAKE SURE THAT 276 00:12:48,742 --> 00:12:50,677 EVERYBODY HAS ACCESS TO THESE 277 00:12:50,677 --> 00:12:52,713 PRODUCTS. THIS INCLUDES BEING 278 00:12:52,713 --> 00:12:54,114 AFFORDABLE, AVAILABLE, 279 00:12:54,114 --> 00:12:56,416 ACCEPTABLE AND BEING 280 00:12:56,416 --> 00:12:57,451 SUSTAINABLE. AND THIS IS 281 00:12:57,451 --> 00:12:59,653 ACTUALLY GOING TO APPLY 282 00:12:59,653 --> 00:13:02,189 BEGINNING JUNE 1ST SO STARTING 283 00:13:02,189 --> 00:13:05,325 NEXT WEEK. SO THAT'S BRINGING 284 00:13:05,325 --> 00:13:07,694 SCIENCE TO PEOPLE. THERE'S ALSO 285 00:13:07,694 --> 00:13:09,796 THE -- A POLICY UPDATE RELATED 286 00:13:09,796 --> 00:13:14,034 TO NIH PUBLIC ACCESS. AND THIS 287 00:13:14,034 --> 00:13:16,570 IS GOING TO APPLY TO ANY PAPER 288 00:13:16,570 --> 00:13:18,305 THAT HAS RESULTED FROM NIH 289 00:13:18,305 --> 00:13:19,773 FUNDING THAT HAS BEEN ACCEPTED 290 00:13:19,773 --> 00:13:22,509 TO PUBLICATION IN A JOURNAL SO 291 00:13:22,509 --> 00:13:25,345 MOVING FORWARD, ACCEPTED 292 00:13:25,345 --> 00:13:27,013 MANUSCRIPTS SHOULD BE SUBMITTED 293 00:13:27,013 --> 00:13:31,184 TO PUBMED FOR PUBLIC 294 00:13:31,184 --> 00:13:32,452 AVAILABILITY WITHOUT EMBARGO AND 295 00:13:32,452 --> 00:13:33,987 THIS IS ALSO GOING TO GIVEN NEXT 296 00:13:33,987 --> 00:13:36,757 WEEK, JUNE 1ST. SO THESE PAPERS 297 00:13:36,757 --> 00:13:38,625 WILL BECOME IMMEDIATELY 298 00:13:38,625 --> 00:13:41,294 AVAILABLE TO THE PUBLIC. UNTIL 299 00:13:41,294 --> 00:13:43,263 THEN, OVER THE NEXT FIVE DAYS OR 300 00:13:43,263 --> 00:13:45,799 SO, THE CURRENT POLICY WILL 301 00:13:45,799 --> 00:13:48,235 REMAIN IN EFFECT. OKAY? THERE 302 00:13:48,235 --> 00:13:50,170 ARE LOTS OF CHANGES, LOTS OF 303 00:13:50,170 --> 00:13:52,873 INITIATIVES AND NEW POLICIES. 304 00:13:52,873 --> 00:13:54,341 HERE IS THE ONE-STOP SHOP, 305 00:13:54,341 --> 00:13:58,545 PLEASE STAKE A... TAKE A LOOK AT 306 00:13:58,545 --> 00:14:00,280 THIS PAGE SO YOU'LL BE ABLE TO 307 00:14:00,280 --> 00:14:02,482 SEE WHAT ALL THE NEW INITIATIVES 308 00:14:02,482 --> 00:14:03,183 AND POLICIES ARE. 309 00:14:03,183 --> 00:14:04,351 THIS IS A CENTRAL LOCATION, 310 00:14:04,351 --> 00:14:06,086 WHERE WE CAN SEE WHAT THE STATUS 311 00:14:06,086 --> 00:14:08,688 IS OF CHANGES THAT WILL IMPACT 312 00:14:08,688 --> 00:14:11,024 THE GRANT'S PROCESS SO PLEASE 313 00:14:11,024 --> 00:14:14,761 TAKE A LOOK. OKAY? THERE ARE 314 00:14:14,761 --> 00:14:21,001 CHANGES RELATED TO NIH GRANTS 315 00:14:21,001 --> 00:14:23,170 AND AWARDS SO LET'S TAKE A FEW 316 00:14:23,170 --> 00:14:24,571 MINUTES LOOKING AT WHAT THIS 317 00:14:24,571 --> 00:14:27,174 WILL LOOK LIKE. IN APRIL OF 318 00:14:27,174 --> 00:14:30,310 THIS YEAR, THERE WERE CHANGES TO 319 00:14:30,310 --> 00:14:33,046 FEDERAL ANTIDISCRIMINATION LAWS. 320 00:14:33,046 --> 00:14:35,115 OKAY? AND SO THERE'S NOW A 321 00:14:35,115 --> 00:14:37,017 NOTICE RELATED TO CIVIL RIGHTS 322 00:14:37,017 --> 00:14:40,554 TERMS AND CONDITIONS OF AWARDS. 323 00:14:40,554 --> 00:14:45,892 AND WHAT THIS MEANS IS THAT ALL 324 00:14:45,892 --> 00:14:48,762 NEW RENEWAL SUPPLEMENTS OR 325 00:14:48,762 --> 00:14:51,131 CONTINUATION AWARDS MUST COMPLY 326 00:14:51,131 --> 00:14:55,702 WITH THIS NEW FEDERAL 327 00:14:55,702 --> 00:14:58,004 ANTIDISCRIMINATION LAW. THERE'S 328 00:14:58,004 --> 00:14:58,772 ALSO BEEN SOME SIGNIFICANT 329 00:14:58,772 --> 00:15:02,742 MOVEMENT OR CHANGES RELATED TO 330 00:15:02,742 --> 00:15:04,377 FOREIGN SUBAWARDS. OKAY? AND 331 00:15:04,377 --> 00:15:07,380 SO WE'LL BE ACTUALLY MOVING AWAY 332 00:15:07,380 --> 00:15:10,483 FROM SUBAWARDS TO SUBPROJECTS. 333 00:15:10,483 --> 00:15:12,552 OKAY? AND WHAT IS GOING TO 334 00:15:12,552 --> 00:15:14,988 HAPPEN IS FOREIGN SUBAWARDS WILL 335 00:15:14,988 --> 00:15:17,691 NO LONGER BE NESTED UNDER THE 336 00:15:17,691 --> 00:15:19,392 PARENT GRANT. OKAY? I WANT YOU 337 00:15:19,392 --> 00:15:21,027 TO RECOGNIZE THAT THIS IS THE 338 00:15:21,027 --> 00:15:25,632 BEGINNING OF A PROCESS WHERE 339 00:15:25,632 --> 00:15:26,366 THEY'LL BE STARTING WITH FOREIGN 340 00:15:26,366 --> 00:15:29,102 SUBAWARD AND MOVING WITH ALL 341 00:15:29,102 --> 00:15:30,136 SUBAWARDS. SO WHAT THIS NEW 342 00:15:30,136 --> 00:15:31,371 AWARD STRUCTURE WILL LOOK LIKE 343 00:15:31,371 --> 00:15:34,007 IS THAT THERE'LL BE A PRIME AND 344 00:15:34,007 --> 00:15:39,179 THEY WILL GET AN INDEPENDENT 345 00:15:39,179 --> 00:15:43,016 AWARD. AND THEN THE SUBPROJECT 346 00:15:43,016 --> 00:15:44,251 WILL BE LINKED TO THE PRIME BUT 347 00:15:44,251 --> 00:15:46,286 THE PERSON WILL APPLY 348 00:15:46,286 --> 00:15:47,454 SEPARATELY. OKAY? AND THIS, 349 00:15:47,454 --> 00:15:49,823 WHAT THIS WILL ALLOW NIH TO DO 350 00:15:49,823 --> 00:15:53,360 IS TO BETTER TRACK THE PROJECT'S 351 00:15:53,360 --> 00:15:55,695 FUNDS INDIVIDUALLY WHILE 352 00:15:55,695 --> 00:15:58,765 SCIENTIFIC PROGRESS WILL BE 353 00:15:58,765 --> 00:15:59,766 REPORTED COLLECTIVELY BY THE 354 00:15:59,766 --> 00:16:03,169 PARENT, OR THE PRIME 355 00:16:03,169 --> 00:16:05,372 INSTITUTION. OKAY? SO THIS IS 356 00:16:05,372 --> 00:16:10,243 ALSO ASSOCIATED WITH MAKING SURE 357 00:16:10,243 --> 00:16:11,878 THAT THERE'LL BE NO ISSUANCE OF 358 00:16:11,878 --> 00:16:15,415 AWARDS TO DOMESTIC OR FOREIGN 359 00:16:15,415 --> 00:16:18,685 ENTITIES IF THERE IS A SUBAWARD 360 00:16:18,685 --> 00:16:20,186 ATTACHED. SO PLEASE PAY 361 00:16:20,186 --> 00:16:21,821 ATTENTION BECAUSE THINGS THAT 362 00:16:21,821 --> 00:16:24,591 WILL COME IN WILL NOT BE 363 00:16:24,591 --> 00:16:26,059 REVIEWED IF YOU HAVE THE 364 00:16:26,059 --> 00:16:27,394 SUBAWARDS ATTACHED THE WAY THAT 365 00:16:27,394 --> 00:16:29,529 WE'VE DONE IT IN THE PAST. 366 00:16:29,529 --> 00:16:32,899 OKAY? NIH IS GOING TO ALLOW 367 00:16:32,899 --> 00:16:34,768 RENEGOTIATION OF AWARDS WHETHER 368 00:16:34,768 --> 00:16:36,403 THEY'RE NEW, RENEWAL OR 369 00:16:36,403 --> 00:16:38,471 NON-COMPETING TO REMOVE THE 370 00:16:38,471 --> 00:16:43,176 SUBAWARDS AND TO BUILD IN THE 371 00:16:43,176 --> 00:16:45,078 SUBPROJECTS. IF THE WORK CAN 372 00:16:45,078 --> 00:16:46,813 ACTUALLY BE PERFORMED 373 00:16:46,813 --> 00:16:48,949 DOMESTICALLY THAT WOULD BE 374 00:16:48,949 --> 00:16:51,184 PREFERABLE, AND WE'LL ALLOW THE 375 00:16:51,184 --> 00:16:53,586 FUNDS TO REBUDGETED FOR USE FOR 376 00:16:53,586 --> 00:16:58,925 THE PRIME RECIPIENT, OKAY? 377 00:16:58,925 --> 00:17:00,827 THERE'S ALSO NEW INFORMATION 378 00:17:00,827 --> 00:17:05,899 RELATED TO SUBAWARDS AND SBIRS 379 00:17:05,899 --> 00:17:06,299 STTRS, OKAY? 380 00:17:06,299 --> 00:17:08,935 SO THERE'S A CHANGE IN POST 381 00:17:08,935 --> 00:17:09,869 AWARD REPORTING REQUIREMENTS FOR 382 00:17:09,869 --> 00:17:14,441 THE SBIRS AND STTRS, THE KEY 383 00:17:14,441 --> 00:17:16,476 HERE IS THE REQUIREMENT TO 384 00:17:16,476 --> 00:17:20,180 DISCLOSE ALL FUNDED AND UNFUNDED 385 00:17:20,180 --> 00:17:21,181 RELATIONSHIPS WITH FOREIGN 386 00:17:21,181 --> 00:17:24,651 COUNTRIES USING A NEW FORM THAT 387 00:17:24,651 --> 00:17:27,187 IS THE REQUIRED DISCLOSURES OF 388 00:17:27,187 --> 00:17:28,421 FOREIGN AFFILIATIONS OR 389 00:17:28,421 --> 00:17:31,424 RELATIONSHIPS FORMS. OKAY? SO 390 00:17:31,424 --> 00:17:34,627 IF THE RECIPIENT REPORTS A 391 00:17:34,627 --> 00:17:35,762 FOREIGN RELATIONSHIP THAT 392 00:17:35,762 --> 00:17:38,898 MEETINGS ANY OF THE RISK 393 00:17:38,898 --> 00:17:42,635 CRITERIA, NIH MAY DEEM IT 394 00:17:42,635 --> 00:17:43,436 NECESSARY TO ACTUALLY TERMINATE 395 00:17:43,436 --> 00:17:46,740 THE AWARD. OKAY? FOR FAILURE 396 00:17:46,740 --> 00:17:49,609 TO COMPLY SO THE KEY HERE IS 397 00:17:49,609 --> 00:17:53,113 COMPLIANCE, PLEASE TAKE A LOOK 398 00:17:53,113 --> 00:17:58,718 AT THIS NOTICE. AGAIN, ANOTHER 399 00:17:58,718 --> 00:18:03,123 REMINDER RELATED TO FOREIGN 400 00:18:03,123 --> 00:18:04,391 JUSTIFICATIONS. SO THERE'S A 401 00:18:04,391 --> 00:18:06,993 FOREIGN JUSTIFICATION ATTACHMENT 402 00:18:06,993 --> 00:18:08,395 THAT SHOULD DESCRIBE RESOURCES 403 00:18:08,395 --> 00:18:10,830 AND CHARACTERISTICS OF THE 404 00:18:10,830 --> 00:18:13,433 RESEARCH PROJECT. INCLUDING WHY 405 00:18:13,433 --> 00:18:15,435 THE FACILITIES OR OTHER ASPECTS 406 00:18:15,435 --> 00:18:18,671 OF THE PROPOSED PROJECT ARE MORE 407 00:18:18,671 --> 00:18:20,407 APPROPRIATELY CONDUCTED IN A 408 00:18:20,407 --> 00:18:22,675 FOREIGN SETTING VERSUS A 409 00:18:22,675 --> 00:18:24,344 DOMESTIC SETTING. THIS 410 00:18:24,344 --> 00:18:26,312 ATTACHMENT'S GOING TO BE 411 00:18:26,312 --> 00:18:27,280 REQUIRED FOR EVERY APPLICATION 412 00:18:27,280 --> 00:18:30,950 THAT INVOLVES ACTIVITIES OUTSIDE 413 00:18:30,950 --> 00:18:33,153 OF THE U.S. OR ANY PARTNERSHIP 414 00:18:33,153 --> 00:18:35,688 WITH AN INTERNATIONAL 415 00:18:35,688 --> 00:18:38,525 COLLABORATOR. IRRESPECTIVE OF 416 00:18:38,525 --> 00:18:39,426 WHETHER THE FOREIGN COMPONENT IS 417 00:18:39,426 --> 00:18:46,066 RECEIVING FUNDS FROM THE NIH, 418 00:18:46,066 --> 00:18:48,968 OKAY? IF THIS ATTACHMENT IS NOT 419 00:18:48,968 --> 00:18:51,171 PROVIDED IN THE APPLICATION THE 420 00:18:51,171 --> 00:18:53,239 APPLICATION WILL NOT BE 421 00:18:53,239 --> 00:18:54,741 REVIEWED. OKAY? THERE'S ALSO 422 00:18:54,741 --> 00:18:56,976 AN UPDATED PROCESS RELATED TO NO 423 00:18:56,976 --> 00:19:00,747 COST EXTENSIONS. AND NIH AS OF 424 00:19:00,747 --> 00:19:03,183 EARLIER THIS MONTH NIH IS 425 00:19:03,183 --> 00:19:13,726 TEMPORARILY (ECHO) GOT IT? HAS 426 00:19:16,096 --> 00:19:20,300 TEMPORARILY DISABLED THE NO COST 427 00:19:20,300 --> 00:19:21,367 EXTENSION NALT. THERE'LL BE AN 428 00:19:21,367 --> 00:19:23,203 ADDITIONAL LAYER OF REVIEW OF 429 00:19:23,203 --> 00:19:26,339 ALL EXISTING GRANTS TO MAKE SURE 430 00:19:26,339 --> 00:19:29,476 THAT NIH IS NOT FUNDING ANY OFF 431 00:19:29,476 --> 00:19:32,979 MISSION ACTIVITIES OR PROJECTS. 432 00:19:32,979 --> 00:19:36,616 ALL REQUESTS FOR -- NO COST 433 00:19:36,616 --> 00:19:38,151 EXTENSIONS MUST BE SUBMITTED AS 434 00:19:38,151 --> 00:19:41,421 PRIOR APPROVAL REQUESTS IN ERA 435 00:19:41,421 --> 00:19:47,193 COMMONS FOR NIH REVIEW AND 436 00:19:47,193 --> 00:19:50,063 APPROVAL. WHAT ABOUT NIDCR? 437 00:19:50,063 --> 00:19:52,365 OKAY? WE'VE GOT SOME STAFF 438 00:19:52,365 --> 00:19:53,633 UPDATES THAT I WOULD LIKE TO 439 00:19:53,633 --> 00:19:56,870 SHARE WITH YOU AND TO WELCOME 440 00:19:56,870 --> 00:20:00,874 OUR NEW STAFF. OKAY? FIRST IS 441 00:20:00,874 --> 00:20:04,144 AARON CON DON HE IS OUR DEPUTY 442 00:20:04,144 --> 00:20:05,512 EXECUTIVE OFFICER AND IS 443 00:20:05,512 --> 00:20:08,882 CURRENTLY OUR ACTING EXECUTIVE 444 00:20:08,882 --> 00:20:11,451 OFFICER. BEFORE COMING TO NIDCR 445 00:20:11,451 --> 00:20:12,619 HE WAS THE DIRECTOR OF 446 00:20:12,619 --> 00:20:15,188 MANAGEMENT FOR THE ALL OF US 447 00:20:15,188 --> 00:20:18,358 RESEARCH PROGRAM AND HAS HAD 448 00:20:18,358 --> 00:20:20,793 ROLES WITH NCI, WITH THE 449 00:20:20,793 --> 00:20:23,496 INSTITUTE OF NURSING AND THE NIH 450 00:20:23,496 --> 00:20:28,168 OFFICE OF THE DIRECTOR. OKAY? 451 00:20:28,168 --> 00:20:30,537 PLEASE JOIN ME IN WELCOMING JAY 452 00:20:30,537 --> 00:20:32,438 CHI YOUR REE KNOW TO A NEW ROLE 453 00:20:32,438 --> 00:20:37,644 WHO BECAME THE ACTING SCIENTIFIC 454 00:20:37,644 --> 00:20:39,179 DIRECTOR EARLIER THIS YEAR. HE 455 00:20:39,179 --> 00:20:42,482 PREVIOUSLY SERVED AS THE ACTING 456 00:20:42,482 --> 00:20:46,252 ASSISTANT SCIENTIFIC DIRECTOR 457 00:20:46,252 --> 00:20:51,191 AND HEADS THE 458 00:20:51,191 --> 00:20:53,226 ADDEKNOW-ASSOCIATED VIRUS 459 00:20:53,226 --> 00:20:58,464 SECTION WHO STUDIES DISEASE AND 460 00:20:58,464 --> 00:21:00,934 GENE THERAPY FOR SALLY VARY 461 00:21:00,934 --> 00:21:02,168 GLAND DISORDERS. 462 00:21:02,168 --> 00:21:06,239 ALSO PLEASE JOIN ME IN WELCOMING 463 00:21:06,239 --> 00:21:08,975 IS A KNOW SUE NAY JA WHO IS THE 464 00:21:08,975 --> 00:21:11,211 ACTING DIRECTOR OF THE DIVISION 465 00:21:11,211 --> 00:21:13,646 OF EXTRAMURAL ACTIVITIES WHO IS 466 00:21:13,646 --> 00:21:17,116 HERE ON DETAIL AT NIDCR AND HE 467 00:21:17,116 --> 00:21:18,284 PREVIOUSLY SERVED AS DEPUTY 468 00:21:18,284 --> 00:21:20,520 DIRECTOR OF THE DIVISION OF 469 00:21:20,520 --> 00:21:21,421 EXTRAMURAL ACTIVITIES AT THE 470 00:21:21,421 --> 00:21:23,189 NATIONAL INSTITUTE ON AGING FOR 471 00:21:23,189 --> 00:21:29,495 OTHER A DECADE. 472 00:21:29,495 --> 00:21:31,197 WE ALSO WELCOME MICHELE MCGIRL 473 00:21:31,197 --> 00:21:33,499 WHO JOINED AS CHIEF OF THE 474 00:21:33,499 --> 00:21:35,335 RESEARCH TRAINING AND CAREER 475 00:21:35,335 --> 00:21:37,971 DEVELOPMENT BRANCH AND SERVED AS 476 00:21:37,971 --> 00:21:43,076 ACTING DEA DIRECTOR PRIOR TO 477 00:21:43,076 --> 00:21:46,913 SANA JA'S JOINING. IN TERMS OF 478 00:21:46,913 --> 00:21:48,815 HER JOINING SHE SERVED AS A 479 00:21:48,815 --> 00:21:50,917 PROGRAM DIRECTOR AT NCI AND THEN 480 00:21:50,917 --> 00:21:52,252 SERVED AS ACTING DIVISION 481 00:21:52,252 --> 00:21:54,621 DIRECTOR AND CHIEF OF RESEARCH 482 00:21:54,621 --> 00:21:58,024 ADVANCEMENT PROGRAMS AT NIGMS 483 00:21:58,024 --> 00:21:59,759 PRIOR TO THAT SHE WAS A FACULTY 484 00:21:59,759 --> 00:22:03,162 MEMBER AT THE UNIVERSITY OF 485 00:22:03,162 --> 00:22:07,166 MONTANA. I'D ALSO LIKE TO 486 00:22:07,166 --> 00:22:08,768 WELCOME TYRONE SPAY DID I WHO IS 487 00:22:08,768 --> 00:22:11,204 ACTING CHIEF OF STAFF HERE AT 488 00:22:11,204 --> 00:22:11,504 NIDCR. 489 00:22:11,504 --> 00:22:13,973 HE'D BEEN PREVIOUSLY SENIOR 490 00:22:13,973 --> 00:22:17,343 ADVISOR TO THE NIH DEPUTY 491 00:22:17,343 --> 00:22:20,179 DIRECTOR IN THE NIH OFFICE OF 492 00:22:20,179 --> 00:22:23,182 THE DIRECTOR. AND PRIOR TO 493 00:22:23,182 --> 00:22:25,718 COMING TO NIH HE HELD POSITIONS 494 00:22:25,718 --> 00:22:27,287 IN GOVERNMENT RELATIONS, AND 495 00:22:27,287 --> 00:22:31,791 ALSO IN ADVOCACY FOR THE 496 00:22:31,791 --> 00:22:34,093 FEDERATION OF AMERICA SOCIETY 497 00:22:34,093 --> 00:22:35,495 FOR EXPERIMENTAL BIOLOGY AND 498 00:22:35,495 --> 00:22:38,765 ALSO THE AMERICA SOCIETY FOR 499 00:22:38,765 --> 00:22:41,467 PLANT BIOLOGISTS. WE ALSO 500 00:22:41,467 --> 00:22:44,570 WELCOME GEOFFREY KROOP NICK WHO 501 00:22:44,570 --> 00:22:47,173 JOINED THE NIDCR AS OUR MEDICAL 502 00:22:47,173 --> 00:22:48,608 MONITOR IN THE OFFICE OF 503 00:22:48,608 --> 00:22:50,410 CLINICAL TRIALS OPERATIONS AND 504 00:22:50,410 --> 00:22:53,379 MANAGEMENT. HE OVERSEAS THE 505 00:22:53,379 --> 00:23:00,653 INSTITUTES BOTH EXTRAMURAL AND 506 00:23:00,653 --> 00:23:02,722 INTRAMURAL MEDICAL PROGRAM. HE 507 00:23:02,722 --> 00:23:05,525 WAS THE MEDICAL OFFICE AT THE 508 00:23:05,525 --> 00:23:07,327 NATIONAL INSTITUTE OF CHILD 509 00:23:07,327 --> 00:23:09,962 HEALTH AND HUMAN DEVELOPMENT, 510 00:23:09,962 --> 00:23:12,832 OKAY? AND WE ALSO HAD SEVERAL 511 00:23:12,832 --> 00:23:14,934 RETIREMENTS. AND I WOULD LOVE 512 00:23:14,934 --> 00:23:18,538 TO THANK THESE INDIVIDUALS FOR 513 00:23:18,538 --> 00:23:21,374 THEIR COMMITMENT AND SERVICE TO 514 00:23:21,374 --> 00:23:24,377 NIDCR. AND I WILL NAME JUST A 515 00:23:24,377 --> 00:23:32,218 FEW DR. LYNN KING, DR. LILLIAN. 516 00:23:32,218 --> 00:23:38,691 AND DR. REENA. SOME BUDGET 517 00:23:38,691 --> 00:23:40,126 UPDATES. OKAY? WHEN WE LOOK AT 518 00:23:40,126 --> 00:23:42,395 OUR BUDGET AGAIN, IT IS NOT 519 00:23:42,395 --> 00:23:44,731 CHANGED, WE REMAIN FLAT. OUR 520 00:23:44,731 --> 00:23:49,669 ACTUALS FOR FY24 WERE 520.2 521 00:23:49,669 --> 00:23:53,373 MILLION AND WHERE DID THAT 522 00:23:53,373 --> 00:23:57,543 MUNGO? MOSTLY TO EXTRAMURAL AT 523 00:23:57,543 --> 00:23:59,145 78.4%. 524 00:23:59,145 --> 00:24:00,012 ABOUT 6.5% FOR RESEARCH 525 00:24:00,012 --> 00:24:01,481 MANAGEMENT TO KEEP THE LIGHTS ON 526 00:24:01,481 --> 00:24:05,518 AND 15.1% TO SUPPORT SPRA MURAL 527 00:24:05,518 --> 00:24:13,326 SCIENCE HERE AT NIDCR. WHEN WE 528 00:24:13,326 --> 00:24:15,595 BREAK DOWN FUNDING WE SEE A 529 00:24:15,595 --> 00:24:17,196 LARGE PORTION OF THIS GOES TO 530 00:24:17,196 --> 00:24:20,233 RESEARCH PROJECT GRANTS ABOUT 531 00:24:20,233 --> 00:24:23,169 80%. 3% GOES TO RESEARCH 532 00:24:23,169 --> 00:24:25,905 TRAINING. ABOUT 6% TO RESEARCH 533 00:24:25,905 --> 00:24:32,178 AND DEVELOPMENT CONTRACTS.4% TO 534 00:24:32,178 --> 00:24:37,417 SBIRS AND STTRS AND 7% TO OTHER 535 00:24:37,417 --> 00:24:38,551 RESEARCH EFFORTS. OVER 400 536 00:24:38,551 --> 00:24:41,521 MILLION TO THE EXTRAMURAL 537 00:24:41,521 --> 00:24:44,891 COMMUNITY. AND WE LOOK AT OUR 538 00:24:44,891 --> 00:24:46,025 APPROPRIATIONS HISTORY JUST BACK 539 00:24:46,025 --> 00:24:49,896 FIVE YEARS TO 2020. WE CAN SEE 540 00:24:49,896 --> 00:24:52,665 THAT THE VALUE OF THE DOLLAR IN 541 00:24:52,665 --> 00:24:54,767 TERMS OF SPENDING JUST DOES NOT 542 00:24:54,767 --> 00:24:56,736 STRETCH LIKE IT HAS IN THE PAST. 543 00:24:56,736 --> 00:25:03,176 SO IN 2020 WE WERE AT 477 544 00:25:03,176 --> 00:25:07,613 MILLION, OKAY? WE'RE NOW AT 520 545 00:25:07,613 --> 00:25:09,749 MILLION, HOWEVER, THE 546 00:25:09,749 --> 00:25:12,718 APPROPRIATIONS IN 2020 DOLLARS 547 00:25:12,718 --> 00:25:15,955 ARE ONLY 452 MILLION. SO WHILE 548 00:25:15,955 --> 00:25:18,458 WE'VE HAD SOME INCREASE, OUR 549 00:25:18,458 --> 00:25:22,094 ACTUAL SPENDING POWER HAS 550 00:25:22,094 --> 00:25:24,797 DECREASED HERE AT NIDCR. OKAY? 551 00:25:24,797 --> 00:25:27,500 AND WHEN WE LOOK AT SUCCESS 552 00:25:27,500 --> 00:25:29,569 RATES, WE HAVE DONE EQUAL TO OR 553 00:25:29,569 --> 00:25:31,804 BETTER THAN NIH OVER THE LAST 554 00:25:31,804 --> 00:25:34,474 FIVE YEARS. ENDING LAST YEAR AT 555 00:25:34,474 --> 00:25:44,984 A SUCCESS RATE OF 19.1%. WE 556 00:25:45,852 --> 00:25:48,187 INVEST SIGNIFICANTLY IN DEMO 557 00:25:48,187 --> 00:25:50,189 SCHOOLS. WHILE PROVIDING ABOUT 558 00:25:50,189 --> 00:25:51,824 61% OF DEMO SCHOOL FUNDING THAT 559 00:25:51,824 --> 00:25:54,093 COMES FROM NIH AND WITH THE 560 00:25:54,093 --> 00:25:57,396 OTHER 39% COMING FROM OTHER 561 00:25:57,396 --> 00:25:59,565 INSTITUTES. DEMO SCHOOL FUNDING 562 00:25:59,565 --> 00:26:03,536 ACCOUNTS FOR ABOUT 45% OF -- OR 563 00:26:03,536 --> 00:26:09,075 43% OF OUR TOTAL EXTRAMURAL 564 00:26:09,075 --> 00:26:11,210 BUDGET. NOW WHAT ABOUT OUR 565 00:26:11,210 --> 00:26:13,045 PHASE AND APPROVED CONCEPTS? 566 00:26:13,045 --> 00:26:16,716 OKAY? IF WE LOOK AT WHAT WAS 567 00:26:16,716 --> 00:26:21,320 AWARDED LAST YEAR THERE WAS 568 00:26:21,320 --> 00:26:22,255 SCIENCE ASSOCIATED WITH 569 00:26:22,255 --> 00:26:25,491 UNDERSTANDING COINFECTIONS OF 570 00:26:25,491 --> 00:26:27,927 HPV AND HIV AND THE IMPORTANCE 571 00:26:27,927 --> 00:26:30,696 OF THESE COINFECTIONS IN THE 572 00:26:30,696 --> 00:26:33,099 DEVELOPMENT OF ORAL PHARYNGEAL 573 00:26:33,099 --> 00:26:35,034 CANCERS, THERE WERE FOUR GRANTED 574 00:26:35,034 --> 00:26:36,135 FUNDED IN THAT SPACE. THERE 575 00:26:36,135 --> 00:26:40,239 WERE TWO GRANTS FUNDED TO REALLY 576 00:26:40,239 --> 00:26:42,275 ENGAGE COLLABORATIVE SCIENCE TO 577 00:26:42,275 --> 00:26:43,476 ACHIEVE DISRUPTIVE INNOVATIONS 578 00:26:43,476 --> 00:26:46,212 IN THE DENTAL, ORAL AND 579 00:26:46,212 --> 00:26:48,247 CRANIOFACIAL SPACE AND THERE 580 00:26:48,247 --> 00:26:52,852 WERE FOUR GRANTS FUNDED TO 581 00:26:52,852 --> 00:26:54,754 DEVELOP CELEBRATORY COMPONENTS 582 00:26:54,754 --> 00:26:58,057 AS THERAPEUTICS FOR ORAL HEALTH. 583 00:26:58,057 --> 00:26:59,091 OKAY? THERE WERE THREE SOAR 584 00:26:59,091 --> 00:27:03,129 AWARDS RELATED TO OUTSTANDING 585 00:27:03,129 --> 00:27:04,363 ACHIEVEMENT AND RESEARCH. AND 586 00:27:04,363 --> 00:27:08,034 THERE WAS ONE UC 2 AWARD FOCUSED 587 00:27:08,034 --> 00:27:10,503 ON STRENGTHENING RESEARCH 588 00:27:10,503 --> 00:27:12,271 OPPORTUNITIES FOR NIH GRANTS. 589 00:27:12,271 --> 00:27:14,907 TO HELP WITH RESOURCE LIMITED 590 00:27:14,907 --> 00:27:17,176 INSTITUTIONS. AND THIS WAS 591 00:27:17,176 --> 00:27:22,381 ACTUALLY LED BY NIMHD. WHEN WE 592 00:27:22,381 --> 00:27:27,186 LOOK AT WHAT'S CURRENTLY THERE, 593 00:27:27,186 --> 00:27:31,190 WE HAVE ORGAN ON A CHIP AND 594 00:27:31,190 --> 00:27:34,994 DENTAL, ORAL AND CRANIOFACIAL 595 00:27:34,994 --> 00:27:38,497 RESEARCH AND THERE ARE R 01S AND 596 00:27:38,497 --> 00:27:40,499 R 21S AVAILABLE THERE. THERE'S 597 00:27:40,499 --> 00:27:43,169 ALSO THE REISSUE OF THE 598 00:27:43,169 --> 00:27:44,170 COLLABORATIVE SCIENCE TO ACHIEVE 599 00:27:44,170 --> 00:27:46,739 RIS RUNTIVE INNOVATIONS IN 600 00:27:46,739 --> 00:27:48,240 DENTAL, ORAL AND CRANIOFACIAL 601 00:27:48,240 --> 00:27:51,711 RESEARCH AND ALSO TMD IMPACT. 602 00:27:51,711 --> 00:27:54,747 FOCUSED ON TMD COLLABORATIVE 603 00:27:54,747 --> 00:27:56,415 THAT WILL IMPROVE PATIENT 604 00:27:56,415 --> 00:27:57,717 CENTERED TRANSLATIONAL RESEARCH. 605 00:27:57,717 --> 00:28:00,386 THESE ARE THE THREE FROM NIDCR, 606 00:28:00,386 --> 00:28:02,321 OKAY? AND THEN THERE ARE THREE 607 00:28:02,321 --> 00:28:04,724 CURRENT RFAS THAT OTHER 608 00:28:04,724 --> 00:28:06,626 INSTITUTES ARE LEADING OUT ON. 609 00:28:06,626 --> 00:28:08,728 THIS INCLUDES THE RARE DISEASES, 610 00:28:08,728 --> 00:28:11,197 CLINICAL RESEARCH CONSORTIA FOR 611 00:28:11,197 --> 00:28:15,167 RARE DISEASE CLINICAL RESEARCH 612 00:28:15,167 --> 00:28:19,105 NETWORK, NCATS IS LEADING OUT 613 00:28:19,105 --> 00:28:21,440 THERE. THERE'S THE PEDIATRIC 614 00:28:21,440 --> 00:28:22,241 COHORT STUDY AND THE WHOLE 615 00:28:22,241 --> 00:28:25,978 PERSON RESEARCH AND COORDINATION 616 00:28:25,978 --> 00:28:28,514 CENTER THAT'S FUND -- THAT NCCIH 617 00:28:28,514 --> 00:28:30,082 OR THE CENTER FOR COMPLEMENTARY 618 00:28:30,082 --> 00:28:34,186 HEALTH IS LEADING OUT ON. OKAY? 619 00:28:34,186 --> 00:28:35,788 I'D ALSO LIKE TO SHARE CONCEPTS 620 00:28:35,788 --> 00:28:40,693 THAT ARE APPROVED BY COUNCIL. 621 00:28:40,693 --> 00:28:43,195 THESE HAVE NOT BEEN RELEASED YET 622 00:28:43,195 --> 00:28:45,131 BUT JUST TO SHARE WITH YOU WHAT 623 00:28:45,131 --> 00:28:48,401 THE CONCEPTS ARE. THEY ARE 624 00:28:48,401 --> 00:28:51,170 EXCITING. AND WELL-ALIGNED WITH 625 00:28:51,170 --> 00:28:53,305 OUR STRATEGIC PLAN AS YOU CAN 626 00:28:53,305 --> 00:28:55,341 SEE IN PURPLE OUR STRATEGIC 627 00:28:55,341 --> 00:28:58,177 PRIORITIES. SO THE FIRST IS TO 628 00:28:58,177 --> 00:29:01,180 ADVANCE PRECISION IMAGING FOR 629 00:29:01,180 --> 00:29:01,947 ENHANCED DIAGNOSIS AND TREATMENT 630 00:29:01,947 --> 00:29:04,250 OF ORAL LESIONS. THE SECOND IS 631 00:29:04,250 --> 00:29:10,156 TO BE ABLE TO MOOD MODULATE THE 632 00:29:10,156 --> 00:29:12,358 MICROBIOME TOWARDS HEALTH. 633 00:29:12,358 --> 00:29:16,195 OKAY? THIRD IS TO INTEGRATE 634 00:29:16,195 --> 00:29:17,563 MEDICALLY NECESSARY PREVENTION 635 00:29:17,563 --> 00:29:21,167 TREATMENT AND MONITORING OF 636 00:29:21,167 --> 00:29:23,569 ONCOLOGIC RELATED ORAL, DENTAL 637 00:29:23,569 --> 00:29:25,938 AND CRANIOFACIAL COMPLICATIONS 638 00:29:25,938 --> 00:29:30,910 BECAUSE AS YOU KNOW, ANY CANCER 639 00:29:30,910 --> 00:29:33,179 ANYWHERE, TREATED WITH 640 00:29:33,179 --> 00:29:34,914 CHEMOTHERAPY THOSE THERAPIES CAN 641 00:29:34,914 --> 00:29:36,082 IMPACT ORAL CAVITY. THERE'S 642 00:29:36,082 --> 00:29:39,852 ALSO COMMUNITY ENGAGED RESEARCH 643 00:29:39,852 --> 00:29:41,587 TO ADVANCE ORAL HEALTH 644 00:29:41,587 --> 00:29:43,789 INTERVENTION MODEL AND A DIGITAL 645 00:29:43,789 --> 00:29:47,193 TWINS CONCEPT THAT IS FOCUSED ON 646 00:29:47,193 --> 00:29:48,627 ADVANCING INNOVATION AND 647 00:29:48,627 --> 00:29:50,596 OPTIMIZING CLINICAL OUTCOMES IN 648 00:29:50,596 --> 00:29:52,732 DENTAL, ORAL AND CRANE OWE 649 00:29:52,732 --> 00:29:54,867 OFFICIAL MEDICINE. AND FINALLY, 650 00:29:54,867 --> 00:29:58,237 THE DENTAL PRIMARY CARE PRACTICE 651 00:29:58,237 --> 00:29:59,839 SPACE RESEARCH NETWORK TO 652 00:29:59,839 --> 00:30:03,909 SUPPORT RESEARCH IN CLINICAL 653 00:30:03,909 --> 00:30:09,648 PRACTICES. OKAY? ONE COMMON 654 00:30:09,648 --> 00:30:11,550 THEME ACROSS ALL OF THESE IS 655 00:30:11,550 --> 00:30:13,552 PARTNERING AND COLLABORATING 656 00:30:13,552 --> 00:30:15,721 WHERE WE'RE WORKING WITH OTHER 657 00:30:15,721 --> 00:30:17,490 INSTITUTES TO MOVE THIS FORWARD: 658 00:30:17,490 --> 00:30:19,358 OTHER NOTICES AND INITIATIVES 659 00:30:19,358 --> 00:30:26,165 FROM NIDCR. NOTICES ANDI II IS 660 00:30:26,165 --> 00:30:27,533 INITIATIVES COME IN THE FORM OF 661 00:30:27,533 --> 00:30:28,901 THESE FUNDING OPPORTUNITIES. 662 00:30:28,901 --> 00:30:31,070 AND TO SHARE WITH YOU MOVING 663 00:30:31,070 --> 00:30:33,272 FORWARD THERE'LL BE FEWER OF 664 00:30:33,272 --> 00:30:38,010 THESE AS NIH IS WORKING TO 665 00:30:38,010 --> 00:30:40,546 CONSOLIDATE AND HAVE BROADER 666 00:30:40,546 --> 00:30:44,650 UMBRELLA NOFOS THAT MULTIPLE 667 00:30:44,650 --> 00:30:46,285 INSTITUTES ARE ABLE TO SIGN 668 00:30:46,285 --> 00:30:47,419 ONTO. I WILL SHARE WITH YOU 669 00:30:47,419 --> 00:30:48,687 WHAT WE HAVE COMING DOWN THE 670 00:30:48,687 --> 00:30:49,588 PIKE BUT JUST RECOGNIZE THAT 671 00:30:49,588 --> 00:30:54,693 MOVING TO -- FORWARD YOU'LL SEE 672 00:30:54,693 --> 00:30:56,595 FEWER OF THESE AVAILABLE TO THE 673 00:30:56,595 --> 00:30:59,098 COMMUNITY BUT THOSE 674 00:30:59,098 --> 00:31:00,099 OPPORTUNITIES STILL EXIST WITHIN 675 00:31:00,099 --> 00:31:05,304 THE UMBRELLA CONCEPT NIDCR WILL 676 00:31:05,304 --> 00:31:07,173 BE THERE. 677 00:31:07,173 --> 00:31:10,242 SO THE FIRST ONE, FIRST SET OF 678 00:31:10,242 --> 00:31:11,710 FUNDING OPPORTUNITIES I WOULD 679 00:31:11,710 --> 00:31:14,013 LIKE TO FOCUS ON ARE THOSE 680 00:31:14,013 --> 00:31:16,081 ASSOCIATED WITH CLINICAL TRIALS. 681 00:31:16,081 --> 00:31:17,683 OKAY? AND THESE ARE COMING UP, 682 00:31:17,683 --> 00:31:22,121 LIKE IN THE NEXT WEEK. WITH THE 683 00:31:22,121 --> 00:31:26,292 FIRST ONE FOCUSED ON DRUG 684 00:31:26,292 --> 00:31:29,161 BIOLOGIC DEVICE AND/OR PROCEDURE 685 00:31:29,161 --> 00:31:29,762 INTERVENTION CLINICAL TRIAL 686 00:31:29,762 --> 00:31:32,565 PLANNING AND IMPLEMENTATION. 687 00:31:32,565 --> 00:31:34,300 OKAY? FOR NEW APPLICATIONS, 688 00:31:34,300 --> 00:31:36,802 THAT'S DUE JUNE 6TH. THE NEXT 689 00:31:36,802 --> 00:31:40,539 ONE IS FOCUSED ON BEHAVIORAL AND 690 00:31:40,539 --> 00:31:41,674 SOCIAL INTERVENTION CLINICAL 691 00:31:41,674 --> 00:31:44,677 TRIAL PLANNING AND 692 00:31:44,677 --> 00:31:45,177 IMPLEMENTATION. THIS 693 00:31:45,177 --> 00:31:47,179 APPLICATION FOR THIS COOPERATIVE 694 00:31:47,179 --> 00:31:50,549 AGREEMENT IS ALSO DUE JUNE 6TH 695 00:31:50,549 --> 00:31:54,053 FOR NEW APPLICATIONS. AND DUE 696 00:31:54,053 --> 00:31:58,724 IN JULY ARE CONTINUATION OR 697 00:31:58,724 --> 00:31:59,692 REVISION OF CLINICAL TRIAL 698 00:31:59,692 --> 00:32:03,162 PLANNING AND IMPLEMENTATION. 699 00:32:03,162 --> 00:32:06,098 COOPERATIVE AGREEMENTS. SO 700 00:32:06,098 --> 00:32:09,368 THAT'S CLINICAL TRIALS RELATED 701 00:32:09,368 --> 00:32:13,739 TO HEAL INITIATIVES THAT ARE 702 00:32:13,739 --> 00:32:15,641 PAIN FOCUSED WHERE NIDCR IS 703 00:32:15,641 --> 00:32:18,043 INVOLVED. LET'S SEE, WE JUST 704 00:32:18,043 --> 00:32:21,780 PASSED ONE, FOCUSED ON ANALGESIC 705 00:32:21,780 --> 00:32:24,283 DISCOVERY. COMING UP IN OCTOBER 706 00:32:24,283 --> 00:32:27,186 IS THE PAIN RESEARCH ENHANCEMENT 707 00:32:27,186 --> 00:32:29,688 PROGRAM INITIATIVE AND THAT IS 708 00:32:29,688 --> 00:32:33,626 DUE OCTOBER 28TH AND ALSO COMING 709 00:32:33,626 --> 00:32:41,700 UP IN JUNE IS THE EARLY STAGE 710 00:32:41,700 --> 00:32:43,202 DISCOVERY PAIN TARGETS WITHIN 711 00:32:43,202 --> 00:32:45,804 THE DRUGGABLE PROTEOME AND THIS 712 00:32:45,804 --> 00:32:50,075 IS DUE JUNE 16TH. AND THE SPACE 713 00:32:50,075 --> 00:32:54,280 OF HIV/AIDS THERE'S BASIC AND 714 00:32:54,280 --> 00:32:55,147 TRANSLATIONAL ORAL HEALTH 715 00:32:55,147 --> 00:32:59,184 RESEARCH RELATED TO THE SYSTEMIC 716 00:32:59,184 --> 00:33:02,288 CONDITION. WITH R 01S DUE IN 717 00:33:02,288 --> 00:33:08,661 JUNE. JUNE 5TH. AND R 21S DUE 718 00:33:08,661 --> 00:33:13,933 JUNE 16TH. THE FOCUS HERE ARE 719 00:33:13,933 --> 00:33:17,469 BASIC STUDIES THAT INVOLVE 720 00:33:17,469 --> 00:33:26,645 HUMANS. OKAY? THIS IS A NOTICE 721 00:33:26,645 --> 00:33:28,013 OF EXPIRATION AND IS NO LONGER 722 00:33:28,013 --> 00:33:30,950 GOING TO BE COVERED. THIS IS ON 723 00:33:30,950 --> 00:33:33,118 CORONAVIRUS DISEASE. THE 724 00:33:33,118 --> 00:33:35,187 INVOLVEMENT OF THE ORAL CAVITY 725 00:33:35,187 --> 00:33:36,288 IN CORONAVIRUS DISEASE WILL NOT 726 00:33:36,288 --> 00:33:39,658 BE MOVING FORWARD. OKAY? WE 727 00:33:39,658 --> 00:33:42,528 ALSO HAVE SOME NOTICES OF 728 00:33:42,528 --> 00:33:47,066 FUNDING OPPORTUNITIES RELATED TO 729 00:33:47,066 --> 00:33:48,434 TRANSLATIONAL RESEARCH. OKAY? 730 00:33:48,434 --> 00:33:50,202 ALL OF THESE ARE ALSO DUE IN 731 00:33:50,202 --> 00:33:52,471 JUNE OF THIS YEAR WITH THE FIRST 732 00:33:52,471 --> 00:33:55,841 ONE FOCUSED ON, IT'S A CTSA 733 00:33:55,841 --> 00:33:58,310 AWARD, FOCUSED ON COLLABORATIVE 734 00:33:58,310 --> 00:34:00,846 AND INNOVATIVE ACCELERATION, THE 735 00:34:00,846 --> 00:34:02,281 SECOND ONE FOCUSED ON 736 00:34:02,281 --> 00:34:05,451 EXPLORATORY AND DEVELOPMENTAL 737 00:34:05,451 --> 00:34:09,755 BUY GROW ENGINEERING AND OF 738 00:34:09,755 --> 00:34:12,524 COURSE ITS APPLICATION TO DOC 739 00:34:12,524 --> 00:34:13,959 AND THE NIDCR PERSPECTIVE 740 00:34:13,959 --> 00:34:15,527 OBSERVATIONAL AND BIOMARKER 741 00:34:15,527 --> 00:34:17,763 VALIDATION STUDIES. ARE ALSO 742 00:34:17,763 --> 00:34:22,301 DUE IN JUNE OF THIS YEAR. OKAY? 743 00:34:22,301 --> 00:34:26,872 WITH REGARD TO DATA ANALYSIS, 744 00:34:26,872 --> 00:34:28,440 OKAY, THERE IS A SMALL RESEARCH 745 00:34:28,440 --> 00:34:31,543 GRANT FOCUSED ON ORAL HEALTH 746 00:34:31,543 --> 00:34:35,014 DATA ANALYSIS AND STATISTICAL 747 00:34:35,014 --> 00:34:35,714 METHODOLOGY DEVELOPMENT. THIS 748 00:34:35,714 --> 00:34:39,718 IS AN R 03. IT'S ALSO DUE JUNE 749 00:34:39,718 --> 00:34:44,390 16TH OF THIS YEAR. AND WE HAVE 750 00:34:44,390 --> 00:34:47,159 ANALYSIS FOR EXISTING GENOMICS 751 00:34:47,159 --> 00:34:50,596 DATA BOTH A SMALL GRANT, R 03 752 00:34:50,596 --> 00:34:53,699 DUE IN JUNE, AND THEN AN R 01 753 00:34:53,699 --> 00:34:55,467 EFFORT THAT'S DUE ALSO IN JUNE 754 00:34:55,467 --> 00:34:59,905 BUT THE APPLICATION DATES ARE 755 00:34:59,905 --> 00:35:02,374 DIFFERENT. WITH THE SMALL GRANT 756 00:35:02,374 --> 00:35:05,244 BEING DUE ON THE 16TH AND THE R 757 00:35:05,244 --> 00:35:10,449 01 DUE ON JUNE 5TH. OKAY? AS 758 00:35:10,449 --> 00:35:11,483 WE'RE SPEAKING ABOUT DATA I JUST 759 00:35:11,483 --> 00:35:13,452 WANT TO SHARE WITH YOU THE 760 00:35:13,452 --> 00:35:17,589 LAUNCH EARLIER THIS YEAR OF THE 761 00:35:17,589 --> 00:35:20,492 DDS HUB WHICH STANDS FOR 762 00:35:20,492 --> 00:35:21,794 DATA-DRIVEN SCIENCE. AND THE 763 00:35:21,794 --> 00:35:25,431 PUN IS INTENDED. DDS HUB PLEASE 764 00:35:25,431 --> 00:35:31,170 GO THERE AND DDS HUB NIH.GOV AND 765 00:35:31,170 --> 00:35:33,238 WITHIN THIS HUB, WE HOPE TO HELP 766 00:35:33,238 --> 00:35:34,706 MOVE FORWARD DATA-DRIVEN 767 00:35:34,706 --> 00:35:37,042 DISCOVERY THAT WILL IMPROVE 768 00:35:37,042 --> 00:35:40,579 HEALTH FOR ALL. THIS HUB IS 769 00:35:40,579 --> 00:35:41,780 CENTERED ON COMMUNITY 770 00:35:41,780 --> 00:35:44,283 ENGAGEMENT, ON COLLABORATION AND 771 00:35:44,283 --> 00:35:47,686 DISSEMINATION AND IS REALLY A 772 00:35:47,686 --> 00:35:52,057 ONE-STOP SHOP HERE FOR DATA, 773 00:35:52,057 --> 00:35:53,725 SHARING AND MANAGEMENT, HOW TO 774 00:35:53,725 --> 00:35:56,061 DO IT, SO WE CAN MAKE SURE THAT 775 00:35:56,061 --> 00:35:58,831 WE ARE PROMOTING TRANSPARENCY, 776 00:35:58,831 --> 00:36:02,734 REPRODUCIBILITY AND DATA REUSE. 777 00:36:02,734 --> 00:36:05,771 AND THEN TAKING THESE DATA AND 778 00:36:05,771 --> 00:36:10,542 UTILIZING IT TO HELP DEVELOP NEW 779 00:36:10,542 --> 00:36:11,777 INFORMATION, NEW DATA, USING 780 00:36:11,777 --> 00:36:14,279 GUIDELINES TO GENERATE FAIR DATA 781 00:36:14,279 --> 00:36:16,215 WITHIN STANDARDIZED THE 782 00:36:16,215 --> 00:36:17,583 TERMINOLOGIES AND COMMON DATA 783 00:36:17,583 --> 00:36:18,283 ELEMENTS. 784 00:36:18,283 --> 00:36:19,751 OKAY IN THAT ALSO ARE 785 00:36:19,751 --> 00:36:21,487 CLOUD-BASED ANALYTIC RESOURCES 786 00:36:21,487 --> 00:36:23,755 THERE. SO YOU CAN BRING THESE 787 00:36:23,755 --> 00:36:26,325 DATA TOGETHER AND ASK NEW 788 00:36:26,325 --> 00:36:29,628 QUESTIONS IN THE CLOUD AND HERE 789 00:36:29,628 --> 00:36:32,464 WE'RE COLLABORATING WITH NIGMS 790 00:36:32,464 --> 00:36:35,200 AND NINHD TO BRING IN 791 00:36:35,200 --> 00:36:40,105 COMPUTATION PAL -- RESOURCES 792 00:36:40,105 --> 00:36:42,374 THAT ARE LOW CODE. AND THERE'S 793 00:36:42,374 --> 00:36:45,777 ALSO DATA CURATION AND REUSE. 794 00:36:45,777 --> 00:36:46,378 WITH OPPORTUNITIES FOR SELF 795 00:36:46,378 --> 00:36:49,681 CURATION SO AS THE DATA GOES IN 796 00:36:49,681 --> 00:36:51,950 IT'LL BE AI AND MACHINE LEARNING 797 00:36:51,950 --> 00:36:54,553 READY TO GO. SO OPPORTUNITIES 798 00:36:54,553 --> 00:36:56,989 TO CURATE EXISTING POPULATION 799 00:36:56,989 --> 00:36:58,590 LEVEL DATA, DOWN TO THE 800 00:36:58,590 --> 00:36:59,958 MOLECULAR DATA ALL THE WAY 801 00:36:59,958 --> 00:37:01,760 THROUGH FROM THE MOLECULE TO THE 802 00:37:01,760 --> 00:37:04,630 MASSES. SO ALL TYPES OF DATA 803 00:37:04,630 --> 00:37:07,166 THERE. AND THERE'LL ALSO BE 804 00:37:07,166 --> 00:37:08,400 INFORMATION FOR YOU THERE. 805 00:37:08,400 --> 00:37:09,935 INFORMATION THAT WILL LET YOU 806 00:37:09,935 --> 00:37:11,737 KNOW ABOUT WHAT'S COMING UP WITH 807 00:37:11,737 --> 00:37:13,505 REGARD TO GRANTS AND FUNDING 808 00:37:13,505 --> 00:37:15,174 OPPORTUNITIES THAT ARE RELATED 809 00:37:15,174 --> 00:37:18,911 TO DATA AND DATA-DRIVEN SCIENCE. 810 00:37:18,911 --> 00:37:21,580 WE'VE BEEN WORKING TO 811 00:37:21,580 --> 00:37:23,081 COLLABORATE WITH MANY GROUPS AND 812 00:37:23,081 --> 00:37:25,350 SO YOU SEE JUST A SNAPSHOT ON 813 00:37:25,350 --> 00:37:26,785 THE RIGHT SIDE OF THE SLIDE OF 814 00:37:26,785 --> 00:37:29,188 THE TYPES OF DATA THAT ARE 815 00:37:29,188 --> 00:37:31,190 THERE. THERE'S DATA FROM ALL OF 816 00:37:31,190 --> 00:37:33,625 US FROM THE WISCONSIN 817 00:37:33,625 --> 00:37:35,160 COLLABORATIVE, FROM THE AMERICAN 818 00:37:35,160 --> 00:37:36,695 DENTAL ASSOCIATION FROM THE BIG 819 00:37:36,695 --> 00:37:38,697 MOUTH REPOSITORY AND APPLE TREE 820 00:37:38,697 --> 00:37:43,168 DENTAL AND OTHERS. SO THAT'S A 821 00:37:43,168 --> 00:37:44,870 SNAPSHOT OF SOME OF THE HUMAN 822 00:37:44,870 --> 00:37:45,037 DA. 823 00:37:45,037 --> 00:37:47,339 BUT THERE ARE ALSO DATA THAT 824 00:37:47,339 --> 00:37:51,176 COME FROM COMPARATIVE GENOMES, 825 00:37:51,176 --> 00:37:56,782 FROM ZEBRAFISH ON UP TO HUMANS. 826 00:37:56,782 --> 00:38:00,085 AND OTHER TYPES OF DATA. SO 827 00:38:00,085 --> 00:38:02,354 TAKE A VISIT TO THE HUB, HERE IS 828 00:38:02,354 --> 00:38:05,023 THE QR CODE HERE AND WHAT YOU'LL 829 00:38:05,023 --> 00:38:07,059 SEE IS THAT WE HERE ARE VERY 830 00:38:07,059 --> 00:38:09,428 ALIGNED WITH THE NIH STRATEGIC 831 00:38:09,428 --> 00:38:13,365 PLAN FOR DATA SCIENCE. SO I 832 00:38:13,365 --> 00:38:16,235 INVITE YOU TO EXPLORE AND TO 833 00:38:16,235 --> 00:38:17,469 TAKE ADVANTAGE AND TO UTILIZE 834 00:38:17,469 --> 00:38:21,707 THE SITE TO REMAIN IN COMPLIANCE 835 00:38:21,707 --> 00:38:24,843 WITH DATA MANAGEMENT AND 836 00:38:24,843 --> 00:38:26,645 SHARING. OKAY? THERE ARE ALSO 837 00:38:26,645 --> 00:38:29,648 SOME SIGNIFICANT ANNOUNCEMENTS 838 00:38:29,648 --> 00:38:34,953 RELATED TO TRAINING. OKAY? SO 839 00:38:34,953 --> 00:38:37,322 OPPORTUNITIES TO COMBAT TO 840 00:38:37,322 --> 00:38:39,891 CAMPUS HERE AT NIH HAS OPENED 841 00:38:39,891 --> 00:38:42,961 BACK UP. SO WE'VE RESTARTED 842 00:38:42,961 --> 00:38:44,496 RECRUITMENT FOR INTRAMURAL 843 00:38:44,496 --> 00:38:45,998 RESEARCH TRAINING AWARDS AND 844 00:38:45,998 --> 00:38:48,700 ALSO FOR THE NCI CANCER RESEARCH 845 00:38:48,700 --> 00:38:52,170 TRAINING PROGRAM SO THE HIRING 846 00:38:52,170 --> 00:38:54,039 MECHANISMS ARE IN PLACE FOR 847 00:38:54,039 --> 00:38:59,177 POSTDOCS FOR PREDOCS AND FOR 848 00:38:59,177 --> 00:39:02,247 POSTBACS WHO HAVE U.S. 849 00:39:02,247 --> 00:39:03,682 CITIZENSHIP OR PERMANENT 850 00:39:03,682 --> 00:39:06,885 RESIDENCY THE REQUIRING WAS 851 00:39:06,885 --> 00:39:08,787 PAUSED IN JANUARY BUT NOW 852 00:39:08,787 --> 00:39:11,123 REOPENED IN APRIL. SO IF YOU'RE 853 00:39:11,123 --> 00:39:12,724 INTERESTED, PLEASE APPLY, AND WE 854 00:39:12,724 --> 00:39:14,793 LOOK FORWARD TO HAVING YOU. 855 00:39:14,793 --> 00:39:16,628 OKAY? THERE HAVE BEEN A 856 00:39:16,628 --> 00:39:18,530 SIGNIFICANT NUMBER OF CHANGE TO 857 00:39:18,530 --> 00:39:20,966 THE TRAINING NOTICES. OKAY? WE 858 00:39:20,966 --> 00:39:25,671 ARE GOING TO BE PARTICIPATING IN 859 00:39:25,671 --> 00:39:31,743 A PARENT AWARD MECHANISMS. 860 00:39:31,743 --> 00:39:34,146 THESE INCLUDE SEVERAL, ALL OF 861 00:39:34,146 --> 00:39:40,552 THE F TYPE NOFOS, THE F 30, 31, 862 00:39:40,552 --> 00:39:44,022 32, 33 AND THE NOFOS ARE IN 863 00:39:44,022 --> 00:39:46,091 PREPARATION FOR AUGUST DUE 864 00:39:46,091 --> 00:39:49,227 DATES. THE KEY HERE IS THAT YOU 865 00:39:49,227 --> 00:39:51,897 MUST USE FORM I. THIS IS A NEW 866 00:39:51,897 --> 00:39:53,332 FORM. OKAY? SO THOSE, THAT'S 867 00:39:53,332 --> 00:39:57,302 THE FORM THAT MUST BE UTILIZED. 868 00:39:57,302 --> 00:39:59,771 OKAY? FOR THOSE WHO ARE MAKING 869 00:39:59,771 --> 00:40:03,208 THE TRANSITION FROM PREDOC TO 870 00:40:03,208 --> 00:40:07,079 POSTDOC THAT FELLOWSHIP AWARD, 871 00:40:07,079 --> 00:40:09,548 NIDCR WILL BE PARTICIPATING IN 872 00:40:09,548 --> 00:40:11,750 THE PARENT F99 K 00. WE WON'T 873 00:40:11,750 --> 00:40:13,752 HAVE A SEPARATE ONE. WE'LL 874 00:40:13,752 --> 00:40:15,654 PARTICIPATE IN THIS PARENT AWARD 875 00:40:15,654 --> 00:40:19,391 THAT'S BEING DEVELOPED. OKAY? 876 00:40:19,391 --> 00:40:23,161 WE ARE ALREADY PARTICIPATING IN 877 00:40:23,161 --> 00:40:25,364 PARENT AWARDS FOR THE K SERIES. 878 00:40:25,364 --> 00:40:31,236 K 01, K 02, K08, K23, K25 AND 879 00:40:31,236 --> 00:40:35,574 THE K99 R 00 NOTICES. OKAY? 880 00:40:35,574 --> 00:40:38,110 AND RELATED TO THE DUAL DEGREE 881 00:40:38,110 --> 00:40:41,446 SCIENTISTS PATHWAY TO 882 00:40:41,446 --> 00:40:42,080 INDEPENDENCE AWARD THE 883 00:40:42,080 --> 00:40:46,318 ANTICIPATED FIRST DUE DATE IS 884 00:40:46,318 --> 00:40:47,486 JULY 12TH. 885 00:40:47,486 --> 00:40:50,021 SO THIS SUMMER OF 2025 AND 886 00:40:50,021 --> 00:40:53,859 FINALLY THE NRSA INSTITUTIONAL 887 00:40:53,859 --> 00:40:55,627 RESEARCH TRAINING GRANTS WHICH 888 00:40:55,627 --> 00:40:58,597 IS A PARENT T32, THE NEXT DUE 889 00:40:58,597 --> 00:40:59,464 DATE FOR THAT WILL BE IN 890 00:40:59,464 --> 00:41:00,899 SEPTEMBER OF THIS YEAR. OKAY? 891 00:41:00,899 --> 00:41:04,136 SO A LOT OF CHANGES RELATED TO 892 00:41:04,136 --> 00:41:05,537 TRAINING, AND PLEASE TAKE A LOOK 893 00:41:05,537 --> 00:41:09,374 AT THE WEBSITE FOR ADDITIONAL 894 00:41:09,374 --> 00:41:11,843 INFORMATION THERE. OKAY? SOME 895 00:41:11,843 --> 00:41:14,446 ADDITIONAL CHANGES HERE ARE THE 896 00:41:14,446 --> 00:41:16,415 TRANSITION AWARD FROM THE DENTAL 897 00:41:16,415 --> 00:41:19,184 SCIENTISTS CAREER AWARD. THAT 898 00:41:19,184 --> 00:41:23,855 IS NEXT DUE IN JUNE 12TH FOR NEW 899 00:41:23,855 --> 00:41:24,790 APPLICATIONS. THERE'S ALSO 900 00:41:24,790 --> 00:41:26,324 OPPORTUNITIES WITH REGARD TO THE 901 00:41:26,324 --> 00:41:28,760 SMALL GRANT PROGRAM FOR NEW 902 00:41:28,760 --> 00:41:30,462 INVESTIGATORS. THESE ARE R 03 903 00:41:30,462 --> 00:41:32,497 AWARDS THOSE ARE ALSO DUE IN 904 00:41:32,497 --> 00:41:35,834 JUNE. OKAY? AND THEN FINALLY, 905 00:41:35,834 --> 00:41:38,637 WE HAVE THE RESEARCH ENHANCEMENT 906 00:41:38,637 --> 00:41:39,671 AWARD PROGRAM FOR HEALTH 907 00:41:39,671 --> 00:41:41,206 PROFESSIONAL SCHOOLS AND 908 00:41:41,206 --> 00:41:43,241 GRADUATE SCHOOLS. THAT'S THE 909 00:41:43,241 --> 00:41:46,411 R15. AND THAT'S ALSO DUE IN 910 00:41:46,411 --> 00:41:51,249 JUNE ON JUNE 25TH FOR NEW 911 00:41:51,249 --> 00:41:53,018 APPLICATIONS. OKAY? AND THEN 912 00:41:53,018 --> 00:41:57,222 WE HAVE THE R 25 RESEARCH 913 00:41:57,222 --> 00:42:00,325 EDUCATION AWARD. THIS IS THE 914 00:42:00,325 --> 00:42:01,693 SCIENCE PARTNERSHIP EDUCATION 915 00:42:01,693 --> 00:42:02,928 AWARD EXPERIENCE. OH, WAIT A 916 00:42:02,928 --> 00:42:04,996 MINUTE, THE RESEARCH EDUCATION 917 00:42:04,996 --> 00:42:11,203 AWARD IS NEXT DUE MARCH 17TH. 918 00:42:11,203 --> 00:42:16,174 THE SEPA AWARD WE EXPECT TO 919 00:42:16,174 --> 00:42:17,876 PARTICIPATE IN. IT'S NOW UNDER 920 00:42:17,876 --> 00:42:19,177 DEVELOPMENT SO KEEP YOUR EYES 921 00:42:19,177 --> 00:42:22,314 OPEN FOR THAT. THIS HELPS TO 922 00:42:22,314 --> 00:42:23,882 SUPPORT EDUCATIONAL ACTIVITIES 923 00:42:23,882 --> 00:42:26,718 FROM PRESCHOOL UP TO K-12. SO 924 00:42:26,718 --> 00:42:29,054 NOT ONLY FOR THE STUDENTS BUT 925 00:42:29,054 --> 00:42:30,789 ALSO THE TEACHERS TO MAKE SURE 926 00:42:30,789 --> 00:42:33,792 THAT PEOPLE KNOW THAT THERE ARE 927 00:42:33,792 --> 00:42:34,659 OPPORTUNITIES THAT THEY TOO CAN 928 00:42:34,659 --> 00:42:38,029 BE A DENTIST OR A DENTAL 929 00:42:38,029 --> 00:42:38,663 RESEARCHER. OF COURSE THAT'S 930 00:42:38,663 --> 00:42:42,968 OUR INTERESTS BUT THE BROADER 931 00:42:42,968 --> 00:42:47,873 INTEREST IS IN PURSUANCE OF STEM 932 00:42:47,873 --> 00:42:50,909 CAREERS, OKAY? THERE HAVE ALSO 933 00:42:50,909 --> 00:42:53,645 BEEN AN UPDATE IN PROCEDURES AND 934 00:42:53,645 --> 00:42:56,014 RELATED TO CHILD CARE COSTS SO 935 00:42:56,014 --> 00:42:58,283 RIGHT NOW THE ANNUAL CHILD CARE 936 00:42:58,283 --> 00:43:01,353 COSTS ARE ABOUT 3,000 DOLLARS 937 00:43:01,353 --> 00:43:08,727 FOR FULL-TIME APPOINTMENT SLOTS. 938 00:43:08,727 --> 00:43:10,896 OKAY. NOW WHEN THE AWARD IS 939 00:43:10,896 --> 00:43:12,898 AWARDED THEY ARE RESTRICTED TO 940 00:43:12,898 --> 00:43:16,101 CHILD CARE EXPENSES. SO IF 941 00:43:16,101 --> 00:43:17,602 THOSE FUNDS AREN'T USED, THEY 942 00:43:17,602 --> 00:43:20,472 JUST NEED TO BE REPORTED AS AN 943 00:43:20,472 --> 00:43:21,640 UNOBLIGATED BALANCE. THEY 944 00:43:21,640 --> 00:43:28,747 CANNOT BE REBUDGETED. OKAY? 945 00:43:28,747 --> 00:43:29,881 THERE'S ALSO BEEN SOME CHANGED 946 00:43:29,881 --> 00:43:32,517 TO THE FELLOWSHIP REVIEW 947 00:43:32,517 --> 00:43:32,817 CRITERIA. 948 00:43:32,817 --> 00:43:34,819 THIS IS AN ALIGNMENT WITH THE 949 00:43:34,819 --> 00:43:37,255 SIMPLIFIED REVIEW PROCESS THAT I 950 00:43:37,255 --> 00:43:41,226 SHARED THE LAST TIME WE SPOKE 951 00:43:41,226 --> 00:43:44,296 LAST FALL. BUT JUST TO LET YOU 952 00:43:44,296 --> 00:43:47,165 ALL KNOW THAT THE FOCUS HERE IN 953 00:43:47,165 --> 00:43:50,201 THE FELLOWSHIP REVIEW IS TO MAKE 954 00:43:50,201 --> 00:43:53,171 SURE THAT THE MOST PROMISING 955 00:43:53,171 --> 00:43:53,772 CANDIDATES ARE CONSISTENTLY 956 00:43:53,772 --> 00:43:55,340 IDENTIFIED. TO MAKE SURE THAT 957 00:43:55,340 --> 00:43:56,975 THERE'S A BROAD RANGE OF 958 00:43:56,975 --> 00:44:00,478 CANDIDATES AND TO REDUCE BIAS BY 959 00:44:00,478 --> 00:44:03,181 EMPHASIZING THE MENTOR'S 960 00:44:03,181 --> 00:44:05,183 COMMITMENT TO THE CANDIDATE 961 00:44:05,183 --> 00:44:09,054 WITHOUT HEAVY EMPHASIS ON THE 962 00:44:09,054 --> 00:44:13,325 REPUTATION OF THE SPONSOR OR OF 963 00:44:13,325 --> 00:44:15,493 THE INSTITUTE. OKAY? SO THESE 964 00:44:15,493 --> 00:44:16,595 REVIEW CRITERIA ARE NOW THREE 965 00:44:16,595 --> 00:44:18,363 FACTORS FOCUSED ON THE 966 00:44:18,363 --> 00:44:19,431 CANDIDATE, HOW PREPARED THEY ARE 967 00:44:19,431 --> 00:44:21,433 AND WHAT THEIR POTENTIAL IS ON 968 00:44:21,433 --> 00:44:22,701 THEIR RESEARCH TRAINING PLAN AND 969 00:44:22,701 --> 00:44:25,437 WHAT THE COMMITMENT IS TO THE 970 00:44:25,437 --> 00:44:26,071 CANDIDATE FROM THE MENTOR AND 971 00:44:26,071 --> 00:44:30,809 FROM THE INSTITUTION. NO GRADES 972 00:44:30,809 --> 00:44:32,877 NEED TO BE SUBMITTED ON THE 973 00:44:32,877 --> 00:44:34,379 BIOSKETCH, OKAY? SO THAT'S 974 00:44:34,379 --> 00:44:35,880 ACTUALLY NO LONGER ALLOWED. AND 975 00:44:35,880 --> 00:44:39,818 THIS WILL APPLY TO ALL THE 976 00:44:39,818 --> 00:44:42,654 DIFFERENT F AWARDS IN THE NOFOS 977 00:44:42,654 --> 00:44:46,591 OR IN THE PROCESS OF BEING 978 00:44:46,591 --> 00:44:49,294 REISSUED. OKAY? SO THERE'S A 979 00:44:49,294 --> 00:44:51,997 LOT GOING ON. THESE DAYS. 980 00:44:51,997 --> 00:44:54,032 OKAY? AND NIDCR IS WORKING TO 981 00:44:54,032 --> 00:44:58,103 ADDRESS THESE AREAS OF CONCERN. 982 00:44:58,103 --> 00:44:59,871 WHY? BECAUSE ORAL HEALTH IS A 983 00:44:59,871 --> 00:45:02,340 MAJOR PUBLIC HEALTH CONCERN. 984 00:45:02,340 --> 00:45:05,043 OKAY? THE COST OF ORAL HEALTH 985 00:45:05,043 --> 00:45:08,880 ARE HIGH TO THE ECONOMY, IT'S A 986 00:45:08,880 --> 00:45:11,216 TOP CONCERN FOR MILITARY 987 00:45:11,216 --> 00:45:12,484 READINESS AND WHEN WE THINK 988 00:45:12,484 --> 00:45:14,185 ABOUT CHRONIC DISEASE, THESE ARE 989 00:45:14,185 --> 00:45:16,955 THE MOST COMMON CHRONIC DISEASES 990 00:45:16,955 --> 00:45:20,859 OR AMONG THE MOST CHRONIC 991 00:45:20,859 --> 00:45:26,331 DISEASES, CARRIES, PER RIO 992 00:45:26,331 --> 00:45:29,534 DONNAL DISEASE, ORAL CANCER, 993 00:45:29,534 --> 00:45:32,037 TMD, AND DISEASES THAT MANIFEST 994 00:45:32,037 --> 00:45:33,705 IN THE HEAD AND NECK. WHEN WE 995 00:45:33,705 --> 00:45:36,041 THINK ABOUT CARIES AND 996 00:45:36,041 --> 00:45:38,076 PERIODONTAL DISEASE THESE ARE 997 00:45:38,076 --> 00:45:40,178 THE MOST COMMON DISEASES AND THE 998 00:45:40,178 --> 00:45:42,947 MOST COMMON DISEASES OF 999 00:45:42,947 --> 00:45:44,549 CHILDHOOD OF ADULTHOOD, THESE 1000 00:45:44,549 --> 00:45:46,217 ARE PREVENTIBLE. OKAY? AND THE 1001 00:45:46,217 --> 00:45:49,254 OTHER THING THAT WE KNOW IS THEY 1002 00:45:49,254 --> 00:45:50,288 CAN REALLY, NEGATIVELY IMPACT 1003 00:45:50,288 --> 00:45:53,391 MANY OTHER CHRONIC DISEASES. SO 1004 00:45:53,391 --> 00:45:55,894 NOT ADDRESSING THESE MEANS IT'LL 1005 00:45:55,894 --> 00:45:59,164 BE VERY DIFFICULT TO SOLVE THE 1006 00:45:59,164 --> 00:46:01,166 CHRONIC DISEASE CRISIS IN THE 1007 00:46:01,166 --> 00:46:03,935 U.S. WITHOUT ADDRESSING THE 1008 00:46:03,935 --> 00:46:05,036 INFLAMMATION OF THE DISEASE THAT 1009 00:46:05,036 --> 00:46:06,371 OCCURS HERE BECAUSE IT'S A 1010 00:46:06,371 --> 00:46:09,607 THREAT TO HEALTH EVERYWHERE 1011 00:46:09,607 --> 00:46:11,609 ELSE. OKAY? AND WHEN WE LOOK 1012 00:46:11,609 --> 00:46:13,978 AT, IF WE JUST LOOK AT IT 1013 00:46:13,978 --> 00:46:15,180 GRAPHICALLY AT CHRONIC DISEASES 1014 00:46:15,180 --> 00:46:17,315 AND WE JUST LOOK AT TOOTH DECAY, 1015 00:46:17,315 --> 00:46:19,651 FOR EXAMPLE, OUR POPULATION IN 1016 00:46:19,651 --> 00:46:23,888 THE U.S. IS 333 MILLION. 90% OF 1017 00:46:23,888 --> 00:46:25,390 THOSE PEOPLE HAVE HAD AN 1018 00:46:25,390 --> 00:46:26,624 EXPERIENCE WITH TOOTH DECAY, 1019 00:46:26,624 --> 00:46:29,294 OKAY? NOW WHEN WE COMPARE THIS 1020 00:46:29,294 --> 00:46:32,530 CHRONIC DISEASE TO OTHER CHRONIC 1021 00:46:32,530 --> 00:46:34,566 DISEASES, THAT THESE ORAL 1022 00:46:34,566 --> 00:46:36,234 CONDITIONS CAN EFFECT, WE CAN 1023 00:46:36,234 --> 00:46:38,770 SEE IT'S MUCH LARGER COMPARED TO 1024 00:46:38,770 --> 00:46:41,840 CARDIOVASCULAR DISEASE, MENTAL 1025 00:46:41,840 --> 00:46:45,110 HEALTH ISSUES, CANCER, 1026 00:46:45,110 --> 00:46:47,912 RESPIRATORY DISEASE AND DIABETES 1027 00:46:47,912 --> 00:46:50,381 IT'S A MAJOR PROBLEM AND HAS BY 1028 00:46:50,381 --> 00:46:51,382 DIRECTIONAL RELATIONSHIPS WITH 1029 00:46:51,382 --> 00:46:55,053 ALL THESE OTHER DISEASES, OKAY? 1030 00:46:55,053 --> 00:46:56,888 WHEN WE THINK ABOUT THE 1031 00:46:56,888 --> 00:46:59,157 PREVENTION OF THIS, OKAY? WHAT 1032 00:46:59,157 --> 00:47:00,992 YOU EAT, WHAT YOUR DIET IS AND 1033 00:47:00,992 --> 00:47:04,829 WE'RE COLLABORATING WITH THE N 1034 00:47:04,829 --> 00:47:05,797 FDA THERE, WHETHER YOU HAVE 1035 00:47:05,797 --> 00:47:07,165 ACCESS AND THE QUALITY OF THE 1036 00:47:07,165 --> 00:47:08,233 ACCESS WHAT YOU'RE ABLE TO 1037 00:47:08,233 --> 00:47:09,868 RECEIVE IN TERMS OF DENTAL CARE 1038 00:47:09,868 --> 00:47:11,703 WHAT YOU DO AT HOME, DO YOU KNOW 1039 00:47:11,703 --> 00:47:13,705 WHAT TO DO IN WHAT YOUR HYGIENE 1040 00:47:13,705 --> 00:47:16,307 IS, WHAT YOUR HABITS ARE? WHAT 1041 00:47:16,307 --> 00:47:17,375 IS YOUR LEVEL OF EDUCATION? AND 1042 00:47:17,375 --> 00:47:19,244 WHETHER YOU HAVE ACCESS TO 1043 00:47:19,244 --> 00:47:21,012 DENTAL PRODUCTS AND PROCEDURES. 1044 00:47:21,012 --> 00:47:23,181 OKAY? ALL OF THESE THINGS ARE 1045 00:47:23,181 --> 00:47:26,117 IMPORTANT TO PREVENT DISEASE. 1046 00:47:26,117 --> 00:47:28,386 OKAY? BUT THESE ARE ALL 1047 00:47:28,386 --> 00:47:29,854 DEPENDENT ON YOUR CONDITIONS OF 1048 00:47:29,854 --> 00:47:31,823 YOUR DAILY LIFE. THESE ARE ALL 1049 00:47:31,823 --> 00:47:41,966 STRUCTURAL FACTORS. OKAY? 1050 00:47:41,966 --> 00:47:48,606 FLUORIDE HELPS PREVENT THESE 1051 00:47:48,606 --> 00:47:51,109 DISEASE? IS IT A MAGIC BULLET? 1052 00:47:51,109 --> 00:47:53,144 NO. IT'S OPTIMALLY A TOOL IN A 1053 00:47:53,144 --> 00:47:54,946 TOOLBOX TOGETHER WITH THESE 1054 00:47:54,946 --> 00:47:56,214 OTHER ONES WHAT WE KNOW IS IF WE 1055 00:47:56,214 --> 00:47:59,184 REMOVE IT FROM THE WATER WE'LL 1056 00:47:59,184 --> 00:48:00,552 SEE A TWOFOLD INCREASE IN 1057 00:48:00,552 --> 00:48:03,888 DISEASE. HOW DO WE KNOW THIS? 1058 00:48:03,888 --> 00:48:05,056 BECAUSE THAT'S WHAT'S HAPPENED 1059 00:48:05,056 --> 00:48:08,159 IN ISRAEL, IN CALGARY, IN CANADA 1060 00:48:08,159 --> 00:48:10,295 AND THAT'S WHAT HAS HAPPENED 1061 00:48:10,295 --> 00:48:14,032 HERE IN THE U.S. IN JUNE NEO, 1062 00:48:14,032 --> 00:48:15,967 ALASKA AND MORE RECENTLY IN 1063 00:48:15,967 --> 00:48:17,569 BUFFALO SO WHAT ARE WE DOING? 1064 00:48:17,569 --> 00:48:19,170 OKAY? WE ARE WORKING TO BOLSTER 1065 00:48:19,170 --> 00:48:20,104 THE RESEARCH. 1066 00:48:20,104 --> 00:48:22,273 BECAUSE WE NEED TO ANSWER 1067 00:48:22,273 --> 00:48:24,108 QUESTIONS ABOUT FLUORIDE'S 1068 00:48:24,108 --> 00:48:27,178 IMPACT ON THE HEALTH OF THE U.S. 1069 00:48:27,178 --> 00:48:28,580 POPULATION AT THE LEVELS THAT 1070 00:48:28,580 --> 00:48:32,083 ARE PROTECT HERE IN THE U.S. 1071 00:48:32,083 --> 00:48:35,753 AND WE NEED TO HAVE THE RESEARCH 1072 00:48:35,753 --> 00:48:37,288 AND THE INFORMATION. SO THAT 1073 00:48:37,288 --> 00:48:40,825 PEOPLE ARE EMPOWERED TO MAKE THE 1074 00:48:40,825 --> 00:48:42,927 DECISION THEMSELVES. ABOUT 1075 00:48:42,927 --> 00:48:44,562 THEIR FLUORIDE USE AND INTAKE. 1076 00:48:44,562 --> 00:48:46,264 SO WHAT IS BOLSTERING RESEARCH 1077 00:48:46,264 --> 00:48:47,966 LOOK LIKE? WE NEED TO HAVE MORE 1078 00:48:47,966 --> 00:48:49,534 STUDY TO REALLY FULLY UNDERSTAND 1079 00:48:49,534 --> 00:48:51,169 THE IMPACTS OF FLUORIDE AT 1080 00:48:51,169 --> 00:48:53,638 LEVELS PRESENT IN THE U.S. WE 1081 00:48:53,638 --> 00:48:55,173 HAVE SOME STUDIES ONGOING THAT 1082 00:48:55,173 --> 00:48:57,442 ARE HELPING US TO ANSWER THESE 1083 00:48:57,442 --> 00:49:01,479 QUESTIONS. IN THE CONTEXT OF 1084 00:49:01,479 --> 00:49:02,714 INVESTIGATOR INITIATED RESEARCH 1085 00:49:02,714 --> 00:49:04,816 BOTH IN NORTH CAROLINA AND IN 1086 00:49:04,816 --> 00:49:07,118 IOWA AND OTHER PLACES. WE NEED 1087 00:49:07,118 --> 00:49:09,621 TO ALSO LEVERAGE ONGOING 1088 00:49:09,621 --> 00:49:10,889 LARGE-SCALE LONGITUDINAL STUDIES 1089 00:49:10,889 --> 00:49:12,924 TO TAP INTO EXISTING HEALTH 1090 00:49:12,924 --> 00:49:15,159 SURVEILLANCE DATA AND TO 1091 00:49:15,159 --> 00:49:16,961 ENCOURAGE SECONDARY DATA 1092 00:49:16,961 --> 00:49:19,163 ANALYSES ACROSS LARGE STUDIES 1093 00:49:19,163 --> 00:49:21,032 WHERE THAT INFORMATION IS 1094 00:49:21,032 --> 00:49:22,700 AVAILABLE OKAY? WE HAVE ALSO A 1095 00:49:22,700 --> 00:49:23,968 SIGNIFICANT AMOUNT OF 1096 00:49:23,968 --> 00:49:25,570 INVESTIGATOR INITIATED RESEARCH 1097 00:49:25,570 --> 00:49:27,939 ON WHAT HAPPENS AT VERY HIGH 1098 00:49:27,939 --> 00:49:29,974 LEVELS OF FLUORIDE EXPOSURE IN 1099 00:49:29,974 --> 00:49:33,144 ANIMAL MODELS AND ELSEWHERE. 1100 00:49:33,144 --> 00:49:35,980 OKAY? BUT HOW DO WE, WHY IS IT 1101 00:49:35,980 --> 00:49:36,915 IMPORTANT TO EMPOWER PEOPLE TO 1102 00:49:36,915 --> 00:49:39,150 MAKE INFORMED DECISIONS? THERE 1103 00:49:39,150 --> 00:49:41,953 ARE A LOT OF CONSIDERATIONS WHEN 1104 00:49:41,953 --> 00:49:43,354 PEOPLE MAKE A DECISION. THESE 1105 00:49:43,354 --> 00:49:47,158 DEPEND ON A LOT OF THINGS, YOUR 1106 00:49:47,158 --> 00:49:49,160 HEALTH, YOUR ETHICS, YOUR 1107 00:49:49,160 --> 00:49:51,162 RELIGION SOMETIMES, YOUR 1108 00:49:51,162 --> 00:49:53,031 POLITICS, SOCIAL, WHAT HAVE YOU. 1109 00:49:53,031 --> 00:49:55,466 OKAY? IF PEOPLE LEAN ON THEIR 1110 00:49:55,466 --> 00:49:57,802 INTUITION IT'S LIKE PUTTING A 1111 00:49:57,802 --> 00:49:59,971 SQUARE PEG INTO A ROUND HOLE. 1112 00:49:59,971 --> 00:50:02,540 OKAY? BUT WE HAVE THE 1113 00:50:02,540 --> 00:50:04,142 OBLIGATION HERE AT NIDCR TO HELP 1114 00:50:04,142 --> 00:50:05,376 PROVIDE THE EVIDENCE, SO PEOPLE 1115 00:50:05,376 --> 00:50:09,714 CAN MAKE SENSE OF IT FOR 1116 00:50:09,714 --> 00:50:11,316 THEMSELVES, ARE EMPOWERED TO 1117 00:50:11,316 --> 00:50:13,718 PULL THE PUZZLE TOGETHER AND 1118 00:50:13,718 --> 00:50:14,652 DECIDE FOR THEM WHAT THEY NEED 1119 00:50:14,652 --> 00:50:16,387 TO MOVE FORWARD. OKAY? AND 1120 00:50:16,387 --> 00:50:19,157 THAT COMES IN THE FORM OF 1121 00:50:19,157 --> 00:50:19,891 INFORMATION AND ACTUALLY HERE'S 1122 00:50:19,891 --> 00:50:21,659 A WEBSITE DOWN ON THE BOTTOM OF 1123 00:50:21,659 --> 00:50:25,563 THE PAGE THAT WILL BRING YOU TO 1124 00:50:25,563 --> 00:50:29,300 OTHER AREAS WHERE WE HAVE GOT 1125 00:50:29,300 --> 00:50:30,902 INFORMATION. WE NEED TO MAKE 1126 00:50:30,902 --> 00:50:33,538 SURE THAT WE'RE SUPPORTING THE 1127 00:50:33,538 --> 00:50:34,539 NATION'S DENTAL RESEARCH. 1128 00:50:34,539 --> 00:50:36,040 THERE'S BEEN LOTS OF CHANGES 1129 00:50:36,040 --> 00:50:37,942 OVER THE RECENT PAST. THERE 1130 00:50:37,942 --> 00:50:39,844 HAVE BEEN CHANGES IN TERMS OF 1131 00:50:39,844 --> 00:50:42,580 THE LEADERSHIP AT HHS AND HERE 1132 00:50:42,580 --> 00:50:43,481 AT NIH AND THERE HAVE BEEN SOME 1133 00:50:43,481 --> 00:50:46,551 NEW POSITIONS THAT HAVE BEEN 1134 00:50:46,551 --> 00:50:47,051 CREATED WITH REGARD TO 1135 00:50:47,051 --> 00:50:50,054 LEADERSHIP HERE. THE RESEARCH 1136 00:50:50,054 --> 00:50:50,822 PRIORITIES ARE ASSOCIATED WITH 1137 00:50:50,822 --> 00:50:53,491 MAKING AMERICA HEALTHY. WHICH 1138 00:50:53,491 --> 00:50:57,095 IS GREAT. AND CHRONIC ILLNESS. 1139 00:50:57,095 --> 00:50:58,663 WHICH IS SIGNIFICANT TO US IN 1140 00:50:58,663 --> 00:51:01,265 ORAL HEALTH AND NUTRITION AS 1141 00:51:01,265 --> 00:51:01,766 WELL. THERE HAVE BEEN 1142 00:51:01,766 --> 00:51:04,602 SIGNIFICANT CHANGES TO THE NIH 1143 00:51:04,602 --> 00:51:06,037 WORKFORCE WITH NIDCR LOSING 1144 00:51:06,037 --> 00:51:09,073 ABOUT 21% OF OUR WORKFORCE AND 1145 00:51:09,073 --> 00:51:10,675 MANY UPDATED POLICIES THAT I'VE 1146 00:51:10,675 --> 00:51:13,011 SHARED WITH YOU EARLIER AND 1147 00:51:13,011 --> 00:51:15,179 THERE'S BEEN A REIMAGINING OF 1148 00:51:15,179 --> 00:51:17,248 THE NIH STRUCTURE WHICH I ALSO 1149 00:51:17,248 --> 00:51:19,183 SHARED WITH YOU EARLIER BUT WHAT 1150 00:51:19,183 --> 00:51:21,586 ARE OUR GOALS? OKAY? OUR GOALS 1151 00:51:21,586 --> 00:51:23,654 ARE TO CONTINUE TO SUPPORT THE 1152 00:51:23,654 --> 00:51:26,557 BEST SCIENCE, TO MAKE SURE THAT 1153 00:51:26,557 --> 00:51:29,293 OUR PORTFOLIO OF DENTAL ORAL AND 1154 00:51:29,293 --> 00:51:29,961 CRANIOFACIAL RESEARCH CAN 1155 00:51:29,961 --> 00:51:31,362 TRANSFORM THE HEALTH OF THE 1156 00:51:31,362 --> 00:51:33,064 NATION AND TO MAKE SURE THAT 1157 00:51:33,064 --> 00:51:35,967 ORAL HEALTH REMAINS AT THE FORE 1158 00:51:35,967 --> 00:51:44,375 FRONT OF HIH AND -- NIH AND THE 1159 00:51:44,375 --> 00:51:44,842 PRIORITIES. 1160 00:51:44,842 --> 00:51:48,046 AND WE'RE OF COURSE FOCUSED ON 1161 00:51:48,046 --> 00:51:49,080 GOAL STANDARD SCIENCE. OKAY? 1162 00:51:49,080 --> 00:51:52,750 SO I AM GOING TO STOP THERE. 1163 00:51:52,750 --> 00:51:54,952 AND TAKE QUESTIONS. AND THEN 1164 00:51:54,952 --> 00:51:58,089 WE'LL HEAR ABOUT SCIENCE 1165 00:51:58,089 --> 00:52:01,192 ADVANCES RELATED TO OUR 1166 00:52:01,192 --> 00:52:02,527 INTRAMURAL PROGRAM. 1167 00:52:02,527 --> 00:52:03,294 >> THANK YOU VERY MUCH 1168 00:52:03,294 --> 00:52:07,098 DR. WEBSTER. WE CAN NOW TAKE 1169 00:52:07,098 --> 00:52:08,266 QUESTIONS FROM COUNCILMEMBERS 1170 00:52:08,266 --> 00:52:11,769 PLEASE UNMUTE YOURSELVES AND ASK 1171 00:52:11,769 --> 00:52:18,209 YOUR QUESTION. DOCTOR? 1172 00:52:18,209 --> 00:52:22,513 >> THANK YOU, THAT'S A LOT OF 1173 00:52:22,513 --> 00:52:25,750 INFORMATION. IS MOST OF THIS ON 1174 00:52:25,750 --> 00:52:28,519 THE WEBSITE? IS MOST OF THIS 1175 00:52:28,519 --> 00:52:29,420 INFORMATION ALREADY ON THE 1176 00:52:29,420 --> 00:52:31,722 WEBSITE THAT WE CAN GO BACK AND 1177 00:52:31,722 --> 00:52:32,957 DIGEST AND STUDY? 1178 00:52:32,957 --> 00:52:33,658 >> YES. 1179 00:52:33,658 --> 00:52:37,128 >> OKAY. AND SECONDLY, YOU 1180 00:52:37,128 --> 00:52:38,896 MENTIONED ABOUT THE BUDGET AND 1181 00:52:38,896 --> 00:52:42,467 THEN YOU MENTIONED ABOUT THE 1182 00:52:42,467 --> 00:52:47,171 PLANNING FOR REORGANIZATION IS 1183 00:52:47,171 --> 00:52:53,377 THAT ACTIVELY BEING PURSUED 1184 00:52:53,377 --> 00:52:55,179 RIGHT NOW BY TEAMS AND WHATEVER 1185 00:52:55,179 --> 00:52:56,514 THAT CONGRESSIONAL PLAN WAS FROM 1186 00:52:56,514 --> 00:52:57,115 LAST YEAR? 1187 00:52:57,115 --> 00:52:59,183 >> SO WE ARE PART OF THE 1188 00:52:59,183 --> 00:53:01,452 EXECUTIVE BRANCH AND SO NIH HAS 1189 00:53:01,452 --> 00:53:03,087 TO ALIGN WITH THE PRESIDENT'S 1190 00:53:03,087 --> 00:53:05,790 BUDGET. AND THE REQUEST FROM 1191 00:53:05,790 --> 00:53:07,191 THE PRESIDENT WAS AN ALIGNMENT 1192 00:53:07,191 --> 00:53:10,461 OF THE NIH BUDGET AND 1193 00:53:10,461 --> 00:53:14,031 ORGANIZATION OF NIH WITH THAT 1194 00:53:14,031 --> 00:53:16,300 PLAN. THAT WILL THEN MOVE TO 1195 00:53:16,300 --> 00:53:18,169 CONGRESS AND THE CONGRESSIONAL 1196 00:53:18,169 --> 00:53:21,572 JUSTIFICATIONS HAVE MOVED 1197 00:53:21,572 --> 00:53:24,809 FORWARD. AND THE CONGRESS WILL 1198 00:53:24,809 --> 00:53:26,210 DECIDE ABOUT THE BUDGET AND 1199 00:53:26,210 --> 00:53:27,745 CONGRESS WILL DECIDE ABOUT THE 1200 00:53:27,745 --> 00:53:29,247 REORGANIZATION. NOT EXACTLY THE 1201 00:53:29,247 --> 00:53:33,384 SAME BUT IN 2017, THERE WAS A 1202 00:53:33,384 --> 00:53:35,953 PROPOSAL THAT THERE WAS A 20 OR 1203 00:53:35,953 --> 00:53:39,891 30% DECREASE TO NIH. AND IN 1204 00:53:39,891 --> 00:53:42,326 FACT CONGRESS DECIDED THAT NIH 1205 00:53:42,326 --> 00:53:45,763 WOULD GET AN INCREASE THAT YEAR. 1206 00:53:45,763 --> 00:53:49,967 SO WE'RE IN THE PROCESS OF 1207 00:53:49,967 --> 00:53:50,801 WAITING. NOTHING'S DEFINITIVE 1208 00:53:50,801 --> 00:53:54,038 AND THERE'S A LOT OF DECISIONS 1209 00:53:54,038 --> 00:54:01,779 THAT REMAIN TO BE MADE. 1210 00:54:01,779 --> 00:54:02,113 >> THANK YOU. 1211 00:54:02,113 --> 00:54:02,647 >> DOCTOR, PLEASE UNMUTE 1212 00:54:02,647 --> 00:54:02,914 YOURSELF. 1213 00:54:02,914 --> 00:54:03,414 >> THANK YOU FOR YOUR 1214 00:54:03,414 --> 00:54:05,216 PRESENTATION, I HAVE A QUESTION 1215 00:54:05,216 --> 00:54:07,985 ABOUT ONE OF THE CHANGES THAT 1216 00:54:07,985 --> 00:54:12,557 YOU ALSO MENTIONED WITH THE 1217 00:54:12,557 --> 00:54:14,025 SUBCONTRACTS. THAT THERE ARE 1218 00:54:14,025 --> 00:54:15,593 GOING TO BE ALLOWANCE OF 1219 00:54:15,593 --> 00:54:16,794 CONTRACTS AND THERE'LL BE A 1220 00:54:16,794 --> 00:54:18,229 PARENT APPLICATION AND THEN, YOU 1221 00:54:18,229 --> 00:54:21,599 KNOW, THERE'S A COLLABORATION 1222 00:54:21,599 --> 00:54:22,900 THAT INSTITUTE WILL NEED TO 1223 00:54:22,900 --> 00:54:24,068 ACTUALLY SUBMIT AN APPLICATION 1224 00:54:24,068 --> 00:54:27,138 LINK TO THE PARENT APPLICATION. 1225 00:54:27,138 --> 00:54:30,708 WHEN IS THAT IMPLEMENTED? THERE 1226 00:54:30,708 --> 00:54:31,909 ARE MANY PEOPLE SUBMITTING 1227 00:54:31,909 --> 00:54:34,011 CONTRACTS UNDER REVIEW IS THAT 1228 00:54:34,011 --> 00:54:35,179 HAPPENING RIGHT NOW OR WHEN IS 1229 00:54:35,179 --> 00:54:37,682 THAT GOING TO BE IMPLEMENTED? 1230 00:54:37,682 --> 00:54:40,418 >> YEAH. THAT'S GOING TO HAPPEN 1231 00:54:40,418 --> 00:54:42,053 RIGHT NOW. OKAY? AND SO 1232 00:54:42,053 --> 00:54:44,288 THERE'S NOT GOING TO REALLY BE 1233 00:54:44,288 --> 00:54:47,024 ANY DELAY AND FOR CURRENT 1234 00:54:47,024 --> 00:54:51,162 AWARDS, THEY'LL NOW NEED TO BE 1235 00:54:51,162 --> 00:54:57,201 REASSESSED. AND THERE'LL NEED 1236 00:54:57,201 --> 00:54:59,036 TO BE JUSTIFICATIONS PROVIDED 1237 00:54:59,036 --> 00:55:00,471 FOR THOSE AND THERE'LL NEED TO 1238 00:55:00,471 --> 00:55:03,074 BE AN OPPORTUNITY FOR THE 1239 00:55:03,074 --> 00:55:05,209 SUBPROJECT TO APPLY. THERE'LL 1240 00:55:05,209 --> 00:55:08,012 ALSO BE THE OPPORTUNITY TO 1241 00:55:08,012 --> 00:55:10,581 REBUDGET AND MOVE THAT PART OF 1242 00:55:10,581 --> 00:55:12,049 THE PROJECT INTO THE U.S. IF 1243 00:55:12,049 --> 00:55:15,753 THERE'S A DOMESTIC COLLABORATOR 1244 00:55:15,753 --> 00:55:18,789 THAT CAN PROVIDE SIMILAR 1245 00:55:18,789 --> 00:55:29,333 SCIENTIFIC EXPERTISE. ANY THANK 1246 00:55:31,235 --> 00:55:33,838 YOU, DR. PIETRO, YOU'RE NEXT 1247 00:55:33,838 --> 00:55:35,072 >> THANK YOU, I WANT TO THANK 1248 00:55:35,072 --> 00:55:38,209 YOU FOR GIVING US THAT TERRIFIC 1249 00:55:38,209 --> 00:55:39,176 UPDATE. IT WON'T SURPRISE 1250 00:55:39,176 --> 00:55:40,411 ANYONE HERE TO KNOW THAT THERE'S 1251 00:55:40,411 --> 00:55:43,180 BEEN A LOT OF ALARM ABOUT THIS 1252 00:55:43,180 --> 00:55:45,716 CONCEPT OF REORGANIZING THE ICS 1253 00:55:45,716 --> 00:55:49,186 AND PARTICULARLY OF CHANGING 1254 00:55:49,186 --> 00:55:51,489 NIDCR OR MERGING IT WITH OTHER 1255 00:55:51,489 --> 00:55:53,324 INSTITUTES PARTICULARLY WHEN I 1256 00:55:53,324 --> 00:55:55,226 THINK ALL OF US AGREE THAT THIS 1257 00:55:55,226 --> 00:55:58,462 IS A VERY IMPORTANT INSTITUTE 1258 00:55:58,462 --> 00:56:01,632 AND IMPORTANT PART OF HUMAN 1259 00:56:01,632 --> 00:56:05,569 HEALTH AND IMPORTANT SCIENTIFIC 1260 00:56:05,569 --> 00:56:07,238 ENDEAVOR. WHAT CAN WE DO? IS 1261 00:56:07,238 --> 00:56:09,407 THERE ANY OPPORTUNITY FOR PUBLIC 1262 00:56:09,407 --> 00:56:11,242 COMMENT? OR OTHER COMMENT AS 1263 00:56:11,242 --> 00:56:14,078 THIS PROCESS UNFOLDS? OR WILL 1264 00:56:14,078 --> 00:56:21,852 THAT BE OF ANY IMPACT? 1265 00:56:21,852 --> 00:56:23,421 >> SO IT'S WITHIN THE RIGHTS OF 1266 00:56:23,421 --> 00:56:25,089 ANY CITIZEN TO SHARE THEIR 1267 00:56:25,089 --> 00:56:28,859 THOUGHTS AND INSIGHTS WITH THEIR 1268 00:56:28,859 --> 00:56:32,396 ELECTED OFFICIALS. SO THAT'S AN 1269 00:56:32,396 --> 00:56:35,166 AREA OF OPPORTUNITY. TO LET 1270 00:56:35,166 --> 00:56:37,401 THOSE INDIVIDUALS KNOW HOW 1271 00:56:37,401 --> 00:56:39,837 CRITICAL ORAL HEALTH IS AND HOW 1272 00:56:39,837 --> 00:56:43,441 CRITICAL THE SCIENCE IS. AND 1273 00:56:43,441 --> 00:56:45,743 HOW DIFFERENT NIDCR MAY BE 1274 00:56:45,743 --> 00:56:47,511 COMPARED TO OTHER INSTITUTE 1275 00:56:47,511 --> 00:56:48,846 WHERE IS WE LEAD A PROFESSION IN 1276 00:56:48,846 --> 00:56:51,582 TERMS OF THE RESEARCH. A FULL 1277 00:56:51,582 --> 00:56:55,019 PROFESSION AND ITS 12 1278 00:56:55,019 --> 00:56:56,921 SPECIALTIES. AND AUXILIARIES. 1279 00:56:56,921 --> 00:56:59,457 >> THANK YOU. AND WHAT IS THE 1280 00:56:59,457 --> 00:57:03,127 TIMING SORT OF OF THIS? BECAUSE 1281 00:57:03,127 --> 00:57:04,161 YOU MENTIONED THERE WOULD BE 1282 00:57:04,161 --> 00:57:07,098 SOME, THE EXECUTIVE I THINK YOU 1283 00:57:07,098 --> 00:57:10,034 CALLED IT THE EXECUTIVE 1284 00:57:10,034 --> 00:57:12,503 COMMITTEE OR BOARD WOULD BE 1285 00:57:12,503 --> 00:57:14,772 ALIGNING WITH RECOMMENDATIONS 1286 00:57:14,772 --> 00:57:15,539 BUT THEN IT WOULD GO BACK TO 1287 00:57:15,539 --> 00:57:19,009 CONGRESS. WHAT IS THE TIMING OF 1288 00:57:19,009 --> 00:57:20,544 THAT? SO I 1289 00:57:20,544 --> 00:57:22,880 >> SO THE CONGRESSIONAL 1290 00:57:22,880 --> 00:57:24,582 JUSTIFICATION HAS ALREADY BEEN 1291 00:57:24,582 --> 00:57:27,084 COMPLETED FROM OUR SIDE AND SENT 1292 00:57:27,084 --> 00:57:27,251 ON. 1293 00:57:27,251 --> 00:57:29,653 I AM NOT SURE EXACTLY WHAT THE 1294 00:57:29,653 --> 00:57:31,155 TIMING WILL BE FOR CONGRESSIONAL 1295 00:57:31,155 --> 00:57:36,227 REVIEW AND DECISION-MAKING. SEE 1296 00:57:36,227 --> 00:57:38,396 IF WE HAVE SOMEONE IN THE ROOM 1297 00:57:38,396 --> 00:57:40,331 WHO MAY HAVE MORE -- DO YOU HAVE 1298 00:57:40,331 --> 00:57:40,965 MORE DETAILED INFORMATION? 1299 00:57:40,965 --> 00:57:42,967 >> IS THAT A PUBLIC DOCUMENT? 1300 00:57:42,967 --> 00:57:45,903 THE CONGRESSIONAL JUSTIFICATION 1301 00:57:45,903 --> 00:57:47,204 FROM YOUR SIDE? 1302 00:57:47,204 --> 00:57:50,241 >> HOLD ON. WENDY IS GOING TO 1303 00:57:50,241 --> 00:57:50,541 RESPOND. 1304 00:57:50,541 --> 00:57:53,544 >> OKAY. THANK YOU. 1305 00:57:53,544 --> 00:57:59,717 >> M-HM. 1306 00:57:59,717 --> 00:58:01,886 >> THAT IS A PUBLIC DOCUMENT, 1307 00:58:01,886 --> 00:58:03,220 THAT WILL BE MADE PUBLIC WE 1308 00:58:03,220 --> 00:58:04,789 DON'T KNOW THE EXACT DATE, WE 1309 00:58:04,789 --> 00:58:06,924 EXPECT IN THE NEXT WEEK OR TWO 1310 00:58:06,924 --> 00:58:10,394 BUT THAT WILL BE PUBLIC. AND IT 1311 00:58:10,394 --> 00:58:12,096 WILL ALIGN WITH THE PRESIDENT'S 1312 00:58:12,096 --> 00:58:15,132 BUDGET. IN TERMS OF ANY 1313 00:58:15,132 --> 00:58:15,766 REORGANIZATION EFFORTS AND THE 1314 00:58:15,766 --> 00:58:18,235 ACTUAL APPROPRIATIONS FOR NIH 1315 00:58:18,235 --> 00:58:20,471 AND NIDCR, THAT IS AT THE HANDS 1316 00:58:20,471 --> 00:58:21,872 OF CONGRESS THEY TYPICALLY WORK 1317 00:58:21,872 --> 00:58:23,174 ON A TIMELINE TO DEVELOP A 1318 00:58:23,174 --> 00:58:28,279 BUDGET BY THE END OF THE FISCAL 1319 00:58:28,279 --> 00:58:29,547 YEAR WHICH IS THE END OF 1320 00:58:29,547 --> 00:58:31,048 SEPTEMBER SO WE EXPECT TO SEE 1321 00:58:31,048 --> 00:58:32,082 HEARINGS AND MORE INFORMATION 1322 00:58:32,082 --> 00:58:33,350 ABOUT THEIR CURRENT PROPOSALS 1323 00:58:33,350 --> 00:58:34,418 AND PLANS THAT THEY'RE 1324 00:58:34,418 --> 00:58:36,220 DEVELOPING IN THE NEXT FEW 1325 00:58:36,220 --> 00:58:37,721 MONTHS AND CAN KEEP AN EYE, 1326 00:58:37,721 --> 00:58:39,990 THAT'S ALL PUBLIC HEARINGS. SO 1327 00:58:39,990 --> 00:58:42,226 YOU CAN KEEP AN EYE ON THE MUSE 1328 00:58:42,226 --> 00:58:46,564 AND -- ON THE NEWS AND 1329 00:58:46,564 --> 00:58:47,832 CONGRESSIONAL HEARINGS. 1330 00:58:47,832 --> 00:58:51,569 WE HAVEN'T SEEN ANY DRAFT BILLS 1331 00:58:51,569 --> 00:58:51,735 YET. 1332 00:58:51,735 --> 00:58:54,205 >> THANK YOU. 1333 00:58:54,205 --> 00:58:55,272 >> THANK YOU DR. NOR, YOU ARE 1334 00:58:55,272 --> 00:58:56,240 NEXT, PLEASE. 1335 00:58:56,240 --> 00:58:58,742 >> THANK YOU, JENNIFER, THANK 1336 00:58:58,742 --> 00:59:02,246 YOU AGAIN FOR THIS EXCELLENT 1337 00:59:02,246 --> 00:59:05,816 REVIEW AND VERY RICH INFORMATION 1338 00:59:05,816 --> 00:59:08,652 THAT YOU PROVIDED TO US. ALONG 1339 00:59:08,652 --> 00:59:10,287 THE LINES WITH PAUL'S AND 1340 00:59:10,287 --> 00:59:14,358 LOUISE'S QUESTION. DO YOU HAVE 1341 00:59:14,358 --> 00:59:16,227 ANY INFORMATION THAT YOU CAN 1342 00:59:16,227 --> 00:59:17,661 SHARE ABOUT THE RATIONALE THAT 1343 00:59:17,661 --> 00:59:22,566 WAS USED TO MERGE THE NIDCR WITH 1344 00:59:22,566 --> 00:59:25,870 NEUROSCIENCE AND BRAIN RESEARCH? 1345 00:59:25,870 --> 00:59:28,138 THAT IS A YES THAT WE'VE BEEN 1346 00:59:28,138 --> 00:59:30,608 ASKED A LOT AND I FLANKLY DON'T 1347 00:59:30,608 --> 00:59:33,711 HAVE A GOOD ANSWER. TO THAT 1348 00:59:33,711 --> 00:59:36,714 QUESTION 1349 00:59:36,714 --> 00:59:39,183 >> NOR DO I HAVE A GOOD ANSWER 1350 00:59:39,183 --> 00:59:41,685 TO THAT QUESTION BUT I WILL 1351 00:59:41,685 --> 00:59:43,187 SHARE IS THAT THIS, THERE HAVE 1352 00:59:43,187 --> 00:59:48,225 BEEN CONGRESSIONAL PROPOSALS 1353 00:59:48,225 --> 00:59:51,362 WITH REORGANIZATION SUGGESTIONS 1354 00:59:51,362 --> 00:59:54,398 THAT WERE SIMILAR TO THIS. FOR 1355 00:59:54,398 --> 00:59:55,733 EXAMPLE, THE ROGERS PLAN THAT 1356 00:59:55,733 --> 01:00:00,204 WAS IN THE PUBLIC DOMAIN. LAST 1357 01:00:00,204 --> 01:00:04,475 FALL. YOU KNOW, WHAT IS THE 1358 01:00:04,475 --> 01:00:06,210 RATIONALE? I MEAN, I THINK THAT 1359 01:00:06,210 --> 01:00:09,413 THAT PLAN WILL GIVE YOU SOME 1360 01:00:09,413 --> 01:00:10,948 INSIGHTS BUT THE RATIONALE 1361 01:00:10,948 --> 01:00:16,353 SPECIFICALLY TO PUT THESE GROUPS 1362 01:00:16,353 --> 01:00:18,956 TOGETHER, I DON'T HAVE A GOOD 1363 01:00:18,956 --> 01:00:22,092 ANSWER FOR YOU. 1364 01:00:22,092 --> 01:00:22,893 >> OKAY. THANK YOU. 1365 01:00:22,893 --> 01:00:26,964 >> SORRY ABOUT THAT 1366 01:00:26,964 --> 01:00:29,633 >> IT'S ALL RIGHT. 1367 01:00:29,633 --> 01:00:32,570 >> THANK YOU, DR. DUE DA, YOU'RE 1368 01:00:32,570 --> 01:00:33,370 NEXT 1369 01:00:33,370 --> 01:00:34,772 >> THANK YOU SO MUCH FOR THIS 1370 01:00:34,772 --> 01:00:35,506 COMPREHENSIVE PRESENTATION. I 1371 01:00:35,506 --> 01:00:36,941 UNDERSTAND THAT COMPLYING WITH 1372 01:00:36,941 --> 01:00:38,642 THESE NEW POLICIES THAT YOU 1373 01:00:38,642 --> 01:00:41,378 SHARED WITH US HAS LED TO A LOT 1374 01:00:41,378 --> 01:00:43,681 OF WORK FLOW COMPLEXITY FOR 1375 01:00:43,681 --> 01:00:44,248 EVERYONE. 1376 01:00:44,248 --> 01:00:46,584 AND AS A RESULT, MANY OF THE ICS 1377 01:00:46,584 --> 01:00:48,352 HAVE HAD DELAYS GETTING THEIR 1378 01:00:48,352 --> 01:00:51,922 NOTICES OF AWARD OUT THE DOOR. 1379 01:00:51,922 --> 01:00:54,825 IS NIDCR ALSO SEEING THESE 1380 01:00:54,825 --> 01:00:56,860 DELAYS AND ARE THERE STRATEGY TO 1381 01:00:56,860 --> 01:01:00,064 ADDRESS IT? 1382 01:01:00,064 --> 01:01:03,968 >> SO THE ANSWER IS YES. THESE 1383 01:01:03,968 --> 01:01:07,204 DELAYS ARE ALSO BEEN, I'LL SAY, 1384 01:01:07,204 --> 01:01:09,273 COMPLICATED OR ASSOCIATED WITH 1385 01:01:09,273 --> 01:01:11,175 ADDITIONAL LEVELS OF REVIEW. 1386 01:01:11,175 --> 01:01:14,612 THAT HAVEN'T BEEN THERE IN THE 1387 01:01:14,612 --> 01:01:16,280 PAST. SO NIDCR AND OTHER 1388 01:01:16,280 --> 01:01:18,015 INSTITUTES ARE WORKING AS HARD 1389 01:01:18,015 --> 01:01:19,883 AS THEY CAN OR AS HARD AS WE CAN 1390 01:01:19,883 --> 01:01:22,620 TO TRY TO MOVE THINGS FORWARD AS 1391 01:01:22,620 --> 01:01:25,489 QUICKLY AS WE CAN GIVEN THE 1392 01:01:25,489 --> 01:01:26,323 CURRENT CIRCUMSTANCE. BUT SOME 1393 01:01:26,323 --> 01:01:28,058 OF THESE ADDITIONAL LAYERS OF 1394 01:01:28,058 --> 01:01:31,195 REVIEW HAVE BEEN DELAYING 1395 01:01:31,195 --> 01:01:33,230 THINGS. SO IT IS OUR HOPE THAT 1396 01:01:33,230 --> 01:01:36,166 WE CAN GET THE GRANTS AND THE 1397 01:01:36,166 --> 01:01:37,768 MONEY OUT THE DOOR AS QUICKLY AS 1398 01:01:37,768 --> 01:01:42,306 WE CAN AND WE'RE WORKING TO DO 1399 01:01:42,306 --> 01:01:45,275 THAT. BUT NIDCR IS NOT, WE'RE 1400 01:01:45,275 --> 01:01:47,111 IN THE SAME BOAT AS ALL THE 1401 01:01:47,111 --> 01:01:57,087 OTHER ICS WITH REGARD TO THIS. 1402 01:01:57,087 --> 01:01:58,222 >> THANK YOU. 1403 01:01:58,222 --> 01:01:59,423 >> DR. SLEP PLEASE UNMUTE 1404 01:01:59,423 --> 01:02:02,926 YOURSELF. ANY YES, HI, AND I 1405 01:02:02,926 --> 01:02:05,129 DON'T KNOW IF THERE IS PUBLICLY 1406 01:02:05,129 --> 01:02:07,197 AVAILABLE INFORMATION ABOUT THE 1407 01:02:07,197 --> 01:02:08,399 CRITERIA NOR THE ADDITIONAL 1408 01:02:08,399 --> 01:02:10,367 LEVELS OF REVIEW OR THE SYSTEM 1409 01:02:10,367 --> 01:02:12,302 FOR THE ADDITIONAL LEVELS OF 1410 01:02:12,302 --> 01:02:12,536 REVIEW. 1411 01:02:12,536 --> 01:02:13,637 I KNOW THAT'S ANOTHER AREA THAT 1412 01:02:13,637 --> 01:02:18,042 THERE'S A LOT OF CONFUSION AND A 1413 01:02:18,042 --> 01:02:19,610 LOT OF CONCERN ABOUT. A LOT OF 1414 01:02:19,610 --> 01:02:21,645 QUESTIONS HAVE BEEN COMING TO ME 1415 01:02:21,645 --> 01:02:24,314 ABOUT THAT. 1416 01:02:24,314 --> 01:02:28,318 >> YEAH. SO THIS IS PUBLICLY 1417 01:02:28,318 --> 01:02:33,323 AVAILABLE INFORMATION. I CANNOT 1418 01:02:33,323 --> 01:02:34,925 POINT YOU THIS MOMENT TO WHAT 1419 01:02:34,925 --> 01:02:37,795 THAT IS BUT PLEASE FOLLOW UP AND 1420 01:02:37,795 --> 01:02:39,029 THEN WHAT I THINK WE CAN DO IS 1421 01:02:39,029 --> 01:02:44,601 PERHAPS MUTT PUT A LINK ON OUR 1422 01:02:44,601 --> 01:02:45,502 WEBSITE SO THAT PEOPLE CAN SEE 1423 01:02:45,502 --> 01:02:46,970 IT. 1424 01:02:46,970 --> 01:02:51,208 >> THAT WOULD BE GREAT, THANK 1425 01:02:51,208 --> 01:02:52,042 YOU. TT PUT A LINK ON OUR 1426 01:02:52,042 --> 01:02:52,676 WEBSITE SO THAT PEOPLE CAN SEE 1427 01:02:52,676 --> 01:02:52,843 IT. 1428 01:02:52,843 --> 01:02:53,444 >> THAT WOULD BE GREAT, THANK 1429 01:02:53,444 --> 01:02:54,011 YOU. TT PUT A LINK ON OUR 1430 01:02:54,011 --> 01:02:54,645 WEBSITE SO THAT PEOPLE CAN SEE 1431 01:02:54,645 --> 01:02:54,812 IT. 1432 01:02:54,812 --> 01:02:55,412 >> THAT WOULD BE GREAT, THANK 1433 01:02:55,412 --> 01:02:55,946 YOU. PUT A LINK ON OUR 1434 01:02:55,946 --> 01:02:56,580 WEBSITE SO THAT PEOPLE CAN SEE 1435 01:02:56,580 --> 01:02:56,747 IT. 1436 01:02:56,747 --> 01:02:57,347 >> THAT WOULD BE GREAT, THANK 1437 01:02:57,347 --> 01:02:57,748 YOU 1438 01:02:57,748 --> 01:02:57,915 YOU. 1439 01:02:57,915 --> 01:02:58,515 >> THIS IS DR. DICKINSON, I 1440 01:02:58,515 --> 01:02:59,183 CAN'T GET MY PICTURE TO SHOW UP. 1441 01:02:59,183 --> 01:02:59,450 AM I ON? 1442 01:02:59,450 --> 01:03:00,651 >> YOU'RE ON. 1443 01:03:00,651 --> 01:03:02,152 >> A COUPLE OF MORE QUESTIONS 1444 01:03:02,152 --> 01:03:06,290 THAT PROBABLY ARE DIFFICULT TO 1445 01:03:06,290 --> 01:03:08,559 ANSWER. YOU KNOW, IF, IT 1446 01:03:08,559 --> 01:03:11,628 APPEARS THAT THE BUDGET WILL 1447 01:03:11,628 --> 01:03:16,967 STAY STABLE UNTIL '26, IS THAT 1448 01:03:16,967 --> 01:03:17,201 CORRECT? 1449 01:03:17,201 --> 01:03:19,203 >> THAT'S CORRECT. 1450 01:03:19,203 --> 01:03:23,006 >> LET'S ASSUME THAT IT COULD BE 1451 01:03:23,006 --> 01:03:24,308 POSSIBLE THAT THAT, IT WOULD BE 1452 01:03:24,308 --> 01:03:28,679 A REDUCTION OF THAT MONEYS, 1453 01:03:28,679 --> 01:03:29,279 WHICH WOULD REFLECT ON ONE OF 1454 01:03:29,279 --> 01:03:31,749 THE THINGS THAT REFLECT UPON IS 1455 01:03:31,749 --> 01:03:35,586 THE ADMINISTRATIVE COSTS AND THE 1456 01:03:35,586 --> 01:03:39,156 ADMINISTRATIVE PEOPLE THAT WORK 1457 01:03:39,156 --> 01:03:42,092 FOR PARTICULARLY NIDCR. WOULD 1458 01:03:42,092 --> 01:03:45,996 THAT BE A POSSIBLE REDUCTION IN 1459 01:03:45,996 --> 01:03:48,065 FORCE IN THAT EFFECTS THE 1460 01:03:48,065 --> 01:03:49,800 BUDGET? AND THEN CONSEQUENTLY 1461 01:03:49,800 --> 01:03:53,203 EFFECTS THE ADMINISTRATIVE PIECE 1462 01:03:53,203 --> 01:03:54,638 OF NIDCR? 1463 01:03:54,638 --> 01:03:58,075 >> SO WE HAVE UNDERGONE 1464 01:03:58,075 --> 01:04:00,310 SIGNIFICANT REDUCTION IN OUR 1465 01:04:00,310 --> 01:04:02,946 WORKFORCE. OVER 20% RIGHT NOW 1466 01:04:02,946 --> 01:04:07,117 WHAT HAS BEEN PROPOSED, WITH 1467 01:04:07,117 --> 01:04:09,219 REGARD TO REDUCTION IN BUDGET IS 1468 01:04:09,219 --> 01:04:15,192 A 40% REDUCTION. AND WE'LL SEE. 1469 01:04:15,192 --> 01:04:19,730 THIS KIND OF GOES ALONG WITH 1470 01:04:19,730 --> 01:04:24,234 CONGRESSIONAL OVERSIGHT OR 1471 01:04:24,234 --> 01:04:24,902 DECISION-MAKING. BECAUSE THAT'S 1472 01:04:24,902 --> 01:04:27,070 WHAT'S BEEN PROPOSED AND WHAT 1473 01:04:27,070 --> 01:04:29,173 WE'LL HAVE TO DO IS SEE WHAT 1474 01:04:29,173 --> 01:04:32,643 DECISIONS ARE MADE. WITH REGARD 1475 01:04:32,643 --> 01:04:38,582 TO THAT BUDGET. THAT DECREASE 1476 01:04:38,582 --> 01:04:43,220 BUT MANY OF THE REDUCTION 1477 01:04:43,220 --> 01:04:45,889 ENFORCERS HAVE ALREADY BEEN 1478 01:04:45,889 --> 01:04:47,124 PRETTY SIGNIFICANT. WE'RE NOT 1479 01:04:47,124 --> 01:04:48,158 SURE IF THERE'LL BE ADDITIONAL 1480 01:04:48,158 --> 01:04:52,963 CUTS BUT THIS IS WHERE WE ARE 1481 01:04:52,963 --> 01:04:53,797 RIGHT NOW 1482 01:04:53,797 --> 01:04:55,165 >> A FOLLOW-UP QUESTION, PROJECT 1483 01:04:55,165 --> 01:04:57,768 THAT 40%, WHO WOULD BE EFFECTED 1484 01:04:57,768 --> 01:04:59,736 BY THAT 40% THE RESEARCHERS? 1485 01:04:59,736 --> 01:05:06,310 THE GRANTS? THE FUNDING? THE 1486 01:05:06,310 --> 01:05:06,577 CURRENT... 1487 01:05:06,577 --> 01:05:08,612 >> EVERYBODY. WOULD BE AFFECTED 1488 01:05:08,612 --> 01:05:12,883 BY THAT 40%. IT'LL BE A VERY 1489 01:05:12,883 --> 01:05:15,953 DEEP CUT. THAT WOULD 1490 01:05:15,953 --> 01:05:18,388 SIGNIFICANTLY EFFECT THE 1491 01:05:18,388 --> 01:05:24,394 RESEARCH ENTERPRISE. 1492 01:05:24,394 --> 01:05:24,895 >> THANK YOU. 1493 01:05:24,895 --> 01:05:25,529 >> M-HM. 1494 01:05:25,529 --> 01:05:27,197 >> THANK YOU COUNCILMEMBERS FOR 1495 01:05:27,197 --> 01:05:28,832 THEIR QUESTIONS WOULD YOU LIKE 1496 01:05:28,832 --> 01:05:30,234 TO PROCEED? 1497 01:05:30,234 --> 01:05:33,904 >> SO I THINK WHAT WE WILL DO IS 1498 01:05:33,904 --> 01:05:36,373 TAKE A BREAK. TEN MINUTE BREAK 1499 01:05:36,373 --> 01:05:39,209 AND WE CAN RESUME AT 11:15? 1500 01:05:39,209 --> 01:05:41,245 >> OKAY, SOUNDS GOOD SO WE WILL 1501 01:05:41,245 --> 01:05:43,280 COME BACK AT 11:15. 1502 01:05:43,280 --> 01:05:50,940 >> RIGHT. THANKS, EVERYONE. 1503 01:05:50,940 --> 01:05:52,442 >> THE SCIENTIFIC ADVANCES THAT 1504 01:05:52,442 --> 01:05:53,376 I WILL SHARE TODAY ARE GOING TO 1505 01:05:53,376 --> 01:05:56,446 BE FOCUSED ON THOSE MADE IN OUR 1506 01:05:56,446 --> 01:05:57,713 INTRAMURAL, OKAY? OUR 1507 01:05:57,713 --> 01:06:00,316 INTRAMURAL PROGRAM THE 1508 01:06:00,316 --> 01:06:02,552 SCIENTISTS HERE AT THE NIDCR 1509 01:06:02,552 --> 01:06:06,122 CAMPUS CONDUCT BASIS LABORATORY 1510 01:06:06,122 --> 01:06:08,357 TRANSLATIONAL AND CLINICAL 1511 01:06:08,357 --> 01:06:09,025 RESEARCH AND PUBLIC HEALTH 1512 01:06:09,025 --> 01:06:12,128 RESEARCH, WHAT'S HAPPENING? AND 1513 01:06:12,128 --> 01:06:14,330 PUBLIC HEALTH RESEARCH IN 1514 01:06:14,330 --> 01:06:16,332 SUPPORT OF DENTAL, ORAL AND 1515 01:06:16,332 --> 01:06:18,734 CRANIOFACIAL HEALTH, OKAY? WE 1516 01:06:18,734 --> 01:06:22,038 USE THE LATEST TECHNIQUES, IN 1517 01:06:22,038 --> 01:06:24,307 BIOMEDICAL SCIENCE, LOOKING AT 1518 01:06:24,307 --> 01:06:28,678 THE SLIDES. YOU GOT IT? OKAY. 1519 01:06:28,678 --> 01:06:31,047 OKAY. GREAT. BUT BOTTOM LINE 1520 01:06:31,047 --> 01:06:32,782 IS, THERE'S A LOT GOING ON HERE, 1521 01:06:32,782 --> 01:06:34,617 THERE'S A LOT OF EXCITING 1522 01:06:34,617 --> 01:06:35,985 SCIENCE AND I'M SO HAPPY TO 1523 01:06:35,985 --> 01:06:37,420 SHARE IT WITH YOU TODAY. ACROSS 1524 01:06:37,420 --> 01:06:39,889 THESE THREE AREAS THAT COME 1525 01:06:39,889 --> 01:06:42,658 TOGETHER TO FOCUS ON ORAL HEALTH 1526 01:06:42,658 --> 01:06:45,061 FOR ALL FROM THE STANDPOINT OF 1527 01:06:45,061 --> 01:06:47,330 INTRAMURAL SCIENCE DONE HERE AT 1528 01:06:47,330 --> 01:06:51,167 NIDCR. AND HERE YOU'RE 1529 01:06:51,167 --> 01:06:53,236 LEVERAGING TECHNOLOGY TO ASK 1530 01:06:53,236 --> 01:06:54,103 CLINICAL QUESTIONS AND TO 1531 01:06:54,103 --> 01:06:55,872 DISCOVER SOLUTIONS FOR UNMET 1532 01:06:55,872 --> 01:06:57,807 NEEDS THIS RANGES FROM THE VERY 1533 01:06:57,807 --> 01:07:01,410 BASIC MOLECULAR STUDY IN 1534 01:07:01,410 --> 01:07:02,879 MULTIPLE AREAS AS WELL AS LARGER 1535 01:07:02,879 --> 01:07:04,447 PUBLIC HEALTH QUESTIONS, OKAY. 1536 01:07:04,447 --> 01:07:07,316 AND ALL OF THESE THINGS COME 1537 01:07:07,316 --> 01:07:09,018 TOGETHER AT THE CLINICAL CENTER 1538 01:07:09,018 --> 01:07:11,687 WHERE WE TAKE THE OPPORTUNITY TO 1539 01:07:11,687 --> 01:07:12,788 TRANSFORM DISCOVERIES TO HEALTH. 1540 01:07:12,788 --> 01:07:15,825 SO LET ME SOMEWHERE START OUT 1541 01:07:15,825 --> 01:07:18,227 WITH OUR CLINICAL RESEARCH IS 1542 01:07:18,227 --> 01:07:21,831 FORWARDING TRANSLATION, CLINICAL 1543 01:07:21,831 --> 01:07:23,266 INVESTIGATION AND PATIENT CARE 1544 01:07:23,266 --> 01:07:27,169 BRANCH BEGAN IN 1976 WITH DAVID 1545 01:07:27,169 --> 01:07:30,106 SCOTT AND THIS HERE HAS THE 1546 01:07:30,106 --> 01:07:31,874 INSIGHT TO INTEGRATE RESEARCH 1547 01:07:31,874 --> 01:07:33,409 AND PATIENT CARE AND THIS 1548 01:07:33,409 --> 01:07:35,878 HOLISTIC APPROACH REMAINS RIGHT 1549 01:07:35,878 --> 01:07:38,781 NOW WITH CLINICAL RESEARCH AND 1550 01:07:38,781 --> 01:07:39,815 PATIENT CARE OCCURRING IN THE 1551 01:07:39,815 --> 01:07:42,084 HOSPITAL DENTAL CLINICAL HERE AT 1552 01:07:42,084 --> 01:07:43,085 THE CLINICAL CENTER. SUPPORTING 1553 01:07:43,085 --> 01:07:48,157 PROTOCOLS FOR NCLI, FOR NIDDK 1554 01:07:48,157 --> 01:07:51,894 AND OTHERS AND WHAT HAPPENS HERE 1555 01:07:51,894 --> 01:07:55,531 IN THE WORDS OF JEN MELVIN IS 1556 01:07:55,531 --> 01:07:56,365 THESE OTHER INVESTIGATORS NOW 1557 01:07:56,365 --> 01:07:57,266 UNDERSTAND BETTER HOW THE 1558 01:07:57,266 --> 01:07:59,835 DISEASE THAT THEY ARE STUDYING 1559 01:07:59,835 --> 01:08:03,306 CAN IMPACT ORAL HEALTH. FOR 1560 01:08:03,306 --> 01:08:04,440 PROTOCOLS DONE AT NIDCR THERE 1561 01:08:04,440 --> 01:08:06,976 ARE ABOUT 25 ACTIVE PROTOCOLS 1562 01:08:06,976 --> 01:08:09,111 ABOUT HALF OF THEM ARE NATURAL 1563 01:08:09,111 --> 01:08:11,447 HISTORY AND HALF ARE 1564 01:08:11,447 --> 01:08:14,283 INTERVENTIONAL TRIALS THESE 1565 01:08:14,283 --> 01:08:15,818 CENTRALIZED CLINICAL RESEARCH 1566 01:08:15,818 --> 01:08:18,387 SERVICES THAT ARE PROVIDED, IT 1567 01:08:18,387 --> 01:08:21,824 IS REALLY ENVIABLE AND I -- WHEN 1568 01:08:21,824 --> 01:08:25,227 I FIRST CAME, I WAS -- IT IS 1569 01:08:25,227 --> 01:08:29,098 REALLY ENVIABLE TO SEE HA WHAT 1570 01:08:29,098 --> 01:08:32,268 THEY HAVE HERE ARE THE 1571 01:08:32,268 --> 01:08:32,935 CENTRALIZED SERVICES AND ALSO 1572 01:08:32,935 --> 01:08:34,036 INDUSTRY STANDARD REGULATION IS 1573 01:08:34,036 --> 01:08:34,737 OCCURRING HERE. 1574 01:08:34,737 --> 01:08:35,871 AND THE COLLABORATION WITH THE 1575 01:08:35,871 --> 01:08:37,607 OFF OF CLINICAL TRIALS 1576 01:08:37,607 --> 01:08:39,942 OPERATIONS AND MANAGEMENT IS 1577 01:08:39,942 --> 01:08:41,544 CENTRAL TO THAT. THERE'S 1578 01:08:41,544 --> 01:08:44,747 TRAINING, TRAINING IS CRITICAL, 1579 01:08:44,747 --> 01:08:46,749 FUEL TO THE ENGINE OF INNOVATION 1580 01:08:46,749 --> 01:08:48,784 AND RESEARCH THAT HAPPENS HERE. 1581 01:08:48,784 --> 01:08:50,653 SO I WILL FIRST TELL YOU A BIT 1582 01:08:50,653 --> 01:08:51,654 ABOUT THE CLINICAL RESEARCH 1583 01:08:51,654 --> 01:08:53,489 TRAINING PROGRAM. THESE ARE 1584 01:08:53,489 --> 01:08:55,257 POST-DOCTORAL RESEARCH TRAINING 1585 01:08:55,257 --> 01:08:56,926 FOR DENTISTS, THERE'S NOT A 1586 01:08:56,926 --> 01:08:59,061 PROGRAM LIKE THAT ANY PLACE 1587 01:08:59,061 --> 01:09:01,897 ELSE. WHERE THERE'S CUSTOMIZED 1588 01:09:01,897 --> 01:09:03,232 YEAR DEVELOPMENT AND RESEARCH 1589 01:09:03,232 --> 01:09:04,567 EXPERIENCE FOR THESE RESEARCH 1590 01:09:04,567 --> 01:09:07,737 FOCUSED DENTISTS THIS IS A 2-3 1591 01:09:07,737 --> 01:09:09,805 YEAR COMMITMENT AND THESE ARE 1592 01:09:09,805 --> 01:09:12,375 PHONES THAT HAVE AN ACTIVE 1593 01:09:12,375 --> 01:09:14,010 DENTAL LICENSE AND YOU SEE THEY 1594 01:09:14,010 --> 01:09:17,980 DO LOTS OF THINGS. BECOME 1595 01:09:17,980 --> 01:09:19,815 FACULTY AT MEDICAL AND DENTAL 1596 01:09:19,815 --> 01:09:23,419 SCHOOLS. SOME STAY HERE. SOME 1597 01:09:23,419 --> 01:09:28,391 GO TO OTHER GOVERNMENT ENTITIES. 1598 01:09:28,391 --> 01:09:31,527 VERY FUGU TO PRIVATE PLAQUE 1599 01:09:31,527 --> 01:09:34,463 'TIS. A FEW OF THEM LEAF THEIR 1600 01:09:34,463 --> 01:09:36,298 FELLOWSHIP IN ORDER TO START 1601 01:09:36,298 --> 01:09:38,334 THEIR OWN RESEARCH PROGRAM AND 1602 01:09:38,334 --> 01:09:39,969 HELP THE FIELD TO GROW. 1603 01:09:39,969 --> 01:09:43,806 THERE ARE MANY DIFFERENT TYPES 1604 01:09:43,806 --> 01:09:45,307 OF TRAINEES AND THE NIDCR OFFICE 1605 01:09:45,307 --> 01:09:48,077 OF TRAINING AND EDUCATION 1606 01:09:48,077 --> 01:09:50,846 SUPPORTS ABOUT 22 PRINCIPLE 1607 01:09:50,846 --> 01:09:51,280 INVESTIGATORS: 1608 01:09:51,280 --> 01:09:53,916 THAT TRANSLATES TO ABOUT 115 1609 01:09:53,916 --> 01:09:55,651 TRAINEE WHO IS ARE 1610 01:09:55,651 --> 01:09:57,319 UNDERGRADUATES OR JUST FINISHED 1611 01:09:57,319 --> 01:10:01,357 THEIR UNDERGRAD. 1612 01:10:01,357 --> 01:10:03,392 THEY'RE POSTBACS, POSTDOCS, YOU 1613 01:10:03,392 --> 01:10:04,927 HEARD ABOUT THE CLINICAL FELLOWS 1614 01:10:04,927 --> 01:10:07,596 BUT THERE'S ALSO DENTAL PUBLIC 1615 01:10:07,596 --> 01:10:09,298 HEALTH FELLOWS THAT YOU'LL HEAR 1616 01:10:09,298 --> 01:10:09,765 FROM LATER TODAY. 1617 01:10:09,765 --> 01:10:11,400 AND PEOPLE EARLIER IN THEIR 1618 01:10:11,400 --> 01:10:13,069 CAREER, STAFF SCIENTISTS AND 1619 01:10:13,069 --> 01:10:14,970 BIOLOGISTS. OKAY? SO WHEN WE 1620 01:10:14,970 --> 01:10:16,305 ARE GOING TO DIVE INTO THE 1621 01:10:16,305 --> 01:10:17,873 SCIENCE A LITTLE BIT, AND I WILL 1622 01:10:17,873 --> 01:10:19,709 GIVE A BIG PICTURE OVERVIEW OF 1623 01:10:19,709 --> 01:10:23,245 WHAT HAPPENS HERE. IN THE AREA 1624 01:10:23,245 --> 01:10:27,483 OF IMMUNOLOGY, INFLAMMATION AND 1625 01:10:27,483 --> 01:10:29,151 MICROBES, OKAY, THERE'S RESEARCH 1626 01:10:29,151 --> 01:10:33,255 ON MUCOSAL IMMUNOLOGY, ON 1627 01:10:33,255 --> 01:10:34,256 AUTOIMMUNITY AND IMMUNE 1628 01:10:34,256 --> 01:10:35,558 TOLERANCE ON THE MICROBES AND 1629 01:10:35,558 --> 01:10:40,396 THE POTENTIAL TO USE THEM AND 1630 01:10:40,396 --> 01:10:43,566 ALSO ON A SUBSET LINEAGE 1631 01:10:43,566 --> 01:10:45,201 DIFFERENTIATION AND FUNCTION. 1632 01:10:45,201 --> 01:10:48,337 THESE CRITICAL THINGS, THE 1633 01:10:48,337 --> 01:10:50,906 MICROBIOME AND MUCOSAL 1634 01:10:50,906 --> 01:10:53,576 IMMUNOLOGY HAD ORAL BEGINNINGS 1635 01:10:53,576 --> 01:10:55,411 AND THOSE WERE HERE STARTING WAY 1636 01:10:55,411 --> 01:10:58,214 BACK WITH THOSE WHO ISOLATED AN 1637 01:10:58,214 --> 01:11:00,082 ORGANISM THAT LAID THE 1638 01:11:00,082 --> 01:11:01,317 FOUNDATION FOR UNDERSTANDING OF 1639 01:11:01,317 --> 01:11:03,886 PAIR RIO. MOVING FORWARD. 1640 01:11:03,886 --> 01:11:08,357 NIDCR FOUNDED THE BIOFILMS 1641 01:11:08,357 --> 01:11:10,159 RESEARCH PROGRAM AND THIS 1642 01:11:10,159 --> 01:11:11,594 BLOSSOMED INTO OUR UNDERSTANDING 1643 01:11:11,594 --> 01:11:14,697 OF THE MICROBIOME WHICH IS NOW 1644 01:11:14,697 --> 01:11:15,831 IN THE COMMON VERNACULAR, OKAY? 1645 01:11:15,831 --> 01:11:17,833 AND WE'RE ALSO VERY EARLY 1646 01:11:17,833 --> 01:11:20,336 STUDIES OF INNATE MEW CROW SAL 1647 01:11:20,336 --> 01:11:20,603 IMMUNITY. 1648 01:11:20,603 --> 01:11:23,873 AND DISCOVERY OF ANTIMICROBIAL 1649 01:11:23,873 --> 01:11:26,408 PEPTIDES SO WHAT'S HAPPENING 1650 01:11:26,408 --> 01:11:27,476 NOW? THERE ARE COLLABORATIVE 1651 01:11:27,476 --> 01:11:30,246 STUDIES THAT OCCUR ACROSS THE 1652 01:11:30,246 --> 01:11:33,516 NIH FOCUSED ON PATHOGENESIS FROM 1653 01:11:33,516 --> 01:11:37,319 BACTERIA DEMONSTRATING THE 1654 01:11:37,319 --> 01:11:39,789 FLAGELLIN CAN INTERACT WITH 1655 01:11:39,789 --> 01:11:41,357 RECEPTORS TO RESULT IN MUCOSAL 1656 01:11:41,357 --> 01:11:44,393 PATHOLOGIES ON INTERACTION WITH 1657 01:11:44,393 --> 01:11:45,461 VIRUSES AND HOW THESE VIRUSES 1658 01:11:45,461 --> 01:11:48,998 JUST RAN RAMPANT IN THE CONTEXT 1659 01:11:48,998 --> 01:11:51,934 OF THE DOC 8 DEFICIENCY SO 1660 01:11:51,934 --> 01:11:53,636 HELPING UNDERSTAND UNDERSTAND 1661 01:11:53,636 --> 01:11:56,238 ABOUT THE PATHOGENESIS AND 1662 01:11:56,238 --> 01:11:57,740 FINALLY BARRIER DEFECTS AND WHAT 1663 01:11:57,740 --> 01:12:00,476 IS HAPPENING AT THAT HOST 1664 01:12:00,476 --> 01:12:02,011 PATHOGEN INTERFACE ADDITIONALLY 1665 01:12:02,011 --> 01:12:03,946 THESE STUDIES HELP US LEARN 1666 01:12:03,946 --> 01:12:05,414 ABOUT ORAL, SKIN AND WOUND 1667 01:12:05,414 --> 01:12:09,752 HEALING AND ALSO THE ROLE OF, 1668 01:12:09,752 --> 01:12:13,289 INTERFERONS IN AUTOIMMUNE 1669 01:12:13,289 --> 01:12:18,828 ILLNESSES. THIS IS ALSO, THE 1670 01:12:18,828 --> 01:12:21,697 WORK HAS HELPED US SHIFT THE 1671 01:12:21,697 --> 01:12:23,098 MINDSET AROUND PERIODONTAL 1672 01:12:23,098 --> 01:12:27,269 DISEASE THAT IS ONLY A BACTERIAL 1673 01:12:27,269 --> 01:12:29,605 DRIVEN INFLAMMATORY CONDITION. 1674 01:12:29,605 --> 01:12:32,441 WE NOW KNOW BASED ON THE WORK 1675 01:12:32,441 --> 01:12:34,410 THAT'S BEEN DONE THAT THERE ARE 1676 01:12:34,410 --> 01:12:36,879 CELLULAR DEFECTS THAT CAN MAKE A 1677 01:12:36,879 --> 01:12:40,416 HUGE DIFFERENCE. OKAY? AND IN 1678 01:12:40,416 --> 01:12:45,087 THE CONTEXT OF IMMUNO 1679 01:12:45,087 --> 01:12:47,690 PATHOLOGIES, JUST THOSE DEFECTS 1680 01:12:47,690 --> 01:12:49,892 CAN RESULT IN PERIODONTAL 1681 01:12:49,892 --> 01:12:54,797 DISEASE AND BONE LOSS LIKEWISE, 1682 01:12:54,797 --> 01:12:57,800 INACTIVATION OR DIS-REGULATION 1683 01:12:57,800 --> 01:13:03,873 OF A CELL CAN DRIVE THE 1684 01:13:03,873 --> 01:13:07,643 NEUTROPHIL CHEMO ATTRACTION 1685 01:13:07,643 --> 01:13:11,447 MECHANISM TO HELP PUSH PERRY OWE 1686 01:13:11,447 --> 01:13:12,481 DONNAL DISEASE. 1687 01:13:12,481 --> 01:13:15,818 WHAT ABOUT PAIN? THIS IS 1688 01:13:15,818 --> 01:13:17,720 UNDERSTANDING THE MECHANISMS OF 1689 01:13:17,720 --> 01:13:19,355 DIFFERENT SENSATION THAT 1690 01:13:19,355 --> 01:13:21,490 INCLUDES TASTE, SE MAT TO 1691 01:13:21,490 --> 01:13:23,359 SENSATION AND PAIN WHICH THIS IS 1692 01:13:23,359 --> 01:13:25,828 TOUCH, PRESSURE AND TEMPERATURE. 1693 01:13:25,828 --> 01:13:27,329 AND TAKING THIS INFORMATION TO 1694 01:13:27,329 --> 01:13:28,964 DEVELOP AND TEST NOVEL 1695 01:13:28,964 --> 01:13:30,766 THERAPEUTICS TO COMBAT PAIN. 1696 01:13:30,766 --> 01:13:33,936 THERE IS A RICH HISTORY OF PAIN 1697 01:13:33,936 --> 01:13:36,272 RESEARCH HERE AT NIDCR. WITH 1698 01:13:36,272 --> 01:13:39,308 THE DISCOVERY OF THE GENETIC 1699 01:13:39,308 --> 01:13:40,743 BASIS OF PAIN, THE RECOGNITION 1700 01:13:40,743 --> 01:13:44,380 OF THE ACUTE TO CHRONIC PAIN 1701 01:13:44,380 --> 01:13:45,948 TRANSITION, THE SIXTH VITAL SIGN 1702 01:13:45,948 --> 01:13:47,783 NOW IS PAIN AND THE OBJECTIVE 1703 01:13:47,783 --> 01:13:50,085 MEASUREMENT OF PAIN. THIS 1704 01:13:50,085 --> 01:13:51,387 SCALES WERE DEVELOPED HERE AT 1705 01:13:51,387 --> 01:13:53,389 NIDCR. AND ALSO THE RECOGNITION 1706 01:13:53,389 --> 01:13:55,991 OF THE IMPORTANCE OF 1707 01:13:55,991 --> 01:13:59,695 MULTIDISCIPLINARY PAIN RESEARCH, 1708 01:13:59,695 --> 01:14:01,931 SPEARHEADED BY RON IN 1983 SO 1709 01:14:01,931 --> 01:14:07,303 WHAT IS HAPPENING NOW? THERE'S 1710 01:14:07,303 --> 01:14:07,937 SIGNIFICANT WORK UNDERSTANDING 1711 01:14:07,937 --> 01:14:09,772 PAIN AND SOMAT TO SENSATION 1712 01:14:09,772 --> 01:14:14,209 LOOKING AT WHAT HAPPENS AT THE 1713 01:14:14,209 --> 01:14:17,546 PERIPHERY, HOW THESE DISEASE AND 1714 01:14:17,546 --> 01:14:19,481 INFLAMMATION CAN INFLUENCE SOMAT 1715 01:14:19,481 --> 01:14:21,617 TO SENSATION TO RESULT IN PAIN 1716 01:14:21,617 --> 01:14:23,319 AND UNDERSTAND THIS AT MULTIPLE 1717 01:14:23,319 --> 01:14:23,552 LEVELS. 1718 01:14:23,552 --> 01:14:25,955 FIRST WHAT ARE THE CELLULAR 1719 01:14:25,955 --> 01:14:29,558 MOLECULAR CHANGES THAT IMPACT 1720 01:14:29,558 --> 01:14:32,194 THE PATHWAYS THAT OCCUR IN THE 1721 01:14:32,194 --> 01:14:35,564 GANGLIA, IN THE PERIPHERAL, IN 1722 01:14:35,564 --> 01:14:37,232 THE TRY GEM THAT NERVE AND THEN 1723 01:14:37,232 --> 01:14:39,601 WHAT IS HAPPENING IN THE BRAIN? 1724 01:14:39,601 --> 01:14:41,704 THERE ARE AREAS IN THE BRAIN 1725 01:14:41,704 --> 01:14:45,708 THAT ARE RESPONDING TO PAIN IN 1726 01:14:45,708 --> 01:14:47,076 DIFFERENT NUCLEI THROUGH 1727 01:14:47,076 --> 01:14:49,578 DIFFERENT SETTINGS IN RESPONSE 1728 01:14:49,578 --> 01:14:52,414 TO TOUCH, TEMPERATURE, 1729 01:14:52,414 --> 01:14:53,849 PROPRIOCEPTION AND NO SEW 1730 01:14:53,849 --> 01:14:55,584 SESSION THERE'S ALSO STUDIES 1731 01:14:55,584 --> 01:14:56,418 ONGOING TO UNDERSTAND HOW THE 1732 01:14:56,418 --> 01:15:01,857 IMMUNE SYSTEM CAN REGULATE PAIN 1733 01:15:01,857 --> 01:15:06,028 AND DETAILED MULTIOHMIC ANALYSIS 1734 01:15:06,028 --> 01:15:07,830 OF DORSAL ROOTS AND TROOI 1735 01:15:07,830 --> 01:15:10,666 GEMINAL GANGLIA TO UNDERSTAND 1736 01:15:10,666 --> 01:15:14,937 PAIN, AND EVEN ORAL FACIAL PAIN. 1737 01:15:14,937 --> 01:15:17,206 THE RECENT WORK PROVIDES NEW 1738 01:15:17,206 --> 01:15:18,140 TARGETS FOR COMBATTING PAIN. 1739 01:15:18,140 --> 01:15:21,877 AND HELPS US UNDERSTAND WHY 1740 01:15:21,877 --> 01:15:24,146 TOUCH BECOMES PAINFUL DURING 1741 01:15:24,146 --> 01:15:27,149 INFLAMMATION? HELPS US 1742 01:15:27,149 --> 01:15:30,719 UNDERSTAND SOUND CIRCUITS AND 1743 01:15:30,719 --> 01:15:33,155 HOW THEY CAN FACILITATE MOVEMENT 1744 01:15:33,155 --> 01:15:35,424 TOWARDS ANALGESIA AND FINALLY 1745 01:15:35,424 --> 01:15:37,459 IDENTIFYING BRAIN CENTERS THAT 1746 01:15:37,459 --> 01:15:39,661 CAN POWERFULLY CONTROL ASPECTS 1747 01:15:39,661 --> 01:15:42,631 OF PAIN. OKAY? THERE ARE ALSO 1748 01:15:42,631 --> 01:15:45,167 CURRENT STUDIES ONGOING IN TMD 1749 01:15:45,167 --> 01:15:49,071 AND PAIN THROUGH THE INTRAMURAL 1750 01:15:49,071 --> 01:15:51,840 HEAL INITIATIVE. WHAT ABOUT 1751 01:15:51,840 --> 01:15:53,175 EPITHELIAL AND SALIVARY GLAND 1752 01:15:53,175 --> 01:15:55,277 BIOLOGY AND DYSFUNCTION THE 1753 01:15:55,277 --> 01:15:57,813 FOCUS HERE IS TO UNDERSTAND 1754 01:15:57,813 --> 01:16:00,416 CELLULAR, MOLECULAR AND GENETIC 1755 01:16:00,416 --> 01:16:02,985 MECHANISMS THAT UNDERLIE 1756 01:16:02,985 --> 01:16:03,952 DEVELOPMENT, DIFFERENCE RATION 1757 01:16:03,952 --> 01:16:06,422 AND SECRETORY PHYSIOLOGY. WHAT 1758 01:16:06,422 --> 01:16:09,224 IS THE GOAL? TO REPAIR AND 1759 01:16:09,224 --> 01:16:10,159 REGENERATE NEW FUNCTION AND YOU 1760 01:16:10,159 --> 01:16:13,562 HEAR MORE ABOUT THAT LATER ON. 1761 01:16:13,562 --> 01:16:17,032 WE LOOK AT FUNDAMENTAL BIOLOGY. 1762 01:16:17,032 --> 01:16:20,536 JUST CHANGING FUNCTIONS LIKE 1763 01:16:20,536 --> 01:16:23,605 CELL ADHESION CAN REENGINEER 1764 01:16:23,605 --> 01:16:32,448 CELLS TO UNDERGO BUD IDING 1765 01:16:32,448 --> 01:16:33,415 GENESIS. WE LEARN ABOUT 1766 01:16:33,415 --> 01:16:35,617 FUNDAMENTAL BIOLOGY 1767 01:16:35,617 --> 01:16:38,787 UNDERSTANDING THE ROLE OF DMRIE 1768 01:16:38,787 --> 01:16:39,388 COSLATION IN DEVELOPMENT AND 1769 01:16:39,388 --> 01:16:41,757 DISEASE IS SOMETHING HAPPENING 1770 01:16:41,757 --> 01:16:43,625 HERE WHERE GLYCOSYLATION IN 1771 01:16:43,625 --> 01:16:45,060 DEVELOPMENT AND FUNCTION, AND 1772 01:16:45,060 --> 01:16:48,430 THAT THESE ENZYMES USE DIVERSE 1773 01:16:48,430 --> 01:16:51,500 SUBSTRATE RECOGNITION MODES TO 1774 01:16:51,500 --> 01:16:54,203 REGULATE CELL FUNCTION AND 1775 01:16:54,203 --> 01:16:57,172 IMMUNITY THIS EFFECTS SECRETION, 1776 01:16:57,172 --> 01:17:00,509 IT EFFECTS SECRETORY MATURATION 1777 01:17:00,509 --> 01:17:04,012 AND ALSO THE STABILITY OF THE 1778 01:17:04,012 --> 01:17:06,949 MICROBIOME BECAUSE THERE'S A 1779 01:17:06,949 --> 01:17:08,183 MIMICRY THAT OCCURS AND YOU CAN 1780 01:17:08,183 --> 01:17:11,987 SEE AT THE BOTTOM THERE THAT THE 1781 01:17:11,987 --> 01:17:15,858 MICRO DRIVEN MUTATION, THE 1782 01:17:15,858 --> 01:17:18,627 ENZYME, LOOKS VERY MUCH LIKE 1783 01:17:18,627 --> 01:17:20,429 THIS ONE AND IN THE CONTEXT OF 1784 01:17:20,429 --> 01:17:24,933 THE MICROBIOME THAT BUGS LIKE 1785 01:17:24,933 --> 01:17:26,802 KNEW COLLIE YACHT TOM CAN 1786 01:17:26,802 --> 01:17:29,671 UTILIZE THESE ENZYMES IN THE 1787 01:17:29,671 --> 01:17:33,308 CONTEXT OF THE XO POLYSACCHARIDE 1788 01:17:33,308 --> 01:17:34,710 MODULATE THE BIOFILM. 1789 01:17:34,710 --> 01:17:38,180 SO THESE, THIS GLYCOSYLATION 1790 01:17:38,180 --> 01:17:39,014 WHICH WE DIDN'T UNDERSTAND VERY 1791 01:17:39,014 --> 01:17:42,151 WELL HAS SIGNIFICANT ROLES IN 1792 01:17:42,151 --> 01:17:43,719 MULTIPLE FUNDAMENTAL PROCESSES. 1793 01:17:43,719 --> 01:17:46,955 WHAT ARE WE DOING TO TRANSLATE 1794 01:17:46,955 --> 01:17:48,423 FUNDAMENTAL SCIENCE? WELL, 1795 01:17:48,423 --> 01:17:49,658 WE'RE UNDERSTANDING THE 1796 01:17:49,658 --> 01:17:51,627 MOLECULAR BASIS OF SALIVARY 1797 01:17:51,627 --> 01:17:55,063 GLAND FUNCTION AND DYSFUNCTION, 1798 01:17:55,063 --> 01:17:58,767 AND WORKING TO FOCUS ON DISEASES 1799 01:17:58,767 --> 01:18:01,837 LIKE SHOW AGAIN'S SYNDROME TO 1800 01:18:01,837 --> 01:18:06,141 DEVELOP STRATEGIES ONE IS INVIVO 1801 01:18:06,141 --> 01:18:11,580 GENERATED T REG BUT YOU'LL HEAR 1802 01:18:11,580 --> 01:18:15,984 MORE ABOUT THAT UTILIZING THE 1803 01:18:15,984 --> 01:18:17,920 UNDERPINNINGS BY BLAKE WARNER IN 1804 01:18:17,920 --> 01:18:19,955 A FEW MINUTES. YOU'LL ALSO HEAR 1805 01:18:19,955 --> 01:18:21,657 ABOUT SKELETAL BIOLOGY. HERE 1806 01:18:21,657 --> 01:18:24,426 THIS FOCUSES ON DEVELOPMENT AND 1807 01:18:24,426 --> 01:18:25,427 MAINTENANCE OF SKELETAL ISSUES 1808 01:18:25,427 --> 01:18:28,263 THAT INCLUDE TEETH, BONE AND 1809 01:18:28,263 --> 01:18:30,132 CARTILAGE, WITH A REAL EMPHASIS 1810 01:18:30,132 --> 01:18:33,869 ON MATRIX ASSOCIATED IN 1811 01:18:33,869 --> 01:18:35,170 MACROMOLECULES AND PROTEASES AND 1812 01:18:35,170 --> 01:18:36,438 YOU'LL HEAR ABOUT THAT FROM 1813 01:18:36,438 --> 01:18:39,875 DR. ROSCOE AND TEAM. YOU'LL 1814 01:18:39,875 --> 01:18:43,145 ALSO HEAR ABOUT MECHANISMS OF 1815 01:18:43,145 --> 01:18:45,914 CELL FATE AND DEVELOPMENT. AND 1816 01:18:45,914 --> 01:18:47,149 THE WORK HERE EXPLORES 1817 01:18:47,149 --> 01:18:49,718 FUNDAMENTAL QUESTIONS RELATED TO 1818 01:18:49,718 --> 01:18:52,287 TISSUE MORPHOGENESIS TO CELLULAR 1819 01:18:52,287 --> 01:18:54,189 FUNCTION TO DIFFERENTIATION AND 1820 01:18:54,189 --> 01:18:56,058 CANCER AND ALSO CRANIOFACIAL 1821 01:18:56,058 --> 01:18:57,726 DEVELOPMENT WITH A GOAL OF 1822 01:18:57,726 --> 01:18:59,528 PREVENTING AND TREATING THESE 1823 01:18:59,528 --> 01:19:02,631 DISORDERS AND YOU'LL HEAR ABOUT 1824 01:19:02,631 --> 01:19:04,032 THIS FROM AKEEM WESTERN 1825 01:19:04,032 --> 01:19:06,235 WESTERNER. OKAY? AND FINALLY 1826 01:19:06,235 --> 01:19:07,736 PUBLIC HEALTH RESEARCH AT NIDCR. 1827 01:19:07,736 --> 01:19:09,905 THIS IS ACTUALLY HOW THIS 1828 01:19:09,905 --> 01:19:13,175 INSTITUTE BEGAN WITH FLUORIDE 1829 01:19:13,175 --> 01:19:16,011 RESEARCH. SPURRED BY TRENDILY 1830 01:19:16,011 --> 01:19:18,313 DEAN IN A SIGNIFICANT EXPERIMENT 1831 01:19:18,313 --> 01:19:21,416 A FIFTEEN YEAR STUDY IN GRAND 1832 01:19:21,416 --> 01:19:23,318 RAPIDS, MICHIGAN THIS LONG-TERM, 1833 01:19:23,318 --> 01:19:24,419 SCHOOL BASED PROGRAM REALLY 1834 01:19:24,419 --> 01:19:26,955 BECAME THE BASIS FOR ONE OF THE 1835 01:19:26,955 --> 01:19:30,292 MOST SUCCESSFUL PUBLIC HEALTH 1836 01:19:30,292 --> 01:19:33,528 EFFORTS IN DENTISTY. WATER 1837 01:19:33,528 --> 01:19:34,096 FLUORIDATION, DEAN BECAME A 1838 01:19:34,096 --> 01:19:36,765 FIRST DIRECTOR OF THE INSTITUTE 1839 01:19:36,765 --> 01:19:39,167 AND HIS FOCUS WAS ON INTRAMURAL 1840 01:19:39,167 --> 01:19:40,936 RESEARCH AND ALSO TRAINING OTHER 1841 01:19:40,936 --> 01:19:44,439 PUBLIC HEALTH EFFORTS WITHIN W 1842 01:19:44,439 --> 01:19:48,176 THE NATIONAL CARRY'S PROGRAM, 1843 01:19:48,176 --> 01:19:51,246 THE NATIONAL SURVEY OF ADULT 1844 01:19:51,246 --> 01:19:55,350 DENTAL HEALTH AND YOU'LL HEAR 1845 01:19:55,350 --> 01:19:58,086 ABOUT THAT FROM DR. AL RAH GOING 1846 01:19:58,086 --> 01:20:01,890 SO IT IS MY PLEASURE TO NOW 1847 01:20:01,890 --> 01:20:04,026 SHARE WITH YOU, YOU'LL HEAR FROM 1848 01:20:04,026 --> 01:20:07,462 OUR SCIENTISTS HERE. 1849 01:20:07,462 --> 01:20:09,765 AND WHEN I THINK IS A GREAT MANY 1850 01:20:09,765 --> 01:20:11,066 SYMPOSIUM OF THE DIFFERENCE THAT 1851 01:20:11,066 --> 01:20:12,367 INTRAMURAL RESEARCH IS MAKING IN 1852 01:20:12,367 --> 01:20:15,203 THE WORLD BECAUSE OF THE 1853 01:20:15,203 --> 01:20:16,772 OPPORTUNITIES HERE TO LEVERAGE 1854 01:20:16,772 --> 01:20:19,875 THINGS THAT DON'T EXIST 1855 01:20:19,875 --> 01:20:23,478 ELSEWHERE. SO WE'LL HEAR FROM 1856 01:20:23,478 --> 01:20:29,484 DR. WARNER ON SHOW AGAIN'S 1857 01:20:29,484 --> 01:20:33,655 SYNDROME AND SERE OWE STOEM YA. 1858 01:20:33,655 --> 01:20:36,058 >> THANK YOU FOR THAT WARM 1859 01:20:36,058 --> 01:20:36,892 INTRODUCTION AND THANK YOU TO 1860 01:20:36,892 --> 01:20:38,193 NIDCR COUNCIL FOR GIVING THE 1861 01:20:38,193 --> 01:20:39,828 DIVISION OF INTRAMURAL RESEARCH 1862 01:20:39,828 --> 01:20:41,396 THE OPPORTUNITY TO SPEAK TODAY. 1863 01:20:41,396 --> 01:20:47,502 MY NAME IS BLAKE WARNER TODAY I 1864 01:20:47,502 --> 01:20:49,438 WILL TALK ABOUT SHAPING THE 1865 01:20:49,438 --> 01:20:51,773 FUTURE OF SALIVARY GLAND 1866 01:20:51,773 --> 01:20:55,844 BIOLOGY, TRANSLATIONAL 1867 01:20:55,844 --> 01:20:56,978 BREAKTHROUGHS FROM THE NIDCR 1868 01:20:56,978 --> 01:20:58,747 IDP. THE AREA OF FOCUS I WILL 1869 01:20:58,747 --> 01:21:00,916 BE SPEAKING ON IS ON THE EP 1870 01:21:00,916 --> 01:21:10,692 THEME V -- EPITHELIAL BIOLOGY 1871 01:21:10,692 --> 01:21:13,595 WHICH INCLUDES ALL THESE FOLKS 1872 01:21:13,595 --> 01:21:18,900 HERE AND MYSELF, BLAKE WARNER, 1873 01:21:18,900 --> 01:21:20,435 NIDCR'S MISSION HAS BEEN FOR 1874 01:21:20,435 --> 01:21:23,238 MORE THAN 40 YEARS, HAS BEEN 1875 01:21:23,238 --> 01:21:25,040 MISSION FOCUSED ON UNDERSTANDING 1876 01:21:25,040 --> 01:21:28,410 MECHANISMS AND DEVELOPING 1877 01:21:28,410 --> 01:21:30,879 THERAPIES FOR ZERO STOEM YA, 1878 01:21:30,879 --> 01:21:34,082 SHOW AGAIN'S DISEASE AND BEYOND. 1879 01:21:34,082 --> 01:21:36,151 THIS HAS REQUIRED LONG-TERM 1880 01:21:36,151 --> 01:21:39,521 VISION AND DEDICATION 1881 01:21:39,521 --> 01:21:40,689 INVESTIGATING THE CONTINUUM FROM 1882 01:21:40,689 --> 01:21:43,859 BASIC PHYSIOLOGY THROUGH 1883 01:21:43,859 --> 01:21:47,596 CLINICAL RESEARCH. ONE MIGHT 1884 01:21:47,596 --> 01:21:50,699 STATE THAT 0 WROTE STOEM YA OR 1885 01:21:50,699 --> 01:21:52,801 DRY MOUTH IS ALL THE SAME BUT I 1886 01:21:52,801 --> 01:21:54,469 THINK IT'S IMPORTANT TO 1887 01:21:54,469 --> 01:21:56,338 DELINEATE THAT INSULTS TO INJURY 1888 01:21:56,338 --> 01:21:58,540 TO THE SALIVARY COMPLEX WHILE 1889 01:21:58,540 --> 01:22:01,610 HAVING DOWNSTREAM EFFECTS ON 1890 01:22:01,610 --> 01:22:03,011 ORAL TISSUES SUCH AS IN THE 1891 01:22:03,011 --> 01:22:04,913 TEETH CAN LEAD TO CHANGES IN 1892 01:22:04,913 --> 01:22:07,249 FUNCTION AND CHANGES IN QUALITY 1893 01:22:07,249 --> 01:22:13,388 OF LIFE IS THAT THEY HAVE UNIQUE 1894 01:22:13,388 --> 01:22:15,924 PATH PHYSIOLOGIC PROCESSES AND 1895 01:22:15,924 --> 01:22:18,160 CAN BE CLASSIFIED BASED ON THE 1896 01:22:18,160 --> 01:22:20,629 TYPE. ONE OF THE MORE COMMON OR 1897 01:22:20,629 --> 01:22:24,399 AUTOIMMUNE OR AUTOINFLAMMATORY 1898 01:22:24,399 --> 01:22:28,036 DISEASES SHOW GLEN'S DISEASE AND 1899 01:22:28,036 --> 01:22:30,238 CHRONIC GRAFT VERSUS HOST WILL 1900 01:22:30,238 --> 01:22:33,475 BE BY MY COLLEAGUE. AND I WILL 1901 01:22:33,475 --> 01:22:35,644 SPEAK ABOUT IYAT ROW GENERALIC 1902 01:22:35,644 --> 01:22:38,280 INJURY, WE CALL THIS RADIATION 1903 01:22:38,280 --> 01:22:40,882 INDUCED SERE ROW STOEM YA WHILE 1904 01:22:40,882 --> 01:22:43,752 THERE ARE OTHER TYPES OF 1905 01:22:43,752 --> 01:22:45,687 DISORDERS THAT HAVE SALIVARY 1906 01:22:45,687 --> 01:22:47,789 GLAND DYSFUNCTION AS A CORE 1907 01:22:47,789 --> 01:22:49,491 COMPONENT OF THAT PATHOLOGY, I 1908 01:22:49,491 --> 01:22:52,661 WILL NOT BE SPEAKING OF THOSE 1909 01:22:52,661 --> 01:22:54,663 TODAY. TO UNDERSTAND PATHOLOGY 1910 01:22:54,663 --> 01:22:56,431 OF THE SALIVARY GLANDS IT'S 1911 01:22:56,431 --> 01:22:59,000 REALLY CRITICAL TO UNDERSTAND 1912 01:22:59,000 --> 01:23:01,102 THE BASIC PHYSIOLOGY OF 1913 01:23:01,102 --> 01:23:03,138 SECRETION, I'M LUCKY ENOUGH TO 1914 01:23:03,138 --> 01:23:04,606 STAND HERE TODAY TO TALK ABOUT 1915 01:23:04,606 --> 01:23:07,876 SHOW AGAIN'S DISEASE BECAUSE OF 1916 01:23:07,876 --> 01:23:09,010 PIONEERING EFFORTS BY THE 1917 01:23:09,010 --> 01:23:09,744 RESEARCH PROGRAM. 1918 01:23:09,744 --> 01:23:15,717 AND THE CONTINUING EFFORTS OF 1919 01:23:15,717 --> 01:23:19,120 THOSE THAT STUDY THE ROLE OF MY 1920 01:23:19,120 --> 01:23:21,423 TO CON THREE Y'ALL FUNCTIONS. 1921 01:23:21,423 --> 01:23:26,928 AND A DOCTOR THAT STUDIES 1922 01:23:26,928 --> 01:23:28,129 BICARBONATE AND ALSO THE 1923 01:23:28,129 --> 01:23:31,800 EXOCRINE FUNCTION IN THE 1924 01:23:31,800 --> 01:23:37,205 PANCREAS AND THE SALIVARY 1925 01:23:37,205 --> 01:23:38,507 PROCESS. AND PROTEIN 1926 01:23:38,507 --> 01:23:39,774 MODIFICATION AND PROTEIN 1927 01:23:39,774 --> 01:23:43,578 SECRETION AND NADINE WHO STUDIES 1928 01:23:43,578 --> 01:23:47,682 DMRIE COSLATION OR POST 1929 01:23:47,682 --> 01:23:48,483 TRANSLATIONAL. AND THEIR ROLE 1930 01:23:48,483 --> 01:23:51,219 IN MUCOSAL INNATE IMMUNITY AND 1931 01:23:51,219 --> 01:23:53,522 WHILE I'M NOT DISCUSSING MANY 1932 01:23:53,522 --> 01:23:55,457 OTHER PIONEERS IN THIS, IT ALL 1933 01:23:55,457 --> 01:23:58,193 BOILS DOWN TO THE FUNCTIONAL 1934 01:23:58,193 --> 01:24:00,428 UNIT OF THE EXOCRINE COMBLANDZ 1935 01:24:00,428 --> 01:24:01,496 THIS IS THE CELLS IN THE 1936 01:24:01,496 --> 01:24:03,665 CONNECTION TO THE DICTS THAT 1937 01:24:03,665 --> 01:24:08,436 TRANSIT TO THE ORAL CAVITY TO 1938 01:24:08,436 --> 01:24:13,542 DELIVER SALIVA. 1939 01:24:13,542 --> 01:24:15,877 ON THE OTHER SIDE OF THIS 1940 01:24:15,877 --> 01:24:17,546 EQUATION IS THE SHOW AGAIN'S 1941 01:24:17,546 --> 01:24:20,448 CLINIC. OVER 40 YEARS AGO THE 1942 01:24:20,448 --> 01:24:22,117 FIRST PROTOCOLS IN SHOW AGAIN'S 1943 01:24:22,117 --> 01:24:24,419 DISEASE WERE INITIATED THESE 1944 01:24:24,419 --> 01:24:25,954 CLINICAL INVESTIGATIONS WERE 1945 01:24:25,954 --> 01:24:27,556 LARGELY LONGITUDINAL STUDIES OR 1946 01:24:27,556 --> 01:24:29,991 OBSERVATIONAL STUDY TO 1947 01:24:29,991 --> 01:24:31,159 CHARACTERIZE SALIVARY GLAND 1948 01:24:31,159 --> 01:24:32,894 DISEASES. BUT THE, ALONG THE 1949 01:24:32,894 --> 01:24:34,129 WAY THERE WERE ALSO 1950 01:24:34,129 --> 01:24:35,764 INTERVENTIONAL STUDIES HERE I 1951 01:24:35,764 --> 01:24:38,500 LABELED THE SAFETY OF SHOW 1952 01:24:38,500 --> 01:24:40,135 AGAIN'S DISEASE WHERE YOU CAN 1953 01:24:40,135 --> 01:24:42,971 LUMP IN THE EARLY STUDIES 1954 01:24:42,971 --> 01:24:46,141 SHOWING THE PILOCARPINE WAS AN 1955 01:24:46,141 --> 01:24:48,276 EFFECTIVE WAY TO INCREASE FLUID 1956 01:24:48,276 --> 01:24:49,844 SECRETION IN DRY MOUTH 1957 01:24:49,844 --> 01:24:51,580 CONDITIONS. THIS ALSO SERVES AS 1958 01:24:51,580 --> 01:24:53,982 A WAY TO COMPREHENSIVELY 1959 01:24:53,982 --> 01:24:55,850 CLINICAL PHENOTYPE PATIENTS, 1960 01:24:55,850 --> 01:24:58,019 COLLECT TISSUE SAMPLES AND OTHER 1961 01:24:58,019 --> 01:24:59,955 BIOFLUIDS AND BRING THEM BACK TO 1962 01:24:59,955 --> 01:25:03,725 THE LAB WHERE BASIC AND 1963 01:25:03,725 --> 01:25:04,359 TRANSLATIONAL INVESTIGATIONS CAN 1964 01:25:04,359 --> 01:25:06,528 HAPPEN IN A BEDSIDE TO BENCH 1965 01:25:06,528 --> 01:25:08,430 APPROACH. BUT ALSO TO TAKE 1966 01:25:08,430 --> 01:25:10,899 THOSE THINGS WE LEARN AT THE 1967 01:25:10,899 --> 01:25:12,334 BENCH AND TRANSLATE THEM BACK 1968 01:25:12,334 --> 01:25:13,835 INTO THE CLINIC AND SO THIS IS 1969 01:25:13,835 --> 01:25:17,305 WHERE I CAME TO NIDCR, I WANTED 1970 01:25:17,305 --> 01:25:19,240 TO UNDERSTAND AND IN FACT TREAT 1971 01:25:19,240 --> 01:25:21,309 SHOW AGAIN'S DISEASE. AND TO DO 1972 01:25:21,309 --> 01:25:25,113 THAT I WANTED TO INVESTIGATE THE 1973 01:25:25,113 --> 01:25:27,282 IMMUNO PATHOLOGY OF SHOW AGAIN'S 1974 01:25:27,282 --> 01:25:28,650 DISEASE TO IDENTIFY THE THERAPY 1975 01:25:28,650 --> 01:25:30,051 IN HUMANS. 1976 01:25:30,051 --> 01:25:32,253 THERE'S TWO BENCH TO BID SIDE 1977 01:25:32,253 --> 01:25:34,255 VIGNETTES THAT THAT ARE FROM OUR 1978 01:25:34,255 --> 01:25:36,424 FOCUS AREA. 1979 01:25:36,424 --> 01:25:39,961 THE FIRST IS FROM DR. SAR CAR 1980 01:25:39,961 --> 01:25:41,663 WHO UNFORTUNATELY IS NOT ABLE TO 1981 01:25:41,663 --> 01:25:43,565 BE HERE WITH US TODAY AND HER 1982 01:25:43,565 --> 01:25:45,867 PRESENTATION WILL BE GIVEN BY 1983 01:25:45,867 --> 01:25:47,936 HER MENTOR. 1984 01:25:47,936 --> 01:25:51,306 WHO WILL BE PRESENTING CORRECTOR 1985 01:25:51,306 --> 01:25:52,774 RESTORES FUNCTION IN 1986 01:25:52,774 --> 01:25:55,343 EXPERIMENTAL SHOW AGAIN'S 1987 01:25:55,343 --> 01:25:58,113 DISEASE AND MY COLLEAGUE AND 1988 01:25:58,113 --> 01:26:01,249 SCHOLAR DR. JACKIE MAYES WHO 1989 01:26:01,249 --> 01:26:03,685 WILL DISCUSS HOST DISEASE IN AN 1990 01:26:03,685 --> 01:26:05,587 INDIVIDUAL WITH VEK SIS 1991 01:26:05,587 --> 01:26:06,087 SYNDROME. 1992 01:26:06,087 --> 01:26:08,456 SO FIRST, I WANT TO TAKE A STEP 1993 01:26:08,456 --> 01:26:10,525 BACK IN TIME AND TALK ABOUT 1994 01:26:10,525 --> 01:26:14,029 RADIATION AFFECTED SALIVARY 1995 01:26:14,029 --> 01:26:15,363 GLANDS. RADIATION OR EXTERNAL 1996 01:26:15,363 --> 01:26:20,368 BEAM REDUATION, PREFERENTIALLY 1997 01:26:20,368 --> 01:26:23,238 DAMAGES THE CELLS SENSITIVE TO 1998 01:26:23,238 --> 01:26:25,573 THE DOUBLE STRAND BREAKS BY BEAM 1999 01:26:25,573 --> 01:26:28,777 RADIATION THIS LEADS TO A LOSS 2000 01:26:28,777 --> 01:26:32,447 OF FUNCTIONAL WHAT RAN KA MA, A 2001 01:26:32,447 --> 01:26:38,253 DECREASE IN THE PROTEINS. 2002 01:26:38,253 --> 01:26:39,621 HOWEVER ONE OF THE EARLY 2003 01:26:39,621 --> 01:26:42,724 PIONEERS IN SALIVARY DISFUNCTION 2004 01:26:42,724 --> 01:26:47,028 RESEARCH WAS DR. BRUCE BAUM WHO 2005 01:26:47,028 --> 01:26:48,496 HYPOTHESIZED THAT YOU COULD 2006 01:26:48,496 --> 01:26:50,765 REENGINEER THE EPITHELIUM 2007 01:26:50,765 --> 01:26:53,935 UNAFFECTED BY BEAM REDUATION TO 2008 01:26:53,935 --> 01:26:55,503 INCREASE FLUID PERMEABILITY IN 2009 01:26:55,503 --> 01:26:58,373 THAT LAYER AND AUGMENT FUNCTION. 2010 01:26:58,373 --> 01:27:02,243 AND THROUGH A LONG-TERM VISION 2011 01:27:02,243 --> 01:27:06,815 AND MANY IN VITRO AND IN VIVO 2012 01:27:06,815 --> 01:27:09,417 LARGE AND SMALL ANIMAL MODELS 2013 01:27:09,417 --> 01:27:10,885 SHOWED PRECLINICAL EFFICACY AND 2014 01:27:10,885 --> 01:27:13,555 THEN WITH A FIRST IN HUMAN 2015 01:27:13,555 --> 01:27:16,191 CLINICAL TRIAL SHOWED THATTED A 2016 01:27:16,191 --> 01:27:19,994 DEKNOW VIRUS DELIVERED TO THE A 2017 01:27:19,994 --> 01:27:24,466 SINGLE GLAND OF PATIENTS COULD 2018 01:27:24,466 --> 01:27:28,536 RESTORE SALIVA FLOW. HOWEVER 2019 01:27:28,536 --> 01:27:31,806 THIS TREATMENT WAS DOSE LIMITED 2020 01:27:31,806 --> 01:27:34,209 AND HAD A VERY SHORT LIFE SPAN 2021 01:27:34,209 --> 01:27:37,879 THIS LED TO AN OPPORTUNITY TO 2022 01:27:37,879 --> 01:27:40,415 CHANGE THE HYPOTHESIS OR CHANGE 2023 01:27:40,415 --> 01:27:42,083 THE APPROACH. 2024 01:27:42,083 --> 01:27:44,986 AND DR. BRUCE BAUM RECRUITED 2025 01:27:44,986 --> 01:27:48,389 DR. JAY WHO WAS AN EXPERT IN AD 2026 01:27:48,389 --> 01:27:51,159 KNOW ASSOCIATED BIOLOGY. JAY IS 2027 01:27:51,159 --> 01:27:54,496 NOW SENIOR INVESTIGATOR AND 2028 01:27:54,496 --> 01:27:56,297 ACTING SCIENTIFIC DIRECTOR OF 2029 01:27:56,297 --> 01:28:01,369 THE INTRAMURAL PROGRAM. AAV 2 2030 01:28:01,369 --> 01:28:05,640 WHICH IS A LOW VECTOR IN FACT WE 2031 01:28:05,640 --> 01:28:09,644 HYPOTHESIZED WE COULD DELIVER TO 2032 01:28:09,644 --> 01:28:11,880 THE SALIVARY EPITHELIUM IN CELLS 2033 01:28:11,880 --> 01:28:13,581 AND DUCT TO RESTORE FUNCTION 2034 01:28:13,581 --> 01:28:15,650 LONG-TERM AND AGAIN THROUGH A 2035 01:28:15,650 --> 01:28:18,086 LONG-TERM VISION IN VITRO, IN 2036 01:28:18,086 --> 01:28:20,088 VIVO MODELS INCLUDING SMALL AND 2037 01:28:20,088 --> 01:28:23,224 LARGE ANIMAL MODELS WAS ABLE TO 2038 01:28:23,224 --> 01:28:25,527 DEMONSTRATE EFFICACY IN EARLY 2039 01:28:25,527 --> 01:28:28,096 FIRST IN HUMAN CLINICAL TRIALS 2040 01:28:28,096 --> 01:28:32,167 OF AV 2 FOR THE TREATMENT OF 2041 01:28:32,167 --> 01:28:33,935 RADIATION INDUCED XEROSTOMIA I 2042 01:28:33,935 --> 01:28:36,004 ALWAYS THINK A PICTURE IS WORTH 2043 01:28:36,004 --> 01:28:37,438 A THOUSAND WORDS BUT IN THIS 2044 01:28:37,438 --> 01:28:39,641 CASE THOSE CLINICAL PHOTOS CAN 2045 01:28:39,641 --> 01:28:42,544 SHOW THAT NOT ONLY DID FLUID 2046 01:28:42,544 --> 01:28:45,180 SECRETION INCREASE BUT YOU HAVE 2047 01:28:45,180 --> 01:28:46,347 RESTORATION OF THOSE ORAL 2048 01:28:46,347 --> 01:28:48,149 TISSUES AS YOU CAN SEE THE SIDE 2049 01:28:48,149 --> 01:28:52,187 BY SIDE OF THIS DAY 56 PHOTO OF 2050 01:28:52,187 --> 01:28:53,488 A PATIENT FROM THE CLINICAL 2051 01:28:53,488 --> 01:28:57,091 TRIAL. THIS STUDY REPRESENTS A 2052 01:28:57,091 --> 01:28:59,894 PRIVATE PUBLIC PARTNERSHIP WITH 2053 01:28:59,894 --> 01:29:02,330 GTX WHERE THEY CAN SUPPORT THE 2054 01:29:02,330 --> 01:29:04,966 CONTINUATION OF THESE TYPES OF 2055 01:29:04,966 --> 01:29:07,235 STUDIES. BUT BEYOND JUST 2056 01:29:07,235 --> 01:29:09,304 RESTORING SALIVARY FLOW, THE 2057 01:29:09,304 --> 01:29:11,406 TECHNOLOGY DEVELOPED AT NIDCR 2058 01:29:11,406 --> 01:29:15,009 AND THIS IS IN FACT A RECURRING 2059 01:29:15,009 --> 01:29:17,245 THEME HAS FAR REACHING EFFECTS 2060 01:29:17,245 --> 01:29:21,015 ACROSS THE SPECTRUM OF WHAT WE, 2061 01:29:21,015 --> 01:29:24,118 OF HUMAN INTERVENTIONS. AND IN 2062 01:29:24,118 --> 01:29:28,923 THIS CASE, AD DEKNOW SERE ROW 2063 01:29:28,923 --> 01:29:32,827 TYPE 5 FIRST ASSOCIATED BY THIS 2064 01:29:32,827 --> 01:29:35,263 DOCTOR IS NOW THAT MOLECULAR 2065 01:29:35,263 --> 01:29:37,832 TRUCK OR THAT VECTOR USED IN TWO 2066 01:29:37,832 --> 01:29:40,935 FDA APPROVED GENE THERAPIES. 2067 01:29:40,935 --> 01:29:44,239 ROCK TAIF YAN APPROVED IN 2023 2068 01:29:44,239 --> 01:29:48,409 AND HEM GENERALICS APPROVED IN 2069 01:29:48,409 --> 01:29:49,744 2022. 2070 01:29:49,744 --> 01:29:52,180 FOR HEMOPHILIA A AND HEMOPHILIA 2071 01:29:52,180 --> 01:29:53,848 B. THERE ARE NOW SEVERAL OTHER 2072 01:29:53,848 --> 01:29:55,250 INDICATION THERE'S THE APPROVAL 2073 01:29:55,250 --> 01:29:57,218 PIPELINE AND YOU'LL CONTINUE TO 2074 01:29:57,218 --> 01:30:00,188 SEE THESE VECTORS WHICH ARE SAFE 2075 01:30:00,188 --> 01:30:03,825 AND LOW IMMUNOGENICITY USED IN 2076 01:30:03,825 --> 01:30:06,327 THESE THERAPIESLY TALK ABOUT THE 2077 01:30:06,327 --> 01:30:07,996 DISEASE I'M FOCUSED ON, SHOW 2078 01:30:07,996 --> 01:30:08,963 AGAIN'S DISEASE THIS REPRESENTS 2079 01:30:08,963 --> 01:30:11,032 ONE OF THOSE MAJOR UNMET MEDICAL 2080 01:30:11,032 --> 01:30:12,133 NEEDS. 2081 01:30:12,133 --> 01:30:14,168 A DISTINCT CHRONIC SYSTEMIC 2082 01:30:14,168 --> 01:30:15,570 AUTOIMMUNE DISEASES EFFECTS 2083 01:30:15,570 --> 01:30:18,039 BETWEEN 2-4 MILLION AMERICANS IN 2084 01:30:18,039 --> 01:30:20,408 THE UNITED STATES. IT HAS A 2085 01:30:20,408 --> 01:30:23,411 STRIKING 9-1 FEMALE PREDILECTION 2086 01:30:23,411 --> 01:30:25,113 AND DIAGNOSED TYPICALLY OTHER 2087 01:30:25,113 --> 01:30:29,717 THE AGE OF 40 YEARS. CONFERS A 2088 01:30:29,717 --> 01:30:33,721 20-40 FOLD RISK OF LYMPHOMA AND 2089 01:30:33,721 --> 01:30:35,256 THE HIGHEST RISK AMONG THE 2090 01:30:35,256 --> 01:30:37,158 AUTOIMMUNE DISEASES. SOME 2091 01:30:37,158 --> 01:30:37,992 PATIENTS ALSO HAVE SYSTEMIC 2092 01:30:37,992 --> 01:30:40,428 INVOLVEMENT OF THE LUNGS, THE 2093 01:30:40,428 --> 01:30:43,932 KIDNEYS THE JOINTS AND THE SKIN 2094 01:30:43,932 --> 01:30:44,565 AND UNFORTUNATELY THERE ARE NO 2095 01:30:44,565 --> 01:30:46,367 YET APPROVED TREATMENTS OR CURES 2096 01:30:46,367 --> 01:30:49,270 FOR SHOW DREN'S DISEASE. IN 2097 01:30:49,270 --> 01:30:55,143 FACT, THIS IS NOT DUE TO EFFORT. 2098 01:30:55,143 --> 01:30:57,912 WE HAVE HAD MANY TRIALS IN SHOW 2099 01:30:57,912 --> 01:30:59,781 AGAIN'S DISEASE WITH MANY 2100 01:30:59,781 --> 01:31:01,416 FAILURES INCLUDING SOME VERY 2101 01:31:01,416 --> 01:31:02,784 INSIGHTFUL CLINICAL TRIALS 2102 01:31:02,784 --> 01:31:07,155 CONDUCTED HERE AT THE NIDCR. 2103 01:31:07,155 --> 01:31:12,961 FOR I HAVE IF A LIZ MAB, 2104 01:31:12,961 --> 01:31:14,829 ANTI-LFA 1. BUT WHAT WE LEARN 2105 01:31:14,829 --> 01:31:17,532 FROM THESE TRIAL IS WE HAD A GAP 2106 01:31:17,532 --> 01:31:19,233 IN UNDERSTANDING THE FUNDAMENTAL 2107 01:31:19,233 --> 01:31:21,336 SHOW AGAIN'S PATHOLOGY, WE 2108 01:31:21,336 --> 01:31:23,404 IDENTIFIED THAT PATIENTS HAD 2109 01:31:23,404 --> 01:31:24,572 EXTREME HETEROGENEITY AND SOME 2110 01:31:24,572 --> 01:31:26,908 OF THE REASONS THAT THESE TRIALS 2111 01:31:26,908 --> 01:31:29,544 FAILED THAT WE HAD POOR OUTCOME 2112 01:31:29,544 --> 01:31:37,418 MEASURES AND POOR TRIAL DESIGN. 2113 01:31:37,418 --> 01:31:43,491 BUT TECHNOLOGICAL ADVANCES HELP 2114 01:31:43,491 --> 01:31:46,794 UNWRAP THE PATHOGENESIS OF SHOW 2115 01:31:46,794 --> 01:31:50,598 AGAIN'S, AND IN THE 2000S THE 2116 01:31:50,598 --> 01:31:51,766 TRANSCRIPTOMICS HELPED TO 2117 01:31:51,766 --> 01:31:55,536 IDENTIFY THOSE CORE PATHWAYS AND 2118 01:31:55,536 --> 01:31:57,805 GENES THAT WERE DIFFERENTIALLY 2119 01:31:57,805 --> 01:31:58,940 REGULATED IN SHOW AGAIN'S 2120 01:31:58,940 --> 01:32:00,608 DISEASE AND THIS TOLD US THAT 2121 01:32:00,608 --> 01:32:03,745 SHOW AGAIN'S WAS RELATED TO AN 2122 01:32:03,745 --> 01:32:05,646 INFILTRATION OF T AND B CELLS 2123 01:32:05,646 --> 01:32:08,149 AND WAS REPRESENTED BY AN 2124 01:32:08,149 --> 01:32:09,417 UPREGULATION OF CLASS ONE AND 2125 01:32:09,417 --> 01:32:13,021 TWO, DIS-REGULATION OF 2126 01:32:13,021 --> 01:32:14,288 INTERFERONS AND INTERFERON 2127 01:32:14,288 --> 01:32:15,890 STIMULATED GENES AND THE 2128 01:32:15,890 --> 01:32:20,294 REGULATION OF IMMUNO DMGLOBULIN 2129 01:32:20,294 --> 01:32:21,629 EVEN THOUGH WE LEARNED A LOT 2130 01:32:21,629 --> 01:32:23,297 ABOUT THIS AUTOIMMUNE DISEASE 2131 01:32:23,297 --> 01:32:26,067 AND WE KNOW WE CAN ACCESS THAT 2132 01:32:26,067 --> 01:32:28,102 TARGET TISSUE, WE TOOK THIS 2133 01:32:28,102 --> 01:32:29,670 AFFECTED TISSUE AND WANTED TO 2134 01:32:29,670 --> 01:32:31,139 DRILL DOWN INTO WHAT WERE THE 2135 01:32:31,139 --> 01:32:35,143 CORE PATHWAYS THAT COULD BE 2136 01:32:35,143 --> 01:32:36,778 TARGETED FOR NEAR TERM 2137 01:32:36,778 --> 01:32:38,546 STRATEGIES TO TREAT SHOW AGAIN'S 2138 01:32:38,546 --> 01:32:39,914 DISEASE WITH THE IDEA THAT IF 2139 01:32:39,914 --> 01:32:42,183 WE'RE ABLE TO CORRECT THOSE 2140 01:32:42,183 --> 01:32:45,086 DYSREGULATED PATHWAYS WE COULD 2141 01:32:45,086 --> 01:32:46,721 BOTH RESTORE FUNCTION, AND 2142 01:32:46,721 --> 01:32:51,726 PERMIT REGEN RATION OF THAT 2143 01:32:51,726 --> 01:32:53,561 ORGAN. TO OPEN THIS DOOR WE 2144 01:32:53,561 --> 01:32:55,496 USED BULK RNA SEQUENCING TO LOOK 2145 01:32:55,496 --> 01:32:58,199 AT THE CORE PATHWAYS IN GENES 2146 01:32:58,199 --> 01:32:59,867 THAT WERE DISREGULATED AND ONE 2147 01:32:59,867 --> 01:33:05,106 OF THE TOP PATHWAYS WAS THE 2148 01:33:05,106 --> 01:33:07,742 JAK-STAT PATHWAY AND SHOWING A 2149 01:33:07,742 --> 01:33:09,977 HUB THAT WAS UPREGULATED AND NOT 2150 01:33:09,977 --> 01:33:12,447 FOUND AT ALL IN HEALTHY 2151 01:33:12,447 --> 01:33:13,981 VOLUNTEERS. FURTHER LEVERAGING 2152 01:33:13,981 --> 01:33:16,284 TECHNOLOGIES SUCH AS SINGLE CELL 2153 01:33:16,284 --> 01:33:19,720 AND SPATIAL TRANSCRIPTOMICS 2154 01:33:19,720 --> 01:33:22,423 SHOWING HERE SINGLE CELL 2155 01:33:22,423 --> 01:33:25,626 TRANSCRIPTOMICS WE CAN IDENTIFY 2156 01:33:25,626 --> 01:33:27,929 THE TARGET AND EFFECTOR CELLS 2157 01:33:27,929 --> 01:33:30,064 AND WHAT THIS TOLD US WAS THAT 2158 01:33:30,064 --> 01:33:34,302 THE MOST EXPANDED CELL TYPE 2159 01:33:34,302 --> 01:33:36,938 FOUND WERE THE CELLS WITH AN 2160 01:33:36,938 --> 01:33:39,640 EXHAUSTED PHENOTYPE BUT THE MOST 2161 01:33:39,640 --> 01:33:42,043 LOST CELL TYPE WERE THE CELLS 2162 01:33:42,043 --> 01:33:43,744 THAT SECRETE A SPECIFIC 2163 01:33:43,744 --> 01:33:45,847 PORTFOLIO OF PROTEINS AND 2164 01:33:45,847 --> 01:33:48,082 FLUIDS. WHEN WE USE THE SINGLE 2165 01:33:48,082 --> 01:33:51,586 CELL RNA SEQUENCING AND WE DO 2166 01:33:51,586 --> 01:33:53,454 BIOINFORMATIC ANALYSES WE CAN 2167 01:33:53,454 --> 01:33:56,057 USE RECEPTOR LIGAND ANALYSIS AND 2168 01:33:56,057 --> 01:34:00,428 HERE SHOWING THE PATHWAY THAT 2169 01:34:00,428 --> 01:34:03,831 THESE CELLS TARGET DIRECTLY 2170 01:34:03,831 --> 01:34:06,100 THOSE MUCUS AND DUCTAL 2171 01:34:06,100 --> 01:34:09,070 EPITHELIA. AND DUE TO THE 2172 01:34:09,070 --> 01:34:11,139 GENEROSITY AND THE FORESIGHT OF 2173 01:34:11,139 --> 01:34:14,475 DR. JAY WE HAD EARLY ACCESS TO 2174 01:34:14,475 --> 01:34:16,878 THE SPATIAL TRANSCRIPTOMIC 2175 01:34:16,878 --> 01:34:19,046 PLATFORM AND HERE SHOWING THE 2176 01:34:19,046 --> 01:34:21,749 SPATIAL TRANSCRIPT TOMIC STUDY 2177 01:34:21,749 --> 01:34:24,418 OF A TISSUE MICROARRAY THAT 2178 01:34:24,418 --> 01:34:27,889 REPRESENTS 22 PATIENTS. 2179 01:34:27,889 --> 01:34:30,091 WE CAN SHOW THAT THOSE SIERRA 2180 01:34:30,091 --> 01:34:33,227 MUCUS CELLS ARE IN FACT ENGAGED 2181 01:34:33,227 --> 01:34:42,303 BY THAT EFFECTOR T-CELL. THIS 2182 01:34:42,303 --> 01:34:44,705 LEVERAGES DATA IN USING CELL TO 2183 01:34:44,705 --> 01:34:46,874 THE PIPELINE SIMILAR TO THE 2184 01:34:46,874 --> 01:34:48,743 LIGAND EXCEPT IT IDENTIFIES 2185 01:34:48,743 --> 01:34:49,510 POTENTIAL DRUGS OR POTENTIAL 2186 01:34:49,510 --> 01:34:52,413 SIDE EFFECTS OF DRUGS. AND SO 2187 01:34:52,413 --> 01:34:55,950 USING OUR TMA AND SPATIAL 2188 01:34:55,950 --> 01:34:58,386 TRANSCRIPTOMICS WE CAN ACTUALLY 2189 01:34:58,386 --> 01:35:02,356 SHOW THAT ONE OF THE DRUGS THAT 2190 01:35:02,356 --> 01:35:06,761 MIGHT BE USEFUL IN SHOW AGAIN'S 2191 01:35:06,761 --> 01:35:08,429 DISEASE WERE IN FACT TOFACITINIB 2192 01:35:08,429 --> 01:35:11,165 THAT HIGHLIGHTS THESE 2193 01:35:11,165 --> 01:35:16,437 INFILTRATES IN A PERRY DUCTAL 2194 01:35:16,437 --> 01:35:18,372 PATTERN AND THIS BEING THAT 2195 01:35:18,372 --> 01:35:20,007 T-CELL INFILTRATED NEIGHBORHOOD 2196 01:35:20,007 --> 01:35:22,310 WHAT WAS REALLY INTERESTING WAS 2197 01:35:22,310 --> 01:35:27,315 NOT ONLY WAS THE -- WAS 2198 01:35:27,315 --> 01:35:28,282 TOFACITINIB MARKETING THOSE 2199 01:35:28,282 --> 01:35:30,685 CELLS BUT ALSO MARKING THOSE 2200 01:35:30,685 --> 01:35:32,453 T-CELL ENGAGED EPITHELIAL CELLS 2201 01:35:32,453 --> 01:35:33,988 AND THIS DRUG MAY IN FACT HIT 2202 01:35:33,988 --> 01:35:36,057 BOTH SIDES OF THAT AND DUE TO 2203 01:35:36,057 --> 01:35:36,991 THAT FACT -- 2204 01:35:36,991 --> 01:35:38,593 >> FIVE MORE MINUTES TO GO. 2205 01:35:38,593 --> 01:35:42,463 >> -- A RANDOMIZED TRIAL TO 2206 01:35:42,463 --> 01:35:44,799 IMPACT SIGNALLING SO TAKING THE 2207 01:35:44,799 --> 01:35:46,968 BEFORE DRUG AND OVER A SIX MONTH 2208 01:35:46,968 --> 01:35:49,837 PERIOD OF TREATMENT. WE COLLECT 2209 01:35:49,837 --> 01:35:52,907 SALIVARY FLOW RATES, WE COLLECT 2210 01:35:52,907 --> 01:35:54,609 WHOLE BLOOD. WE HOPEFULLY WOULD 2211 01:35:54,609 --> 01:35:56,978 BE ABLE TO SHOW A RESTORED GLAND 2212 01:35:56,978 --> 01:35:59,313 INCLUDING RESTORED FUNCTION. 2213 01:35:59,313 --> 01:36:02,049 AND IN THE TWELVE PATIENTS IN 2214 01:36:02,049 --> 01:36:03,217 THE INTENT TO TREAT GROUP THERE 2215 01:36:03,217 --> 01:36:06,053 WERE NO LIFE-THREATENING AES, 2216 01:36:06,053 --> 01:36:07,755 PATIENTS REPORTED LESS FATIGUE 2217 01:36:07,755 --> 01:36:09,991 AND OBJECTIVELY MORE SALIVA AND 2218 01:36:09,991 --> 01:36:12,360 SOME HAD REDUCED DISEASE 2219 01:36:12,360 --> 01:36:13,861 ACTIVITY AND INFLAMMATION IN THE 2220 01:36:13,861 --> 01:36:17,231 GLANDS AND JUST TO SHOW THIS AND 2221 01:36:17,231 --> 01:36:18,499 I WILL TALK ABOUT THE GRAPH ON 2222 01:36:18,499 --> 01:36:20,201 THE RIGHT YOU CAN SEE THE 2223 01:36:20,201 --> 01:36:24,338 DISEASE ACTIVITY OR THE SCORE AT 2224 01:36:24,338 --> 01:36:26,040 FS THAT FIVE OUT OF THE EIGHT 2225 01:36:26,040 --> 01:36:27,241 PATIENTS WHO RECEIVE DRUG HAD 2226 01:36:27,241 --> 01:36:30,645 OBJECTIVE IMPROVEMENTS. THIS 2227 01:36:30,645 --> 01:36:32,680 LEADS TO OUR CURRENT AND FUTURE 2228 01:36:32,680 --> 01:36:34,315 DIRECTIONS, THAT WE HAVE 2229 01:36:34,315 --> 01:36:36,083 IDENTIFIED MULTIPLE THERAPEUTIC 2230 01:36:36,083 --> 01:36:37,885 APPROACHES TO TREAT SHOW AGAIN'S 2231 01:36:37,885 --> 01:36:40,087 AS WELL I DIDN'T TALK ABOUT THIS 2232 01:36:40,087 --> 01:36:43,724 TODAY THAT JAK INHIBITORS MAY 2233 01:36:43,724 --> 01:36:45,059 BLOCK INTERFERENCE SIGNALLING 2234 01:36:45,059 --> 01:36:46,560 THAT THERE ARE OTHER PATHWAYS 2235 01:36:46,560 --> 01:36:51,432 THAT THIS, THESE TYPES OF 2236 01:36:51,432 --> 01:37:01,976 STUDIES ILLUMINATED. THANK YOU. 2237 01:37:02,410 --> 01:37:05,346 BEFORE I JUMP OFF I WANT TO 2238 01:37:05,346 --> 01:37:08,449 INTRODUCE THE NEXT SPEAKER 2239 01:37:08,449 --> 01:37:18,626 DR. JOEL 2240 01:37:19,126 --> 01:37:22,396 >> THE DOCTOR SHOULD BE SHARING 2241 01:37:22,396 --> 01:37:32,940 HIS OWN PRESENTATION. YEP. IS 2242 01:37:42,583 --> 01:37:43,517 THE DOCTOR ONLINE. 2243 01:37:43,517 --> 01:37:44,452 >> HELLO. I THINK I WILL BE 2244 01:37:44,452 --> 01:37:48,456 PRESENTING. CAN YOU HEAR ME? 2245 01:37:48,456 --> 01:37:51,926 >> OKAY. IS THIS THE DOCTOR? 2246 01:37:51,926 --> 01:37:54,695 >> YEAH. 2247 01:37:54,695 --> 01:37:59,100 >> OKAY. GO AHEAD, PLEASE. 2248 01:37:59,100 --> 01:38:09,377 >> SO LET ME... 2249 01:38:11,011 --> 01:38:13,848 ABOUT MORNING EVERYBODY. 2250 01:38:13,848 --> 01:38:15,149 WE'RE IN THE TRANSPORT SECTION. 2251 01:38:15,149 --> 01:38:21,155 I'M GOING TO TALK ABOUT HOW 2252 01:38:21,155 --> 01:38:23,290 THERE'S A FUNCTION THAT REPAIRS 2253 01:38:23,290 --> 01:38:26,494 THE GLAND AND FUNCTION. 2254 01:38:26,494 --> 01:38:32,266 SO SJOGREN'S DISEASE IS 2255 01:38:32,266 --> 01:38:35,870 ASSOCIATED WITH REDUCED SALIVARY 2256 01:38:35,870 --> 01:38:38,339 FUNCTION AND WE ASK THE QUESTION 2257 01:38:38,339 --> 01:38:41,842 IF THE EXPRESSION IS REDUCED AND 2258 01:38:41,842 --> 01:38:46,213 ALTERED IN MODELS OF SJOGREN'S 2259 01:38:46,213 --> 01:38:49,850 DISEASE AND IF WE CAN IMPROVE 2260 01:38:49,850 --> 01:38:51,051 THE FUNCTION. 2261 01:38:51,051 --> 01:38:57,158 FOR THE STUDY WE USED TWO MOUSE 2262 01:38:57,158 --> 01:39:00,428 MODELS IN COLLABORATION AND 2263 01:39:00,428 --> 01:39:03,330 TRANSDUCED THE MICE TO DEVELOP 2264 01:39:03,330 --> 01:39:09,003 THE SJOGREN'S SYNDROME. 2265 01:39:09,003 --> 01:39:13,207 SO OUR WESTERN BLOT AND 2266 01:39:13,207 --> 01:39:15,376 LOCALIZATION STUDY SHOWS THERE'S 2267 01:39:15,376 --> 01:39:21,382 A MARK REDUCTION IN THE PROTEINS 2268 01:39:21,382 --> 01:39:23,350 AND WE LOOKED AT THE LUMINAL 2269 01:39:23,350 --> 01:39:28,222 MEMBRANE AND THERE'S A LACK OF 2270 01:39:28,222 --> 01:39:33,994 CFTR IN BOTH LOCALIZATION AND 2271 01:39:33,994 --> 01:39:36,997 EXPRESSION AND WITH THE 2272 01:39:36,997 --> 01:39:40,234 CORRECTOR IS USED CLINICALLY TO 2273 01:39:40,234 --> 01:39:42,069 TREAT THE CYSTIC FIBROSIS 2274 01:39:42,069 --> 01:39:42,970 PATIENTS SHOWED MARK EXPRESSION 2275 01:39:42,970 --> 01:39:45,372 IN EXPRESSION AND LOCALIZATION 2276 01:39:45,372 --> 01:39:51,045 BACK TO THE DUCTS. 2277 01:39:51,045 --> 01:39:59,954 SO WE TRIED TO FIND THE DUCTS 2278 01:39:59,954 --> 01:40:03,357 FROM THE MICE AND TREATED WITH 2279 01:40:03,357 --> 01:40:06,527 C18 AND THE DUCTS ARE USED TO 2280 01:40:06,527 --> 01:40:08,662 MEASURE THE FLUID SECRETION IN 2281 01:40:08,662 --> 01:40:10,264 THE HUMAN LUMEN. 2282 01:40:10,264 --> 01:40:13,801 THE TREATMENT PARTIALLY RESTORED 2283 01:40:13,801 --> 01:40:18,138 THE DUCTAL SECRETION AND IT'S 2284 01:40:18,138 --> 01:40:20,841 MEDIATED WE MEASURED THE 2285 01:40:20,841 --> 01:40:22,943 SALVATION IN THE MICE IF IT'S 2286 01:40:22,943 --> 01:40:24,812 REPAIRING THE DUCTS AND GLANDS 2287 01:40:24,812 --> 01:40:25,212 AND FUNCTION. 2288 01:40:25,212 --> 01:40:31,619 THE MICE WERE TREATED AND TO OUR 2289 01:40:31,619 --> 01:40:33,187 SURPRISE NOT ONLY THE FLUID 2290 01:40:33,187 --> 01:40:36,590 SECRETION WAS SIGNIFICANTLY 2291 01:40:36,590 --> 01:40:39,793 RECOVERED BUT ALSO THE CELLS 2292 01:40:39,793 --> 01:40:43,631 WERE RESTORED SO IN OUR 2293 01:40:43,631 --> 01:40:54,141 CONCLUSION, THE TREATMENT WAS 2294 01:40:57,745 --> 01:40:59,313 PROMISING IN THE TREATMENT OF 2295 01:40:59,313 --> 01:41:00,180 SJOGREN'S DISEASE. 2296 01:41:00,180 --> 01:41:01,815 >> THANK YOU. 2297 01:41:01,815 --> 01:41:02,883 >> THANK YOU SO MUCH. 2298 01:41:02,883 --> 01:41:07,521 WE'LL NOW MOVE TO CLINICALLY 2299 01:41:07,521 --> 01:41:09,456 SESSION TWO ON CELLULAR AND 2300 01:41:09,456 --> 01:41:11,358 MATRIX BIOLOGY. 2301 01:41:11,358 --> 01:41:14,562 DR. KELLY VIGNETTE 2302 01:41:14,562 --> 01:41:17,264 TO FOLLOW FOLLOWED BY 2303 01:41:17,264 --> 01:41:20,768 DR. CONSTANTINA. 2304 01:41:20,768 --> 01:41:23,571 >> GREAT. THANK YOU. SO TODAY 2305 01:41:23,571 --> 01:41:25,105 I'LL TELL YOU ABOUT SOME OF THE 2306 01:41:25,105 --> 01:41:27,308 WORK FROM THESE FIVE PIS WHO 2307 01:41:27,308 --> 01:41:29,877 STUDY SKELETAL MATRIX AND 2308 01:41:29,877 --> 01:41:32,146 MECHANOBIOLOGY HERE AT THE 2309 01:41:32,146 --> 01:41:34,014 NIDCR. SO THE LONG HISTORY OF 2310 01:41:34,014 --> 01:41:35,916 DISCOVERY AND THE FIELD OF 2311 01:41:35,916 --> 01:41:38,152 SKELETAL AND MATRIX RESEARCH AT 2312 01:41:38,152 --> 01:41:39,753 THE NIDCR BEGAN WITH DR. DAVID 2313 01:41:39,753 --> 01:41:43,190 SCOTT FORMER DIRECTOR OF THE 2314 01:41:43,190 --> 01:41:45,893 NIDCR AND DR. MA ROOE WHO 2315 01:41:45,893 --> 01:41:49,930 STUDIED MINERALIZED TISSUE USING 2316 01:41:49,930 --> 01:41:52,333 THE TECHNIQUE OF MICROSCOPY. 2317 01:41:52,333 --> 01:41:54,902 THIS CONTINUED WITH DR. PEE YEZ 2318 01:41:54,902 --> 01:41:58,906 AND MARTIN WORKING ON COLLAGENS, 2319 01:41:58,906 --> 01:42:02,343 VINCE HAS CALENDAR, AND HARRY 2320 01:42:02,343 --> 01:42:06,080 WORKED ON BMP. THEN JOHN 2321 01:42:06,080 --> 01:42:08,449 DEVELOPED METHODS FOR ISOLATED 2322 01:42:08,449 --> 01:42:10,651 BONE PROTEINS WITHOUT ENZYMATIC 2323 01:42:10,651 --> 01:42:11,986 DIGESTION AND PUT TOGETHER A 2324 01:42:11,986 --> 01:42:14,888 TEAM CONSISTING OF DR. AVA WHO 2325 01:42:14,888 --> 01:42:16,724 STUDIED BONE MARROW, LARRY 2326 01:42:16,724 --> 01:42:19,093 FISHER WHO CHARACTER IDEAS THE 2327 01:42:19,093 --> 01:42:21,729 PROTEINS, PAM WHO ISOLATED THE 2328 01:42:21,729 --> 01:42:24,064 CELLS, MARY ANN YOUNG WHO 2329 01:42:24,064 --> 01:42:24,999 STUDIED THE GENES AND MIKE COLIN 2330 01:42:24,999 --> 01:42:27,267 WHO IS TRANSLATED ALL THIS WORK 2331 01:42:27,267 --> 01:42:28,836 INTO PATIENTS WITH DISORDERS OF 2332 01:42:28,836 --> 01:42:35,909 BONE AND MARROW HOMEOSTASIS. 2333 01:42:35,909 --> 01:42:37,911 SORRY, CAN YOU SEE MY SCREEN? 2334 01:42:37,911 --> 01:42:39,546 THERE'S THIS TEAMS THING IN THE 2335 01:42:39,546 --> 01:42:39,713 WAY. 2336 01:42:39,713 --> 01:42:40,881 >> YES. 2337 01:42:40,881 --> 01:42:42,816 >> OKAY. THANK YOU. SO OUR 2338 01:42:42,816 --> 01:42:44,418 GOAL IS TO INVESTIGATE SKELETAL 2339 01:42:44,418 --> 01:42:47,855 ISSUES THAT INCLUDE CARTILAGE, 2340 01:42:47,855 --> 01:42:49,590 BONES AND TEETH AS WELL AS BONE 2341 01:42:49,590 --> 01:42:51,291 MARROW, TENDONS AND LIGAMENT 2342 01:42:51,291 --> 01:42:52,760 WHICH IS ARE IMPORTANT AS THEY 2343 01:42:52,760 --> 01:42:55,295 COMPRISE THE DENTAL, ORAL, 2344 01:42:55,295 --> 01:42:56,864 CRANIOFACIAL COMPLEX AND WE AIM 2345 01:42:56,864 --> 01:43:01,035 TO REDUCE CHRONIC DISEASES BY 2346 01:43:01,035 --> 01:43:02,970 APPLYING CLINICAL RESEARCH TO 2347 01:43:02,970 --> 01:43:05,606 GAIN INSIGHT INTO 2348 01:43:05,606 --> 01:43:07,841 PATHOPHYSIOLOGIC AND DEVELOPMENT 2349 01:43:07,841 --> 01:43:11,245 MECHANISMS SO OUR APPROACH IS 2350 01:43:11,245 --> 01:43:15,282 WITH MODEL SUCH AS STEM CELLS, 2351 01:43:15,282 --> 01:43:16,183 AND COMPUTATIONAL ANALYSES AND 2352 01:43:16,183 --> 01:43:17,818 WE HAVE SHOWN ACROSS MANY 2353 01:43:17,818 --> 01:43:18,986 DISORDERS OUR ABILITY TO 2354 01:43:18,986 --> 01:43:21,088 TRANSLATE THE PRINCIPLES WE FIND 2355 01:43:21,088 --> 01:43:22,389 DIRECTLY TO PATIENT CARE THROUGH 2356 01:43:22,389 --> 01:43:24,792 CLINICAL TRIALS THAT IMPROVE 2357 01:43:24,792 --> 01:43:25,693 PROGNOSIS AND TREATMENT OF 2358 01:43:25,693 --> 01:43:28,962 SEVERAL DISORDERS. SO THE 2359 01:43:28,962 --> 01:43:30,431 GROUP'S ACTIVITIES ENCOMPASS A 2360 01:43:30,431 --> 01:43:32,599 BROAD SPECTRUM OF COLLABORATIVE 2361 01:43:32,599 --> 01:43:34,601 STUDIES WITHIN SKELETAL AND 2362 01:43:34,601 --> 01:43:36,603 CRANIOFACIAL BIOLOGY. WE 2363 01:43:36,603 --> 01:43:39,339 TRANSLATE WORK ON FUNDAMENTAL 2364 01:43:39,339 --> 01:43:40,240 CELL TYPES AND HORMONES INTO 2365 01:43:40,240 --> 01:43:42,576 SEVERAL PATIENT COHORTS OF RARE 2366 01:43:42,576 --> 01:43:44,111 DISEASES WHICH CAN THEN INFORM 2367 01:43:44,111 --> 01:43:46,814 MUCH MORE COMMON DISEASES. AND 2368 01:43:46,814 --> 01:43:49,516 THE USE OF RARE DISEASES TO GAIN 2369 01:43:49,516 --> 01:43:51,919 INSIGHTS INTO COMMON DISEASES IS 2370 01:43:51,919 --> 01:43:54,488 A STRATEGIC DECISION AS THESE 2371 01:43:54,488 --> 01:43:56,123 RARE DISEASES ARE OFTEN MONO 2372 01:43:56,123 --> 01:43:57,391 GENERALIC AND THEREFORE THEY 2373 01:43:57,391 --> 01:43:59,593 HAVE FEWER COMPOUNDING VARIABLES 2374 01:43:59,593 --> 01:44:02,329 THAN CHRONIC CONDITIONS DO. FOR 2375 01:44:02,329 --> 01:44:05,065 INSTANCE, STUDYING HYPO FOZ FOE 2376 01:44:05,065 --> 01:44:07,067 TEAM YA ELIMINATES THE VARIABLES 2377 01:44:07,067 --> 01:44:10,437 OF STUDYING IN CHRONIC KIDNEY 2378 01:44:10,437 --> 01:44:11,405 DISEASES WHERE THOSE PATIENTS 2379 01:44:11,405 --> 01:44:13,807 HAVE COMORBID CONDITIONS SUCH AS 2380 01:44:13,807 --> 01:44:16,777 HYPERTENSION SO THIS ALLOWS A 2381 01:44:16,777 --> 01:44:19,880 CLEARER RESULT IN INTERPRETING A 2382 01:44:19,880 --> 01:44:25,119 CLINICAL TRIAL. AN EXAMPLE OF 2383 01:44:25,119 --> 01:44:26,220 THIS IS THE RARE DISEASE 2384 01:44:26,220 --> 01:44:28,255 SYNDROME AND THIS IS STUDIED. 2385 01:44:28,255 --> 01:44:30,324 THIS PATIENT HERE DEMONSTRATES 2386 01:44:30,324 --> 01:44:33,827 THE CHARACTERISTIC FEATURES 2387 01:44:33,827 --> 01:44:37,231 INCLUDING THIS EYES, LOW SET 2388 01:44:37,231 --> 01:44:39,299 EARS, ALL OF WHICH ARE 2389 01:44:39,299 --> 01:44:43,637 CONSISTENT WITH A CRANIAL BASE 2390 01:44:43,637 --> 01:44:45,305 ABNORMALITY AND PATH MNEMONIC 2391 01:44:45,305 --> 01:44:47,341 FOR THIS CONDITION. SO THIS 2392 01:44:47,341 --> 01:44:51,345 SYNDROME IS A DISORDER OF TGF 2393 01:44:51,345 --> 01:44:53,380 BETA SIGNALLING AND CAUSE THIS 2394 01:44:53,380 --> 01:44:58,285 IS PATHOLOGY, ENAMEL DEFECTS AS 2395 01:44:58,285 --> 01:45:01,221 SEEN HERE AND AORTIC ANEURYSMS 2396 01:45:01,221 --> 01:45:03,323 THAT CAN BE FATAL SO THEY USE 2397 01:45:03,323 --> 01:45:05,893 THIS MODEL DISEASE TO STUDY 2398 01:45:05,893 --> 01:45:09,329 CRANIOFACIAL ANOMALIES AS WELL 2399 01:45:09,329 --> 01:45:12,800 AS TMJ DISORDER THAT CAN BE 2400 01:45:12,800 --> 01:45:13,600 TRANSLATED TO THE GENERAL 2401 01:45:13,600 --> 01:45:17,571 POPULATION WHO SUFFER FROM TMJ, 2402 01:45:17,571 --> 01:45:19,373 AND FROM DENTAL CARIES. 2403 01:45:19,373 --> 01:45:21,341 ADDITIONALLY, THE USE OF THE NIH 2404 01:45:21,341 --> 01:45:22,943 CLINICAL CENTER TO STUDY RARE 2405 01:45:22,943 --> 01:45:24,711 DISEASES IS A GOOD USE OF 2406 01:45:24,711 --> 01:45:25,779 RESOURCES SINCE PATIENTS FROM 2407 01:45:25,779 --> 01:45:27,314 ALL OVER THE COUNTRY CAN COME 2408 01:45:27,314 --> 01:45:29,449 TOGETHER HERE AT THE NIH 2409 01:45:29,449 --> 01:45:31,685 ENABLING THIS TRULY SPECIALIZED 2410 01:45:31,685 --> 01:45:33,387 MEDICAL CARE AND STUDIES THAT 2411 01:45:33,387 --> 01:45:35,022 REALLY CANNOT BE DONE WHEN ONLY 2412 01:45:35,022 --> 01:45:39,326 ONE CASE EXISTS IN ANY GIVEN 2413 01:45:39,326 --> 01:45:41,061 REGION. SO COMPILING RESOURCES 2414 01:45:41,061 --> 01:45:42,963 FOR THESE RARE DISEASES IN ONE 2415 01:45:42,963 --> 01:45:44,898 SPACE AND BRINGING IN PATIENTS 2416 01:45:44,898 --> 01:45:48,335 FROM ALL FIFTY STATES IS MORE 2417 01:45:48,335 --> 01:45:49,236 FEASIBLE AND COST-EFFECTIVE FOR 2418 01:45:49,236 --> 01:45:51,338 EACH SINGLE PATIENT. THE 2419 01:45:51,338 --> 01:45:52,739 RESOURCES HERE AT THE CLINICAL 2420 01:45:52,739 --> 01:45:54,708 CENTER PROVIDE A UNIQUE 2421 01:45:54,708 --> 01:45:55,475 OPPORTUNITY FOR TRANSLATION 2422 01:45:55,475 --> 01:45:57,411 WHICH CAN REALLY ONLY BE DONE IN 2423 01:45:57,411 --> 01:46:00,581 OUR INTRAMURAL RESEARCH PROGRAM. 2424 01:46:00,581 --> 01:46:02,649 SO TODAY I'D LIKE TO TELL YOU 2425 01:46:02,649 --> 01:46:06,053 ABOUT TWO OF MANY OF THESE 2426 01:46:06,053 --> 01:46:07,120 TRANSLATIONAL PROGRAMS ANDLY 2427 01:46:07,120 --> 01:46:08,856 START WITH FIBROUS DISPLAY SHA 2428 01:46:08,856 --> 01:46:13,126 OR ACUTE ALBRIGHT SYNDROME. SO 2429 01:46:13,126 --> 01:46:15,162 YEARS AGO DR. PAM WAS WORKING ON 2430 01:46:15,162 --> 01:46:18,866 BONE MARROW SKELETAL STEM CELLS 2431 01:46:18,866 --> 01:46:23,337 OR SSCS THAT MAKE BONE, 2432 01:46:23,337 --> 01:46:26,406 CARTILAGE, MARROW FAT AND STROMA 2433 01:46:26,406 --> 01:46:29,243 CELLS WHICH SUPPORT HE MAT TOPO 2434 01:46:29,243 --> 01:46:32,846 WEE SIS, SHE CONFIRMED THIS IS 2435 01:46:32,846 --> 01:46:35,215 TRUE BY GROWING CELLS AND THEN 2436 01:46:35,215 --> 01:46:36,216 TRANSPLANTING THEM INTO A MOUSE 2437 01:46:36,216 --> 01:46:38,685 MODEL AND INDEED THESE 2438 01:46:38,685 --> 01:46:39,453 TRANSPLANTS WERE ABLE TO MAKE 2439 01:46:39,453 --> 01:46:42,289 EACH LINE OF CELLS AND THEY WERE 2440 01:46:42,289 --> 01:46:43,957 ABLE TO SUPPORT HE MAT TOPO WEE 2441 01:46:43,957 --> 01:46:47,094 SIS WHICH IS A DEFINING 2442 01:46:47,094 --> 01:46:48,061 CHARACTERISTIC OF STROMA CELLS 2443 01:46:48,061 --> 01:46:50,430 SHE THEN HYPOTHESIZED THAT THESE 2444 01:46:50,430 --> 01:46:52,766 CELLS ARE CENTRAL TO SKELETAL 2445 01:46:52,766 --> 01:46:53,834 HOMEOSTASIS IT WAS FOUND THAT 2446 01:46:53,834 --> 01:46:57,671 THEY SECRETE FACTORS SUCH AS SGF 2447 01:46:57,671 --> 01:47:00,007 23 THE BASIS OF MY RESEARCH 2448 01:47:00,007 --> 01:47:01,975 PROGRAM AND COPEP TIN THE 2449 01:47:01,975 --> 01:47:04,945 PRECURSOR OF VASOPRESSIN THAT 2450 01:47:04,945 --> 01:47:05,746 CONTROLS BLEEDING PROCESS 2451 01:47:05,746 --> 01:47:07,981 STUDIED BY DR. AVA. AND 2452 01:47:07,981 --> 01:47:09,082 FURTHERMORE SHE HYPOTHESIZED 2453 01:47:09,082 --> 01:47:11,418 THAT A MUTATION IN THESE 2454 01:47:11,418 --> 01:47:13,587 SKELETAL STEM CELLS COULD CAUSE 2455 01:47:13,587 --> 01:47:14,187 SKELETAL DISEASE AND THIS 2456 01:47:14,187 --> 01:47:19,359 BROUGHT HER TO THE STUDY OF THE 2457 01:47:19,359 --> 01:47:21,428 ALBRIGHT SYNDROME A DISORDER 2458 01:47:21,428 --> 01:47:22,863 CAUSED BY THE FUNCTION VARIANTS 2459 01:47:22,863 --> 01:47:24,798 SO PATIENTS WITH THIS DISEASE 2460 01:47:24,798 --> 01:47:27,301 HAVE EXPANSE BONE LESIONS KNOWN 2461 01:47:27,301 --> 01:47:28,969 AS DISPLAY THAT THAT CAN RESULT 2462 01:47:28,969 --> 01:47:31,705 IN DEFORMATIVES, FRACTURES AND 2463 01:47:31,705 --> 01:47:34,875 PAIN AND THERE ARE NO 2464 01:47:34,875 --> 01:47:36,543 ESTABLISHED TREATMENTS FOR THIS 2465 01:47:36,543 --> 01:47:38,045 THIS DISORDER SO SHE AND HER 2466 01:47:38,045 --> 01:47:41,348 TEAM OBSERVED THIS AND 2467 01:47:41,348 --> 01:47:42,282 POSTULATED THAT STEM CELLS WOULD 2468 01:47:42,282 --> 01:47:45,018 BE THE DRIVING FACTOR IN FD. SO 2469 01:47:45,018 --> 01:47:46,853 THIS MODEL OF TRANSLATIONAL 2470 01:47:46,853 --> 01:47:48,488 RESEARCH THAT I SHOW HERE IS ONE 2471 01:47:48,488 --> 01:47:50,724 THAT WE'VE EMPLOYED IN SEVERAL 2472 01:47:50,724 --> 01:47:53,560 DISEASE MODELS HERE. SO WE MAKE 2473 01:47:53,560 --> 01:47:55,629 OBSERVATIONS, COLLECT BIO 2474 01:47:55,629 --> 01:47:57,064 SPECIMENS AND DRAW HYPOTHESES 2475 01:47:57,064 --> 01:47:59,333 FROM OUR PATIENT TO DRIVE BASIC 2476 01:47:59,333 --> 01:48:01,835 SCIENCE WORK AT THE BENCH 2477 01:48:01,835 --> 01:48:03,337 GAINING MECHANIC IN THIS CASIC 2478 01:48:03,337 --> 01:48:04,805 KNOWLEDGE THAT DRIVES PREVENTION 2479 01:48:04,805 --> 01:48:06,807 AND CLINICAL TREATMENT TRIALS. 2480 01:48:06,807 --> 01:48:10,010 SO, SHE STUDIED THE SKELETAL 2481 01:48:10,010 --> 01:48:14,748 STEM CELL WITH AN ACTIVATED GENE 2482 01:48:14,748 --> 01:48:17,217 ALPHA S AND FOUND THIS PREVENTED 2483 01:48:17,217 --> 01:48:19,553 THE CELL FROM MAKING CARTILAGE 2484 01:48:19,553 --> 01:48:22,422 OR BAN MARROW STROMA CELLS IN 2485 01:48:22,422 --> 01:48:24,725 FACT THIS MADE ONLY ABNORMAL 2486 01:48:24,725 --> 01:48:25,325 OSTEOBLASTS. WHICH ARE THE 2487 01:48:25,325 --> 01:48:32,099 CAUSE OF THIS DISORDER. SO HERE 2488 01:48:32,099 --> 01:48:33,166 YOU CAN SEE NORMAL BONE BUT HERE 2489 01:48:33,166 --> 01:48:36,636 IN THE SAMPLE FROM A PATIENT BE 2490 01:48:36,636 --> 01:48:39,339 FD YOU CAN SEE WOVEN BONE AND 2491 01:48:39,339 --> 01:48:41,975 MARROW FIBROSIS AND NOTABLY BLI 2492 01:48:41,975 --> 01:48:43,877 SHE TRANSPLANTED CELLS INTO THE 2493 01:48:43,877 --> 01:48:45,312 MOUSE AND FOUND A PAT PERSON 2494 01:48:45,312 --> 01:48:47,314 THAT REALLY IMICED THIS PATIENT 2495 01:48:47,314 --> 01:48:49,383 BIOPSY THAT YOU CAN SEE HERE. 2496 01:48:49,383 --> 01:48:51,618 SO THIS BASIC WORK HAS BEEN 2497 01:48:51,618 --> 01:48:52,753 TRANSLATED TO CLINICAL CARE WHEN 2498 01:48:52,753 --> 01:48:54,855 DR. MICHAEL COLLINS BEGAN OUR 2499 01:48:54,855 --> 01:48:57,257 CLINICAL PROTOCOL IN 1998 WITH 2500 01:48:57,257 --> 01:49:00,460 THE GOAL OF DEFINING THE 2501 01:49:00,460 --> 01:49:02,062 SPECTRUM OF DISEASE ESTABLISHING 2502 01:49:02,062 --> 01:49:03,630 STANDARDS OF CARE AND DEVELOPING 2503 01:49:03,630 --> 01:49:08,201 NOVEL TREATMENTS. DR. ALISON, A 2504 01:49:08,201 --> 01:49:10,337 SCHOLAR AND TENURED TRACK 2505 01:49:10,337 --> 01:49:12,239 INVESTIGATOR NOW LEADS THIS 2506 01:49:12,239 --> 01:49:13,407 STUDY THAT HAS OVER 300 PATIENTS 2507 01:49:13,407 --> 01:49:16,009 SO PATIENTS TYPICALLY VISIT THE 2508 01:49:16,009 --> 01:49:17,144 CLINICAL CENTER FOR A WEEK 2509 01:49:17,144 --> 01:49:17,944 DURING WHICH THEY HAVE 2510 01:49:17,944 --> 01:49:21,481 LABORATORY STUDIES AND 2511 01:49:21,481 --> 01:49:22,149 RADIOLOGIC STUDIES AND THEY SEE 2512 01:49:22,149 --> 01:49:23,483 SEVERAL DIFFERENT CONSULTANTS 2513 01:49:23,483 --> 01:49:26,086 AND THIS STUDY HAS TRULY CHANGED 2514 01:49:26,086 --> 01:49:28,889 THE LANDSCAPE FOR PATIENTS WITH 2515 01:49:28,889 --> 01:49:31,324 FDMAS. SO YOU MIGHT RECALL IN 2516 01:49:31,324 --> 01:49:35,028 THIS IMAGE A FIBROUS BONE THAT 2517 01:49:35,028 --> 01:49:36,963 WAS SEEN ON HISTOLOGY AND SHE 2518 01:49:36,963 --> 01:49:37,998 WONDERED WHAT ROLE THEY MIGHT 2519 01:49:37,998 --> 01:49:42,369 PLAY IN THE PATHOGENESIS OF FD. 2520 01:49:42,369 --> 01:49:44,938 SO OSTEOBLAST ARE KNOWN TO 2521 01:49:44,938 --> 01:49:47,340 INTERACT WITH OSTEOCLASTS. AND 2522 01:49:47,340 --> 01:49:50,143 THIS CROSSTALK BETWEEN CELLS 2523 01:49:50,143 --> 01:49:52,079 INDUCES OSTEOPLAST PRECURSORS TO 2524 01:49:52,079 --> 01:49:53,580 FUSE AND DIFFERENTIATE INTO 2525 01:49:53,580 --> 01:49:57,784 THESE ACTIVE OSTEOCLASTS. AND 2526 01:49:57,784 --> 01:50:02,022 INTERESTINGLY, RANKL IS HIGHLY 2527 01:50:02,022 --> 01:50:03,423 EXPRESSED AS YOU CAN SEE WITH 2528 01:50:03,423 --> 01:50:09,062 THE ARROWS HERE ILLUSTRATING THE 2529 01:50:09,062 --> 01:50:10,831 CELLS AND YOU CAN SEE THE RANKL 2530 01:50:10,831 --> 01:50:12,866 LEVELS CORRELATED WITH THE 2531 01:50:12,866 --> 01:50:15,102 BURDEN IN FD PATIENTS AND THE 2532 01:50:15,102 --> 01:50:17,070 OBSERVATIONS GAINED FROM THESE 2533 01:50:17,070 --> 01:50:19,339 PATIENT SAMPLE LED HER TO A NEW 2534 01:50:19,339 --> 01:50:22,342 INTERESTING HYPOTHESIS. SO SHE 2535 01:50:22,342 --> 01:50:25,078 HYPOTHESIZE THAT HAD SHE COULD 2536 01:50:25,078 --> 01:50:27,914 REPURPOSE THE DRUG DENOS SAY MAB 2537 01:50:27,914 --> 01:50:31,118 TO SERVE AS A NOVEL TREATMENT 2538 01:50:31,118 --> 01:50:33,820 STRATEGY TO DECREASE FD LESION 2539 01:50:33,820 --> 01:50:35,755 ACTIVITY AND INCREASE LESION 2540 01:50:35,755 --> 01:50:38,792 MINERAL SAYINGS SO BY 2541 01:50:38,792 --> 01:50:42,462 INTERFERING HERE WITH RANKL 2542 01:50:42,462 --> 01:50:43,997 SIGNALLING AT THE PRECURSORS 2543 01:50:43,997 --> 01:50:46,733 INTO THE ACTIVE OSTEOCLASTS AT 2544 01:50:46,733 --> 01:50:49,136 THE BENCH, THEY USED A MOUSE 2545 01:50:49,136 --> 01:50:51,805 MODEL TO SHOW THE POTENTIAL FOR 2546 01:50:51,805 --> 01:50:53,707 RANKL INHIBITION TO INCREASE 2547 01:50:53,707 --> 01:50:54,941 BONE INFLAMMATION AND YOU CAN 2548 01:50:54,941 --> 01:50:58,245 SEE HERE THE BIOPSY OF THE WILD 2549 01:50:58,245 --> 01:51:00,480 TYPE MOUSE SHOWING THE BONE 2550 01:51:00,480 --> 01:51:01,481 MARROW CONSISTENT WITH THE 2551 01:51:01,481 --> 01:51:04,117 PATIENT PHENOTYPE HERE HERE THE 2552 01:51:04,117 --> 01:51:09,422 FD MOUSE HAS THIS WOVEN BONE AND 2553 01:51:09,422 --> 01:51:10,657 MARROW FIBROSIS AND 2554 01:51:10,657 --> 01:51:12,058 ADMINISTRATION OF ANTI-RANKL WAS 2555 01:51:12,058 --> 01:51:13,793 ABLE TO SUPPRESS THE ACTIVITY 2556 01:51:13,793 --> 01:51:17,130 AND RESTORE THIS NORMAL LA 2557 01:51:17,130 --> 01:51:18,532 MEDICAL LAR BONE FORMATION AND 2558 01:51:18,532 --> 01:51:20,167 IN INDEED THIS PRECLINICAL WORK 2559 01:51:20,167 --> 01:51:22,802 WAS TRANSLATED INTO THE PATIENT 2560 01:51:22,802 --> 01:51:24,271 POPULATION IN A CLINICAL TRIAL 2561 01:51:24,271 --> 01:51:28,542 LED BY DR. BOISE WHERE PATIENTS 2562 01:51:28,542 --> 01:51:33,880 WERE GIVENS IS DENOS SUE MAB AND 2563 01:51:33,880 --> 01:51:35,348 SAW IMPROVEMENT. ADDITIONALLY 2564 01:51:35,348 --> 01:51:38,952 SEEN HERE ARE THE PET SCANS THAT 2565 01:51:38,952 --> 01:51:40,921 SHOWED MARKED DECREASE IN 2566 01:51:40,921 --> 01:51:43,323 ACTIVITY SO AT BASELINE THESE 2567 01:51:43,323 --> 01:51:44,391 LESIONS ARE REFLECTED BY THIS 2568 01:51:44,391 --> 01:51:46,459 DARK ACTIVE REMODELLING BONE BUT 2569 01:51:46,459 --> 01:51:50,463 AFTER SIX MONTHS ON DENOS SUE 2570 01:51:50,463 --> 01:51:53,500 MAB THE ACTIVITY IS DECREASED 2571 01:51:53,500 --> 01:51:54,668 SIGNIFICANTLY AND REALLY 2572 01:51:54,668 --> 01:51:55,769 IMPORTANTLY, THE PATIENTS 2573 01:51:55,769 --> 01:51:57,571 REPORTED IMPROVEMENT IN THEIR 2574 01:51:57,571 --> 01:52:00,640 PAIN, AND IN THE PHYSICAL 2575 01:52:00,640 --> 01:52:01,942 FUNCTION. SO BACK TO THE BENCH 2576 01:52:01,942 --> 01:52:03,610 NOW. AS WORK ON THE SKELETAL 2577 01:52:03,610 --> 01:52:06,913 STEM CELLS HAS CONTINUED, THE 2578 01:52:06,913 --> 01:52:10,650 LAB NOTED BASED ON THEIR 2579 01:52:10,650 --> 01:52:12,552 MULTIPOTENT NATURE SKELETAL STEM 2580 01:52:12,552 --> 01:52:14,487 CELLS ARE PRIME CANDIDATES FOR 2581 01:52:14,487 --> 01:52:16,056 THE DEVELOPMENT OF TREATMENT IN 2582 01:52:16,056 --> 01:52:17,557 BOOSTING THESE VARIOUS CELL 2583 01:52:17,557 --> 01:52:18,992 TYPES AND THIS COULD REALLY HAVE 2584 01:52:18,992 --> 01:52:21,595 IMPLICATIONS IN THE TREATMENT OF 2585 01:52:21,595 --> 01:52:23,330 OSTEOPOROSIS, OSTEOARTHRITIS AND 2586 01:52:23,330 --> 01:52:25,899 AGING SO THE GROUP IS WORK 2587 01:52:25,899 --> 01:52:26,466 EXTENSIVELY ON DEVELOPING 2588 01:52:26,466 --> 01:52:28,001 METHODS TO USE THESE CELLS FOR 2589 01:52:28,001 --> 01:52:30,203 REGEN RATION OF BONE AND 2590 01:52:30,203 --> 01:52:33,473 CARTILAGE, LOSS DUE TO TRAUMA 2591 01:52:33,473 --> 01:52:36,109 AND DISEASE. SO THEY ALSO NOW 2592 01:52:36,109 --> 01:52:39,179 ROUTINELY USE CD34 POSITIVE 2593 01:52:39,179 --> 01:52:41,081 PERIPHERAL BLOOD CELL TO DEVELOP 2594 01:52:41,081 --> 01:52:44,584 IPSCS GIVING US A HUMAN BASED 2595 01:52:44,584 --> 01:52:46,987 MODEL THUS CELLS FOR NORMAL 2596 01:52:46,987 --> 01:52:48,488 INDIVIDUALS AND CELLS FROM 2597 01:52:48,488 --> 01:52:50,390 PATIENTS WITH VARIOUS DISORDERS 2598 01:52:50,390 --> 01:52:52,125 CAN BE USED TO DEVELOP IPCS THAT 2599 01:52:52,125 --> 01:52:55,462 CAN STUDY NEW DISEASES, STUDY 2600 01:52:55,462 --> 01:52:57,430 REGEN RATION OF A VARIETY OF 2601 01:52:57,430 --> 01:53:00,000 TISSUES AND DEVELOP CURES SO NOW 2602 01:53:00,000 --> 01:53:01,968 I WOULD LIKE TO SHIFT GEARS A 2603 01:53:01,968 --> 01:53:05,071 LITTLE BIT AND TALK ABOUT A 2604 01:53:05,071 --> 01:53:07,274 DISEASE I'M STUDYING. HNTC. 2605 01:53:07,274 --> 01:53:12,145 THIS IS A DISORDER OF FTF 2606 01:53:12,145 --> 01:53:13,380 DEFICIENCY THAT LEADS TO HIGH 2607 01:53:13,380 --> 01:53:15,882 PHOSPHATE LEVELS AND CAN CAUSE 2608 01:53:15,882 --> 01:53:18,351 LARGE CALCIFICATIONS AS YOU CAN 2609 01:53:18,351 --> 01:53:19,853 SEE OVER HERE AND THE MOST 2610 01:53:19,853 --> 01:53:21,221 PENETRATING FEATURE OF THIS CELL 2611 01:53:21,221 --> 01:53:22,789 IS THE DENTAL PHENOTYPE 2612 01:53:22,789 --> 01:53:25,492 CONSISTING OF THE SHORT BULBOUS 2613 01:53:25,492 --> 01:53:27,594 ROOTS AND PULP STONES AND HFTC 2614 01:53:27,594 --> 01:53:30,263 HAS THE POTENTIAL TO INFORM 2615 01:53:30,263 --> 01:53:32,399 CHRONIC COMMON DISORDERS SUCH AS 2616 01:53:32,399 --> 01:53:34,868 HYPER PHOSPHOTEAM YA OF CHRONIC 2617 01:53:34,868 --> 01:53:38,171 RENAL FAILURE AND VASCULAR 2618 01:53:38,171 --> 01:53:39,339 CALCIFICATION. SO MY GROUP 2619 01:53:39,339 --> 01:53:41,207 FOLLOWS RESEARCH AT THE BENCH 2620 01:53:41,207 --> 01:53:42,742 WHERE ACTIVELY TESTING THE ROLE 2621 01:53:42,742 --> 01:53:44,711 OF PRESSURE AND CALCIFICATION 2622 01:53:44,711 --> 01:53:46,146 DEVELOPMENT AS WELL AS THE 2623 01:53:46,146 --> 01:53:47,480 EFFECTS OF TREATMENT WITH THE 2624 01:53:47,480 --> 01:53:48,982 NOVEL COMPOUNDS ON 2625 01:53:48,982 --> 01:53:49,783 CALCIFICATION. AND WE'RE ALSO 2626 01:53:49,783 --> 01:53:52,752 IN THE PROCESS OF INITIATING AN 2627 01:53:52,752 --> 01:53:54,120 IND CLINICAL TRIAL TO REPURPOSE 2628 01:53:54,120 --> 01:53:58,158 A DRUG FOR USE IN PATIENTS WITH 2629 01:53:58,158 --> 01:54:00,193 HFTC. MUCH LIKE THE WORK I 2630 01:54:00,193 --> 01:54:03,196 DESCRIBED IN FDMAS WE'VE BEEN 2631 01:54:03,196 --> 01:54:04,230 DEFINING THE NATURAL HISTORY OF 2632 01:54:04,230 --> 01:54:05,365 THESE PATIENTS AND WE NOW CARE 2633 01:54:05,365 --> 01:54:07,867 FOR THE WORLD'S LARGEST WE'LL 2634 01:54:07,867 --> 01:54:10,270 STUDIED COHORT OF PATIENTS WITH 2635 01:54:10,270 --> 01:54:11,771 HFTC. SO WE'RE ESTABLISHING NEW 2636 01:54:11,771 --> 01:54:14,074 STANDARDS OF CARE AND DEVELOPING 2637 01:54:14,074 --> 01:54:15,342 A NEW TREATMENT TRIALS AND TODAY 2638 01:54:15,342 --> 01:54:17,177 I'M GOING TO TELL YOU ABOUT MY 2639 01:54:17,177 --> 01:54:19,879 WORK TO CHARACTERIZE VASCULAR 2640 01:54:19,879 --> 01:54:21,114 CALCIFICATION AND TO IDENTIFY 2641 01:54:21,114 --> 01:54:22,816 BUY QUO MARKERS. REMEMBER 2642 01:54:22,816 --> 01:54:24,117 BIOMARKERS ARE CRITICAL TO THE 2643 01:54:24,117 --> 01:54:25,285 ABILITY TO ASSESS THE 2644 01:54:25,285 --> 01:54:27,320 PROGRESSION OF A DISEASE AND THE 2645 01:54:27,320 --> 01:54:29,055 EFFICACY OF TREATMENT AND TO 2646 01:54:29,055 --> 01:54:31,324 DEFINE MININGFUL AND POINTS SO 2647 01:54:31,324 --> 01:54:33,326 THAT WE CAN CONDUCT A CLINICAL 2648 01:54:33,326 --> 01:54:34,994 TRIAL. SO THROUGH OUR CLINICAL 2649 01:54:34,994 --> 01:54:36,696 OBSERVATIONS, WE HAVE REALIZED 2650 01:54:36,696 --> 01:54:38,298 THE NEED TO UNDERSTAND THE 2651 01:54:38,298 --> 01:54:39,332 EVOLUTION OF PATIENT 2652 01:54:39,332 --> 01:54:42,135 CALCIFICATIONS SO WE INITIATED 2653 01:54:42,135 --> 01:54:45,205 THE USE OF SODIUM FLUORIDE PET 2654 01:54:45,205 --> 01:54:46,740 SCANS IN THIS PATIENT POPULATION 2655 01:54:46,740 --> 01:54:48,942 AND DEVELOPED A TECHNIQUE TO 2656 01:54:48,942 --> 01:54:50,677 IDENTIFY AND QUANTIFY VASCULAR 2657 01:54:50,677 --> 01:54:54,781 CALCIFICATION IN HFTC BY 2658 01:54:54,781 --> 01:54:56,983 ISOLATING AND THEN DISSECTING 2659 01:54:56,983 --> 01:54:59,953 OUT THE AORTA. AND THIS LED TO 2660 01:54:59,953 --> 01:55:03,323 OUR FINDING THAT VASCULAR 2661 01:55:03,323 --> 01:55:04,991 CALCIFICATION WAS PREVALENT AS 2662 01:55:04,991 --> 01:55:07,327 PEFDED BY THE SCORE IN THIS 2663 01:55:07,327 --> 01:55:10,296 GRAPH WHERE THE YAY GREY AREA IS 2664 01:55:10,296 --> 01:55:12,432 THE NORMAL RANGE AND EACH LINE 2665 01:55:12,432 --> 01:55:13,933 REPRESENTS A PATIENT. WE WERE 2666 01:55:13,933 --> 01:55:15,001 SURPRISED TO FIND THAT THE 2667 01:55:15,001 --> 01:55:17,670 CALCIFICATION WAS PRESENT IN OUR 2668 01:55:17,670 --> 01:55:18,738 PEDIATRIC PATIENTS AND THIS 2669 01:55:18,738 --> 01:55:21,474 FINDING HAS LED US TO INCREASE 2670 01:55:21,474 --> 01:55:23,343 MONITOR FOR PATIENTS AT HIGH 2671 01:55:23,343 --> 01:55:25,812 RISK SO EARLY INTERVENTION CAN 2672 01:55:25,812 --> 01:55:26,846 TAKE PLACE IMPORTANTLY WE WERE 2673 01:55:26,846 --> 01:55:28,348 ABLE TO MONITOR CHANGES OVER 2674 01:55:28,348 --> 01:55:29,716 TIME IN THE RESPONSE TO 2675 01:55:29,716 --> 01:55:32,685 TREATMENT AND THIS IS A PATIENT 2676 01:55:32,685 --> 01:55:34,788 WITH EXTENSIVE INFLAMMATION WHO 2677 01:55:34,788 --> 01:55:36,856 WAS TREATED WITH AN ANTAGONIST 2678 01:55:36,856 --> 01:55:38,625 FOR FIFTEEN MONTHS BRINGING HER 2679 01:55:38,625 --> 01:55:41,227 INFLAMMATORY MARKER FROM HIGH 2680 01:55:41,227 --> 01:55:42,662 DOWN INTO THE NORMAL RANGE AND 2681 01:55:42,662 --> 01:55:45,632 AS YOU CAN SEE SHE HAD IMPROVED 2682 01:55:45,632 --> 01:55:47,066 CALCIFICATION WHICH WE COULD 2683 01:55:47,066 --> 01:55:49,002 BOTH DEFECT AND QUANTITY TODAY. 2684 01:55:49,002 --> 01:55:50,403 SO THE POTENTIAL FOR THIS 2685 01:55:50,403 --> 01:55:54,174 TECHNIQUE TO ACT AS A NEW 2686 01:55:54,174 --> 01:55:55,074 BIOMARKER AND THUS AN END POINT 2687 01:55:55,074 --> 01:55:56,943 FOR OUR CLINICAL TRIAL IS 2688 01:55:56,943 --> 01:55:58,711 SIGNIFICANT AND NOTABLY THIS 2689 01:55:58,711 --> 01:56:02,382 TECHNIQUE IS DETECTING THE 2690 01:56:02,382 --> 01:56:03,316 ACTIVITY WITH CALCIFICATION AT 2691 01:56:03,316 --> 01:56:04,517 AN EARLY TIME POINT BEFORE IT 2692 01:56:04,517 --> 01:56:06,986 CAN BE SEEN ON TRADITIONAL CT 2693 01:56:06,986 --> 01:56:09,088 SCAN. AND WE'RE CURRENTLY USING 2694 01:56:09,088 --> 01:56:10,857 ARTIFICIAL INTELLIGENCE OR AI TO 2695 01:56:10,857 --> 01:56:12,759 CREATE A COMPUTATIONAL METHOD TO 2696 01:56:12,759 --> 01:56:14,194 DO THIS ANALYSIS. THUS 2697 01:56:14,194 --> 01:56:16,129 INCREASING RELIABILITY AND 2698 01:56:16,129 --> 01:56:18,031 REPRODUCIBILITY OF THE DATA 2699 01:56:18,031 --> 01:56:19,299 WHILE MINIMIZING THE TIME NEEDED 2700 01:56:19,299 --> 01:56:21,901 TO MANUALLY CALCULATE THAT 2701 01:56:21,901 --> 01:56:23,336 CALCIFICATION SCORE AND THIS 2702 01:56:23,336 --> 01:56:24,904 TECHNIQUE IS APPLICABLE TO 2703 01:56:24,904 --> 01:56:26,606 NUMEROUS OTHER DISEASES OF 2704 01:56:26,606 --> 01:56:29,509 VASCULAR CALCIFICATION AND WE 2705 01:56:29,509 --> 01:56:31,044 HAVE SEVERAL NEPHROLOGISTS FROM 2706 01:56:31,044 --> 01:56:33,213 CENTERS WHO ARE EAGER TO 2707 01:56:33,213 --> 01:56:35,248 COLLABORATE AND TRANSLATE THIS 2708 01:56:35,248 --> 01:56:36,249 TECHNIQUE TO PATIENTS WITH 2709 01:56:36,249 --> 01:56:38,852 CHRONIC RENAL FAILURE AND ALONG 2710 01:56:38,852 --> 01:56:39,352 THESE SAME LINES WITH 2711 01:56:39,352 --> 01:56:43,022 COMPUTATIONAL ANALYSES THE NEXT 2712 01:56:43,022 --> 01:56:45,692 TALK WILL BE ABOUT THE WORK FROM 2713 01:56:45,692 --> 01:56:50,697 DR. JAN'S LAB OF THE ANALYSIS OF 2714 01:56:50,697 --> 01:56:52,565 CRANIOFACIAL GROWTH AND 2715 01:56:52,565 --> 01:56:53,199 DEVELOPMENT. IN SUMMARY I'VE 2716 01:56:53,199 --> 01:56:54,767 SHONE YOU ONLY A FEW EXAMPLES OF 2717 01:56:54,767 --> 01:56:56,336 THE WORK FROM THE SKELETAL 2718 01:56:56,336 --> 01:56:59,005 MATRIX AND MECHANICAL BIOLOGY 2719 01:56:59,005 --> 01:57:01,207 GROUP AND YOU CAN SEE HOUR MODEL 2720 01:57:01,207 --> 01:57:02,609 OF MORTGAGING RESEARCH AND 2721 01:57:02,609 --> 01:57:04,644 CLINICAL CARE WHICH INFORMS 2722 01:57:04,644 --> 01:57:06,112 QUESTIONS AND HYPOTHESES ABOUT 2723 01:57:06,112 --> 01:57:08,047 OUR PATIENTS. WE THEN EMPLOY 2724 01:57:08,047 --> 01:57:10,950 SEVERAL MODEL SYSTEMS INCLUDING 2725 01:57:10,950 --> 01:57:12,986 IPSCS, MOUSE MODELS AND 2726 01:57:12,986 --> 01:57:14,187 COMPUTATIONAL ANALYSES TO ANSWER 2727 01:57:14,187 --> 01:57:16,656 THESE QUESTIONS. AND WE TAKE 2728 01:57:16,656 --> 01:57:17,690 THIS INFORMATION INTO 2729 01:57:17,690 --> 01:57:19,092 PRECLINICAL AND CLINICAL TRIALS. 2730 01:57:19,092 --> 01:57:21,728 TO REALLY DIRECTLY IMPROVE 2731 01:57:21,728 --> 01:57:23,329 DIAGNOSIS. PROGNOSIS AND 2732 01:57:23,329 --> 01:57:27,267 TREATMENT OF OUR PATIENTS. SO 2733 01:57:27,267 --> 01:57:28,334 THANK YOU SO MUCH FOR YOUR TIME 2734 01:57:28,334 --> 01:57:30,503 AND NOW I WOULD LIKE TO 2735 01:57:30,503 --> 01:57:33,673 INTRODUCE DR. AL PAN KNOW, A 2736 01:57:33,673 --> 01:57:35,975 STAFF CLINICIAN IN THE DOCTOR'S 2737 01:57:35,975 --> 01:57:39,345 LABORATORY WHO WILL PRESENT 2738 01:57:39,345 --> 01:57:49,556 ABOUT CRANIOFACIAL GROWTH. 2739 01:57:49,556 --> 01:57:51,858 >> THANK YOU FOR THE SP 2740 01:57:51,858 --> 01:57:54,928 INTRODUCTION CAN YOU SEE MY 2741 01:57:54,928 --> 01:57:55,328 TITLE SLIDE? 2742 01:57:55,328 --> 01:57:56,095 >> YES. 2743 01:57:56,095 --> 01:57:57,664 >> SO MY PRESENTATION IS GOING 2744 01:57:57,664 --> 01:58:01,200 TO BE ABOUT THE PREDICTION OF 2745 01:58:01,200 --> 01:58:03,303 CRANIOFACIAL GROWTH. 2746 01:58:03,303 --> 01:58:04,704 CRANIOFACIAL DIFFERENCES ARE 2747 01:58:04,704 --> 01:58:07,106 BIRTH DEFECTS THAT AFFECT THE 2748 01:58:07,106 --> 01:58:09,676 STRUCTURE AND SCAPE OF THE SKULL 2749 01:58:09,676 --> 01:58:13,780 AND FACE. THEY CAN APPEAR AS AN 2750 01:58:13,780 --> 01:58:15,081 ISOLATED DEFORMITY SUCH AS CLEFT 2751 01:58:15,081 --> 01:58:19,185 PALATE OR AS PART OF THE 2752 01:58:19,185 --> 01:58:20,086 CONDITION LIKE THE SYNDROME 2753 01:58:20,086 --> 01:58:21,821 MENTIONED EARLIER. OUR STUDY OF 2754 01:58:21,821 --> 01:58:26,859 RARE DISEASES INFORMS MORE 2755 01:58:26,859 --> 01:58:31,064 CRANIOFACIAL DIFFERENCES SUCH AS 2756 01:58:31,064 --> 01:58:32,198 SKELETAL MALOCCLUSION IS 2757 01:58:32,198 --> 01:58:33,700 CHARACTERIZED BY THESE AND 2758 01:58:33,700 --> 01:58:39,305 OCCURS IN 19% OF THE U.S. 2759 01:58:39,305 --> 01:58:42,575 POPULATION. YOU CAN SEE THE OR 2760 01:58:42,575 --> 01:58:43,776 NOTHING NATTIC TYPE. AND YOU 2761 01:58:43,776 --> 01:58:47,180 CAN SEE THE OVERBITE WITH THE 2762 01:58:47,180 --> 01:58:48,681 CONVEX PROFILE. AND CLASS THREE 2763 01:58:48,681 --> 01:58:51,317 WHICH IS AN UNDERBITE WHERE A 2764 01:58:51,317 --> 01:58:55,054 CONCAVE PROFILE. MODERATE TO 2765 01:58:55,054 --> 01:58:57,457 SEVERE TYPES OF MALOCCLUSION 2766 01:58:57,457 --> 01:58:59,325 HAVE BEEN ASSOCIATED WITH 2767 01:58:59,325 --> 01:59:00,760 PROBLEMS SUCH AS CHEWING OR 2768 01:59:00,760 --> 01:59:06,165 SPEECH OR SLEEP APNEA, JOINT 2769 01:59:06,165 --> 01:59:08,968 DISORDERS AND DIGESTIVE ISSUE AS 2770 01:59:08,968 --> 01:59:12,138 WELL AS BURDEN WITH REDUCED ORAL 2771 01:59:12,138 --> 01:59:13,506 RELATED QUALITY OF LIFE. 2772 01:59:13,506 --> 01:59:14,707 DEVELOPMENT OF THE HUMAN SKULL 2773 01:59:14,707 --> 01:59:17,543 AND FACE IS A HIGHLY 2774 01:59:17,543 --> 01:59:19,779 ORCHESTRATED THREE-DIMENSIONAL 2775 01:59:19,779 --> 01:59:22,682 MORE FOE GENETIC PROCESS. 2776 01:59:22,682 --> 01:59:24,917 THERE'S THEREFORE NOT SURPRISING 2777 01:59:24,917 --> 01:59:27,687 THAT GENETIC INSULTS APPEAR IN 2778 01:59:27,687 --> 01:59:31,157 CRANIOFACIAL DIFFERENCES. 2779 01:59:31,157 --> 01:59:32,158 INCLUDING THE OCCLUSION. WE 2780 01:59:32,158 --> 01:59:33,192 ALSO KNOW THAT THE ROLE OF THE 2781 01:59:33,192 --> 01:59:36,029 CRANIAL BASE IN THE DEVELOPMENT 2782 01:59:36,029 --> 01:59:38,164 OF THE COMPLEX IS VERY IMPORTANT 2783 01:59:38,164 --> 01:59:39,332 HOWEVER IT'S ROLE IN THE 2784 01:59:39,332 --> 01:59:41,801 DEVELOPMENT OF THE MALOCCLUSION 2785 01:59:41,801 --> 01:59:43,703 REMAINS CONTROVERSIAL. IT IS 2786 01:59:43,703 --> 01:59:46,806 IMPORTANT TO NOTE THAT THE 2787 01:59:46,806 --> 01:59:49,409 GROWTH OF THE ENTIRE ANTERIOR 2788 01:59:49,409 --> 01:59:52,145 CRANIAL BASE IS COMPLETE BEFORE 2789 01:59:52,145 --> 01:59:54,914 THE AGE OF SIX YEARS. AS WELL 2790 01:59:54,914 --> 01:59:56,783 AS THE MANDIBLE. AS SHOWN ON 2791 01:59:56,783 --> 01:59:58,351 THE RIGHT-HAND SIDE OUR 2792 01:59:58,351 --> 02:00:00,953 HYPOTHESIS IS THAT THE CRANIAL 2793 02:00:00,953 --> 02:00:02,088 BASE DICTATES THE GROWTH AND THE 2794 02:00:02,088 --> 02:00:05,024 DEVELOPMENT OF THE MAXILLA AND 2795 02:00:05,024 --> 02:00:07,326 MANDIBLE. UNLIKE CRANIAL BASE 2796 02:00:07,326 --> 02:00:09,395 DEVELOPMENT, THE PHENOTYPE IS 2797 02:00:09,395 --> 02:00:10,730 NOT EXPRESSED UNTIL EARLY 2798 02:00:10,730 --> 02:00:12,465 ADOLESCENCE, HOWEVER, THE 2799 02:00:12,465 --> 02:00:15,334 PREVENTION OR TREATMENT OF 2800 02:00:15,334 --> 02:00:15,902 SKELETAL MALOCCLUSION IS 2801 02:00:15,902 --> 02:00:17,637 IMPORTANT FOR THE WELL-BEING OF 2802 02:00:17,637 --> 02:00:20,807 THOSE INDIVIDUALS MOREOVER, 2803 02:00:20,807 --> 02:00:21,574 EARLY DIAGNOSIS IN THIS CASE 2804 02:00:21,574 --> 02:00:23,743 WILL ENABLE MORE EFFECTIVE 2805 02:00:23,743 --> 02:00:26,846 TREATMENT AMROECHS IN DEFINING 2806 02:00:26,846 --> 02:00:30,149 THE BEST TIMING AND TYPE OF 2807 02:00:30,149 --> 02:00:31,350 INTERVENTION. ESPECIALLY THE 2808 02:00:31,350 --> 02:00:34,220 CASE OF OCCLUSION OR UNDERBITE 2809 02:00:34,220 --> 02:00:36,055 THIS IS EVEN MORE CRUCIAL. THE 2810 02:00:36,055 --> 02:00:38,624 REASON IS THAT SOME OF THESE 2811 02:00:38,624 --> 02:00:41,928 CASES WHEN THE MAIN ETIOLOGY OF 2812 02:00:41,928 --> 02:00:43,996 THE UNDERBITE IS THE 2813 02:00:43,996 --> 02:00:45,732 UNDERDEVELOPMENT OF THE MAXILLA 2814 02:00:45,732 --> 02:00:48,668 RESPOND WELL TO THE TREATMENT 2815 02:00:48,668 --> 02:00:51,003 WITH PROTRACTION WHICH IN MOST 2816 02:00:51,003 --> 02:00:52,138 CASES CAN RESOLVE THE PROBLEM. 2817 02:00:52,138 --> 02:00:53,906 IN THE CASE OF SKELETAL 2818 02:00:53,906 --> 02:00:55,241 UNDERBITE THAT IS DUE TO 2819 02:00:55,241 --> 02:00:57,043 OVERDEVELOPMENT OF THE MANDIBLE 2820 02:00:57,043 --> 02:00:59,345 WHICH IS NAMED AS CLASS THREE B 2821 02:00:59,345 --> 02:01:00,446 THERE'S NOTHING WE CAN DO 2822 02:01:00,446 --> 02:01:02,315 CLINICALLY TO CONTROL THE GROWTH 2823 02:01:02,315 --> 02:01:04,183 OF THE MANDIBLE WHICH CAN ALSO 2824 02:01:04,183 --> 02:01:06,152 CONTINUE TO GROW UNTIL LATE 2825 02:01:06,152 --> 02:01:08,721 ADOLESCENCE, MANY OF THESE CASES 2826 02:01:08,721 --> 02:01:11,657 REQUIRE SURGE DUE TO THE 2827 02:01:11,657 --> 02:01:13,326 MAGNITUDE. SO AT THE AGE OF 2828 02:01:13,326 --> 02:01:14,393 POTENTIAL INTERVENTION WHICH IS 2829 02:01:14,393 --> 02:01:16,863 BEFORE PUBERTY THE SKELETAL 2830 02:01:16,863 --> 02:01:18,030 MALOCCLUSION FEN TYPE IS NOT 2831 02:01:18,030 --> 02:01:20,466 FULLY EXPRESSED AND THE 2832 02:01:20,466 --> 02:01:22,869 DIAGNOSIS CANNOT BE MADE AS YOU 2833 02:01:22,869 --> 02:01:24,971 CAN IMAGINE THIS IS VERY 2834 02:01:24,971 --> 02:01:26,506 FRUSTRATING FOR CLINICIANS AND 2835 02:01:26,506 --> 02:01:29,008 OF COURSE THE PATIENTS AND THEIR 2836 02:01:29,008 --> 02:01:31,210 FAMILIES. OUR AIM WAS TO 2837 02:01:31,210 --> 02:01:33,679 EXPLORE THE ROLE. AND THEN 2838 02:01:33,679 --> 02:01:36,082 DETERMINE WHETHER CANE E CRANIAL 2839 02:01:36,082 --> 02:01:39,152 BASE SHAPE COULD ASSIST US IN 2840 02:01:39,152 --> 02:01:41,721 THE EARLY DIAGNOSIS OF THE 2841 02:01:41,721 --> 02:01:43,389 PHENOTYPE. SO THIS AN OLD 2842 02:01:43,389 --> 02:01:45,057 PROBLEM BUT THERE'S NOW NEW 2843 02:01:45,057 --> 02:01:45,925 TECHNOLOGY AVAILABLE THAT WE CAN 2844 02:01:45,925 --> 02:01:48,060 USE TO SOLVE IT WHICH IN THIS 2845 02:01:48,060 --> 02:01:53,599 CASE IS 3D IMAGING WE USE 306 2846 02:01:53,599 --> 02:01:55,334 FULL HEAD COMPUTER TOMOGRAPHY 2847 02:01:55,334 --> 02:01:57,203 SCAN THERE'S HEALTHY INDIVIDUALS 2848 02:01:57,203 --> 02:02:01,874 AS PART OF A NORMATIVE COHORT. 2849 02:02:01,874 --> 02:02:08,114 43, 3D VALIDATED LANDMARKS AND 2850 02:02:08,114 --> 02:02:09,782 THAT PROVIDE THE SUFFICIENT 2851 02:02:09,782 --> 02:02:11,250 COVERAGE OF THE CRANIOFACIAL 2852 02:02:11,250 --> 02:02:13,920 COMPLEX AND WERE ANNOTATED ON 2853 02:02:13,920 --> 02:02:17,523 THE VOLUMES. THESE WERE 2854 02:02:17,523 --> 02:02:19,358 EXPORTED AND USED FOR THE 2855 02:02:19,358 --> 02:02:21,594 CONDUCTION OF ANALYSIS WHICH IS 2856 02:02:21,594 --> 02:02:23,963 A TYPE OF SHAPE ANALYSIS. AFTER 2857 02:02:23,963 --> 02:02:26,899 REGRESSING FOR SIDES, AGE AND 2858 02:02:26,899 --> 02:02:29,368 SEX WE CONDUCTED THE ANALYSIS 2859 02:02:29,368 --> 02:02:30,369 FOR THE EXPLORATION OF THE SHAPE 2860 02:02:30,369 --> 02:02:32,471 OF VARIATION BETWEEN THE 2861 02:02:32,471 --> 02:02:33,306 SKELETAL MALOCCLUSION GROUPS IN 2862 02:02:33,306 --> 02:02:35,808 THE PCA PLOT ON THE RIGHT WHICH 2863 02:02:35,808 --> 02:02:38,444 EXPLAINS 100% OF THE SHAPE 2864 02:02:38,444 --> 02:02:40,379 VARIATION IN OUR DATASET YOU CAN 2865 02:02:40,379 --> 02:02:42,849 APPRECIATE THE DISTINCT 2866 02:02:42,849 --> 02:02:44,817 CLUSTERING OF THE GROUPS IN DOT 2867 02:02:44,817 --> 02:02:46,586 IN THIS PLOT REPRESENTS ONE 2868 02:02:46,586 --> 02:02:47,954 INDIVIDUAL. AND WE ALSO 2869 02:02:47,954 --> 02:02:49,188 EXPLORED THE SHAPE OF THE 2870 02:02:49,188 --> 02:02:51,157 CRANIAL BASE BETWEEN THE MAIN 2871 02:02:51,157 --> 02:02:55,328 GROUPS. WITH A USE OF CANONICAL 2872 02:02:55,328 --> 02:02:57,763 VARIATE ANALYSIS WHICH SHOWED 2873 02:02:57,763 --> 02:02:59,365 THE DIFFERENCES BETWEEN THE ONE 2874 02:02:59,365 --> 02:03:01,567 AND TWO GROUPS. BE THE 2875 02:03:01,567 --> 02:03:03,269 ADDITIONAL SEPARATION BETWEEN 2876 02:03:03,269 --> 02:03:05,938 THE CLUSTER A AND 3B SUBGROUPS 2877 02:03:05,938 --> 02:03:07,306 BASED ON THE CROSS VALIDATION 2878 02:03:07,306 --> 02:03:09,208 ANALYSIS FOR THE QUALITATIVE 2879 02:03:09,208 --> 02:03:10,710 ASSESSMENT OF THE PROBABILITY OF 2880 02:03:10,710 --> 02:03:12,044 AN INDIVIDUAL CLASSIFYING AS 2881 02:03:12,044 --> 02:03:13,946 CLASS 3A OR CLASS 3B THE 2882 02:03:13,946 --> 02:03:19,352 ACCURACY OF THE MODEL WAS 90.3%. 2883 02:03:19,352 --> 02:03:21,787 FOR THE REPRODUCIBILITY WE USE 2884 02:03:21,787 --> 02:03:25,524 TEN TEST CASES TO TEST OUR MODEL 2885 02:03:25,524 --> 02:03:27,793 WHICH WERE INDIVIDUALS BEFORE OR 2886 02:03:27,793 --> 02:03:30,329 DURING PUBE IRTY AND SKELETAL 2887 02:03:30,329 --> 02:03:33,199 CELL MATURATION. I USE HERE THE 2888 02:03:33,199 --> 02:03:36,068 EXAMPLE THE CASE OF THE MALE 2889 02:03:36,068 --> 02:03:37,436 PATIENT THAT PRESENTS WITH THE 2890 02:03:37,436 --> 02:03:38,771 SKELETAL RELATIONSHIPS AND NO 2891 02:03:38,771 --> 02:03:40,940 DENTAL UNDERBITE. WE CAN SEE ON 2892 02:03:40,940 --> 02:03:42,074 TRIETH THAT THE SAME INDIVIDUAL 2893 02:03:42,074 --> 02:03:45,811 AT AGE 19 HAS A FULL UNDERBITE 2894 02:03:45,811 --> 02:03:47,413 IN THE MANDIBLE. WHEN 2895 02:03:47,413 --> 02:03:48,414 PROJECTING THIS INDIVIDUAL IN 2896 02:03:48,414 --> 02:03:51,317 THE NORMATIVE COHORT PCA PLOT WE 2897 02:03:51,317 --> 02:03:54,020 CAN SEE THAT AT T 1 WITH THE 2898 02:03:54,020 --> 02:03:55,755 YELLOW CIRCUMSTANTIAL DOT IS 2899 02:03:55,755 --> 02:03:57,790 CLOSER TO THE CLASS 3B GROUP 2900 02:03:57,790 --> 02:03:59,325 WHICH WAS CONFIRMED WITH THE 2901 02:03:59,325 --> 02:04:03,095 CROSS VALIDATION ANALYSIS SO OUR 2902 02:04:03,095 --> 02:04:04,397 CONNOTATIVE APPROACH COULD HAVE 2903 02:04:04,397 --> 02:04:06,165 SUCCESSFULLY PREDICTED THE 2904 02:04:06,165 --> 02:04:07,833 OVERDEVELOPMENT OF THE MANDIBLE 2905 02:04:07,833 --> 02:04:09,368 AND WE HAD THE SAME SUCCESS WITH 2906 02:04:09,368 --> 02:04:11,570 THE REST OF OUR TEST CASES WE 2907 02:04:11,570 --> 02:04:13,406 CONFIRMED THE HYPOTHESIS THAT 2908 02:04:13,406 --> 02:04:15,975 THE CRANIAL BASE DICTATES THE 2909 02:04:15,975 --> 02:04:18,210 PHENOTYPE. GEOMETRIC ANALYSIS 2910 02:04:18,210 --> 02:04:19,679 IS A COMPETITIONAL TOOL THAT CAN 2911 02:04:19,679 --> 02:04:21,781 BE USED FOR THE EARLY ACCURATE 2912 02:04:21,781 --> 02:04:23,182 DIAGNOSIS OF THE TYPE OF 2913 02:04:23,182 --> 02:04:25,618 SKELETAL MALOCCLUSION A LOT 2914 02:04:25,618 --> 02:04:26,919 SOONER THAN WHEN THE PHENOTYPE 2915 02:04:26,919 --> 02:04:30,690 IS EXPRESSED CLINICALLY THIS 2916 02:04:30,690 --> 02:04:32,024 CRANIOFACIAL TOOL CAN BE USED 2917 02:04:32,024 --> 02:04:35,328 FOR CUSTOMIZED PLANNING AND IS 2918 02:04:35,328 --> 02:04:37,196 TO INCREASE THE BLANK OF 2919 02:04:37,196 --> 02:04:43,336 PATIENTS. THANK YOU FOR YOUR 2920 02:04:43,336 --> 02:04:47,206 ATTENTION. 2921 02:04:47,206 --> 02:04:52,945 >> THANK YOU. WE'LL NOW MOVE TO 2922 02:04:52,945 --> 02:04:57,350 PLENARY SESSION THREE. ON 2923 02:04:57,350 --> 02:04:59,885 GENOTYPE APPROACHES. DR. KEEN 2924 02:04:59,885 --> 02:05:06,959 AND DR. JACKIE MAYS. AKEEN 2925 02:05:06,959 --> 02:05:07,426 AND DR. JACKIE MAYS. 2926 02:05:07,426 --> 02:05:09,295 DR. ACHKEEN AND DR. JACKIKEEN A 2927 02:05:09,295 --> 02:05:10,096 MAYMKEEN AND DR. JACKIE 2928 02:05:10,096 --> 02:05:10,463 MAYS. DR. ACHIMN 2929 02:05:10,463 --> 02:05:11,697 AND DR. JACKIE 2930 02:05:11,697 --> 02:05:12,231 AND DR. JACKIE MAYS. 2931 02:05:12,231 --> 02:05:12,732 >> THANK YOU VERY MUCH 2932 02:05:12,732 --> 02:05:13,933 DR. WEBSTER. I HOPE THAT YOU 2933 02:05:13,933 --> 02:05:16,369 CAN SEE MY SLIDES AND EVERYTHING 2934 02:05:16,369 --> 02:05:17,670 CORRECTLY AND I DON'T HEAR 2935 02:05:17,670 --> 02:05:18,671 ANYTHING RIGHT NOW I WILL JUST 2936 02:05:18,671 --> 02:05:20,506 CONTINUE. SO I AM REALLY 2937 02:05:20,506 --> 02:05:23,009 EXCITED TO BE HERE TODAY. I'M A 2938 02:05:23,009 --> 02:05:28,347 RECENKRENTCENT LY TENURED INVES 2939 02:05:28,347 --> 02:05:29,382 AND I WANT TO CONTINUE WITH THIS 2940 02:05:29,382 --> 02:05:30,883 BASIC RESEARCH THAT IS REALLY 2941 02:05:30,883 --> 02:05:33,319 POSSIBLE HERE IN THE INTRAMURAL 2942 02:05:33,319 --> 02:05:34,954 PROGRAM THAT YOU'VE HEARD FROM 2943 02:05:34,954 --> 02:05:39,325 DR. WEBSTER, FROM DR. WARNER AND 2944 02:05:39,325 --> 02:05:44,096 DR. ROSCOE AND I WANT TO DO IT 2945 02:05:44,096 --> 02:05:45,798 DIFFERENTLY. I WANT TO SHARE MY 2946 02:05:45,798 --> 02:05:46,966 JOURNEY WHICH HAS BEEN CRUCIALLY 2947 02:05:46,966 --> 02:05:50,202 SHAPED BY MANY COLLABORATIONS 2948 02:05:50,202 --> 02:05:55,307 WITHIN NIH. AND ALSO BY THE 2949 02:05:55,307 --> 02:05:58,577 UNIQUE CLINICAL ENVIRONMENT. I 2950 02:05:58,577 --> 02:06:00,546 AM A CHEMIST BY TRAINING AND 2951 02:06:00,546 --> 02:06:03,315 ALSO A STEM CELL BIOLOGIST AND 2952 02:06:03,315 --> 02:06:05,851 MY LAB CENTERS AROUND THE 2953 02:06:05,851 --> 02:06:07,386 CENTRAL REGRESSION OF MY LAB IS 2954 02:06:07,386 --> 02:06:10,723 HOW CELLS ARE DETERMINED DURING 2955 02:06:10,723 --> 02:06:13,759 DEVELOPMENT AND WE FOCUS ON A 2956 02:06:13,759 --> 02:06:19,065 SMALL PROTEIN CALLED YUBIQUITIN 2957 02:06:19,065 --> 02:06:21,167 THAT LOOKS AT DIFFERENTIATION. 2958 02:06:21,167 --> 02:06:22,368 TO GIVE YOU AN INTRODUCTION, YOU 2959 02:06:22,368 --> 02:06:25,237 CAN SEE HERE A STEM CELL THAT IS 2960 02:06:25,237 --> 02:06:29,542 ABLE TO REVERSIBLY EXIT A STATE 2961 02:06:29,542 --> 02:06:31,977 AND GIVE RISE TO MORE STEM CELLS 2962 02:06:31,977 --> 02:06:33,879 OR THE CELL CAN ALSO DECIDE TO 2963 02:06:33,879 --> 02:06:35,314 UNDERGO DIFFERENTIATION TO GIVE 2964 02:06:35,314 --> 02:06:36,849 RISE TO THE MORE THAN 200 2965 02:06:36,849 --> 02:06:38,584 DIFFERENT CELL TYPES THAT MAKE 2966 02:06:38,584 --> 02:06:42,121 UP OUR HUMAN BODY. MANY IF NOT 2967 02:06:42,121 --> 02:06:45,891 ALL OF THESE CELL DECISIONS ARE 2968 02:06:45,891 --> 02:06:47,793 CRUCIALLY CONTROLLED BY YOU PICK 2969 02:06:47,793 --> 02:06:49,295 RITY REGULATION AND I CAN SHOW 2970 02:06:49,295 --> 02:06:50,963 YOU HOW THESE ACHIEVE THIS. 2971 02:06:50,963 --> 02:06:52,798 BUT HAVE WORKED ON DURING MY 2972 02:06:52,798 --> 02:06:54,467 GRADUATE AND POSTGRADUATE CAREER 2973 02:06:54,467 --> 02:06:58,571 BEFORE COMING TO THE NIH. NOT 2974 02:06:58,571 --> 02:07:01,440 SURPRISINGLY FROM THESE 2975 02:07:01,440 --> 02:07:02,741 ESSENTIAL FUNCTIONS THE 2976 02:07:02,741 --> 02:07:04,810 MUTATIONS IN THE ENZYMES HAVE 2977 02:07:04,810 --> 02:07:06,245 BEEN FREQUENTLY LINKED TO HUMAN 2978 02:07:06,245 --> 02:07:08,013 DISEASES THAT ARE STUDIED ACROSS 2979 02:07:08,013 --> 02:07:12,485 THE NIH AND INCLUDE CANCER, 2980 02:07:12,485 --> 02:07:13,085 NEURODEGENERATION AND I WILL 2981 02:07:13,085 --> 02:07:15,888 GIVE YOU EXAMPLES TODAY, 2982 02:07:15,888 --> 02:07:17,857 CONGENITAL DISEASES THAT EFFECT 2983 02:07:17,857 --> 02:07:19,825 BRAIN AND CRANIOFACIAL 2984 02:07:19,825 --> 02:07:21,393 DEVELOPMENT AS WELL AS 2985 02:07:21,393 --> 02:07:23,028 AUTOINFLAMMATION. SO WHAT ARE 2986 02:07:23,028 --> 02:07:28,067 THESE UBIQUITYLATION ENZYMES. 2987 02:07:28,067 --> 02:07:31,170 THEY ARE IDENTIFIED BY A 2988 02:07:31,170 --> 02:07:33,906 CASCADE, CONSISTING OF E 1, E 2 2989 02:07:33,906 --> 02:07:37,076 AND E 3 LIE GIETING ENZYMES THAT 2990 02:07:37,076 --> 02:07:38,410 ALL COLLABORATE TO ATTACH THE 2991 02:07:38,410 --> 02:07:41,113 SMALL PROTEIN TO A SUBSTRATE. 2992 02:07:41,113 --> 02:07:45,551 THIS IS VE VERSABLE AND CAN BE 2993 02:07:45,551 --> 02:07:49,088 REVERSED BY THE YOU DEUBIQUITY 2994 02:07:49,088 --> 02:07:51,123 LACES AND THIS PROCESS CAN HAVE 2995 02:07:51,123 --> 02:07:53,859 MANY DIFFERENT FUNCTIONS IN 2996 02:07:53,859 --> 02:07:56,428 CELLS INCLUDING MEDIATING 2997 02:07:56,428 --> 02:07:58,531 PROTEASE SOME MALL DEGRADATION 2998 02:07:58,531 --> 02:08:00,199 OR CELLULAR SIGNALLING. 2999 02:08:00,199 --> 02:08:04,069 AND THIS CODES TO THE ENZYMES 3000 02:08:04,069 --> 02:08:10,943 ROUGHLY 2 E 1S, 40 E 2S, AND 600 3001 02:08:10,943 --> 02:08:13,812 E 3S. AND DESPITE FOR US DOING 3002 02:08:13,812 --> 02:08:15,114 RESEARCH ON THE SYSTEM FOR MORE 3003 02:08:15,114 --> 02:08:21,487 THAN 40 YEARS NOW, WE KNOW 3004 02:08:21,487 --> 02:08:22,955 SURPRISINGLY LITTLE OF MOST OF 3005 02:08:22,955 --> 02:08:26,759 THE ENZYMES SO DEFINING THOSE IS 3006 02:08:26,759 --> 02:08:28,561 STILL A MAJOR QUESTION TO BE 3007 02:08:28,561 --> 02:08:31,697 SOLVED IN OUR RESEARCH FIELD. 3008 02:08:31,697 --> 02:08:34,099 SO MY LAB HAS COMBINED 3009 02:08:34,099 --> 02:08:36,001 BIOCHEMICAL APPROACHES WITH 3010 02:08:36,001 --> 02:08:38,904 INDUCED STEM CELL MODEL TO 3011 02:08:38,904 --> 02:08:39,905 ASSIGN PHYSIOLOGICAL FUNCTIONS 3012 02:08:39,905 --> 02:08:43,309 OF THE ENZYMES DURING 3013 02:08:43,309 --> 02:08:45,911 DEVELOPMENT AND CELL-FATE 3014 02:08:45,911 --> 02:08:48,614 DECISIONS AND WE HAVE THE 3015 02:08:48,614 --> 02:08:51,884 PROGRAM THAT LEVERAGES THE 3016 02:08:51,884 --> 02:08:54,119 UNIQUENESS OF THE NIH AND 3017 02:08:54,119 --> 02:08:57,456 TOGETHER WE IDENTIFY UNDIAGNOSED 3018 02:08:57,456 --> 02:09:02,161 DISEASE PATIENTS WHO CARRY 3019 02:09:02,161 --> 02:09:04,563 VARIANTS AND STUDY THESE 3020 02:09:04,563 --> 02:09:06,632 VARIANTS IN OUR INVITRO AND 3021 02:09:06,632 --> 02:09:08,167 CELLULAR MODELS TO LEARN ABOUT 3022 02:09:08,167 --> 02:09:10,502 THE PHYSIOLOGICAL FUNCTIONS. WE 3023 02:09:10,502 --> 02:09:12,438 THEN CONFIRM OUR INVIVO FINDINGS 3024 02:09:12,438 --> 02:09:17,109 IN ANIMAL MODELS BY 3025 02:09:17,109 --> 02:09:17,710 COLLABORATING WITH BIOLOGISTS 3026 02:09:17,710 --> 02:09:19,345 AND ALSO STARTED TO USE 3027 02:09:19,345 --> 02:09:20,546 STRUCTURAL BIOLOGY APPROACHES 3028 02:09:20,546 --> 02:09:24,049 INTO OUR INVESTIGATIONS BY 3029 02:09:24,049 --> 02:09:25,684 COLLABORATING WITH LOCAL EXPERTS 3030 02:09:25,684 --> 02:09:27,886 IN STRUCTURAL BIOLOGY. AND THIS 3031 02:09:27,886 --> 02:09:30,055 REALLY INTEGRATED AND HIGHLY 3032 02:09:30,055 --> 02:09:31,357 COLLABORATIVE APPROACH USING 3033 02:09:31,357 --> 02:09:33,892 GENOTYPE FIRST STRATEGIES AND 3034 02:09:33,892 --> 02:09:35,327 STARTING FROM UNDIAGNOSED 3035 02:09:35,327 --> 02:09:37,563 DISEASE PATIENTS AND GOING INTO 3036 02:09:37,563 --> 02:09:39,331 DEEP MOLECULAR MECHANISM THAT 3037 02:09:39,331 --> 02:09:42,368 ALLOWED US NOT ONLY TO DISCOVER 3038 02:09:42,368 --> 02:09:43,636 UNRECOGNIZED DISEASES BUT ALSO 3039 02:09:43,636 --> 02:09:47,306 HAS PROVIDED FUNDAMENTAL 3040 02:09:47,306 --> 02:09:50,776 PRINCIPLES OF YOU WICK PI TEN. 3041 02:09:50,776 --> 02:09:54,213 OVER THE LAST SEVEN YEARS WE 3042 02:09:54,213 --> 02:09:54,813 ESTABLISHED THREE INDEPENDENT 3043 02:09:54,813 --> 02:09:55,414 AREAS THAT CENTER AROUND THE 3044 02:09:55,414 --> 02:09:57,483 QUESTION HOW PARTICULAR CLASSES 3045 02:09:57,483 --> 02:10:01,086 OF THESE UBIQUITYLATION ENZYMES 3046 02:10:01,086 --> 02:10:02,221 CONTROL SUBSTRATE FATE TO 3047 02:10:02,221 --> 02:10:04,290 DETERMINE THE HEALTH AND 3048 02:10:04,290 --> 02:10:04,556 DISEASE. 3049 02:10:04,556 --> 02:10:06,825 IN TWO OF THESE AREAS, HAVE BEEN 3050 02:10:06,825 --> 02:10:10,095 DONE IN VERY CLOSE COLLABORATION 3051 02:10:10,095 --> 02:10:16,702 WITH LAURA WITH A STAFF INVE 3052 02:10:16,702 --> 02:10:19,338 INVESTOR -- INVESTIGATOR. AND 3053 02:10:19,338 --> 02:10:23,309 WE LOOK AT HOW THESE CAUSE 3054 02:10:23,309 --> 02:10:27,313 DEFECTS IN NEURAL CRESTS AND 3055 02:10:27,313 --> 02:10:30,582 NEURAL DEGRADATION THAT AFFECT 3056 02:10:30,582 --> 02:10:32,951 THE BRAIN AND CRANIOFACIAL 3057 02:10:32,951 --> 02:10:35,054 DEVELOPMENT AND THE CELL TYPE, 3058 02:10:35,054 --> 02:10:37,156 EARLY DEVELOPMENT OF THE BRAIN 3059 02:10:37,156 --> 02:10:38,957 AND THE FACE. TODAY HOWEVER I 3060 02:10:38,957 --> 02:10:41,960 WANT TO FOCUS ON THIS FIRST 3061 02:10:41,960 --> 02:10:43,595 RESEARCH AREA HERE IN WHICH WE 3062 02:10:43,595 --> 02:10:46,365 INVESTIGATE THE INITIAL STEPS OF 3063 02:10:46,365 --> 02:10:50,669 THE YOU WICK WETILATION CASCADE 3064 02:10:50,669 --> 02:10:54,106 WHICH IS EYE PICK WE TIN 3065 02:10:54,106 --> 02:10:56,909 ISOLATION. IN HERE WE HAVE THE 3066 02:10:56,909 --> 02:11:00,045 MUTATIONS IN THE ENZYME WHICH 3067 02:11:00,045 --> 02:11:02,614 CAUSE A LATE ONSET 3068 02:11:02,614 --> 02:11:03,916 AUTOINFLAMMATORY DISEASE AND BY 3069 02:11:03,916 --> 02:11:05,617 STUDYING THESE MUTATIONS WE 3070 02:11:05,617 --> 02:11:08,721 REALLY UNCOVERED NEW PRINCIPLES 3071 02:11:08,721 --> 02:11:11,890 OF HOW REGULATION CONTROLS THE 3072 02:11:11,890 --> 02:11:13,459 CELL DECISIONS. AND I'M REALLY 3073 02:11:13,459 --> 02:11:15,327 EXCITED TO TALK ABOUT THIS 3074 02:11:15,327 --> 02:11:16,995 RESEARCH AREA HERE TODAY. 3075 02:11:16,995 --> 02:11:18,997 BECAUSE IN MY OPINION IT REALLY 3076 02:11:18,997 --> 02:11:20,933 ILLUSTRATES THE STRENGTHS OF THE 3077 02:11:20,933 --> 02:11:22,334 NIH AND THE INTRAMURAL PROGRAMS 3078 02:11:22,334 --> 02:11:23,602 THAT REALLY BRING TOGETHER ALL 3079 02:11:23,602 --> 02:11:25,971 THE NECESSARY EXPERTISE AND 3080 02:11:25,971 --> 02:11:27,906 INFRASTRUCTURE TO ALLOW TO START 3081 02:11:27,906 --> 02:11:29,908 WITH DISEASE DISCOVERY THEN 3082 02:11:29,908 --> 02:11:31,710 STUDY THE UNDERLYING MECHANISM 3083 02:11:31,710 --> 02:11:34,079 AND LEARN ABOUT BASIC BIOLOGICAL 3084 02:11:34,079 --> 02:11:36,515 PROCESSES BUT THEN ALSO GO BACK 3085 02:11:36,515 --> 02:11:38,751 FULL CIRCLE AND USE THE GAINED 3086 02:11:38,751 --> 02:11:42,921 KNOWLEDGE TO INFORM AND DEVELOP 3087 02:11:42,921 --> 02:11:44,323 THERAPIES. SO THIS RESEARCH 3088 02:11:44,323 --> 02:11:45,791 AREA STARTED WHEN I FIRST CAME 3089 02:11:45,791 --> 02:11:50,596 TO THE NIDCR. AND I MET DOCTORS 3090 02:11:50,596 --> 02:11:54,366 DAVID BECK AND DANIEL CAST 3091 02:11:54,366 --> 02:11:57,436 NEVER, WHO RESEARCHERS AND GIVEN 3092 02:11:57,436 --> 02:11:59,338 THAT MUTATIONS IN THE ENZYMES 3093 02:11:59,338 --> 02:12:01,106 ARE FREQUENTLY LINKED TO HUMAN 3094 02:12:01,106 --> 02:12:03,342 DISEASES, WE DECIDED TO TAKE 3095 02:12:03,342 --> 02:12:05,778 GENOTYPE FIRST DISEASE DISCOVERY 3096 02:12:05,778 --> 02:12:07,346 STRATEGY AND SYSTEMATICALLY 3097 02:12:07,346 --> 02:12:11,717 SEARCHED EXOME AND GENOMES OF 3098 02:12:11,717 --> 02:12:13,585 PATIENTS IN THE AUTOINFLAMMATORY 3099 02:12:13,585 --> 02:12:16,588 AND UNDIAGNOSED DISEASE COHORTS 3100 02:12:16,588 --> 02:12:19,358 FOR VARIANTS IN UBIQUITYLATION 3101 02:12:19,358 --> 02:12:21,827 ENZYMES FOCUSING ON ESSENTIAL 3102 02:12:21,827 --> 02:12:26,231 GENES, VARIANTS THAT ARE NOT 3103 02:12:26,231 --> 02:12:31,336 FOUND IN THE GENERAL FOUND IN 3104 02:12:31,336 --> 02:12:38,444 THE HUMAN POPULATION. AND THIS 3105 02:12:38,444 --> 02:12:40,679 INCLUDED THREE MIDDLE-AGED MEN 3106 02:12:40,679 --> 02:12:43,315 AT THE SAME RESIDUE AND WHAT WAS 3107 02:12:43,315 --> 02:12:45,851 UNUSUAL FOR THESE INFLAMMATORY 3108 02:12:45,851 --> 02:12:47,152 DISEASES IS THAT THESE MUTATIONS 3109 02:12:47,152 --> 02:12:51,056 ARE NOT GERMLINE BUT RATHER 3110 02:12:51,056 --> 02:12:52,858 ACQUIRED SOMATIC. THEORY 3111 02:12:52,858 --> 02:12:55,160 STRICTED TO THE LINEAGE WHERE 3112 02:12:55,160 --> 02:12:56,428 THEY ARE PRESENT IN THE STEM 3113 02:12:56,428 --> 02:12:58,230 CELLS AND THEN THEY GET ENRICHED 3114 02:12:58,230 --> 02:13:01,266 IN THE LINEAGE ALL THE WHILE 3115 02:13:01,266 --> 02:13:03,368 TYPE CELL BUT NOT AT THE LYMPH 3116 02:13:03,368 --> 02:13:06,138 NODE WHERE THEY'RE CALLED LARGE 3117 02:13:06,138 --> 02:13:09,541 VACUOLES IN THE INFLAMMATORY 3118 02:13:09,541 --> 02:13:10,843 SIGNALLING AND WE FIND THEM TO 3119 02:13:10,843 --> 02:13:13,345 BE THE SOURCE OF INFLAMMATION 3120 02:13:13,345 --> 02:13:20,986 THAT IS CALLED VEXAS. THIS IS 3121 02:13:20,986 --> 02:13:29,628 CHARACTERIZED BY SEVERE 3122 02:13:29,628 --> 02:13:30,229 AUTOINFLAMMATION THAT EFFECTS 3123 02:13:30,229 --> 02:13:31,797 MANY SYSTEMS. THERE'S THIS 3124 02:13:31,797 --> 02:13:33,732 REALLY LARGE CHARACTERISTIC 3125 02:13:33,732 --> 02:13:39,304 VACUOLES THAT WE SEE IN THE BONE 3126 02:13:39,304 --> 02:13:42,508 MARROW CELLS. UNFORTUNATELY, 3127 02:13:42,508 --> 02:13:45,110 THIS IS OFTEN FATAL AND IT TURNS 3128 02:13:45,110 --> 02:13:48,647 OUT TO BE SURPRISINGLY PREVALENT 3129 02:13:48,647 --> 02:13:50,015 AS EVIDENCED BY THE RECENT 3130 02:13:50,015 --> 02:13:52,451 REPORT THAT IT AFFECTS ONE IN 3131 02:13:52,451 --> 02:13:54,953 FOUR THOUSAND MALES OVER 50 3132 02:13:54,953 --> 02:14:00,526 MAKING IT THE MOST COMMON 3133 02:14:00,526 --> 02:14:02,427 GENETIC AUTOIMMUNE DISEASE TO 3134 02:14:02,427 --> 02:14:05,297 DATE AND PUTTING IT IN THE RANGE 3135 02:14:05,297 --> 02:14:07,332 OF SICKLE CELL ANEMIA. THUS 3136 02:14:07,332 --> 02:14:09,434 WITH THOUSANDS OF PATIENTS WORLD 3137 02:14:09,434 --> 02:14:13,105 WIDE, THIS IS A SIGNIFICANT 3138 02:14:13,105 --> 02:14:14,573 HEALTH BURDEN AND WE NEED AN 3139 02:14:14,573 --> 02:14:15,674 UNDERSTANDING OF THE DISEASE TO 3140 02:14:15,674 --> 02:14:16,975 COME UP WITH EFFECTIVE 3141 02:14:16,975 --> 02:14:20,045 THERAPIES. SO THIS END WE 3142 02:14:20,045 --> 02:14:23,348 ALREADY SHOWN THAT THIS IS 3143 02:14:23,348 --> 02:14:27,152 TRANSLATED INTO AN ISOFORM. 3144 02:14:27,152 --> 02:14:29,855 WHICH GIVES US THEN RISE TO 3145 02:14:29,855 --> 02:14:31,990 DIFFERENTLY SUBCELLULAR 3146 02:14:31,990 --> 02:14:36,261 ISOFORMS. THE MAJORITY OF VEXAS 3147 02:14:36,261 --> 02:14:39,965 MUTATIONS ARE AT NET 41 AND 3148 02:14:39,965 --> 02:14:45,037 CAUSE LOSS OF FUNCTION BUT FIRST 3149 02:14:45,037 --> 02:14:46,605 TRANSLATING AND THEN BY USING 3150 02:14:46,605 --> 02:14:49,908 TRUNCATED IMPAIRED ISOFORM THAT 3151 02:14:49,908 --> 02:14:53,412 WE TERMED UBA 1C IN A 3152 02:14:53,412 --> 02:14:54,680 COLLABORATIVE FOLLOW UP STUDY WE 3153 02:14:54,680 --> 02:14:57,583 CAN THEN SHOW THAT THE B AMOUNTS 3154 02:14:57,583 --> 02:15:01,219 ARE AN IMPORTANT PREDICTOR OF 3155 02:15:01,219 --> 02:15:03,221 THE PATHOGENESIS. STUDYING A 3156 02:15:03,221 --> 02:15:05,791 LARGE COHORT OF PATIENTS OF 3157 02:15:05,791 --> 02:15:09,194 ROUGHLY ONE HUNDRED WE COULD 3158 02:15:09,194 --> 02:15:12,698 SHOW THAT PATIENTS WITH THE B 3159 02:15:12,698 --> 02:15:14,466 PHENOTYPES SHOW HIGHER MORTALITY 3160 02:15:14,466 --> 02:15:18,003 BUT THIS PHENOTYPE PRODUCED 3161 02:15:18,003 --> 02:15:20,806 SIGNIFICANTLY LESS RESIDUE OF B 3162 02:15:20,806 --> 02:15:24,376 LEVELS THAN THE OTHER PHENOTYPES 3163 02:15:24,376 --> 02:15:26,445 REVEALING AN ASSOCIATION BETWEEN 3164 02:15:26,445 --> 02:15:30,616 THE RESIDUE AND MORTALITY IN 3165 02:15:30,616 --> 02:15:32,417 VEXAS AND THIS STUDY INFORMED 3166 02:15:32,417 --> 02:15:33,285 PATIENT TREATMENT AND PATIENT 3167 02:15:33,285 --> 02:15:36,455 WITH A SEVERE ALLELE ARE 3168 02:15:36,455 --> 02:15:37,589 RECOMMENDED FOR TRANSPORT THAT 3169 02:15:37,589 --> 02:15:42,794 WE DO HERE AT NIH AND IN THE 3170 02:15:42,794 --> 02:15:44,763 FOLLOWING TALK DR. JACKIE MAYS 3171 02:15:44,763 --> 02:15:46,898 WILL TELL YOU HOW SHE CARES FOR 3172 02:15:46,898 --> 02:15:48,066 THESE PATIENTS AFTER TRANSPLANT 3173 02:15:48,066 --> 02:15:51,970 AND THE CONTEXT OF A LARGER 3174 02:15:51,970 --> 02:15:55,207 CLINICAL RESEARCH PROGRAM 3175 02:15:55,207 --> 02:15:58,810 STUDYING THE ORAL MANIFESTATIONS 3176 02:15:58,810 --> 02:16:01,913 OF THIS DISEASE. IN ADDITION TO 3177 02:16:01,913 --> 02:16:07,319 THESE THAT LEAD TO THE ISOFORM 3178 02:16:07,319 --> 02:16:09,988 SWAP WE ALSO IDENTIFIED THERE'S 3179 02:16:09,988 --> 02:16:12,224 OTHER NON-CANONICAL MUTATIONS. 3180 02:16:12,224 --> 02:16:14,726 IN A CLOSE COLLABORATION WITH 3181 02:16:14,726 --> 02:16:22,134 DR. NADINE SAMARA WHO IS AN 3182 02:16:22,134 --> 02:16:23,135 INVESTIGATOR WE DETERMINED 3183 02:16:23,135 --> 02:16:26,672 VARIOUS MECHANISMS BY WHICH 3184 02:16:26,672 --> 02:16:28,707 THESE AFFECT THIS. AND I DON'T 3185 02:16:28,707 --> 02:16:30,342 WANT TO GO INTO ALL THE DETAILS 3186 02:16:30,342 --> 02:16:33,512 BUT WHAT WE CAN SHOW IS TOGETHER 3187 02:16:33,512 --> 02:16:35,247 WITH NADINE IS THAT ALL OF THESE 3188 02:16:35,247 --> 02:16:39,217 MUTATIONS, MOST PROMINENTLY 3189 02:16:39,217 --> 02:16:40,919 AFFECTED THE LAST STEP OF THIS 3190 02:16:40,919 --> 02:16:43,855 INTO THE TWO ENZYMES WHICH WE 3191 02:16:43,855 --> 02:16:47,292 CALL A TWO TRANSFER BOTTLENECK 3192 02:16:47,292 --> 02:16:49,594 WHICH AFFECTED THEM BOTH NUCLEAR 3193 02:16:49,594 --> 02:16:52,397 AND THE CYTOPLASMIC ISOFORM. SO 3194 02:16:52,397 --> 02:16:54,199 TOGETHER FROM THESE STUDIES OF 3195 02:16:54,199 --> 02:16:57,502 CANONICAL AND NON-CANONICAL 3196 02:16:57,502 --> 02:16:59,137 MUTATIONS WE THEN PROPOSED THAT 3197 02:16:59,137 --> 02:17:03,308 A MAJOR MECHANISM UNDERLYING THE 3198 02:17:03,308 --> 02:17:05,744 VEXAS IS THE LOSS OF CONJUGATION 3199 02:17:05,744 --> 02:17:09,214 TO CYTOPLASMIC E 2S, HOWEVER, 3200 02:17:09,214 --> 02:17:11,316 HOW THIS UNIQUE STATE CAUSES THE 3201 02:17:11,316 --> 02:17:13,485 ACTUAL INFLAMMATORY CYCLING IN 3202 02:17:13,485 --> 02:17:15,320 THE MATURE CELLS IS STILL AN 3203 02:17:15,320 --> 02:17:16,922 IMPORTANT OUTSTANDING QUESTION. 3204 02:17:16,922 --> 02:17:18,623 SO IN THE LAST COUPLE OF SLIDES 3205 02:17:18,623 --> 02:17:21,426 I'M EXCITED TO SHARE YOU, WITH 3206 02:17:21,426 --> 02:17:23,328 YOU OUR UNPUBLISHED WORK WHICH 3207 02:17:23,328 --> 02:17:27,332 WE ADDRESSED THIS QUESTION, WE 3208 02:17:27,332 --> 02:17:29,334 ENGINEERED AN INDUCIBLE MONOCYTE 3209 02:17:29,334 --> 02:17:31,369 MODEL THAT ALLOWS FOR A 3210 02:17:31,369 --> 02:17:34,740 REPLACEMENT OF THE ENDOGENOUS 3211 02:17:34,740 --> 02:17:37,509 WITH AN EITHER AN ECTOPIC WILD 3212 02:17:37,509 --> 02:17:39,244 TYPE OR A VEXAS ALLELE. WE'RE 3213 02:17:39,244 --> 02:17:44,483 EXCITED TO SEE THIS MODEL 3214 02:17:44,483 --> 02:17:45,584 RECAPITULATES THE VEXAS 3215 02:17:45,584 --> 02:17:48,153 HALLMARKS AS YOU CAN SEE HERE BY 3216 02:17:48,153 --> 02:17:50,055 THESE CLEARLY VISIBLE VACUOLES 3217 02:17:50,055 --> 02:17:53,725 AND WE CAN SHOW THAT THEY'RE 3218 02:17:53,725 --> 02:17:55,327 EXPRESSING THE VEXAS 3219 02:17:55,327 --> 02:17:58,597 CHARACTERISTIC CYTOKINES THAT 3220 02:17:58,597 --> 02:18:02,667 INCLUDE THE INTERFERONS. WE 3221 02:18:02,667 --> 02:18:04,069 THEN HYPOTHESIZE THAT HAD 3222 02:18:04,069 --> 02:18:06,104 PROTEOMIC ANALYSIS OF THESE 3223 02:18:06,104 --> 02:18:08,507 VEXAS MODEL CELLS IN AN EARLY 3224 02:18:08,507 --> 02:18:09,875 TYPE POINT AND THEN COMPARING IT 3225 02:18:09,875 --> 02:18:13,178 WITH THE DYSREGULATED PATHWAY 3226 02:18:13,178 --> 02:18:14,379 THAT WE FIND IN PATIENT CELLS 3227 02:18:14,379 --> 02:18:17,916 WOULD ALLOW US TO IDENTIFY THE 3228 02:18:17,916 --> 02:18:21,286 EARLY EVENTS THAT FOLLOW THIS 3229 02:18:21,286 --> 02:18:22,821 CYTOPLASMIC FUNCTION AND CAN 3230 02:18:22,821 --> 02:18:25,557 INITIATE THE CYCLING. IN THE 3231 02:18:25,557 --> 02:18:26,424 EXPERIMENTS THAT I DON'T HAVE 3232 02:18:26,424 --> 02:18:29,761 TIME TO SHOW YOU WE THEN 3233 02:18:29,761 --> 02:18:31,329 IDENTIFY THE PATHWAY AS AN EARLY 3234 02:18:31,329 --> 02:18:34,533 PATHWAY FOLLOWING DISRUPTION OF 3235 02:18:34,533 --> 02:18:37,636 SAY TO PLASMA UBIQUITYLATION 3236 02:18:37,636 --> 02:18:39,905 THAT DRIVES THE CELL 3237 02:18:39,905 --> 02:18:41,306 INFLAMMATION AND VERY EXCITINGLY 3238 02:18:41,306 --> 02:18:43,308 WE CAN DEMONSTRATE THIS IS 3239 02:18:43,308 --> 02:18:44,509 INDEED THE CASE WHICH I'M 3240 02:18:44,509 --> 02:18:46,678 SHOWING YOU THAT ONE OF MANY 3241 02:18:46,678 --> 02:18:50,415 EXPERIMENTS THAT WE PERFORMED, 3242 02:18:50,415 --> 02:18:52,684 WE ISOLATED EITHER MYELOID CELLS 3243 02:18:52,684 --> 02:18:58,056 OR HEALTHY DONORS, TREATED THEM 3244 02:18:58,056 --> 02:19:00,091 WITH INHIBITORS AND MONITORED 3245 02:19:00,091 --> 02:19:04,062 THE INFLAMMATION AND WE MIND 3246 02:19:04,062 --> 02:19:06,498 THAT THIS TREATED CELLS COMPARED 3247 02:19:06,498 --> 02:19:08,967 TO THE HEALTHY DONORS HAVE 3248 02:19:08,967 --> 02:19:11,303 UPREGULATION OF ALL THESE 3249 02:19:11,303 --> 02:19:12,270 DIVERSE PATHWAYS HOWEVER AS SOON 3250 02:19:12,270 --> 02:19:14,973 AS WE TREAT WITH AN INHIBITOR 3251 02:19:14,973 --> 02:19:16,641 YOU CAN SEE THESE PATHWAYS ARE 3252 02:19:16,641 --> 02:19:18,877 DOWN-REGULATED REALLY 3253 02:19:18,877 --> 02:19:20,712 DEMONSTRATING AN IMPORTANT ROLE 3254 02:19:20,712 --> 02:19:22,380 OF ASSOCIATED INFLAMMATION. SO 3255 02:19:22,380 --> 02:19:23,982 IN SUMMARY WHAT, I HAVE SHOWN 3256 02:19:23,982 --> 02:19:26,084 YOU TODAY IS THAT BY 3257 02:19:26,084 --> 02:19:27,819 COLLABORATING WITH DIFFERENT NIH 3258 02:19:27,819 --> 02:19:30,021 AGENTS IN THE LABS WE WERE ABLE 3259 02:19:30,021 --> 02:19:32,457 TO USE GENOTYPE FIRST DISEASE 3260 02:19:32,457 --> 02:19:34,826 DISCOVERY APPROACHES TO UNCOVER 3261 02:19:34,826 --> 02:19:37,462 A NEW PREVALENT AUTOINFLAMMATORY 3262 02:19:37,462 --> 02:19:41,199 DISEASE, STUDY ITS UNDERLYING 3263 02:19:41,199 --> 02:19:42,067 DISEASE MECHANISMS LEARNING 3264 02:19:42,067 --> 02:19:47,339 ABOUT FUNDAMENTAL PRINCIPLES OF 3265 02:19:47,339 --> 02:19:48,607 HOW UBIQUITY AND KNOW WE ARE IN 3266 02:19:48,607 --> 02:19:52,077 THE PROCESS TO GO FULL CIRCLE 3267 02:19:52,077 --> 02:19:54,746 AND REALLY TRY TO APPLY THIS 3268 02:19:54,746 --> 02:19:56,214 KNOWLEDGE TO DEVELOP NEW 3269 02:19:56,214 --> 02:19:58,884 THERAPIES, EXPLORING THE 3270 02:19:58,884 --> 02:20:01,486 POSSIBILITIES OF REDIRECTING THE 3271 02:20:01,486 --> 02:20:02,287 PATHWAY INHIBITORS THAT PASSED 3272 02:20:02,287 --> 02:20:06,157 PHASE ONE CLINICAL TRIALS. IN 3273 02:20:06,157 --> 02:20:08,627 ADDITION, WE'RE ALSO THRIVING TO 3274 02:20:08,627 --> 02:20:10,061 HERE -- IN THE INTRAMURAL 3275 02:20:10,061 --> 02:20:11,329 PROGRAM TO MAKE THE 3276 02:20:11,329 --> 02:20:12,264 TRANSMUTATION A VIABLE THERAPY 3277 02:20:12,264 --> 02:20:14,199 FOR THESE PATIENTS AND WITH 3278 02:20:14,199 --> 02:20:16,668 THIS, I'M HANDING IT OTHER TO 3279 02:20:16,668 --> 02:20:24,009 DR. JACKIE MAYS. 3280 02:20:24,009 --> 02:20:26,711 >> THANK YOU SO MUCH DR. WARNER, 3281 02:20:26,711 --> 02:20:28,013 IT IS A PRIVILEGE TO BE HERE 3282 02:20:28,013 --> 02:20:31,950 TODAY I AM A DENTIST AND AN 3283 02:20:31,950 --> 02:20:33,685 IMMUNOLOGIST AND MY GROUP HAS 3284 02:20:33,685 --> 02:20:36,288 BEEN ABLE TO MAKE ADVANCE TO 3285 02:20:36,288 --> 02:20:38,657 IMPROVE HUMAN HEALTH AND CANCER 3286 02:20:38,657 --> 02:20:41,593 SURVIVORS AT THE NIDCR MY GROUP 3287 02:20:41,593 --> 02:20:43,328 WORKS CLOSELY WITH THE CELL 3288 02:20:43,328 --> 02:20:45,030 TRANSPLANT PROGRAM WITHIN THE 3289 02:20:45,030 --> 02:20:48,300 NIH CLINICAL CENTER TO MONITOR 3290 02:20:48,300 --> 02:20:52,037 AND TREAT CHANGES IN THE ORAL 3291 02:20:52,037 --> 02:20:56,675 CAVITY. TRABS PLANT OF A NEW 3292 02:20:56,675 --> 02:20:58,877 IMMUNE SYSTEM IS FOR LIMB FOE IF 3293 02:20:58,877 --> 02:21:01,780 AS AND VEXAS SYNDROME. 3294 02:21:01,780 --> 02:21:04,049 THE USE OF HEMATIC CELL 3295 02:21:04,049 --> 02:21:06,618 TRANSPLANT IS LIMITED BY THE 3296 02:21:06,618 --> 02:21:08,086 CHRONIC GRAFT VERSUS HOST 3297 02:21:08,086 --> 02:21:09,587 DISEASE A CHRONIC 3298 02:21:09,587 --> 02:21:10,155 AUTOIMMUNE-LIKE DISEASE IN 3299 02:21:10,155 --> 02:21:12,857 TRANSPLANT SURVIVORS MY 3300 02:21:12,857 --> 02:21:15,226 LABORATORY TAKES A BEDSIDE TO 3301 02:21:15,226 --> 02:21:18,330 BENCH APPROACH TO INVESTIGATION 3302 02:21:18,330 --> 02:21:22,033 OF BOTH THE PATHOGENESIS AND 3303 02:21:22,033 --> 02:21:23,601 TREATMENT OF GRAFT VERSUS HOST 3304 02:21:23,601 --> 02:21:24,636 DISEASE IN THE ORAL CAVITY AND 3305 02:21:24,636 --> 02:21:28,073 TODAY I AM SHARING WITH YOU A 3306 02:21:28,073 --> 02:21:29,574 VIGNETTE ABOUT NOVEL TREATMENT 3307 02:21:29,574 --> 02:21:34,145 FOR ORAL GRAFT VERSUS HOST 3308 02:21:34,145 --> 02:21:34,779 DISE 3309 02:21:34,779 --> 02:21:39,317 DISEASE IN THE ORAL CAVITY THIS 3310 02:21:39,317 --> 02:21:40,618 MANIFESTS IN THE ORAL MUCOSA AS 3311 02:21:40,618 --> 02:21:42,387 YOU CAN SEE FROM THE CLINICAL 3312 02:21:42,387 --> 02:21:46,124 IMAGES TAKEN WITHIN THE NIDCR 3313 02:21:46,124 --> 02:21:47,258 CLINIC AND ALSO WITHIN THE 3314 02:21:47,258 --> 02:21:48,626 SALIVARY GLANDS THIS IMPACTS 3315 02:21:48,626 --> 02:21:51,329 PATIENT PAIN LEVELS AND 3316 02:21:51,329 --> 02:21:53,932 NUTRITIONAL IMPACT INTAKE IN 3317 02:21:53,932 --> 02:21:55,700 ADDITION TO QUALITY OF LIFE AT 3318 02:21:55,700 --> 02:21:59,270 THE NIH WE ARE TRACKING PATIENT 3319 02:21:59,270 --> 02:22:01,740 WHO IS UNDERGO TRANSPLANT FOR 3320 02:22:01,740 --> 02:22:02,807 VEXAS SYNDROME. SO FAR WE'VE 3321 02:22:02,807 --> 02:22:04,142 TRACKED FIVE OF THESE PATIENTS. 3322 02:22:04,142 --> 02:22:05,877 THREE OUT OF THE FIVE 3323 02:22:05,877 --> 02:22:10,148 TRANSPLANTED HAVE DEVELOPED ORAL 3324 02:22:10,148 --> 02:22:11,316 SEQU 3325 02:22:11,316 --> 02:22:18,690 SEQUELA 0 50% DEVELOPED ORAL 3326 02:22:18,690 --> 02:22:21,559 HOST DISEASE. AS THE DOCTOR 3327 02:22:21,559 --> 02:22:23,395 MENTIONED FOR PATIENTS WITH THE 3328 02:22:23,395 --> 02:22:25,864 MOST SEVERE, IT CAN BE KAURTIVE 3329 02:22:25,864 --> 02:22:29,567 AND ONE TOO FAR FEW TREATMENT 3330 02:22:29,567 --> 02:22:29,834 OPTIONS. 3331 02:22:29,834 --> 02:22:34,139 THIS BLOOD SMEAR ACCOMPANYING 3332 02:22:34,139 --> 02:22:36,207 QUANTITATION SHOWED THAT THE 3333 02:22:36,207 --> 02:22:39,310 SYNDROME ARE FOUND WITHIN HE MAT 3334 02:22:39,310 --> 02:22:43,715 TOPO WETTIC CELLS AND THESE ARE 3335 02:22:43,715 --> 02:22:46,151 REPLACED WITH THE TRABS PLANT. 3336 02:22:46,151 --> 02:22:50,388 NEW THERAPEUTICS ARE NEEDED THAT 3337 02:22:53,958 --> 02:22:57,062 IS . WE ARE PARTNERED AT THE 3338 02:22:57,062 --> 02:22:58,797 UNIVERSITY OF PITTSBURGH MEDICAL 3339 02:22:58,797 --> 02:23:01,099 CENTER TO STUDY BOTH THE SAFETY 3340 02:23:01,099 --> 02:23:04,135 AND EFFICACY OF PHOTO BIO 3341 02:23:04,135 --> 02:23:05,837 MODULATION THERAPY USING A 3342 02:23:05,837 --> 02:23:08,073 DEVICE TO TREAT THE INTRAORAL 3343 02:23:08,073 --> 02:23:09,741 TISSUES AND THE EXTRA ORAL 3344 02:23:09,741 --> 02:23:12,277 TISSUES IMPACTED BY ORAL GRAFT 3345 02:23:12,277 --> 02:23:14,012 VERSUS HOST DISEASE USING RED 3346 02:23:14,012 --> 02:23:18,049 LIGHT THERAPY AT 660 AND 850 3347 02:23:18,049 --> 02:23:18,750 NANOMETERS. 3348 02:23:18,750 --> 02:23:26,558 IN THIS DOUBLE BLIND PLACMRAPLA 3349 02:23:26,558 --> 02:23:29,260 CONTROLLED TRIAL. AND THEN THEY 3350 02:23:29,260 --> 02:23:31,329 ARE ABLE TO CONTINUE OPEN LABEL 3351 02:23:31,329 --> 02:23:34,099 TREATMENT FOR AN ADDITIONAL 3352 02:23:34,099 --> 02:23:36,301 MONTH. THE EFFICACY OF PHOTO 3353 02:23:36,301 --> 02:23:41,339 BIO MODULATION HINGES ON THE 3354 02:23:41,339 --> 02:23:43,908 MITOCHONDRIA THAT LEADS TO 3355 02:23:43,908 --> 02:23:46,578 INCREASED ATP AND OXYGEN 3356 02:23:46,578 --> 02:23:50,915 REDUCTION IN THE ACTIVITY AND 3357 02:23:50,915 --> 02:23:51,950 THE CORRESPONDING REDUCTION IN 3358 02:23:51,950 --> 02:23:54,853 THE PRODUCTION OF THE CYTOKINES 3359 02:23:54,853 --> 02:23:58,022 AND ALSO VEII SEW LIE DAGS THAT 3360 02:23:58,022 --> 02:24:00,925 IMPROVES TISSUE PROSOLUTION. 3361 02:24:00,925 --> 02:24:03,328 THIS BREAKS THE CIRCUIT. AND 3362 02:24:03,328 --> 02:24:11,002 PROMOTES TISSUE HEALING. COMING 3363 02:24:11,002 --> 02:24:14,005 BACK TO VEXAS, IN A PATIENT, AT 3364 02:24:14,005 --> 02:24:16,107 FOUR MONTHS POST TRANSPLANT THIS 3365 02:24:16,107 --> 02:24:17,709 PATIENT DEVELOPED CHRONIC GRAFT 3366 02:24:17,709 --> 02:24:19,244 VERSUS HOST DISEASE OF THE 3367 02:24:19,244 --> 02:24:21,346 MOUTH, THE SKIN AND THE EYES 3368 02:24:21,346 --> 02:24:24,816 THAT WAS INITIALLY TREATED WITH 3369 02:24:24,816 --> 02:24:28,653 A JAK 1/2 INHIBITOR THAT IS 3370 02:24:28,653 --> 02:24:31,389 EXPECTED TO BLOCK THE CYTOKINES 3371 02:24:31,389 --> 02:24:36,661 WHEN IT WAS TAPERED ISOLATED 3372 02:24:36,661 --> 02:24:41,566 GRAFT VERSUS HOST DISEASE FLARED 3373 02:24:41,566 --> 02:24:42,700 YOU CAN APPRECIATE HERE ON THE 3374 02:24:42,700 --> 02:24:45,270 HARD PALLET YOU CAN SEE THE 3375 02:24:45,270 --> 02:24:46,104 LESIONS HERE THROUGH THE LINE 3376 02:24:46,104 --> 02:24:51,342 AND EXTENDING OUT TO THE 3377 02:24:51,342 --> 02:24:54,245 DENTITION. THE PATIENT WAS 3378 02:24:54,245 --> 02:24:56,080 ENROLLED ON THE LIGHT TRIAL 3379 02:24:56,080 --> 02:25:00,985 WHICH IS THE PHOTO STUDY THAT I 3380 02:25:00,985 --> 02:25:02,520 JUST MENTIONED AND WAS GIVEN 18 3381 02:25:02,520 --> 02:25:04,155 TREATMENTS OF THE THERAPY. I 3382 02:25:04,155 --> 02:25:06,424 SHOULD MENTION THIS STUDY IS NOT 3383 02:25:06,424 --> 02:25:08,193 YET UNBLINDED SO IT'S NOT CLEAR 3384 02:25:08,193 --> 02:25:10,161 IF THE PATIENT RECEIVED ACTIVE 3385 02:25:10,161 --> 02:25:12,630 THERAPY DURING BOTH PHASES. 3386 02:25:12,630 --> 02:25:15,433 HOWEVER, AT DAY 56 AT THE 3387 02:25:15,433 --> 02:25:17,735 CONCLUSION OF THE OPEN LABEL 3388 02:25:17,735 --> 02:25:20,004 PERIOD WE WERE ABLE TO OBSERVE 3389 02:25:20,004 --> 02:25:20,605 COMPLETE MEDICAL RESOLUTION 3390 02:25:20,605 --> 02:25:24,375 SHOWN HERE ON THE PALLET OF THE 3391 02:25:24,375 --> 02:25:26,077 PATIENT. THE NIDCR IS 3392 02:25:26,077 --> 02:25:28,379 WELL-INTEGRATED INTO THE NIH 3393 02:25:28,379 --> 02:25:30,348 DISCOVERY ENGINE THAT IS 3394 02:25:30,348 --> 02:25:32,684 DIRECTED TOWARDS IMPROVING HUMAN 3395 02:25:32,684 --> 02:25:33,985 HEALTH OUR INTRAMURAL NETWORK 3396 02:25:33,985 --> 02:25:36,020 BRINGS STUDIES TO IMPROVE HUMAN 3397 02:25:36,020 --> 02:25:38,156 HEALTH FULL CIRCLE. FROM WORK 3398 02:25:38,156 --> 02:25:40,425 TO IDENTIFY AND CHARACTERIZE 3399 02:25:40,425 --> 02:25:43,361 UNDIAGNOSED DISEASES TO DEFINING 3400 02:25:43,361 --> 02:25:46,064 AND FACILITATING NEW TREATMENTS. 3401 02:25:46,064 --> 02:25:48,032 DR. WESTERNER AND I THINK THE 3402 02:25:48,032 --> 02:25:48,866 SCIENTISTS AND STAFF IN OUR 3403 02:25:48,866 --> 02:25:52,003 RESPECTIVE LABORATORIES ON OUR 3404 02:25:52,003 --> 02:25:54,539 CLINICAL TEAMS BOTH INSIDE AND 3405 02:25:54,539 --> 02:25:56,207 OUTSIDE THE NIDCR FOR THEIR 3406 02:25:56,207 --> 02:25:58,176 CLINICAL ROLES IN THIS GROUND 3407 02:25:58,176 --> 02:26:02,880 BREAK WOING WORK AND THANK YOU L 3408 02:26:02,880 --> 02:26:04,582 FOR YOUR ATTENTION. 3409 02:26:04,582 --> 02:26:06,818 >> THANK YOU SO MUCH. NOW WE'LL 3410 02:26:06,818 --> 02:26:09,087 HAVE OUR FINAL PLENARY. FOCUSED 3411 02:26:09,087 --> 02:26:13,925 ON DENTIST PUBLIC HEALTH AT 3412 02:26:13,925 --> 02:26:24,569 NIDCR. BY DOCTORS HOE SAM 3413 02:26:25,870 --> 02:26:28,172 >> HELLO, I AM THE DIRECTOR OF 3414 02:26:28,172 --> 02:26:32,010 THE FELLOWSHIP AT NIDCR. I'M 3415 02:26:32,010 --> 02:26:34,245 HAPPY TO PROVIDE A BRIEF 3416 02:26:34,245 --> 02:26:36,414 OVERVIEW OF DENTAL PUBLIC HEALTH 3417 02:26:36,414 --> 02:26:38,483 ADVANCEMENT AT THE INSTITUTE AND 3418 02:26:38,483 --> 02:26:41,185 TALK BRIEFLY ABOUT OUR 3419 02:26:41,185 --> 02:26:44,455 FELLOWSHIP PROGRAM. THEN, LOOK 3420 02:26:44,455 --> 02:26:47,725 DOCTOR LEAH WILL TALK ABOUT HER 3421 02:26:47,725 --> 02:26:50,361 RESEARCH EXPERIENCE. BEFORE I 3422 02:26:50,361 --> 02:26:52,497 BEGIN I WOULD LIKE TO SHARE TWO 3423 02:26:52,497 --> 02:26:56,434 POINTS ONE IS THAT NIDCR SINCE 3424 02:26:56,434 --> 02:26:58,236 THE BEGINNING HAS SUPPORTED 3425 02:26:58,236 --> 02:26:59,537 CLINICAL AND EVIDENCE-BASED 3426 02:26:59,537 --> 02:27:02,974 POPULATION HEALTH INTERVENTIONS 3427 02:27:02,974 --> 02:27:05,710 STARTING FROM SMALL SCALE AND 3428 02:27:05,710 --> 02:27:07,345 BASIC SCIENCE AND EXPANDING 3429 02:27:07,345 --> 02:27:11,349 THROUGH EPIDEMIOLOGY AND 3430 02:27:11,349 --> 02:27:13,117 DISSEMINATION. NUMBER TWO, ONCE 3431 02:27:13,117 --> 02:27:15,286 AN INITIATIVE ACHIEVES ITS 3432 02:27:15,286 --> 02:27:19,390 GOALS, OR PRIORITIES HAVE 3433 02:27:19,390 --> 02:27:22,226 CHANGED, THE WORK TYPICALLY 3434 02:27:22,226 --> 02:27:27,332 BECOMES INTEGRATED INTO THE 3435 02:27:27,332 --> 02:27:31,102 BROADER INSTITUTE STRUCTURE FOR 3436 02:27:31,102 --> 02:27:34,238 THE NEXT AGENDA TO BEGIN. IT 3437 02:27:34,238 --> 02:27:39,344 ALL BEGAN IN 1948 WHEN THE 3438 02:27:39,344 --> 02:27:39,977 DR. DEAN BECAME THE FOUNDING 3439 02:27:39,977 --> 02:27:44,282 DIRECTOR OF THE INSTITUTE. 3440 02:27:44,282 --> 02:27:46,818 DR. DEAN WAS A PUBLIC HEALTH 3441 02:27:46,818 --> 02:27:50,088 SCIENTIST AND EPIDEMIOLOGIST AND 3442 02:27:50,088 --> 02:27:52,190 HE LED THE FIRST LARGE U.S. 3443 02:27:52,190 --> 02:27:54,926 STUDY THAT CONFIRMED THE ROLE OF 3444 02:27:54,926 --> 02:27:57,662 FLUORIDE IN PREVENTING TOOTH 3445 02:27:57,662 --> 02:27:59,330 DECAY SHOWING A DECLINE IN TOOTH 3446 02:27:59,330 --> 02:28:02,333 DECAY UP TO 60% IN CHILDREN 3447 02:28:02,333 --> 02:28:04,669 AFTER THE IMPLEMENTATION OF THE 3448 02:28:04,669 --> 02:28:07,271 NATION'S FIRST COMMUNITY WATER 3449 02:28:07,271 --> 02:28:12,143 FLUORIDATION PROGRAM. A PICTURE 3450 02:28:12,143 --> 02:28:14,645 ON THE RIGHT SHOWS DR. LIE KINS 3451 02:28:14,645 --> 02:28:18,649 WAS ONE OF THE STAFF SCIENTISTS 3452 02:28:18,649 --> 02:28:21,886 TAKING PART OF THE STUDY. THE 3453 02:28:21,886 --> 02:28:27,325 NIDCR EARLY STUDY IN PER RIO 3454 02:28:27,325 --> 02:28:28,793 DONNAL DISEASE LED TO 3455 02:28:28,793 --> 02:28:31,195 DEVELOPMENT OF THE PERIODONTAL 3456 02:28:31,195 --> 02:28:34,165 INDEX IN 1956. THE INDEX BECAME 3457 02:28:34,165 --> 02:28:37,802 A VITAL TOOL FOR EPIDEMIOLOGISTS 3458 02:28:37,802 --> 02:28:41,406 TO MEASURE PERIODONTAL DISEASE 3459 02:28:41,406 --> 02:28:49,046 ACROSS POPULATIONS. BY 1964, 3460 02:28:49,046 --> 02:28:51,349 NIDCR RESEARCHERS HAD SHONE THAT 3461 02:28:51,349 --> 02:28:53,317 TOPICAL FLUORIDE COULD REDUCE 3462 02:28:53,317 --> 02:28:58,222 CARIES IN ANIMALS THAT LED TO A 3463 02:28:58,222 --> 02:29:01,859 SCHOOL BASED FLUORIDE GEL TRIAL 3464 02:29:01,859 --> 02:29:03,628 IN NEW YORK SHOWN THAT TOPICAL 3465 02:29:03,628 --> 02:29:05,396 FLUORIDE IS EFFECTIVE IN 3466 02:29:05,396 --> 02:29:10,234 REDUCING TOOTH DECAY UP TO 80%. 3467 02:29:10,234 --> 02:29:14,038 IN 1971 THE NATIONAL CARIES 3468 02:29:14,038 --> 02:29:22,213 PROGRAM WAS LAUNCHED BY FLSNIDCO 3469 02:29:22,213 --> 02:29:23,514 SPEED UP TOOTH DECAY EFFORTS. 3470 02:29:23,514 --> 02:29:26,584 MANY PREVENTATIVE MEASURES 3471 02:29:26,584 --> 02:29:28,219 INCLUDING DENTAL SEALANTS AND 3472 02:29:28,219 --> 02:29:31,355 FOOD SCREENING METHODS WERE 3473 02:29:31,355 --> 02:29:33,191 IDENTIFIED AND TESTED THROUGH 3474 02:29:33,191 --> 02:29:36,894 CLINICAL AND COMMUNITY TRIALS. 3475 02:29:36,894 --> 02:29:38,830 A GREAT EXAMPLE IS FLUORIDE 3476 02:29:38,830 --> 02:29:40,231 MOUTH RINSE DEMONSTRATION 3477 02:29:40,231 --> 02:29:44,302 PROJECT COMPLETED IN 1979. 3478 02:29:44,302 --> 02:29:45,336 DESIGNED SPECIFICALLY TO 3479 02:29:45,336 --> 02:29:47,305 COMPLEMENT COMMUNITY WATER 3480 02:29:47,305 --> 02:29:50,308 FLUORIDATION EFFORTS, RESULTS 3481 02:29:50,308 --> 02:29:53,144 SHOWED HIGH RISK CHILDREN HAD A 3482 02:29:53,144 --> 02:29:56,481 50% REDUCTION IN NEW CARIES AND 3483 02:29:56,481 --> 02:29:58,216 AS A RESULT, SCHOOL RINSE 3484 02:29:58,216 --> 02:30:01,819 PROGRAMS EXPANDED FROM 2-13 3485 02:30:01,819 --> 02:30:03,287 MILLION CHILDREN OUT OF A TARGET 3486 02:30:03,287 --> 02:30:06,324 POPULATION OF 25 MILLION. 3487 02:30:06,324 --> 02:30:16,067 REACHING 44 STATES IN 1985. AND 3488 02:30:16,067 --> 02:30:16,868 NIDCR CONDUCTED THE FIRST SCHOOL 3489 02:30:16,868 --> 02:30:19,370 CHILDREN SURVEY COMPLETED IN 3490 02:30:19,370 --> 02:30:23,608 1980 THE SURVEY WAS DESIGNED TO 3491 02:30:23,608 --> 02:30:28,145 ASSESS BASELINE DATA AND CHANGES 3492 02:30:28,145 --> 02:30:29,747 OVER TIME TO SEE IF THE 3493 02:30:29,747 --> 02:30:30,448 INTERVENTIONS WERE WORKING. 3494 02:30:30,448 --> 02:30:33,351 ABOUT ONE-THIRD OF THE CHILDREN 3495 02:30:33,351 --> 02:30:36,687 AT THE TIME WERE CARIES-FREE AND 3496 02:30:36,687 --> 02:30:39,757 ON AVERAGE EACH CHILD HAD A 3497 02:30:39,757 --> 02:30:43,327 THREE PERMANENT TEETH THAT WERE 3498 02:30:43,327 --> 02:30:46,230 DECAYED OR HAD FILLINGS. SEVEN 3499 02:30:46,230 --> 02:30:48,799 YEARS LATER THE SECOND SCHOOL 3500 02:30:48,799 --> 02:30:50,468 CHILDREN SURVEY SHOWED 3501 02:30:50,468 --> 02:30:53,070 SIGNIFICANT REDUCTION IN TOOTH 3502 02:30:53,070 --> 02:30:58,209 DECAY PREVALENCE AND SEVERITY. 3503 02:30:58,209 --> 02:31:05,216 WITH HALF OF THE CHILDREN WERE 3504 02:31:05,216 --> 02:31:07,351 CARIES-FREE AND THE AVERAGE THAT 3505 02:31:07,351 --> 02:31:08,653 THE NUMBER OF PERMANENT TEETH 3506 02:31:08,653 --> 02:31:11,856 THAT WERE DECAYED OR HAD 3507 02:31:11,856 --> 02:31:14,358 FILLINGS WAS TWO TEETH. 3508 02:31:14,358 --> 02:31:15,726 COMPARED TO THREE TEETH IN THE 3509 02:31:15,726 --> 02:31:22,667 FIRST SURVEY. IN 1986, NIDCR 3510 02:31:22,667 --> 02:31:25,836 CONDUCTED THE FIRST STUDY OF 3511 02:31:25,836 --> 02:31:28,105 ORAL HEALTH OF EMPLOYED ADULTS 3512 02:31:28,105 --> 02:31:31,175 AND OTHER ADULTS. THE VAST 3513 02:31:31,175 --> 02:31:33,444 MAJORITY OF PARTICIPANTS HAD 3514 02:31:33,444 --> 02:31:37,148 EXPERIENCED TOOTH DECAY AND HAD 3515 02:31:37,148 --> 02:31:39,150 PERRY OWE DONNAL DISEASE AND 3516 02:31:39,150 --> 02:31:41,852 CARRIES WERE COMMON IN OLDER 3517 02:31:41,852 --> 02:31:42,153 ADULTS. 3518 02:31:42,153 --> 02:31:43,754 THIS IS THE FIRST NATIONAL 3519 02:31:43,754 --> 02:31:47,358 SURVEY THAT MEASURED THIS IN 3520 02:31:47,358 --> 02:31:50,828 AMERICA. THE -- THE INSTITUTE 3521 02:31:50,828 --> 02:31:54,198 COLLABORATIVE GLOBAL ORAL HEALTH 3522 02:31:54,198 --> 02:31:58,636 EFFORTS INCLUDED THE 3523 02:31:58,636 --> 02:32:00,004 COLLABORATION OF SPECIFIC HEALTH 3524 02:32:00,004 --> 02:32:02,306 PROFILES, DEVELOPMENT OF THE 3525 02:32:02,306 --> 02:32:03,608 ORAL HEALTH RESEARCH AGENDA 3526 02:32:03,608 --> 02:32:07,345 INCLUDING VARIOUS TOPICS 3527 02:32:07,345 --> 02:32:12,283 INCLUDING GUM AND FLUORIDE. TWO 3528 02:32:12,283 --> 02:32:15,353 COLLABORATIVE STUDIES ON ORAL 3529 02:32:15,353 --> 02:32:20,524 HELL HEALTH SYSTEMS ACROSS 3530 02:32:20,524 --> 02:32:22,360 STUDIES AND THE LECTURE SERIES 3531 02:32:22,360 --> 02:32:25,930 THAT CONTINUES TO THIS DAY. 3532 02:32:25,930 --> 02:32:31,335 IN THE YEAR 2000 NIDCR LED AND 3533 02:32:31,335 --> 02:32:33,337 PROVIDE MUCH OF THE EVIDENCE 3534 02:32:33,337 --> 02:32:35,940 CITED IN THE ORAL HEALTH IN 3535 02:32:35,940 --> 02:32:39,076 AMERICA WORK OF THE SURGEON 3536 02:32:39,076 --> 02:32:40,177 GENERAL WHICH ESTABLISHED ORAL 3537 02:32:40,177 --> 02:32:42,647 HEALTH AS A NATIONAL HEALTH 3538 02:32:42,647 --> 02:32:45,016 PRIORITY. BIG THEMES WERE ORAL 3539 02:32:45,016 --> 02:32:47,184 HEALTH IS ESSENTIAL IN GENERAL 3540 02:32:47,184 --> 02:32:48,886 HEALTH AND ORAL HEALTH MEANS 3541 02:32:48,886 --> 02:32:51,255 MUCH MORE THAN HEALTHY TEETH AND 3542 02:32:51,255 --> 02:32:53,257 INCLUDE THE CRANIAL FACIAL 3543 02:32:53,257 --> 02:32:55,026 STRUCTURE AND THE PSYCHOSOCIAL 3544 02:32:55,026 --> 02:32:58,295 ASPECTS OF HEALTH. ORAL HEALTH 3545 02:32:58,295 --> 02:33:01,632 CANNOT BE ACHIEVED BY ALL 3546 02:33:01,632 --> 02:33:02,933 AMERICANS NONETHELESS THERE IS A 3547 02:33:02,933 --> 02:33:05,503 SILENT EPIDEMIC OF ORAL DISEASES 3548 02:33:05,503 --> 02:33:08,205 AFFECTING THE MOST VULNERABLE 3549 02:33:08,205 --> 02:33:11,308 INCLUDING CHILDREN, OLDER ADULTS 3550 02:33:11,308 --> 02:33:16,313 AND CERTAIN ETHNIC GROUPS. 3551 02:33:16,313 --> 02:33:19,383 TWENTY YEARS LATER NIDCR ALSO 3552 02:33:19,383 --> 02:33:22,453 LED THE SECOND ORAL HEALTH IN 3553 02:33:22,453 --> 02:33:24,655 AMERICA REPORT. SHOWING 3554 02:33:24,655 --> 02:33:26,223 CONTINUED IMPROVEMENT IN ORAL 3555 02:33:26,223 --> 02:33:29,593 HEALTH OUTCOMES INCLUDING FEWER 3556 02:33:29,593 --> 02:33:31,328 CAVITIES IN CHILDREN AND BETTER 3557 02:33:31,328 --> 02:33:33,531 TOOTH RETENTION IN OLDER ADULTS. 3558 02:33:33,531 --> 02:33:36,534 THE REPORT ALSO HIGHLIGHTED 3559 02:33:36,534 --> 02:33:38,135 ADVANCES AND TECHNOLOGY AND 3560 02:33:38,135 --> 02:33:41,172 SCIENCE SUCH AS DIGITAL TOOLS 3561 02:33:41,172 --> 02:33:43,040 AND DEEPER UNDERSTANDING OF THE 3562 02:33:43,040 --> 02:33:48,112 ORAL MICROBIOME HOWEVER, 3563 02:33:48,112 --> 02:33:49,513 DISPARITIES, ORAL HEALTH 3564 02:33:49,513 --> 02:33:51,382 DISPARITIES CONTINUED TO EXIST 3565 02:33:51,382 --> 02:33:54,485 AND EMERGE. TODAY, THE DENTAL 3566 02:33:54,485 --> 02:33:56,454 PUBLIC HEALTH RESEARCH 3567 02:33:56,454 --> 02:34:00,491 FELLOWSHIP EXPERIENCE STANDS AS 3568 02:34:00,491 --> 02:34:03,060 A LEGACY OF PUBLIC HEALTH 3569 02:34:03,060 --> 02:34:05,463 LEADERSHIP. THIS STARTED IN 3570 02:34:05,463 --> 02:34:08,733 1980 UNDER THE NATIONAL CARIES 3571 02:34:08,733 --> 02:34:11,168 PROGRAM AND EVOLVE OVER TIME IN 3572 02:34:11,168 --> 02:34:14,405 2016 WAS COMBINED WITH ORAL 3573 02:34:14,405 --> 02:34:16,440 HEALTH INFORMATICS WORKING WITH 3574 02:34:16,440 --> 02:34:17,074 THE NATIONAL LIBRARY OF MEDICINE 3575 02:34:17,074 --> 02:34:22,146 AND IN 2021 THE SCOPE WAS 3576 02:34:22,146 --> 02:34:24,081 BROADENED TO INCLUDE 3577 02:34:24,081 --> 02:34:26,350 COLLABORATION WITH NIH RESEARCH 3578 02:34:26,350 --> 02:34:28,319 PROGRAMS. SO THE FIRST YEAR IS 3579 02:34:28,319 --> 02:34:31,255 A DENTAL PUBLIC HEALTH RESIDENCY 3580 02:34:31,255 --> 02:34:32,890 FOLLOWED BY INTENSIVE RESEARCH 3581 02:34:32,890 --> 02:34:36,460 IN THE YEAR TWO AND THREE 3582 02:34:36,460 --> 02:34:38,763 WORKING ON A RESEARCH AGENDA 3583 02:34:38,763 --> 02:34:40,297 THAT BRIDGES GAPS BETWEEN PUBLIC 3584 02:34:40,297 --> 02:34:42,666 HEALTH AND BIOMEDICAL SCIENCES. 3585 02:34:42,666 --> 02:34:47,338 OUR RESEARCH AGENDA IS BROAD. 3586 02:34:47,338 --> 02:34:51,742 WITH EMERGING FOCUS ON ORAL 3587 02:34:51,742 --> 02:34:55,346 HEALTH AND SYSTEMIC HEALTH 3588 02:34:55,346 --> 02:35:02,319 CONNECTIONS. OVER THE PAST 45 3589 02:35:02,319 --> 02:35:05,923 YEARS, THIS FROM THE RESIDENCY, 3590 02:35:05,923 --> 02:35:08,259 60 GRADUATES JOINED THE FIELD AS 3591 02:35:08,259 --> 02:35:11,862 SUBJECT MATTER EXPERTS IN DENTAL 3592 02:35:11,862 --> 02:35:14,265 PUBLIC HEALTH. ABOUT HALF HAD 3593 02:35:14,265 --> 02:35:17,802 PURSUED CAREERS IN THE FEDERAL 3594 02:35:17,802 --> 02:35:19,003 GOVERNMENT PRIMARILY IN THE 3595 02:35:19,003 --> 02:35:22,106 MILITARY AND THE OTHER HALF 3596 02:35:22,106 --> 02:35:23,340 ENTERED ACADEMIA OR OTHER 3597 02:35:23,340 --> 02:35:26,577 SECTORS OR CONTINUED THEIR 3598 02:35:26,577 --> 02:35:32,049 EDUCATION. OVER THE YEARS THE 3599 02:35:32,049 --> 02:35:33,450 TRAINEES CONTINUED TO TRAVERSE 3600 02:35:33,450 --> 02:35:36,353 THE AGENDA USING DATA FROM 3601 02:35:36,353 --> 02:35:39,089 VARIOUS SOURCES INCLUDING THE 3602 02:35:39,089 --> 02:35:41,292 MILITARY, CMS, COMMERCIAL 3603 02:35:41,292 --> 02:35:44,595 SERVICES, AND OTHER FEDERAL AND 3604 02:35:44,595 --> 02:35:47,097 NATIONAL PROGRAMS. IN GENERAL, 3605 02:35:47,097 --> 02:35:50,000 WE USE A CROSS-SECTIONAL 3606 02:35:50,000 --> 02:35:52,169 LONGITUDINAL DATA WHICH NOT ONLY 3607 02:35:52,169 --> 02:35:55,306 ALLOW US TO INVESTIGATE 3608 02:35:55,306 --> 02:35:57,408 ASSOCIATION BUT ALSO TIME BASED 3609 02:35:57,408 --> 02:36:01,078 PATTERNS AND POSSIBLE CAUSE AND 3610 02:36:01,078 --> 02:36:05,549 EFFECT RELATIONSHIPS. THESE ARE 3611 02:36:05,549 --> 02:36:06,984 OUR CURRENT COLLABORATIONS 3612 02:36:06,984 --> 02:36:10,321 COVERING VARIOUS TOPICS 3613 02:36:10,321 --> 02:36:13,457 INCLUDING TASTE AND SMELL, SLEEP 3614 02:36:13,457 --> 02:36:15,159 HEALTH, COGNITIVE HEALTH, CANCER 3615 02:36:15,159 --> 02:36:18,896 AND ORAL CANCER AND ALCOHOL USE 3616 02:36:18,896 --> 02:36:20,898 DISORDER. THESE COLLABORATIONS 3617 02:36:20,898 --> 02:36:23,801 ALLOW US TO ASK NEW QUESTIONS 3618 02:36:23,801 --> 02:36:26,837 AND BRING ORAL HEALTH INTO AREAS 3619 02:36:26,837 --> 02:36:29,039 WHERE IT HASN'T BEEN 3620 02:36:29,039 --> 02:36:31,342 TRADITIONALLY INCLUDED AND WITH 3621 02:36:31,342 --> 02:36:33,577 THAT, THANK YOU VERY MUCH, NEXT 3622 02:36:33,577 --> 02:36:37,047 THE DOCTOR TO TALK ABOUT HER 3623 02:36:37,047 --> 02:36:46,123 RESEARCH EXPERIENCE. 3624 02:36:46,123 --> 02:36:48,826 >> GREAT, THANK YOU FOR THAT 3625 02:36:48,826 --> 02:36:50,995 LOVELY INTRODUCTION AS WELL. I 3626 02:36:50,995 --> 02:36:52,296 AM DR. LEAH AND THANK YOU FOR 3627 02:36:52,296 --> 02:36:53,597 THE OPPORTUNITY TO SHARE MY 3628 02:36:53,597 --> 02:36:56,700 EXPERIENCES OVER THE LAST THREE 3629 02:36:56,700 --> 02:36:58,035 YEARS. BEFORE WE GET INTO THAT 3630 02:36:58,035 --> 02:37:00,804 LET ME TELL YOU ABOUT HOW WE GOT 3631 02:37:00,804 --> 02:37:02,973 HERE. PRIOR TO JOINING NIH I 3632 02:37:02,973 --> 02:37:04,775 CARED FOR PATIENTS IN MARYLAND 3633 02:37:04,775 --> 02:37:06,377 AND PENNSYLVANIA. AND IT WAS A 3634 02:37:06,377 --> 02:37:08,212 PRIVILEGE TO CARE FOR PATIENTS 3635 02:37:08,212 --> 02:37:10,314 AND PEOPLE AT SOME OF THE WORST 3636 02:37:10,314 --> 02:37:11,048 TIMES IN THEIR LIVES AND THROUGH 3637 02:37:11,048 --> 02:37:13,250 THIS I HEARD SIMILAR STORIES 3638 02:37:13,250 --> 02:37:14,618 FROM PATIENTS ABOUT THEIR 3639 02:37:14,618 --> 02:37:16,320 EXPERIENCES WITH US AND WITH THE 3640 02:37:16,320 --> 02:37:17,288 HEALTH CARE SYSTEM. SOME OF 3641 02:37:17,288 --> 02:37:20,057 WHICH ARE SUMMARIZED IN THE BLUE 3642 02:37:20,057 --> 02:37:23,327 BOX HERE. I DECIDED TO SEE IF I 3643 02:37:23,327 --> 02:37:24,695 COULD TRANSLATE THIS APPEARANCE 3644 02:37:24,695 --> 02:37:27,331 FROM PATIENT TO POPULATION AND 3645 02:37:27,331 --> 02:37:29,767 BACK AGAIN CONTRIBUTING TO 3646 02:37:29,767 --> 02:37:31,769 SYSTEMS LEVEL CHANGE. SO ONE 3647 02:37:31,769 --> 02:37:34,238 THING I OBSERVED WHILE COVERING 3648 02:37:34,238 --> 02:37:34,905 EMERGENCY DEPARTMENTS DURING THE 3649 02:37:34,905 --> 02:37:36,907 BEGINNING OF THE COVID-19 3650 02:37:36,907 --> 02:37:40,311 PANDEMIC IS ALL OF OUR PRACTICE 3651 02:37:40,311 --> 02:37:42,579 PATTERNS CHANGED WITH A SHIFT 3652 02:37:42,579 --> 02:37:43,347 TOWARDS MANAGEMENT OF DENTAL 3653 02:37:43,347 --> 02:37:45,249 PROBLEMS AND I WONDERED IF THIS 3654 02:37:45,249 --> 02:37:47,151 WAS WHAT I WAS OBSERVING AT THE 3655 02:37:47,151 --> 02:37:51,522 HOSPITALS I HAVE WO -- I WAS WO 3656 02:37:51,522 --> 02:37:53,557 AT BUT ALSO IN THE POPULATION AS 3657 02:37:53,557 --> 02:37:53,757 WELL. 3658 02:37:53,757 --> 02:37:57,127 AND WAS THIS FOR CONTINUED 3659 02:37:57,127 --> 02:37:57,761 INVESTIGATION AND INTERVENTION 3660 02:37:57,761 --> 02:37:58,595 SO THE ANSWER TO THIS QUESTION, 3661 02:37:58,595 --> 02:38:00,731 WE LOOKED AT THE NATIONAL 3662 02:38:00,731 --> 02:38:03,334 HOSPITAL AM BUT LA STORY MEDICAL 3663 02:38:03,334 --> 02:38:05,502 CARE SURVEY TO LOOK AT 3664 02:38:05,502 --> 02:38:08,973 PRESCRIPTIONS FOR PATIENTS 3665 02:38:08,973 --> 02:38:11,575 PRESENTING U.S. EDS. 3666 02:38:11,575 --> 02:38:12,643 WE FOUND THEY WERE MOST 3667 02:38:12,643 --> 02:38:14,478 PRESCRIBED IN 2020 AS EXPECTED. 3668 02:38:14,478 --> 02:38:16,847 BUT THE VAST MAJORITY OF THEM 3669 02:38:16,847 --> 02:38:19,283 WERE NONSTEROIDAL 3670 02:38:19,283 --> 02:38:21,452 ANTI-INFLAMMATORIES AS OPPOSED 3671 02:38:21,452 --> 02:38:25,022 TO OPIOIDS, THINGS LIKE ADVIL 3672 02:38:25,022 --> 02:38:27,358 THAT CARRY LOWER RISKS THAN 3673 02:38:27,358 --> 02:38:29,126 OPIOIDS. ANTIBIOTICS WERE MOST 3674 02:38:29,126 --> 02:38:31,328 COMMON IN 2020 AS WELL BUT NOT A 3675 02:38:31,328 --> 02:38:33,797 HUGE DIFFERENCE IN THE 3676 02:38:33,797 --> 02:38:35,232 PROPORTION OF THE ANTIBIOTIC 3677 02:38:35,232 --> 02:38:37,468 THAT WE OBSERVED OVER TIME SO 3678 02:38:37,468 --> 02:38:39,336 THIS SUGGESTS AN OPPORTUNITY TO 3679 02:38:39,336 --> 02:38:40,170 FURTHER REDUCE THE NEED FOR BOTH 3680 02:38:40,170 --> 02:38:42,940 THE ED VISITS AT THEIR CAUSE AND 3681 02:38:42,940 --> 02:38:45,442 ALSO THE UNINTENDED CONSEQUENCES 3682 02:38:45,442 --> 02:38:49,947 OF THE EXPOSURES TO MEDICATIONS 3683 02:38:49,947 --> 02:38:51,348 SUCH AS ANTIBIOTICS AND OPIOIDS 3684 02:38:51,348 --> 02:38:54,051 AND THESE FINDINGS ARE PUBLISHED 3685 02:38:54,051 --> 02:38:55,853 IN THE JOURNAL OF HEALTH 3686 02:38:55,853 --> 02:38:58,155 DENTISTY. ANOTHER GROUP I CARED 3687 02:38:58,155 --> 02:38:59,690 FOR WHERE PEOPLE WERE UNDERGOING 3688 02:38:59,690 --> 02:39:02,593 ACTIVE CANCER TREATMENT. I SAW 3689 02:39:02,593 --> 02:39:04,361 HOW SMALL ORAL HEALTH PROBLEMS 3690 02:39:04,361 --> 02:39:07,297 COULD BALLOON INTO COSTLY AND 3691 02:39:07,297 --> 02:39:08,232 UNNECESSARILY MORBID CONDITIONS 3692 02:39:08,232 --> 02:39:11,402 IF UNTREATED OR TREATED WITHOUT 3693 02:39:11,402 --> 02:39:14,405 CONSIDERATION OF THE PATIENTS 3694 02:39:14,405 --> 02:39:17,007 HISTORY. I WONDERED IF WE COULD 3695 02:39:17,007 --> 02:39:22,279 LOOK AT THE ORAL HEALTH PROBLEMS 3696 02:39:22,279 --> 02:39:24,982 AMONG THOSE WITH HAEMATOLOGIC 3697 02:39:24,982 --> 02:39:26,216 CONDITIONS. AND THIS WAS WITH 3698 02:39:26,216 --> 02:39:28,952 INVESTIGATORS FROM THE NIH 3699 02:39:28,952 --> 02:39:30,387 CLINICAL CENTER AND THE NATIONAL 3700 02:39:30,387 --> 02:39:31,321 CANCER INSTITUTE. THIS STUDY 3701 02:39:31,321 --> 02:39:34,758 HERE WE USED THE DATA FROM AN 3702 02:39:34,758 --> 02:39:36,693 ONGOING HISTORY OF PATIENTS WITH 3703 02:39:36,693 --> 02:39:37,895 A HISTORY OF STEM CELL 3704 02:39:37,895 --> 02:39:39,329 TRANSPLANTATION TO ASSESS 3705 02:39:39,329 --> 02:39:40,330 CLINICAL AND PATIENT REPORTED 3706 02:39:40,330 --> 02:39:45,936 OUTCOMES OVER TWO YEARS. WE 3707 02:39:45,936 --> 02:39:47,337 FOUND REDUCTIONS IN ORAL HEALTH 3708 02:39:47,337 --> 02:39:50,741 STATUS WORKED WITH PAIN 3709 02:39:50,741 --> 02:39:53,877 SPECIFICALLY AND DECREASED 3710 02:39:53,877 --> 02:39:58,015 QUALITY OF LIFE EVEN TWO YEARS 3711 02:39:58,015 --> 02:40:00,217 AFTER TRANSPLANT. AND THIS 3712 02:40:00,217 --> 02:40:01,452 PRESENTED AN OPPORTUNITY FOR 3713 02:40:01,452 --> 02:40:03,987 TEAM CARE THROUGHOUT THE 3714 02:40:03,987 --> 02:40:04,855 SURVIVORSHIP PERIOD PARTICULAR 3715 02:40:04,855 --> 02:40:05,689 WHEN PATIENTS TRANSITION BACK 3716 02:40:05,689 --> 02:40:07,791 INTO THE COMMUNITY CARE AND OUT 3717 02:40:07,791 --> 02:40:09,493 OF TRANSPLANT CENTERS. AND 3718 02:40:09,493 --> 02:40:11,395 THESE FINDINGS ARE PUBLISHED IN 3719 02:40:11,395 --> 02:40:14,198 THE GENERAL DENTAL RESEARCH. 3720 02:40:14,198 --> 02:40:16,166 AND SO THAT LAST PROJECT GREW 3721 02:40:16,166 --> 02:40:18,469 INTO ANOTHER PROJECT WITH 3722 02:40:18,469 --> 02:40:19,369 EXISTING COLLABORATORS. HERE WE 3723 02:40:19,369 --> 02:40:21,705 ARE ANALYZING DATA FROM THE SAME 3724 02:40:21,705 --> 02:40:25,275 COHORT I MENTIONED BEFORE, TO 3725 02:40:25,275 --> 02:40:25,876 SPECIFICALLY EXAMINE PATIENTS 3726 02:40:25,876 --> 02:40:28,011 WITH ORAL CHRONIC GRAPHS VERSUS 3727 02:40:28,011 --> 02:40:30,414 HOST DISEASE AS WE HEARD TODAY, 3728 02:40:30,414 --> 02:40:31,882 CHRONIC GRAPHS VERSUS HOST 3729 02:40:31,882 --> 02:40:33,517 DISEASE IS AN IMMUNE MEDIATED 3730 02:40:33,517 --> 02:40:35,352 CONDITION THAT CAN OCCUR IN 3731 02:40:35,352 --> 02:40:36,987 PATIENTS FOLLOWING STEM CELL 3732 02:40:36,987 --> 02:40:38,222 TRANSPLANT THIS CAN LEAD TO 3733 02:40:38,222 --> 02:40:40,157 SIGNIFICANT PAIN, DISCOVERT AND 3734 02:40:40,157 --> 02:40:42,559 REDUCED QUALITY OF LIFE. IT CAN 3735 02:40:42,559 --> 02:40:45,129 ALSO BE DIFFICULT AND EXPENSIVE 3736 02:40:45,129 --> 02:40:47,331 TO TREAT PARTICULARLY IN 3737 02:40:47,331 --> 02:40:48,999 PATIENTS WHO ARE NOT RESPONSIVE 3738 02:40:48,999 --> 02:40:50,601 TO STEROIDS AND HERE WE HAVE THE 3739 02:40:50,601 --> 02:40:53,303 BURDEN AND QUALITY OF LIFE AT 3740 02:40:53,303 --> 02:40:58,342 THE TIME OF ORAL DIAGNOSIS AND 3741 02:40:58,342 --> 02:41:01,912 PRELIMINARY FINDINGS SHOW THAT 3742 02:41:01,912 --> 02:41:04,314 QUALITY OF LIFE ARE ALL 3743 02:41:04,314 --> 02:41:04,982 OBSERVED. AND LONGITUDINAL 3744 02:41:04,982 --> 02:41:07,317 ANALYSES ARE ONGOING. AND WITH 3745 02:41:07,317 --> 02:41:09,753 THAT, I WILL THANK YOU AGAIN FOR 3746 02:41:09,753 --> 02:41:11,221 THE OPPORTUNITY TO PRESENT AND 3747 02:41:11,221 --> 02:41:14,591 FOR YOUR TIME AND CONSIDERATION. 3748 02:41:14,591 --> 02:41:17,161 THANK YOU VERY MUCH. 3749 02:41:17,161 --> 02:41:19,363 >> THANK YOU, EVERYONE, FOR THE 3750 02:41:19,363 --> 02:41:22,332 GREAT MANY SYMPOSIUM. 3751 02:41:22,332 --> 02:41:27,337 COUNCILMEMBERS, DO YOU HAVE 3752 02:41:27,337 --> 02:41:33,343 QUESTIONS? HEARING NONE, WE ARE 3753 02:41:33,343 --> 02:41:35,879 ABOUT FIVE MINUTES BEHIND. SO 3754 02:41:35,879 --> 02:41:38,081 MY SUGGESTION IS THAT WE BREAK 3755 02:41:38,081 --> 02:41:42,452 UNTIL 1:05. DOES THAT SOUND 3756 02:41:42,452 --> 02:41:46,423 GOOD TO EVERYONE? OKAY. ALL 3757 02:41:46,423 --> 02:41:50,761 RIGHT. OKAY. UNTIL 1:00. 3758 02:41:50,761 --> 02:41:51,995 OKAY? AND THEN WE'LL START BACK 3759 02:41:51,995 --> 02:41:56,841 ON TIME. THANKS, EVERYONE. 3760 02:41:56,841 --> 02:42:00,845 >> WELCOME, BACK, EVERYONE TO, 3761 02:42:00,845 --> 02:42:04,549 THE OPEN SESSION COUNCIL AGAIN. 3762 02:42:04,549 --> 02:42:06,151 WE'RE GOING TO START WITH 3763 02:42:06,151 --> 02:42:07,886 CONCEPT CLEARANCES: JUST A BRIEF 3764 02:42:07,886 --> 02:42:09,320 BACKGROUND ON CONCEPT 3765 02:42:09,320 --> 02:42:12,424 CLEARANCES, THEY REPRESENT AN 3766 02:42:12,424 --> 02:42:13,958 EARLY PLANNING STAGE FOR 3767 02:42:13,958 --> 02:42:19,964 POTENTIAL (ECHO) POTENTIAL NIDCR 3768 02:42:19,964 --> 02:42:28,173 AND TRANS-NIH. THEY COVER 3769 02:42:28,173 --> 02:42:30,208 MULTIPLE INITIATIVES AND NOTICES 3770 02:42:30,208 --> 02:42:32,811 OF FUNDING OPPORTUNITIES OR 3771 02:42:32,811 --> 02:42:35,613 NOFOS. THROUGH THE CONCEPT 3772 02:42:35,613 --> 02:42:36,981 CLEARANCE PROCESS NIDCR RECEIVES 3773 02:42:36,981 --> 02:42:39,517 INPUT FROM THE NATIONAL ADVISORY 3774 02:42:39,517 --> 02:42:40,852 COUNCIL REGARDING THE MERITS OF 3775 02:42:40,852 --> 02:42:44,055 THE CONCEPTS. COUNCILMEMBERS 3776 02:42:44,055 --> 02:42:45,857 ARE ASKED TO SERVE AS PRIMARY 3777 02:42:45,857 --> 02:42:49,961 AND SECONDARY REVIEWERS. 3778 02:42:49,961 --> 02:42:54,999 FOLLOWING THE PRESENTATION BY 3779 02:42:54,999 --> 02:42:58,236 NIDCR STAFF THERE'LL BE A 3780 02:42:58,236 --> 02:42:59,871 DISCUSSION AND A VOTE AS A 3781 02:42:59,871 --> 02:43:01,406 BASIS. TODAY WE ARE PLEASED TO 3782 02:43:01,406 --> 02:43:04,109 PRESENT THREE CONCEPTS THAT HAVE 3783 02:43:04,109 --> 02:43:06,811 RECEIVED APPROVAL BY THE NIH 3784 02:43:06,811 --> 02:43:10,115 LEADERSHIP FOR IMMEDIATE COUNCIL 3785 02:43:10,115 --> 02:43:20,658 CLEARANCE. THE FIRST WILL BE BY 3786 02:43:20,892 --> 02:43:31,102 THE DR. MCGIRL. 3787 02:43:32,137 --> 02:43:34,005 >> THANK YOU, YASMIN, CAN 3788 02:43:34,005 --> 02:43:35,607 EVERYONE SEE MY SLIDES? 3789 02:43:35,607 --> 02:43:35,974 >> YES. 3790 02:43:35,974 --> 02:43:39,144 >> GREAT, THANK YOU SO MUCH FOR 3791 02:43:39,144 --> 02:43:44,482 THAT. TODAY I'M HERE TO TALK TO 3792 02:43:44,482 --> 02:43:47,552 YOU ABOUT TWO TRAINING AWARD 3793 02:43:47,552 --> 02:43:48,820 CONCEPTS. THE R 90 3794 02:43:48,820 --> 02:43:50,889 INSTITUTIONAL TRAINING AWARD AND 3795 02:43:50,889 --> 02:43:55,226 THE UE 5 MENTORING AWARD BUT 3796 02:43:55,226 --> 02:43:56,561 FIRST I WANT TO UPDATE YOU ON 3797 02:43:56,561 --> 02:43:59,330 SOME CHANGES TO THE NIH CONCEPT 3798 02:43:59,330 --> 02:44:02,000 CLEARANCE AND NOFO DEVELOPMENT 3799 02:44:02,000 --> 02:44:03,168 PROCESS ESPECIALLY TO CALL YOUR 3800 02:44:03,168 --> 02:44:07,438 ATTENTION TO ONE IMPORTANT 3801 02:44:07,438 --> 02:44:10,241 ADDITION. WOULD YOU PLEASE MUTE 3802 02:44:10,241 --> 02:44:12,844 THE ROOM? THANK YOU. AFTER 3803 02:44:12,844 --> 02:44:14,045 NIDCR COMES UP WITH AN IDEA FOR 3804 02:44:14,045 --> 02:44:18,950 AN NOFO, WE NOW WRITE A 3805 02:44:18,950 --> 02:44:20,051 DESCRIPTION A VERY BRIEF 3806 02:44:20,051 --> 02:44:20,818 DESCRIPTION CALLED A FORECAST 3807 02:44:20,818 --> 02:44:22,787 FOR APPROVAL BY NIH LEADERSHIP. 3808 02:44:22,787 --> 02:44:24,822 AND WHEN IT'S APPROVED THAT 3809 02:44:24,822 --> 02:44:30,361 FORECAST GETS PUBLISHED AT 3810 02:44:30,361 --> 02:44:31,262 GRANTS.GOV NOW THIS ADDED 3811 02:44:31,262 --> 02:44:32,664 FORECAST STEP HAS PLANNED FOR 3812 02:44:32,664 --> 02:44:33,932 SEVERAL YEARS AND WILL BRING US 3813 02:44:33,932 --> 02:44:36,100 INTO ALIGNMENT WITH HOW OTHER 3814 02:44:36,100 --> 02:44:38,870 FEDERAL AGENCIES MANAGE THEIR 3815 02:44:38,870 --> 02:44:40,638 NOTICES OF FUNDING OPPORTUNITY 3816 02:44:40,638 --> 02:44:42,207 BUT MOST IMPORTANTLY FOR THE 3817 02:44:42,207 --> 02:44:44,042 EXTRAMURAL COMMUNITY IS THAT IF 3818 02:44:44,042 --> 02:44:47,445 YOU, YOU CAN SEEN UP ON 3819 02:44:47,445 --> 02:44:48,813 GRANTS.GOV TO RECEIVE 3820 02:44:48,813 --> 02:44:50,048 NOTIFICATION E-MAILS ABOUT 3821 02:44:50,048 --> 02:44:50,715 FORECASTS NOW REMEMBER FORECASTS 3822 02:44:50,715 --> 02:44:53,418 ARE PLANNED BUT NOT YET OFFICIAL 3823 02:44:53,418 --> 02:44:55,853 GRANT OPPORTUNITIES. SO PLEASE 3824 02:44:55,853 --> 02:45:00,558 GO TO GRANTS.GOV AND SIGN 3825 02:45:00,558 --> 02:45:01,960 YOURSELF UP. ONCE THE FORECAST 3826 02:45:01,960 --> 02:45:04,295 HAS BEEN APPROVED THE NEXT STEP 3827 02:45:04,295 --> 02:45:06,631 IS TO BRING IT TO CONCEPT, TO 3828 02:45:06,631 --> 02:45:07,732 COUNCIL FOR A CONCEPT CLEARANCE 3829 02:45:07,732 --> 02:45:09,934 WHICH IS THE STAGE WE'RE AT 3830 02:45:09,934 --> 02:45:12,270 RIGHT NOW AND ONCE COUNCIL 3831 02:45:12,270 --> 02:45:15,406 APPROVES OF A CONCEPT, THEN 3832 02:45:15,406 --> 02:45:19,844 NIDCR WILL WRITE UP THE NOFO OR 3833 02:45:19,844 --> 02:45:23,181 NOFOS AS THE CASE MAY BE AND NIH 3834 02:45:23,181 --> 02:45:25,617 WILL WILL APPROVE THE DRAFT 3835 02:45:25,617 --> 02:45:26,417 PRIOR TO ITS PUBLICATION. 3836 02:45:26,417 --> 02:45:28,553 AND THIS ENTIRE PROCESS FROM 3837 02:45:28,553 --> 02:45:31,856 START TO FINISH MAY TAKE UP TO A 3838 02:45:31,856 --> 02:45:36,427 YEAR. NOW THE FIRST CONCEPT IS 3839 02:45:36,427 --> 02:45:40,632 THE T 90 R 90 INDECISION 3840 02:45:40,632 --> 02:45:42,333 CONSTITUTIONAL TRAINING AWARD. 3841 02:45:42,333 --> 02:45:47,672 THE NIH HAS SET UP A GOAL TO 3842 02:45:47,672 --> 02:45:49,474 REDUCE THE NUMBERS ISSUED. 3843 02:45:49,474 --> 02:45:50,975 WE'RE TAKING THE LEAD TO TAKE 3844 02:45:50,975 --> 02:45:55,813 OUR T 90/R 90 NOFO AND REVISING 3845 02:45:55,813 --> 02:45:57,582 AN IT A BIT SO IT CAN BE A 3846 02:45:57,582 --> 02:46:00,585 PARENT TYPE OF NOFO THAT CAN 3847 02:46:00,585 --> 02:46:04,255 SERVE MULTIPLE INSTITUTES OR 3848 02:46:04,255 --> 02:46:06,424 CENTERS. NIDCR ISSUES BY FAR 3849 02:46:06,424 --> 02:46:09,694 THE MOST T 90 AWARDS OF ALL OF 3850 02:46:09,694 --> 02:46:13,765 THE NIH ICS AND SO WE REALLY 3851 02:46:13,765 --> 02:46:15,366 WANT THE PROGRAM TO CONTINUE BUT 3852 02:46:15,366 --> 02:46:17,769 THIS MULTIIC APPROACH DOES MEAN 3853 02:46:17,769 --> 02:46:21,873 THAT THE T 90/R 90 NOFO WILL BE 3854 02:46:21,873 --> 02:46:24,842 WRITTEN WITHOUT SPECIFYING A 3855 02:46:24,842 --> 02:46:27,545 VERY SPECIFIC MISSION AREA THAT 3856 02:46:27,545 --> 02:46:29,247 IS SPECIFIC TO AN IC. WE PLAN 3857 02:46:29,247 --> 02:46:32,817 TO USE THE PARENT T32 AS THE 3858 02:46:32,817 --> 02:46:35,787 BLUEPRINT FOR THE T 90 PORTION 3859 02:46:35,787 --> 02:46:40,258 AND THE T32 IS A ROBUST NOFO IT 3860 02:46:40,258 --> 02:46:41,726 INCLUDES BEST PRACTICES TRAINING 3861 02:46:41,726 --> 02:46:44,829 FOR MENTORS, TRACKING OUTCOMES, 3862 02:46:44,829 --> 02:46:47,765 IDENTIFYING ROOT CAUSES WHEN 3863 02:46:47,765 --> 02:46:50,101 THERE'S LESS THAN OPTIMAL 3864 02:46:50,101 --> 02:46:51,803 TRAINEE OUTCOMES AND IT ALSO 3865 02:46:51,803 --> 02:46:53,538 ASKS TO INCORPORATE CHANGES TO 3866 02:46:53,538 --> 02:46:55,640 ADDRESS THOSE CAUSES IT ALLOWS 3867 02:46:55,640 --> 02:46:59,310 PROGRAMS TO INCLUDE JAB 3868 02:46:59,310 --> 02:47:00,345 SHADOWING AND INTERNSHIPS AS 3869 02:47:00,345 --> 02:47:10,922 APPROPRIATE THIS WILL BE 3870 02:47:10,922 --> 02:47:12,824 CONSIDERED AS A REISSUE. THE 3871 02:47:12,824 --> 02:47:13,725 GOOD NEWS ABOUT THIS IS THAT 3872 02:47:13,725 --> 02:47:18,162 THIS ENSURES THAT NIDCR CURRENT 3873 02:47:18,162 --> 02:47:20,431 GRANTEES CAN APPLY AS RENEWALS 3874 02:47:20,431 --> 02:47:21,899 AS OPPOSED TO BRAND NEW AWARDS. 3875 02:47:21,899 --> 02:47:24,268 SO THEY GET CREDIT FOR ALL THEIR 3876 02:47:24,268 --> 02:47:27,772 PRIOR SUCCESS. AND A PLANNED 3877 02:47:27,772 --> 02:47:28,840 PRE-APPLICATION WEBINAR WILL BE 3878 02:47:28,840 --> 02:47:32,043 HELD TO EXPLAIN TO POTENTIAL 3879 02:47:32,043 --> 02:47:36,547 NIDCR APPLICANTS WHAT NIDCR IS 3880 02:47:36,547 --> 02:47:38,649 LOOKING FOR THE HALLMARKS OF THE 3881 02:47:38,649 --> 02:47:41,519 T 90/R 90 REMAIN EXACTLY THE 3882 02:47:41,519 --> 02:47:44,689 SAME. THE PURPOSE IS TO BUILD A 3883 02:47:44,689 --> 02:47:46,057 ROBUST BIOMEDICAL WORKFORCE BY 3884 02:47:46,057 --> 02:47:48,059 TRAINING GRAD STUDENTS INCLUDING 3885 02:47:48,059 --> 02:47:52,830 THESE ENROLLED IN DUAL DEGREE 3886 02:47:52,830 --> 02:47:55,666 PROGRAMS LIKE DENTAL SCIENTISTS 3887 02:47:55,666 --> 02:47:59,837 AS WELL AS POSTDOCS AND CLINICAL 3888 02:47:59,837 --> 02:48:01,572 SCIENTISTS. WE HAVE THE PROGRAM 3889 02:48:01,572 --> 02:48:02,807 THAT SUPPORTS U.S. CITIZENS AND 3890 02:48:02,807 --> 02:48:04,842 GREEN CARD HOLDERS. BUT UNIQUE 3891 02:48:04,842 --> 02:48:07,779 TO THE T 90 IS THE, TO THIS 3892 02:48:07,779 --> 02:48:10,014 MECHANISM IS THE R 90 RESEARCH 3893 02:48:10,014 --> 02:48:11,516 EDUCATION PROGRAM. THAT ALLOWS 3894 02:48:11,516 --> 02:48:14,018 SUPPORT FOR NON-CITIZENS WHO 3895 02:48:14,018 --> 02:48:16,120 HOLD U.S. VISAS AND ARE TRAINING 3896 02:48:16,120 --> 02:48:17,355 HERE IN THE U.S. NOW ONE 3897 02:48:17,355 --> 02:48:21,526 ADVANTAGE OF IT BEING A MULTIIC 3898 02:48:21,526 --> 02:48:23,594 NOFO IS THIS WILL BE ISSUED 3899 02:48:23,594 --> 02:48:24,829 REGULARLY MEANING THERE'LL BE 3900 02:48:24,829 --> 02:48:27,131 LIKE ONE DUE DATE PER YEAR BUT 3901 02:48:27,131 --> 02:48:28,599 NO PAUSES WHEN THERE'S YEARS 3902 02:48:28,599 --> 02:48:30,968 WHERE THERE'S NO ACTIVE NOFO TO 3903 02:48:30,968 --> 02:48:33,538 APPLY FOR AND THAT ALIGNS WITH 3904 02:48:33,538 --> 02:48:34,372 THE RECOMMENDATION MADE LAST 3905 02:48:34,372 --> 02:48:38,109 YEAR BY THE ORAL HEALTH RESEARCH 3906 02:48:38,109 --> 02:48:42,346 WORKFORCE WORKING GROUP. THE T 3907 02:48:42,346 --> 02:48:46,284 90/R 90 HAS SERVED NIDCR REALLY 3908 02:48:46,284 --> 02:48:48,052 WELL, THE R 90 COMPONENT ALLOWS 3909 02:48:48,052 --> 02:48:49,420 US TO SUPPORT THE RESEARCH 3910 02:48:49,420 --> 02:48:50,955 TRAINING OF DENTISTS, PEOPLE WHO 3911 02:48:50,955 --> 02:48:52,423 RECEIVE THEIR DENTAL DEGREES 3912 02:48:52,423 --> 02:48:54,826 FROM FOREIGN INSTITUTIONS, AND 3913 02:48:54,826 --> 02:48:58,396 THAT HAS BEEN A VITAL PIPELINE 3914 02:48:58,396 --> 02:49:00,331 LEADING TO INDEPENDENT DOC 3915 02:49:00,331 --> 02:49:01,866 RESEARCHERS. THE TRAINEES ARE 3916 02:49:01,866 --> 02:49:03,568 SUCCESSFUL AS YOU CAN SEE ON 3917 02:49:03,568 --> 02:49:05,703 THIS CHART. AND WHILE I HAVE TO 3918 02:49:05,703 --> 02:49:07,972 ADMIT I'D LIKE TO SEE MORE R 90 3919 02:49:07,972 --> 02:49:10,708 TRAINEES SUBMIT TO THE NIH. WE 3920 02:49:10,708 --> 02:49:12,443 ARE TRULY DELIGHTED THAT THOSE 3921 02:49:12,443 --> 02:49:14,345 WHO DO ARE JUST AS SUCCESSFUL AS 3922 02:49:14,345 --> 02:49:16,280 OTHER TRAINEES AND IMPORTANTLY, 3923 02:49:16,280 --> 02:49:20,151 THEY SUBMIT TO NIDCR. I SHOULD 3924 02:49:20,151 --> 02:49:22,787 MENTION TOO THAT ANOTHER 3925 02:49:22,787 --> 02:49:25,389 RESEARCHER OUTCOME IS THAT T 90, 3926 02:49:25,389 --> 02:49:30,595 R 90 TRAINEES ACCEPT TEACHING 3927 02:49:30,595 --> 02:49:32,163 RECIPIENTS AS WELL. AND NOW 3928 02:49:32,163 --> 02:49:36,133 WE'LL HEAR FROM COUNCIL STARTING 3929 02:49:36,133 --> 02:49:39,871 WITH DR. PAUL AND DR. LOUISA TO 3930 02:49:39,871 --> 02:49:40,872 TALK ABOUT WHAT THEIR THOUGHTS 3931 02:49:40,872 --> 02:49:42,773 ARE ON THIS MECHANISM. 3932 02:49:42,773 --> 02:49:45,209 >> I AM VERY SORRY, THIS IS 3933 02:49:45,209 --> 02:49:48,813 JACQUES. I BELIEVE I AM IN 3934 02:49:48,813 --> 02:49:50,047 CONFLICT. CAN YOU -- 3935 02:49:50,047 --> 02:49:51,849 >> YOU DON'T NEED TO BE LEFT 3936 02:49:51,849 --> 02:49:53,918 OUT. YOU JUST DON'T COMMENT ON 3937 02:49:53,918 --> 02:49:56,153 IT. THIS IS OPEN. 3938 02:49:56,153 --> 02:49:59,156 >> OKAY. THANK YOU. 3939 02:49:59,156 --> 02:50:00,424 >> SURE. 3940 02:50:00,424 --> 02:50:01,225 >> ALL RIGHT. MICHELE, THANK 3941 02:50:01,225 --> 02:50:03,628 YOU. I WILL BE BRIEF BECAUSE MY 3942 02:50:03,628 --> 02:50:06,697 COMMENTS ARE VERY SIMILAR TO 3943 02:50:06,697 --> 02:50:14,138 YOUR PRESENTATION. I KNOW IT'S 3944 02:50:14,138 --> 02:50:16,674 A FORMALITY HERE. THE REISSUE 3945 02:50:16,674 --> 02:50:21,512 OF THIS T 90/R 90 MECHANISM 3946 02:50:21,512 --> 02:50:23,481 PRESENTS A SOUND INITIATIVE THAT 3947 02:50:23,481 --> 02:50:24,849 REINFORCES THE INSTITUTE'S 3948 02:50:24,849 --> 02:50:28,252 COMMITMENT AS YOU MENTIONED TO 3949 02:50:28,252 --> 02:50:29,487 DEVELOPING WELL-TRAINED DENTAL 3950 02:50:29,487 --> 02:50:31,822 ORAL AND CRANIOFACIAL WORKFORCE. 3951 02:50:31,822 --> 02:50:33,925 THE CONCEPT BUILDS ON THE 3952 02:50:33,925 --> 02:50:36,294 SUCCESS OF THE PREVIOUS T 90 AND 3953 02:50:36,294 --> 02:50:38,062 R 90 PROGRAMMINGS. WHILE 3954 02:50:38,062 --> 02:50:40,865 ALIGNING WITH THE BROADER NIH 3955 02:50:40,865 --> 02:50:42,967 DIRECTIVE TO STREAMLINE THE 3956 02:50:42,967 --> 02:50:46,737 PROCESS AND AS YOU MENTION THIS 3957 02:50:46,737 --> 02:50:56,147 WOULD SERVE THEN AS THE PARENT 3958 02:50:56,147 --> 02:50:57,014 ANNOUNCEMENT. THE CONCEPT 3959 02:50:57,014 --> 02:50:59,216 ADDRESSES KEY QUESTIONS RELATED 3960 02:50:59,216 --> 02:51:00,818 TO THE SCIENTIFIC SCOPE 3961 02:51:00,818 --> 02:51:03,254 INSTITUTIONAL FLEXIBILITY AND 3962 02:51:03,254 --> 02:51:04,789 TRAINING ELIGIBILITY IT OUTLINES 3963 02:51:04,789 --> 02:51:09,060 OUT THE T 90/R 90 MECHANISM CAN 3964 02:51:09,060 --> 02:51:11,596 ADAPT TO EVOLVING PRIORITIES 3965 02:51:11,596 --> 02:51:12,830 INCLUDING AI AND 3966 02:51:12,830 --> 02:51:14,532 INTERDISCIPLINARY RESEARCH WHILE 3967 02:51:14,532 --> 02:51:15,733 PROVIDING APPROPRIATE MENTORSHIP 3968 02:51:15,733 --> 02:51:19,437 AND TRAINING ENVIRONMENTS. 3969 02:51:19,437 --> 02:51:21,639 HOWEVER, AS THIS CONCEPT PLANS 3970 02:51:21,639 --> 02:51:23,774 MOVE FORWARD TO BECOMING A 3971 02:51:23,774 --> 02:51:24,642 FUNDING OPPORTUNITY, ADDITIONAL 3972 02:51:24,642 --> 02:51:27,011 DETAILS WILL NEED TO BE ADDED. 3973 02:51:27,011 --> 02:51:29,380 SPECIFICALLY MORE CLARITY ON THE 3974 02:51:29,380 --> 02:51:31,282 REVIEW CRITERIA, EXPECTATIONS 3975 02:51:31,282 --> 02:51:34,552 FOR MENTORING OUTCOMES, METRICS 3976 02:51:34,552 --> 02:51:37,054 FOR TRAINING, TRANSITION, WOULD 3977 02:51:37,054 --> 02:51:38,623 STRENGTHEN THAT AND MICHELE DID 3978 02:51:38,623 --> 02:51:40,358 MENTION THAT, THAT THAT'S WHAT 3979 02:51:40,358 --> 02:51:41,892 WILL HAPPEN AS IT KIND OF 3980 02:51:41,892 --> 02:51:50,401 MIRRORS THE T IF 2. OVERALL I 3981 02:51:50,401 --> 02:51:54,271 SUPPORT THE MECHANISM. I THINK 3982 02:51:54,271 --> 02:51:55,640 THE CONTINUATION IS NEEDED FOR 3983 02:51:55,640 --> 02:51:58,476 EXTENDING THE RESEARCHERS. 3984 02:51:58,476 --> 02:52:00,811 IT'S AN INVESTMENT IN OUR 3985 02:52:00,811 --> 02:52:04,015 FUTURE. BIOMEDICAL RESEARCH. 3986 02:52:04,015 --> 02:52:05,883 AND WILL BENEFIT ALL OF THE 3987 02:52:05,883 --> 02:52:08,819 NIDCR AND THE BROADER SCIENTIFIC 3988 02:52:08,819 --> 02:52:12,823 COMMUNITY AS WELL. SO I THINK 3989 02:52:12,823 --> 02:52:16,627 IF AA -- THE APPROVAL IS 3990 02:52:16,627 --> 02:52:17,528 WARRANTED WITH THE UNDERSTANDING 3991 02:52:17,528 --> 02:52:20,131 THAT THESE REFINEMENT WILL FIND 3992 02:52:20,131 --> 02:52:24,835 THEIR WAY INTO THE FINAL 3993 02:52:24,835 --> 02:52:26,137 MECHANISM. THANK YOU. 3994 02:52:26,137 --> 02:52:28,105 >> THANK YOU. THANKS, PAUL, 3995 02:52:28,105 --> 02:52:29,707 LOUISA, WOULD YOU LIKE TO 3996 02:52:29,707 --> 02:52:30,741 DISCUSS SOME THINGS AS WELL AND 3997 02:52:30,741 --> 02:52:33,911 >> JUST A FEW THINGS, FIRST OF 3998 02:52:33,911 --> 02:52:35,479 ALL THANK YOU SO MUCH 3999 02:52:35,479 --> 02:52:37,515 DR. MCGUIRL FOR PUTTING THIS 4000 02:52:37,515 --> 02:52:38,549 TOGETHER. I AGREE WITH 4001 02:52:38,549 --> 02:52:40,851 EVERYTHING THE DOCTOR SAID. I 4002 02:52:40,851 --> 02:52:42,920 THINK THIS IS REALLY AN 4003 02:52:42,920 --> 02:52:43,888 ESSENTIAL PROGRAM MECHANISM TO 4004 02:52:43,888 --> 02:52:45,756 CONTINUE AND I ALSO THINK THAT 4005 02:52:45,756 --> 02:52:47,391 NOW MORE THAN EVER WE HAVE TO 4006 02:52:47,391 --> 02:52:48,826 THINK ABOUT THE LONG GAME AND 4007 02:52:48,826 --> 02:52:50,461 THAT IS TO CONTINUE TO SUPPORT 4008 02:52:50,461 --> 02:52:52,830 THE DEVELOPMENT OF YOUNG 4009 02:52:52,830 --> 02:52:54,131 SCIENTISTS AND RESEARCHERS WHO 4010 02:52:54,131 --> 02:52:55,766 WILL CARRY THE MISSION FORWARD. 4011 02:52:55,766 --> 02:52:58,502 THEY NEED OUR SUPPORT NOW. MORE 4012 02:52:58,502 --> 02:53:02,206 THAN EVER. I JUST HAVE A FEW 4013 02:53:02,206 --> 02:53:04,375 SUGGESTIONS, ONE, OF COURSE I 4014 02:53:04,375 --> 02:53:06,277 THINK YOU'RE ALREADY TAKING THIS 4015 02:53:06,277 --> 02:53:07,578 INTO ACCOUNT I REALLY OF COURSE 4016 02:53:07,578 --> 02:53:10,781 HAVING BEEN INVOLVED WITH THE 4017 02:53:10,781 --> 02:53:14,218 WORKING GROUP ON THE ORAL HEALTH 4018 02:53:14,218 --> 02:53:16,620 RESEARCH WORKFORCE REPORT HAVING 4019 02:53:16,620 --> 02:53:18,322 BEEN INVOLVED WITH THAT, I 4020 02:53:18,322 --> 02:53:19,457 REALLY LIKE IT THAT YOU'RE 4021 02:53:19,457 --> 02:53:21,459 TAKING THAT INTO ACCOUNT AND 4022 02:53:21,459 --> 02:53:23,461 TAKING SOME OF OUR SUGGESTIONS. 4023 02:53:23,461 --> 02:53:25,129 I APPRECIATE THAT THERE'LL BE NO 4024 02:53:25,129 --> 02:53:28,065 PAUSES THIS I THINK IS A REALLY 4025 02:53:28,065 --> 02:53:29,667 DIFFICULT SITUATION WHEN PAUSES 4026 02:53:29,667 --> 02:53:32,203 OCCUR SO THAT'S WONDERFUL GOING 4027 02:53:32,203 --> 02:53:33,704 FORWARD I ALSO HOPE YOU'LL 4028 02:53:33,704 --> 02:53:34,739 UTILIZE SOME OF THE OTHER 4029 02:53:34,739 --> 02:53:35,740 SUGGESTIONS THAT ARE IN THERE 4030 02:53:35,740 --> 02:53:37,808 AND I KNOW YOU TALKED A LITTLE 4031 02:53:37,808 --> 02:53:39,276 BIT ABOUT HOW THEY'VE BEEN 4032 02:53:39,276 --> 02:53:41,178 SUCCESSFUL AND I KNOW THAT NIDCR 4033 02:53:41,178 --> 02:53:42,546 DOES COLLECT DATA ON TRAINEES 4034 02:53:42,546 --> 02:53:44,081 BUT I THINK WE NEED VERY 4035 02:53:44,081 --> 02:53:45,449 LONG-TERM DATA. AND ONE THING 4036 02:53:45,449 --> 02:53:46,617 THAT CAME UP IN OUR WORKING 4037 02:53:46,617 --> 02:53:50,187 GROUP IS THAT WE DON'T HAVE MUCH 4038 02:53:50,187 --> 02:53:52,823 DATA ON THOSE THAT LEAVE, YOU 4039 02:53:52,823 --> 02:53:55,993 KNOW, AND WHO DON'T CONTINUE IN 4040 02:53:55,993 --> 02:53:56,527 RESEARCH CAREERS OR EVEN 4041 02:53:56,527 --> 02:53:58,028 ACADEMIC CAREERS. WE KIND OF 4042 02:53:58,028 --> 02:53:59,730 LOSE TRACK OF THEM AND I 4043 02:53:59,730 --> 02:54:00,264 UNDERSTAND THIS IS VERY 4044 02:54:00,264 --> 02:54:01,198 DIFFICULT SOMETIMES TO TRACK 4045 02:54:01,198 --> 02:54:02,433 DOWN THOSE INDIVIDUALS BUT I 4046 02:54:02,433 --> 02:54:05,569 THINK WE CAN LEARN A LOT FROM 4047 02:54:05,569 --> 02:54:08,372 THEM. AND MAY BE ABLE TO 4048 02:54:08,372 --> 02:54:11,075 MITIGATE SOME OF THAT LOSS OF 4049 02:54:11,075 --> 02:54:12,009 TRAINEES BECAUSE THEY ARE A 4050 02:54:12,009 --> 02:54:14,211 PRECIOUS RESOURCE SO IF WE LEARN 4051 02:54:14,211 --> 02:54:15,813 WHY PEOPLE ARE LEAVING MAYBE WE 4052 02:54:15,813 --> 02:54:17,815 CAN DO SOMETHING ELSE AND IN OUR 4053 02:54:17,815 --> 02:54:19,683 REPORT WE DISCUSS HOW THIS 4054 02:54:19,683 --> 02:54:20,584 TRANSITION PERIOD IS VERY 4055 02:54:20,584 --> 02:54:24,021 DIFFICULT FOR TRAINEES SO I 4056 02:54:24,021 --> 02:54:26,090 UNDERSTAND SOME OF THAT, YOU 4057 02:54:26,090 --> 02:54:27,057 KNOW, MITIGATING THE LOSS AND 4058 02:54:27,057 --> 02:54:30,327 ASSISTANCE AND MENTORING THROUGH 4059 02:54:30,327 --> 02:54:33,430 THE TRANSITION PERIODS COULD BE 4060 02:54:33,430 --> 02:54:34,565 NIDCR SPECIFIC BUT I HOPE YOU'LL 4061 02:54:34,565 --> 02:54:37,635 CONSIDER IT FOR THE NIDCR 4062 02:54:37,635 --> 02:54:39,136 SPECIFIC PORTION OF THIS. WHICH 4063 02:54:39,136 --> 02:54:40,104 I UNDERSTAND WILL BE DIFFERENT 4064 02:54:40,104 --> 02:54:43,774 THAN THE PARENT NOFO BUT I'M 4065 02:54:43,774 --> 02:54:44,842 VERY SUPPORTIVE AND THANK YOU. 4066 02:54:44,842 --> 02:54:47,011 >> OKAY, LOUISA, I THINK THOSE 4067 02:54:47,011 --> 02:54:47,912 ARE GREAT SUGGESTIONS AND I 4068 02:54:47,912 --> 02:54:50,080 AGREE WITH YOUR ASSESSMENT THAT 4069 02:54:50,080 --> 02:54:51,582 THEY'RE NEEDED TO MAKE THE 4070 02:54:51,582 --> 02:54:54,451 PROGRAM EVEN MORE SUCCESSFUL. 4071 02:54:54,451 --> 02:54:55,719 ARE THERE OTHER COMMENTS AND 4072 02:54:55,719 --> 02:55:00,825 DISCUSSION BY THE 4073 02:55:00,825 --> 02:55:03,794 COUNCILMEMBERS? OKAY? WELL 4074 02:55:03,794 --> 02:55:06,397 HEARING NONE I WILL HAND IT OVER 4075 02:55:06,397 --> 02:55:10,000 TO YASMIN TO CALL THE VOTE. 4076 02:55:10,000 --> 02:55:12,436 >> YES, THANK YOU DR. MCGUIRL. 4077 02:55:12,436 --> 02:55:14,705 WOULD A MEMBER OF COUNCIL LIKE 4078 02:55:14,705 --> 02:55:19,076 TO MAKE A MOTION TO APPROVE THIS 4079 02:55:19,076 --> 02:55:22,079 CONCEPT? EXCEPT DR. NOR. 4080 02:55:22,079 --> 02:55:23,180 >> SO MOVED, PAUL. 4081 02:55:23,180 --> 02:55:24,148 >> SECOND. 4082 02:55:24,148 --> 02:55:32,223 >> THANK YOU, ALL IN FAVOR. ANY 4083 02:55:32,223 --> 02:55:36,427 OPPOSED? THANK YOU WE'LL MOVE 4084 02:55:36,427 --> 02:55:38,229 TO THE NEXT COUNCIL CONCEPT 4085 02:55:38,229 --> 02:55:44,235 PRESENTED BY DR. MCGUIRL AS 4086 02:55:44,235 --> 02:55:54,712 WELL. OKAY, YOU'RE MUTED. 4087 02:56:01,685 --> 02:56:02,152 DR. MCGUIRL YOU'RE MUTED. 4088 02:56:02,152 --> 02:56:04,088 >> I JUST GOT IT UNMUTED. THANK 4089 02:56:04,088 --> 02:56:05,556 YOU, I APPRECIATE IT. HOPEFULLY 4090 02:56:05,556 --> 02:56:07,124 YOU CAN SEE THESE SLIDES AS 4091 02:56:07,124 --> 02:56:08,659 WELL. THIS IS ANOTHER REISSUE 4092 02:56:08,659 --> 02:56:09,560 CONCEPT THAT WE'RE ASKING 4093 02:56:09,560 --> 02:56:12,730 COUNCIL TO APPROVE. IT'S THE UE 4094 02:56:12,730 --> 02:56:14,131 5 MENTORING NETWORK AWARD. AND, 4095 02:56:14,131 --> 02:56:16,834 AGAIN, THIS WILL BE ISSUED AS A 4096 02:56:16,834 --> 02:56:18,502 PARENT OR MULTIIC AWARD AND THE 4097 02:56:18,502 --> 02:56:20,237 CONTENT WHICH WAS INITIALLY 4098 02:56:20,237 --> 02:56:22,740 FOCUSED ON PROMOTING DIVERSITY 4099 02:56:22,740 --> 02:56:26,210 WILL BE REVISED TO ALIGN WITH 4100 02:56:26,210 --> 02:56:28,812 NIH PRIORITIES. THE UE 5 4101 02:56:28,812 --> 02:56:31,348 PURPOSE IS TO PROVIDE SKILLS, 4102 02:56:31,348 --> 02:56:32,216 DEVELOPMENT OPPORTUNITIES, AS 4103 02:56:32,216 --> 02:56:35,319 WELL AS ONE-ON-ONE MENTORING TO 4104 02:56:35,319 --> 02:56:36,687 AN ANNUAL COHORT OF TRAINEE TO 4105 02:56:36,687 --> 02:56:39,056 HELP THEM SUCCEED IN BECOMING 4106 02:56:39,056 --> 02:56:43,360 INDEPENDENTLY FUNDED NIH 4107 02:56:43,360 --> 02:56:43,794 INVESTIGATORS. 4108 02:56:43,794 --> 02:56:46,730 THESE COHORT OF TRAINEES, THESE 4109 02:56:46,730 --> 02:56:48,766 MENTEES CAN BE EARLY CAREER 4110 02:56:48,766 --> 02:56:50,701 FACULTY, POSTDOCS, CLINICIAN 4111 02:56:50,701 --> 02:56:53,137 SCIENTISTS, OR GRADUATE 4112 02:56:53,137 --> 02:56:55,472 STUDENTS, NOW GRAD STUDENTS WERE 4113 02:56:55,472 --> 02:56:58,509 IMPORTANT TOPICS FOR UE 5 NOFOS 4114 02:56:58,509 --> 02:57:03,080 ISSUED BY OTHER ICS AND SO THIS 4115 02:57:03,080 --> 02:57:05,783 PARENT TYPE WILL HAVE TO BE 4116 02:57:05,783 --> 02:57:06,951 BROADER THAN WHAT NIDCR HAD 4117 02:57:06,951 --> 02:57:08,786 INITIALLY INCLUDED IN THEIR 4118 02:57:08,786 --> 02:57:08,986 NOFO. 4119 02:57:08,986 --> 02:57:10,487 BUT THIS WILL MEET THE NEED AND 4120 02:57:10,487 --> 02:57:12,823 AGAIN, WE EXPECT THIS TO BE AN 4121 02:57:12,823 --> 02:57:16,360 ACTIVE NOFO EVERY YEAR PROBABLY 4122 02:57:16,360 --> 02:57:19,997 WITH ONE DUE DATE PER YEAR. THE 4123 02:57:19,997 --> 02:57:21,598 UE 5 HAS BEEN VERY SUCCESSFUL 4124 02:57:21,598 --> 02:57:23,567 FOR NIDCR AND WE CONTINUE TO 4125 02:57:23,567 --> 02:57:25,703 CONTINUE OUR FOCUS ON EARLY 4126 02:57:25,703 --> 02:57:26,203 CAREER FACULTY. 4127 02:57:26,203 --> 02:57:28,839 AND LATE STAGE TRAINEES OVER 4128 02:57:28,839 --> 02:57:30,341 GRADUATE STUDENTS WHO ARE BEING 4129 02:57:30,341 --> 02:57:34,278 SERVED BY OUR OTHER TRAINING 4130 02:57:34,278 --> 02:57:36,547 MECHANISMS. AND WE PLAN TO HOLD 4131 02:57:36,547 --> 02:57:38,215 A PRE-APPLICATION WEBINAR TO 4132 02:57:38,215 --> 02:57:39,850 MAKE ITS SPECIFIC INTERESTS 4133 02:57:39,850 --> 02:57:42,319 KNOWN AS SOON AS THE NOFO IS 4134 02:57:42,319 --> 02:57:43,988 RELEASE THIS HAD TYPE OF 4135 02:57:43,988 --> 02:57:47,491 MENTORING THE THE UE 5 PROVIDES 4136 02:57:47,491 --> 02:57:49,326 IS JUST TRULY MAKING A HUGE 4137 02:57:49,326 --> 02:57:49,660 DIFFERENCE. 4138 02:57:49,660 --> 02:57:52,463 DATA FROM A PRIOR UE 5 MENTORING 4139 02:57:52,463 --> 02:57:53,897 AWARD SHOWS JUST HOW EFFECTIVE 4140 02:57:53,897 --> 02:57:56,266 THAT MENTORING CAN BE. 4141 02:57:56,266 --> 02:58:00,170 LOOKING AT THE YEARS 2020-2023, 4142 02:58:00,170 --> 02:58:05,809 FROM A RECENT AWARD. YOU CAN 4143 02:58:05,809 --> 02:58:09,313 SEE THAT ALL OF THEM WERE 4144 02:58:09,313 --> 02:58:11,115 SUCCESSFUL, RIGHT? MOST OF THEM 4145 02:58:11,115 --> 02:58:12,816 WERE VERY GOOD THEY APPLIED, 4146 02:58:12,816 --> 02:58:14,818 NEARLY ALL OF THEM APPLIED FOR 4147 02:58:14,818 --> 02:58:16,587 FUNDING AND THEIR SUCCESS RATE 4148 02:58:16,587 --> 02:58:18,689 WAS TRULY REMARKABLE. SO WE 4149 02:58:18,689 --> 02:58:22,226 THINK YOU NEED THIS EXTRA PUNCH, 4150 02:58:22,226 --> 02:58:24,962 THIS ADDED MENTORING STEP TO BE, 4151 02:58:24,962 --> 02:58:27,531 TO JUST INCREASE THE SUCCESS OF 4152 02:58:27,531 --> 02:58:29,933 OUR TRAINEES IN BECOMING 4153 02:58:29,933 --> 02:58:31,368 INDEPENDENTLY FUNDED. RESEARCH 4154 02:58:31,368 --> 02:58:33,070 INVESTIGATORS AND SO WITH THAT, 4155 02:58:33,070 --> 02:58:34,738 WE'RE ASKING THE COUNCIL TO 4156 02:58:34,738 --> 02:58:38,876 APPROVE THE REISSUE OF THE UE 5 4157 02:58:38,876 --> 02:58:43,213 MENTORING NETWORK AWARD AND 4158 02:58:43,213 --> 02:58:47,117 DR. JACQUES NOR AND DR. AMY SLEP 4159 02:58:47,117 --> 02:58:49,219 WILL LEAD OUR DISCUSSION. 4160 02:58:49,219 --> 02:58:52,689 >> THANK YOU DR. MCGUIRL, I'M 4161 02:58:52,689 --> 02:58:54,391 HAPPY TO PROVIDE SOME COMMENTS 4162 02:58:54,391 --> 02:58:57,895 ABOUT THE UE 5 THIS CONCEPT IS 4163 02:58:57,895 --> 02:59:00,497 FOCUSED ON THE DEVELOPMENT OF 4164 02:59:00,497 --> 02:59:01,598 STRUCTURED NETWORKS TO SUPPORT 4165 02:59:01,598 --> 02:59:04,802 THE CAREERS OF NEW 4166 02:59:04,802 --> 02:59:05,436 INVESTIGATORS. 4167 02:59:05,436 --> 02:59:08,839 THE REISSUING OF THIS CONCEPT 4168 02:59:08,839 --> 02:59:10,074 SHOWS A CLEAR UNDERSTANDING OF 4169 02:59:10,074 --> 02:59:12,843 THE ENVIRONMENT AND A STRONG 4170 02:59:12,843 --> 02:59:16,146 COMMITMENT TO THE CRANIOFACIAL 4171 02:59:16,146 --> 02:59:18,315 RESEARCH IN THE UNITED STATES. 4172 02:59:18,315 --> 02:59:20,017 THE GAP TO FILL IS THE OBSERVED 4173 02:59:20,017 --> 02:59:21,985 LACK OF STRUCTURED PROGRAMS 4174 02:59:21,985 --> 02:59:24,054 FOCUSED ON SUPPORTING THE 4175 02:59:24,054 --> 02:59:26,090 CAREERS OF THE RESEARCHERS. 4176 02:59:26,090 --> 02:59:28,826 THIS UE 5 IS RESPONSIVE TO THE 4177 02:59:28,826 --> 02:59:30,461 RECOMMENDATIONS OF OUR RECENT 4178 02:59:30,461 --> 02:59:33,330 REPORT DEVELOPED BY THE NIH BY A 4179 02:59:33,330 --> 02:59:35,032 MEDICAL WORKFORCE WORKING GROUP 4180 02:59:35,032 --> 02:59:37,534 THAT IDENTIFIED THE NEED TO GROW 4181 02:59:37,534 --> 02:59:42,573 THE DOC RESEARCH WORKFORCE AS A 4182 02:59:42,573 --> 02:59:46,443 HIGH PRIORITY. IT'S FOCUS FROM 4183 02:59:46,443 --> 02:59:49,213 A POSTDOC POSITION IN THE AWARD 4184 02:59:49,213 --> 02:59:51,782 OF THE FIRST GRANT FROM THE NIH 4185 02:59:51,782 --> 02:59:55,119 OR EQUIPMENTE CONSIST FOSTERED 4186 02:59:55,119 --> 02:59:56,386 THROUGH THIS NETWORK WILL 4187 02:59:56,386 --> 02:59:59,456 INVOLVE MENTORS WITH THE GOAL OF 4188 02:59:59,456 --> 03:00:00,757 EXPANDING AND REACHING SUPPORT 4189 03:00:00,757 --> 03:00:02,159 RECEIVED BY EARLY CAREER 4190 03:00:02,159 --> 03:00:03,827 INVESTIGATORS AND ENHANCE THEIR 4191 03:00:03,827 --> 03:00:06,130 ABILITY TO SUBMIT COMPETITIVE 4192 03:00:06,130 --> 03:00:08,665 GRANTS APPLICATIONS. 4193 03:00:08,665 --> 03:00:10,868 PRIOR FUNDING THROUGH THIS UE 5 4194 03:00:10,868 --> 03:00:13,504 SUPPORT AND THE HIGHLY 4195 03:00:13,504 --> 03:00:14,738 SUCCESSFUL FUTURE PROGRAM IN THE 4196 03:00:14,738 --> 03:00:17,241 FIRST CYCLE THE PROGRAM PROVIDED 4197 03:00:17,241 --> 03:00:18,275 MENTORSHIP AND SUPPORT TO THE 4198 03:00:18,275 --> 03:00:21,678 CAREER PROGRESSIONS OF MORE THAN 4199 03:00:21,678 --> 03:00:26,283 50 EARLY STAGE DOC 4200 03:00:26,283 --> 03:00:27,518 INVESTIGATORS. AS DR. MCGUIRL 4201 03:00:27,518 --> 03:00:30,521 JUST SHOWED ABOUT 70% OF THE 4202 03:00:30,521 --> 03:00:32,556 PARTICIPANTS BETWEEN 2020-23 4203 03:00:32,556 --> 03:00:36,026 RECEIVED NIH FUNDING WHICH IS 4204 03:00:36,026 --> 03:00:37,227 TRULY REMARKABLE. IN 4205 03:00:37,227 --> 03:00:40,397 CONCLUSION, THE IMPACT AND 4206 03:00:40,397 --> 03:00:41,198 SIGNIFICANCE OF SUPPORTING 4207 03:00:41,198 --> 03:00:43,167 NATIONWIDE MENTORING NETWORKS 4208 03:00:43,167 --> 03:00:45,602 FOR EARLY CAREER INVESTIGATORS 4209 03:00:45,602 --> 03:00:48,639 ARE TRULY EXCEPTIONAL. INDEED 4210 03:00:48,639 --> 03:00:50,307 THE FUTURE OF THE CRANIOFACIAL 4211 03:00:50,307 --> 03:00:52,809 RESEARCH RELIES ON EFFECTIVE 4212 03:00:52,809 --> 03:00:56,046 MENTORING OF POST-DOCTORAL 4213 03:00:56,046 --> 03:00:57,748 FELLOWS AND JUNIOR FACULTY IN 4214 03:00:57,748 --> 03:01:00,184 INTENSIVE CAREERS. AS SUCH THE 4215 03:01:00,184 --> 03:01:02,953 REISSUING OF THIS UE 5 IS TIMELY 4216 03:01:02,953 --> 03:01:06,423 AND HAS MY HIGHEST, MY STRONGEST 4217 03:01:06,423 --> 03:01:07,824 AND UNCONDITIONAL SUPPORT. 4218 03:01:07,824 --> 03:01:08,091 THANK YOU. 4219 03:01:08,091 --> 03:01:10,360 >> THANKS. DR. SLEP, WOULD YOU 4220 03:01:10,360 --> 03:01:10,861 LIKE TO ADD? 4221 03:01:10,861 --> 03:01:12,796 >> I DON'T KNOW HOW I CAN ADD TO 4222 03:01:12,796 --> 03:01:16,833 THAT. THAT WAS INCREDIBLY 4223 03:01:16,833 --> 03:01:18,669 ELOQUENT. SO I CONCUR THAT THIS 4224 03:01:18,669 --> 03:01:22,706 IS INCREDIBLY IMPORTANT, VERY 4225 03:01:22,706 --> 03:01:32,516 TIMELY AND THAT OUR WORKFORCE IS 4226 03:01:32,516 --> 03:01:33,750 INCREDIBLE ANYWAY WITH SO MANY 4227 03:01:33,750 --> 03:01:37,287 PRESSURES THAT ARE KIND OF 4228 03:01:37,287 --> 03:01:39,089 ALIGNING TO EITHER PULL THEM 4229 03:01:39,089 --> 03:01:40,824 INTO PRIVATE PRACTICE OR PULL 4230 03:01:40,824 --> 03:01:43,627 THEM INTO OTHER AREAS OF 4231 03:01:43,627 --> 03:01:44,294 RESEARCH. AND THIS KIND OF 4232 03:01:44,294 --> 03:01:46,263 NATIONAL MENTORING IS CRITICAL 4233 03:01:46,263 --> 03:01:47,898 AND IF THIS ISN'T REISSUED I 4234 03:01:47,898 --> 03:01:52,502 WOULD BE SCARED. AND SO I THINK 4235 03:01:52,502 --> 03:01:56,039 IT'S... I AGREE IT'S VERY, VERY 4236 03:01:56,039 --> 03:02:01,044 TEAM -- TIMELY AND IMPORTANT 4237 03:02:01,044 --> 03:02:02,379 THAT IT GET REISSUED. 4238 03:02:02,379 --> 03:02:03,780 >> THANK YOU, ANY DISCUSSION 4239 03:02:03,780 --> 03:02:09,519 FROM THE OTHER COUNCILORS. 4240 03:02:09,519 --> 03:02:12,723 HEARING NONE, I WILL TURN IT 4241 03:02:12,723 --> 03:02:15,259 OVER TO DR. SHIR RAZI. 4242 03:02:15,259 --> 03:02:16,560 >> THANK YOU, WOULD ANY MEMBER 4243 03:02:16,560 --> 03:02:18,061 OF COUNCIL LIKE TO MAKE A MOTION 4244 03:02:18,061 --> 03:02:20,297 TO APPROVE THIS CONCEPT? 4245 03:02:20,297 --> 03:02:22,332 >> SO MOVED, JACQUES. 4246 03:02:22,332 --> 03:02:25,902 >> WOULD SOMEONE LIKE TO SECOND 4247 03:02:25,902 --> 03:02:27,471 THE MOTION? SECOND? 4248 03:02:27,471 --> 03:02:29,806 >> I WILL SECOND THAT. 4249 03:02:29,806 --> 03:02:36,613 >> THANK YOU. ALL IN FAVOR? 4250 03:02:36,613 --> 03:02:38,081 ANY OPPOSED? THANK YOU SO MUCH. 4251 03:02:38,081 --> 03:02:40,317 THE NEXT CONCEPT WILL BE 4252 03:02:40,317 --> 03:02:42,119 PRESENTED BY DR. BILL ELWOOD WHO 4253 03:02:42,119 --> 03:02:44,121 IS THE CHIEF OF BEHAVIORAL AND 4254 03:02:44,121 --> 03:02:45,455 SOCIAL SCIENCES RESEARCH BRANCH 4255 03:02:45,455 --> 03:02:47,724 IN THE DIVISION OF EXTRAMURAL 4256 03:02:47,724 --> 03:02:48,792 RESEARCH AT THE NIDCR. 4257 03:02:48,792 --> 03:02:52,095 DR. ELWOOD, PLEASE SHARE YOUR 4258 03:02:52,095 --> 03:02:52,829 PRESENTATION. 4259 03:02:52,829 --> 03:03:00,837 >> YES, MA'AM, DR. SHIRAZ ZEE, 4260 03:03:00,837 --> 03:03:04,107 WOOPS. FORGIVE ME. EE, 4261 03:03:04,107 --> 03:03:04,574 WOOPS. FORGIVE ME. , 4262 03:03:04,574 --> 03:03:05,042 WOOPS. FORGIVE ME. , 4263 03:03:05,042 --> 03:03:16,253 WOOPS. FORGIVHOOPS. FORGIVE M 4264 03:03:19,122 --> 03:03:23,226 GOAL FOR THIS CONCEPT IS PARTLY 4265 03:03:23,226 --> 03:03:26,163 INSPIRED BY THE NIH MOVEMENT 4266 03:03:26,163 --> 03:03:32,402 TOWARD FEWER NOFOS WITH MULTIPLE 4267 03:03:32,402 --> 03:03:34,071 PURPOSES AND THE NIDCR STRATEGIC 4268 03:03:34,071 --> 03:03:35,372 PLAN WHICH IS BACK ONLINE AGAIN 4269 03:03:35,372 --> 03:03:39,176 IF YOU HAVEN'T SEEN IT. 4270 03:03:39,176 --> 03:03:43,146 SPECIFICALLY, IT'S TO INVITE 4271 03:03:43,146 --> 03:03:44,848 APPLICATIONS THAT PROPOSE 4272 03:03:44,848 --> 03:03:46,817 RESEARCH THAT REFLECTED ON ALSO 4273 03:03:46,817 --> 03:03:49,853 FACTORS FOR HUMAN BEHAVIORS AND 4274 03:03:49,853 --> 03:03:52,856 HOW THOSE BEHAVIORS HAVE AN 4275 03:03:52,856 --> 03:03:57,928 IMPACT ON DOC AND ORAL SYSTEMIC 4276 03:03:57,928 --> 03:04:01,732 HEALTH OUTCOMES. AND YOU CAN 4277 03:04:01,732 --> 03:04:06,903 SEE THE MANY DIFFERENT KINDS OF 4278 03:04:06,903 --> 03:04:17,447 CAUSAL HYPOTHESES THAT CAN LOOK 4279 03:04:18,281 --> 03:04:22,319 AT THE PROPOSAL. WE HAVE A VERY 4280 03:04:22,319 --> 03:04:32,863 FINE THIS MIGHT HELP MANY THAT 4281 03:04:34,965 --> 03:04:39,169 REGARD. IT MAY NOT BE NECESSARY 4282 03:04:39,169 --> 03:04:41,238 FOR CAUSATION. THERE'S CAUSAL 4283 03:04:41,238 --> 03:04:44,841 INFLUENCE AND CAUSAL 4284 03:04:44,841 --> 03:04:50,781 EXPLANATION. SO HOW DOES OUR 4285 03:04:50,781 --> 03:04:54,751 STRATEGIC PLAN RELATE TO THIS 4286 03:04:54,751 --> 03:04:56,520 CONCEPT? THERE YOU GO, MULTIPLE 4287 03:04:56,520 --> 03:04:58,588 FACTORS, BIOLOGICAL, 4288 03:04:58,588 --> 03:05:00,857 ENVIRONMENTAL, COMMERCIAL, AND 4289 03:05:00,857 --> 03:05:04,227 DOC HEALTH AND ORAL SYSTEM. 4290 03:05:04,227 --> 03:05:07,063 WHILE I LET YOU READ THAT, I 4291 03:05:07,063 --> 03:05:10,700 WILL POINT OUT THE ANCIENT PHOTO 4292 03:05:10,700 --> 03:05:15,472 ON THE RIGHT WHICH REMINDS ME OF 4293 03:05:15,472 --> 03:05:16,807 TIME I SPENT IN SOUTH FLORIDA 4294 03:05:16,807 --> 03:05:19,709 WHEN I MET A NUMBER OF PEOPLE 4295 03:05:19,709 --> 03:05:24,181 WHO HAD OF A CERTAIN AGE WHO HAD 4296 03:05:24,181 --> 03:05:27,717 BEEN EXPOSED TO DDT. NOT ONLY 4297 03:05:27,717 --> 03:05:30,554 HAD THEY BEEN EXPOSED BUT THEY 4298 03:05:30,554 --> 03:05:32,456 FOUND GREAT DELIGHT IN DANCING 4299 03:05:32,456 --> 03:05:35,625 DOWN THE STREETS BEHIND THE 4300 03:05:35,625 --> 03:05:38,094 TRUCKS AS THEY WENT THROUGH THE 4301 03:05:38,094 --> 03:05:39,763 NEIGHBORHOODS. THAT WAS BEFORE 4302 03:05:39,763 --> 03:05:44,401 WE KNEW THE NEGATIVE EFFECTS FOR 4303 03:05:44,401 --> 03:05:46,870 AN UNDERSTATEMENT OF DDT SO 4304 03:05:46,870 --> 03:05:49,539 THERE'S ALSO ENVIRONMENTAL 4305 03:05:49,539 --> 03:05:52,843 EXPOSURES THAT COULD BE PART OF 4306 03:05:52,843 --> 03:05:57,047 THIS PROJECT. I ALSO MIGHT 4307 03:05:57,047 --> 03:06:00,784 POINT OUT THAT PROJECTS COULD BE 4308 03:06:00,784 --> 03:06:02,419 SPECIFICALLY SECONDARY DATA. 4309 03:06:02,419 --> 03:06:05,188 THE D DS HUB, THE BEHAVIORAL 4310 03:06:05,188 --> 03:06:07,491 RISK FACTOR SURVEILLANCE STUDY 4311 03:06:07,491 --> 03:06:08,859 AT C DC. 4312 03:06:08,859 --> 03:06:11,461 THE HEALTH AND RETIREMENT SURVEY 4313 03:06:11,461 --> 03:06:14,364 SUPPORTED BY NIA AT THE 4314 03:06:14,364 --> 03:06:16,366 UNIVERSITY OF MICHIGAN. THOSE 4315 03:06:16,366 --> 03:06:20,403 ARE ONLY THREE EXAMPLES. BUT 4316 03:06:20,403 --> 03:06:26,142 THERE ARE ACTIVE AND PAST NIDCR 4317 03:06:26,142 --> 03:06:28,011 FUNDED PROJECTS WHOSE DATA MAY 4318 03:06:28,011 --> 03:06:31,915 NOT HAVE BEEN USED TO GENERATE 4319 03:06:31,915 --> 03:06:33,650 KNOWLEDGE TO THE EXTENT 4320 03:06:33,650 --> 03:06:38,421 POSSIBLE. FOR EXAMPLE, THIS, 4321 03:06:38,421 --> 03:06:44,861 YOU CAN SEE HERE THAT, THIS 4322 03:06:44,861 --> 03:06:48,965 FIRST PROJECT SUGGESTS THAT 4323 03:06:48,965 --> 03:06:53,637 CLINICIANS COULD BENEFIT FROM 4324 03:06:53,637 --> 03:06:56,406 TRAINING. THE SECOND PROJECT IS 4325 03:06:56,406 --> 03:07:00,810 FROM DONALD CHI. ADDITIONAL 4326 03:07:00,810 --> 03:07:02,712 GAPS IN OPPORTUNITIES. WE'VE 4327 03:07:02,712 --> 03:07:04,214 TALKED A LOT TODAY ABOUT 4328 03:07:04,214 --> 03:07:06,349 MULTIPLE CHRONIC CONDITIONS. 4329 03:07:06,349 --> 03:07:10,320 AND I WILL ALSO POINT OUT THAT 4330 03:07:10,320 --> 03:07:14,424 OUR HISTORY HAS BEEN 4331 03:07:14,424 --> 03:07:18,461 INTRINSICALLY TIED TO MILITARY 4332 03:07:18,461 --> 03:07:24,834 HEALTH SINCE OUR BEGINNING. AND 4333 03:07:24,834 --> 03:07:28,672 THERE ARE, WE ARE UNIQUELY 4334 03:07:28,672 --> 03:07:32,842 POISED TO LEAD A PROJECT ON 4335 03:07:32,842 --> 03:07:37,147 MILITARY READINESS, DOC HEALTH 4336 03:07:37,147 --> 03:07:40,450 AND THAT MAY INCLUDE OTHER ICS 4337 03:07:40,450 --> 03:07:43,353 IN THE DEFENSE DEPARTMENT, IT 4338 03:07:43,353 --> 03:07:46,556 MAY NOT. BUT IT'S REALLY 4339 03:07:46,556 --> 03:07:50,427 IMPORTANT WORK THAT NEEDS TO BE 4340 03:07:50,427 --> 03:07:51,828 DONE. THANK YOU. AND LET ME 4341 03:07:51,828 --> 03:07:55,231 TURN THINGS OVER TO THE DOCTORS 4342 03:07:55,231 --> 03:08:05,475 TO CONSIDER. 4343 03:08:07,944 --> 03:08:09,579 >> DR. DUE DA, I BELIEVE YOU'RE 4344 03:08:09,579 --> 03:08:11,381 THE PRIMARY REVIEWER. 4345 03:08:11,381 --> 03:08:12,916 >> THANK YOU SO MUCH DR. ELWOOD. 4346 03:08:12,916 --> 03:08:15,819 TO YOU AND YOUR TEAM. FOR 4347 03:08:15,819 --> 03:08:20,290 PREPARING THIS CONCEPT AND THIS 4348 03:08:20,290 --> 03:08:22,025 PRESENTATION. SO TO ME, THIS 4349 03:08:22,025 --> 03:08:25,462 CONCEPT IS PROPOSING THIS NEW 4350 03:08:25,462 --> 03:08:27,263 INVESTIGATION INTO CAUSAL 4351 03:08:27,263 --> 03:08:28,865 HYPOTHESES FOR HUMAN BEHAVIORS 4352 03:08:28,865 --> 03:08:32,502 THAT EFFECT OUR DOC HEALTH 4353 03:08:32,502 --> 03:08:35,038 OUTCOMES AND EVERYTHING BEYOND. 4354 03:08:35,038 --> 03:08:37,807 BECAUSE WE KNOW THAT ORAL HEALTH 4355 03:08:37,807 --> 03:08:41,945 HAS WHOLE BODY EFFECTS. SO TO 4356 03:08:41,945 --> 03:08:45,015 DATE NIDCR HAS A REALLY STRONG 4357 03:08:45,015 --> 03:08:46,449 BEHAVIORAL SCIENCE PORTFOLIO. 4358 03:08:46,449 --> 03:08:48,752 BECAUSE WE KNOW SO MANY ASPECTS 4359 03:08:48,752 --> 03:08:51,821 OF DOC HEALTH ARE LINKED TO OUR 4360 03:08:51,821 --> 03:08:53,423 BEHAVIORS. AND WE CAN BEST 4361 03:08:53,423 --> 03:08:56,493 ADDRESS THOSE BEHAVIORS WHEN WE 4362 03:08:56,493 --> 03:08:57,661 UNDERSTAND THEM. SO THE 4363 03:08:57,661 --> 03:08:59,129 DIRECTION OF THIS CONCEPT TO ME 4364 03:08:59,129 --> 03:09:03,166 IS CLEARLY ALIGNED WITH MANY 4365 03:09:03,166 --> 03:09:04,701 ASPECTS OF THE NIDCR STRATEGIC 4366 03:09:04,701 --> 03:09:08,204 PLAN AS WE JUST HEARD. THOSE 4367 03:09:08,204 --> 03:09:09,305 ASPECTS EMPHASIZE RESEARCH ON 4368 03:09:09,305 --> 03:09:12,642 BEHAVIORS AS A WAY TO INFORM 4369 03:09:12,642 --> 03:09:13,543 CLINICAL DECISION-MAKING FOR 4370 03:09:13,543 --> 03:09:15,679 BOTH PATIENTS AND HEALTH CARE 4371 03:09:15,679 --> 03:09:19,349 PROFESSIONALS. AS A WAY TO 4372 03:09:19,349 --> 03:09:20,483 DESIGN ORGANIZATIONAL STRUCTURES 4373 03:09:20,483 --> 03:09:24,087 THAT CAN OPTIMIZE CARE PATHWAYS. 4374 03:09:24,087 --> 03:09:26,289 TO HELP US BETTER UNDERSTAND 4375 03:09:26,289 --> 03:09:28,858 DENTAL, ORAL AND CRANIOFACIAL 4376 03:09:28,858 --> 03:09:30,860 PAIN AND OF COURSE TO BETTER 4377 03:09:30,860 --> 03:09:33,496 INFORM COST-EFFECTIVE 4378 03:09:33,496 --> 03:09:34,364 INTERVENTIONS. I ALSO THINK 4379 03:09:34,364 --> 03:09:38,501 THAT IN THIS CONCEPT THE FOCUS 4380 03:09:38,501 --> 03:09:39,269 ON BEHAVIORS AND THEIR ORAL 4381 03:09:39,269 --> 03:09:42,472 SYSTEMIC OUTCOMES ALIGNS WITH 4382 03:09:42,472 --> 03:09:45,208 THAT IDEA OF ORAL HEALTH BEING 4383 03:09:45,208 --> 03:09:47,544 AN ESSENTIAL COMPONENT OF WHOLE 4384 03:09:47,544 --> 03:09:50,513 BODY HEALTH WHICH WE AFFIRMED AT 4385 03:09:50,513 --> 03:09:54,751 THIS MEETING LAST YEAR. I AM 4386 03:09:54,751 --> 03:09:57,854 ALSO REALLY POSITIVE AND 4387 03:09:57,854 --> 03:09:59,656 INTERESTED IN THIS TRAJECTORY TO 4388 03:09:59,656 --> 03:10:01,558 LOOK AT ORAL HEALTH IMPROVEMENTS 4389 03:10:01,558 --> 03:10:03,893 FOR OUR MILITARY PREPAREDNESS 4390 03:10:03,893 --> 03:10:05,762 THAT SEEMS HIGHLY RELEVANT AND 4391 03:10:05,762 --> 03:10:08,264 LIKELY TO HAVE A HIGH IMPACT SO 4392 03:10:08,264 --> 03:10:10,734 OF COURSE THE CHALLENGE WITH 4393 03:10:10,734 --> 03:10:14,304 THIS NEW STRATEGY FOR CONCEPT IS 4394 03:10:14,304 --> 03:10:15,739 THAT A CONCEPT THIS BROAD, 4395 03:10:15,739 --> 03:10:17,907 RIGHT? IT'S HARD TO ENVISION A 4396 03:10:17,907 --> 03:10:20,844 SPECIFIC NOFO THAT MAY COME OUT 4397 03:10:20,844 --> 03:10:24,280 OF IT. AND SO I UNDERSTAND 4398 03:10:24,280 --> 03:10:25,749 WE'RE LOOKING AT THE PICTURE AS 4399 03:10:25,749 --> 03:10:28,485 A WHOLE. THIS MAY BE MULTIPLE 4400 03:10:28,485 --> 03:10:30,386 FUNDING ANNOUNCEMENTS. IT MAY 4401 03:10:30,386 --> 03:10:32,088 BE IN PARTNERSHIP WITH DIFFERENT 4402 03:10:32,088 --> 03:10:36,860 OTHER FUNDING AGENCIES. SO I 4403 03:10:36,860 --> 03:10:43,933 STRONGLY ENCOURAGE NIDCR TO 4404 03:10:43,933 --> 03:10:45,802 ENVISION AND MAKE CLEAR THE 4405 03:10:45,802 --> 03:10:47,837 INDIVIDUAL NOFOS THAT WILL COME 4406 03:10:47,837 --> 03:10:49,205 OUT OF THIS. OTHER THAN THAT I 4407 03:10:49,205 --> 03:10:51,908 FEEL THE CONCEPT ADDRESSES AN 4408 03:10:51,908 --> 03:10:52,675 IMPORTANT AND IMPACTFUL AREA AND 4409 03:10:52,675 --> 03:10:56,479 I AM PLEASED TO SUPPORT IT. 4410 03:10:56,479 --> 03:11:02,485 THANK YOU. 4411 03:11:02,485 --> 03:11:04,154 >> THANK YOU. 4412 03:11:04,154 --> 03:11:04,420 >> SORRY. 4413 03:11:04,420 --> 03:11:07,390 >> OKAY. SORRY, I WAS JUST 4414 03:11:07,390 --> 03:11:11,194 GOING TO ASK DR. DICKINSON TO 4415 03:11:11,194 --> 03:11:21,604 PROVIDE HIS COMMENTS. 4416 03:11:23,907 --> 03:11:24,440 DR. DICKINSON? 4417 03:11:24,440 --> 03:11:26,109 >> SORRY I KEEP FORGETTING THAT. 4418 03:11:26,109 --> 03:11:29,179 BUT THANK YOU, DR. ELWOOD FOR A 4419 03:11:29,179 --> 03:11:31,414 GREAT PRESENTATION ON SOMETHING 4420 03:11:31,414 --> 03:11:33,316 THAT IS CRITICALLY IMPORTANT. 4421 03:11:33,316 --> 03:11:36,853 BEING IN THE CLINIC AT BCU IN 4422 03:11:36,853 --> 03:11:40,390 THE DENTAL CLINIC AND SEEING 4423 03:11:40,390 --> 03:11:42,926 INTERACTIONS BETWEEN PATIENTS 4424 03:11:42,926 --> 03:11:44,494 AND STUDENTS THAT ARE TREATING 4425 03:11:44,494 --> 03:11:48,832 THEM SO OFTEN I SEE A LACK OF 4426 03:11:48,832 --> 03:11:49,699 SKILLS IN BEHAVIOR MANAGEMENT 4427 03:11:49,699 --> 03:11:55,338 NOT ONLY ON THE PATIENT BUT IN 4428 03:11:55,338 --> 03:11:56,472 UNDERSTANDING THAT IT'S MUCH 4429 03:11:56,472 --> 03:11:58,808 MORE THAN PUTTING A HOLE IN A 4430 03:11:58,808 --> 03:12:02,478 TOOTH. THAT THEY'RE THERE FOR. 4431 03:12:02,478 --> 03:12:05,281 AND HAVING MORE RESEARCH IN THIS 4432 03:12:05,281 --> 03:12:07,050 AREA I THINK IS EXCEPTIONALLY 4433 03:12:07,050 --> 03:12:09,853 GOOD TO NOT ONLY FOR THE 4434 03:12:09,853 --> 03:12:11,154 STUDENTS THEMSELVES BUT THE 4435 03:12:11,154 --> 03:12:12,589 PATIENTS THAT ARE COMING THERE 4436 03:12:12,589 --> 03:12:15,491 FOR CARE. SO I CERTAINLY WOULD 4437 03:12:15,491 --> 03:12:16,426 SUPPORT THIS AND HOPE THAT 4438 03:12:16,426 --> 03:12:20,496 EVERYBODY WOULD AGREE WITH THAT. 4439 03:12:20,496 --> 03:12:22,599 THANK YOU. 4440 03:12:22,599 --> 03:12:24,467 >> THANK YOU. ARE THERE ANY 4441 03:12:24,467 --> 03:12:27,170 COMMENTS OR QUESTIONS FROM OTHER 4442 03:12:27,170 --> 03:12:32,041 COUNCILMEMBERS BEFORE WE VOTE ON 4443 03:12:32,041 --> 03:12:35,845 THIS CONCEPT? DR. SLEP? YOU 4444 03:12:35,845 --> 03:12:36,279 HAVE YOUR HAND UP? 4445 03:12:36,279 --> 03:12:38,281 >> THANK YOU, I'M LIKE WAIT, 4446 03:12:38,281 --> 03:12:39,415 WHERE'S THE THING THAT ACTUALLY 4447 03:12:39,415 --> 03:12:43,686 RAISE MY HAND IN THE YELLOW 4448 03:12:43,686 --> 03:12:45,755 EMOJI RATHER THAN MY HAND I KNOW 4449 03:12:45,755 --> 03:12:46,890 SOMEONE HAD MENTIONED THAT THERE 4450 03:12:46,890 --> 03:12:49,893 WERE REVISIONS IS THE VERSION 4451 03:12:49,893 --> 03:12:54,364 THAT'S POSTED IN THE ELECTRONIC 4452 03:12:54,364 --> 03:12:56,566 COUNCIL BOOK IN THE FINAL OR 4453 03:12:56,566 --> 03:12:57,433 JUST CURIOUS. 4454 03:12:57,433 --> 03:13:00,536 >> YEAH. THAT IS THE SAME 4455 03:13:00,536 --> 03:13:01,838 PRESENTATION AT DR. ELWOOD. 4456 03:13:01,838 --> 03:13:03,573 >> PERFECT. OKAY. GREAT. I 4457 03:13:03,573 --> 03:13:05,308 JUST WANTED TO MAKE SURE I WAS 4458 03:13:05,308 --> 03:13:08,578 TRACKING EVERYTHING. NO OTHER 4459 03:13:08,578 --> 03:13:08,845 QUESTIONS. 4460 03:13:08,845 --> 03:13:11,447 >> GREAT. THANK YOU. SO WE'RE 4461 03:13:11,447 --> 03:13:12,849 GOING TO VOTE ON THIS CONCEPT 4462 03:13:12,849 --> 03:13:14,083 WOULD A MEMBER OF COUNCIL LIKE 4463 03:13:14,083 --> 03:13:17,754 TO MAKE A MOTION TO APPROVE THIS 4464 03:13:17,754 --> 03:13:17,987 CONCEPT? 4465 03:13:17,987 --> 03:13:20,590 >> I MOTION TO APPROVE THIS 4466 03:13:20,590 --> 03:13:20,857 CONCEPT. 4467 03:13:20,857 --> 03:13:21,557 >> THANK YOU. 4468 03:13:21,557 --> 03:13:23,426 >> I SECOND THAT. 4469 03:13:23,426 --> 03:13:28,298 >> GREAT. AND ALL IN FAVOR? 4470 03:13:28,298 --> 03:13:32,535 OKAY. ANY OPPOSED? OKAY. 4471 03:13:32,535 --> 03:13:36,072 HEARING NONE, THANK YOU VERY 4472 03:13:36,072 --> 03:13:38,841 MUCH. THIS MARKS THE END OF THE 4473 03:13:38,841 --> 03:13:40,710 CONCEPT CLEARANCES AND THE FINAL 4474 03:13:40,710 --> 03:13:45,548 ITEM ON THE AGENDA IS THE 4475 03:13:45,548 --> 03:13:47,283 NIDCR'S TRIENNIAL CLINICAL 4476 03:13:47,283 --> 03:13:51,321 RESEARCH REPORT ON TRACKING OF 4477 03:13:51,321 --> 03:13:53,423 WOMEN AND MINORITIES IN CLINICAL 4478 03:13:53,423 --> 03:13:54,891 RESEARCH. THIS REPORT HAS 4479 03:13:54,891 --> 03:13:56,859 ALREADY BEEN ACCEPTED 4480 03:13:56,859 --> 03:13:57,827 ELECTRONICALLY IN FEBRUARY THIS 4481 03:13:57,827 --> 03:14:00,263 YEAR BUT WE ARE REQUIRED TO 4482 03:14:00,263 --> 03:14:02,565 PRESENT IT AT THE OPEN SESSION 4483 03:14:02,565 --> 03:14:05,802 OF COUNCIL. DR. DINA FISHER 4484 03:14:05,802 --> 03:14:06,703 WILL PRESENT A VERY SHORT 4485 03:14:06,703 --> 03:14:09,639 SUMMARY OF THE REPORT. THANK 4486 03:14:09,639 --> 03:14:10,106 YOU. 4487 03:14:10,106 --> 03:14:12,342 >> GREAT. THANKS VERY MUCH, 4488 03:14:12,342 --> 03:14:17,380 EVERYONE, I THINK HALF OF MY 4489 03:14:17,380 --> 03:14:18,982 BRIEF PRESENTATION THE DOCTOR 4490 03:14:18,982 --> 03:14:20,249 JUST MENTIONED BUT I WILL OFFER 4491 03:14:20,249 --> 03:14:24,854 A SUMMARY OF THE 2025 TRIENNIAL 4492 03:14:24,854 --> 03:14:25,722 ADVISORY COUNCIL REPORT ON 4493 03:14:25,722 --> 03:14:30,827 COMPLIANCE WITH NIH'S CLINICAL 4494 03:14:30,827 --> 03:14:36,866 RESEARCH GUIDELINES. SO THE 4495 03:14:36,866 --> 03:14:39,268 COLLEGE RESEARCH GUIDELINES 4496 03:14:39,268 --> 03:14:41,771 WHICH REQUIRE THAT STUDY 4497 03:14:41,771 --> 03:14:45,875 PARTICIPANTS IN NIH SUPPORTED 4498 03:14:45,875 --> 03:14:49,946 CLINICAL RESEARCH ARE THE 4499 03:14:49,946 --> 03:14:55,218 REPORTING OF STUDY PARTICIPATION 4500 03:14:55,218 --> 03:14:59,088 BY SEX, ETHNICITY, RACE, AND AGE 4501 03:14:59,088 --> 03:15:02,258 ARE BOUND BY THESE TWO LAWS. 4502 03:15:02,258 --> 03:15:05,695 AND THAT'S HOW THESE GUIDELINES 4503 03:15:05,695 --> 03:15:10,266 CAME ABOUT. THE DOCTOR ALREADY 4504 03:15:10,266 --> 03:15:11,768 MENTIONED THE REPORTING THAT 4505 03:15:11,768 --> 03:15:13,102 THIS HAS ALREADY BEEN -- THE 4506 03:15:13,102 --> 03:15:14,470 REPORT HAS BEEN ACCEPTED BY 4507 03:15:14,470 --> 03:15:16,539 COUNCIL. THIS IS A TRIENNIAL 4508 03:15:16,539 --> 03:15:18,441 REPORT THAT'S REPORTING ON 4509 03:15:18,441 --> 03:15:24,647 FISCAL YEAR 2022-24 AND I'M 4510 03:15:24,647 --> 03:15:25,681 GOING TO PROVIDE A BRIEF 4511 03:15:25,681 --> 03:15:31,821 OVERVIEW OF THE DATA AND THIS IS 4512 03:15:31,821 --> 03:15:34,624 REPORTED BY AWARD RECIPIENTS IN 4513 03:15:34,624 --> 03:15:36,259 ANNUAL AND FINAL PROGRESS 4514 03:15:36,259 --> 03:15:40,096 REPORT. DURING THE FISCAL YEARS 4515 03:15:40,096 --> 03:15:44,200 OF INTEREST. SO IN GENERAL THE 4516 03:15:44,200 --> 03:15:46,836 NUMBER OF STUDIES THAT HAVE 4517 03:15:46,836 --> 03:15:50,573 CONTRIBUTED TO DATA HAVE 4518 03:15:50,573 --> 03:15:56,579 INCREASED. AND FOCUSING ON 4519 03:15:56,579 --> 03:16:00,850 ENROLLMENT BY SEX FIRST FEMALE 4520 03:16:00,850 --> 03:16:02,351 ENROLLMENT HAS BEEN MORE FEMALES 4521 03:16:02,351 --> 03:16:04,320 THAN MALES HAVE BEEN ENROLLED IN 4522 03:16:04,320 --> 03:16:06,956 CLINICAL RESEARCH STUDIES THAT 4523 03:16:06,956 --> 03:16:09,092 HAVE BEEN SUPPORTED BY NIDCR AND 4524 03:16:09,092 --> 03:16:12,462 REGARDING ETHNICITY, HIS TANNIC 4525 03:16:12,462 --> 03:16:14,764 OR LATINO HAS BEEN CONSTANTLY 4526 03:16:14,764 --> 03:16:21,104 THE SAME. MOVING ONTO RACE. IN 4527 03:16:21,104 --> 03:16:22,405 GENERAL MORE WHITE PARTICIPANTS 4528 03:16:22,405 --> 03:16:24,941 ARE IDENTIFYING AS WHITE HAVE 4529 03:16:24,941 --> 03:16:27,877 PARTICIPATED IN NIDCR SUPPORTED 4530 03:16:27,877 --> 03:16:29,078 CLINICAL RESEARCH. THERE HAS 4531 03:16:29,078 --> 03:16:30,446 BEEN AN INCREASE IN THE 4532 03:16:30,446 --> 03:16:34,050 REPORTING PERIOD IN BLACK OR 4533 03:16:34,050 --> 03:16:35,351 AFRICAN AMERICAN STUDY 4534 03:16:35,351 --> 03:16:39,689 PARTICIPATION AND FOR OTHER 4535 03:16:39,689 --> 03:16:45,528 RACES, THE PROPORTION OF 4536 03:16:45,528 --> 03:16:47,263 PARTICIPANTS HAS BEEN RELATIVELY 4537 03:16:47,263 --> 03:16:48,831 CONSISTENT. THE NEXT THREE 4538 03:16:48,831 --> 03:16:51,868 SLIDES I WILL JUST HIGHLIGHT 4539 03:16:51,868 --> 03:16:54,437 NIDCR SUPPORTED PHASE THREE 4540 03:16:54,437 --> 03:16:56,572 CLINICAL TRIALS. AND THE NUMBER 4541 03:16:56,572 --> 03:16:59,242 OF TRIALS THAT NIDCR HAS 4542 03:16:59,242 --> 03:17:00,877 SUPPORTED OVER THE REPORTING 4543 03:17:00,877 --> 03:17:08,117 YEARS OF FY 22-24 HAS BEEN 7-11 4544 03:17:08,117 --> 03:17:11,921 TRIALS. FEMALE ENROLLMENT 4545 03:17:11,921 --> 03:17:12,855 SIMILAR HAS BEEN CONSISTENT AND 4546 03:17:12,855 --> 03:17:16,025 MORE FEMALES HAVE ENROLLED IN 4547 03:17:16,025 --> 03:17:19,262 TRIAL, PHASE THREE TRIALS THAN 4548 03:17:19,262 --> 03:17:23,332 MALES HAVE. HISPANIC OR LATINO 4549 03:17:23,332 --> 03:17:24,500 ETHNICITY A LITTLE BIT OF AN 4550 03:17:24,500 --> 03:17:26,569 INTERESTING STORY BECAUSE THIS, 4551 03:17:26,569 --> 03:17:31,607 THOSE IDENTIFYING AS HISPANIC OR 4552 03:17:31,607 --> 03:17:32,842 LATINO IS A SUBSTANTIAL 4553 03:17:32,842 --> 03:17:34,310 PROPORTION OF STUDY PARTICIPANTS 4554 03:17:34,310 --> 03:17:37,813 AND HAS INCREASED OVER THE 4555 03:17:37,813 --> 03:17:42,251 REPORTING PERIOD. THOSE, FOR 4556 03:17:42,251 --> 03:17:44,654 RACE, WHITE AND BLACK OR AFRICAN 4557 03:17:44,654 --> 03:17:45,922 AMERICAN STUDY PARTICIPATION HAS 4558 03:17:45,922 --> 03:17:49,091 BEEN RELATIVELY SIMILAR FROM 4559 03:17:49,091 --> 03:17:51,627 THOSE TWO RACIAL CATEGORIES. 4560 03:17:51,627 --> 03:17:56,132 AND I JUST WILL MAKE A NOTE THAT 4561 03:17:56,132 --> 03:17:58,668 UNKNOWN OR NOT REPORTED RACE IS 4562 03:17:58,668 --> 03:18:02,338 SIGNIFICANT AND HAS INCREASED 4563 03:18:02,338 --> 03:18:04,840 OVER THE REPORTING PERIOD. BUT 4564 03:18:04,840 --> 03:18:08,144 JUST TO SUMMARIZE, THIS BRIEF 4565 03:18:08,144 --> 03:18:08,811 PRESENTATION, THERE'S A GENERAL 4566 03:18:08,811 --> 03:18:13,482 TREND OF INCREASED STUDY 4567 03:18:13,482 --> 03:18:15,718 PARTICIPATION ENROLLMENT WITH AN 4568 03:18:15,718 --> 03:18:16,852 INCREASE IN MINORITY ENROLLMENT 4569 03:18:16,852 --> 03:18:20,623 OVERALL IN FY24 MORE FEMALES 4570 03:18:20,623 --> 03:18:21,524 THAN MALES HAVE BEEN ENROLLED IN 4571 03:18:21,524 --> 03:18:27,496 CLINICAL RESEARCH STUDY 4572 03:18:27,496 --> 03:18:28,831 SUPPORTED BY NIDCR. THE RACIAL 4573 03:18:28,831 --> 03:18:31,701 AND ETHNIC DISTRIBUTION OF STUDY 4574 03:18:31,701 --> 03:18:33,469 PARTICIPANTS HAS REMAINED 4575 03:18:33,469 --> 03:18:35,304 RELATIVELY CONSISTENT OVER THIS 4576 03:18:35,304 --> 03:18:36,572 REPORTING TIMEFRAME. AND FOR 4577 03:18:36,572 --> 03:18:39,809 PHASE THREE TRIALS AS I HAD 4578 03:18:39,809 --> 03:18:41,811 BRIEFLY MENTIONED, THERE IS THIS 4579 03:18:41,811 --> 03:18:44,380 INCREASING TREND. THIS IS 4580 03:18:44,380 --> 03:18:46,315 PRIMARILY DUE TO THREE CLINICAL 4581 03:18:46,315 --> 03:18:48,851 TRIALS THAT FOCUSED ON HISPANIC 4582 03:18:48,851 --> 03:18:52,188 AND LATINO REPORTING ENROLLMENT 4583 03:18:52,188 --> 03:18:58,461 AND MANY OF THOSE INDIVIDUALS 4584 03:18:58,461 --> 03:19:01,864 REPORTED UNKNOWN OR NOT REPORTED 4585 03:19:01,864 --> 03:19:05,167 RACIAL CATEGORIES. AND FINALLY, 4586 03:19:05,167 --> 03:19:06,402 JUST TO OFFER AN OVERVIEW OF THE 4587 03:19:06,402 --> 03:19:10,172 TYPES OF PHASE THREE TRIALS THAT 4588 03:19:10,172 --> 03:19:11,641 NIDCR HAS SUPPORTED, THESE HAVE 4589 03:19:11,641 --> 03:19:18,614 BEEN FOCUSED ON CARR CARIES 4590 03:19:18,614 --> 03:19:19,915 PREVENTION OR TREATMENT. 4591 03:19:19,915 --> 03:19:22,451 REDUCTION OF DENTAL ANXIETY AND 4592 03:19:22,451 --> 03:19:28,124 TOBACCO CESSATION. RR CARIES 4593 03:19:28,124 --> 03:19:28,658 PREVENTION OR TREATMENT. 4594 03:19:28,658 --> 03:19:29,292 REDUCTION OF DENTAL ANXIETY AND 4595 03:19:29,292 --> 03:19:29,859 TOBACCO CESSATION. CARIES 4596 03:19:29,859 --> 03:19:30,393 PREVENTION OR TREATMENT. 4597 03:19:30,393 --> 03:19:31,027 REDUCTION OF DENTAL ANXIETY AND 4598 03:19:31,027 --> 03:19:31,594 TOBACCO CESSATION. CARIES 4599 03:19:31,594 --> 03:19:32,128 PREVENTION OR TREATMENT. 4600 03:19:32,128 --> 03:19:32,762 REDUCTION OF DENTAL ANXIETY AND 4601 03:19:32,762 --> 03:19:33,396 TOBACCO CESSATION. AND THAT'S 4602 03:19:33,396 --> 03:19:33,562 ALL. 4603 03:19:33,562 --> 03:19:34,730 >> THANK YOU VERY MUCH 4604 03:19:34,730 --> 03:19:38,567 DR. FISHER. OKAY. SO BEFORE WE 4605 03:19:38,567 --> 03:19:41,037 CLOSE THE MEETING I WOULD LIKE 4606 03:19:41,037 --> 03:19:43,606 TO ASK DR. JENNIFER WEBSTER FOR 4607 03:19:43,606 --> 03:19:46,676 SOME CLOSING COMMENTS ON THE 4608 03:19:46,676 --> 03:19:48,844 OPEN SESSION AND OTHER ITEMS 4609 03:19:48,844 --> 03:19:51,814 THAT SHE WOULD LIKE TO SHARE 4610 03:19:51,814 --> 03:19:57,053 WITH YOU, THANK YOU. 4611 03:19:57,053 --> 03:19:59,255 >> WELL FIRST LET ME THANK YOU 4612 03:19:59,255 --> 03:20:00,856 FOR JOINING US FOR THIS OPEN 4613 03:20:00,856 --> 03:20:03,392 SESSION. THERE WAS A LOT OF 4614 03:20:03,392 --> 03:20:04,727 OPPORTUNITIES TO SHARE AND TO 4615 03:20:04,727 --> 03:20:07,763 SHARE SOME SCIENCE. LET ME TAKE 4616 03:20:07,763 --> 03:20:10,900 THIS OPPORTUNITY TO THANK OUR 4617 03:20:10,900 --> 03:20:13,302 RETIRING MEMBERS THERE COUNCIL, 4618 03:20:13,302 --> 03:20:15,604 DR. JACQUES NOR AND DR. AMY 4619 03:20:15,604 --> 03:20:18,374 SLEP. THANK YOU FOR YOUR 4620 03:20:18,374 --> 03:20:20,343 COMMITMENT. THANK YOU FOR YOUR 4621 03:20:20,343 --> 03:20:22,712 EXPERTISE AND THANK YOU FOR YOUR 4622 03:20:22,712 --> 03:20:24,347 UNWAVERING SERVICE TO NIDCR. 4623 03:20:24,347 --> 03:20:28,451 KNOW THAT YOU ARE APPRECIATED. 4624 03:20:28,451 --> 03:20:32,621 AND I WILL NOW CLOSE OUR 239TH 4625 03:20:32,621 --> 03:20:34,757 COUNCIL. THANK YOU. 4626 03:20:34,757 --> 03:20:44,757 >> THANK YOU.